MAST CELLS AND BASOPHILS
This Page Intentionally Left Blank
MAST CELLS AND BASOPHILS Edited by GIANNI MARONE Universitgt degli Studi di Napoli Federico II, Naples, Italy
LAWRENCE M. LICHTENSTEIN Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
STEPHENJ. GALLi Department of Pathology, Stanford University Medical Center, Stanford, California, U.S.A.
ACADEMIC PRESS A HarcourtScienceand lechnoioqyCompany San Diego
San Francisco New York London Sydney Tokyo
Boston
This book is printed on acid-free paper. Copyright 9 2000 by ACADEMIC PRESS All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Academic Press A Harcourt Science and Technology Company Harcourt Place, 32 Jamestown Road, London NW 1 7BY, UK http://www.academicpress.com Academic Press A Harcourt Science and Technology Company 525 B Street, Suite 1900, San Diego, California 92101-4495, USA http://www.academicpress.com ISBN 0-12-473335-2 A catalogue record for this book is available from the British Library
Typeset by Kenneth Burnley, Wirral, Cheshire Printed in Great Britain by MPG, Bodmin, Cornwall 00 01 02 03 04 05 M P 9 8 7 6 5 4 3 2 1
To Giancarlo, Elizabeth, Joshua, Rebekah and David. As a token of our gratitude for their love and understanding.
This Page Intentionally Left Blank
Contents
CONTRIBUTORS PREFACE ACKNOWLEDGEMENTS
xix xxv xxvii
Section One DEVELOPMENT OF MAST CELLS AND BASOPHILS Chapter 1
Regulation of Mast Cell and Basophil Development by Stem Cell Factor and Interleukin-3 Mindy Tsai, Chris S. Lantz and Stephen J. Galli
Chapter 2
Introduction SCE a Ligand for the c-kit Receptor Multiple Effects of SCF in Mast Cell Biology SCF can Regulate Mast Cell Function In Vitro and In Vivo Interleukin-3 Using IL-3 - / - Mice to Assess the Role of IL-3 in Mast Cell and Basophil Development Summary Acknowledgements References
10 13 14 14
Gain-of-function Mutations of c-kit in Human Diseases
21
Yukihiko Kitamura, Seiichi Hirota, Eiichi Morii and Toshirou Nishicla
Chapter 3
Introduction Loss-of-function Mutation of c-kit Stomach Lesions of W/Wv and SI/SId Mice Gain-of-function Mutation of c-kit in Mast Cell Neoplasms Sporadic Gastrointestinal Stromal Turnouts Familial GIST Conclusion References
21 21 23 23 25 26 27 27
Modulation of Mast Cell Development from Embryonic Haematopoietic Progenitors by Eotaxin
31
Elizabeth J. Quackenbush, Barry K. Wershil and Jose-Carlos Gutierrez-Ramos Chemokines and their Receptors Play Diverse Roles as Mediators of Inflammation Chemokines Participate in Multiple Mast Cell and Basophil Functions
31 32
CONTENTS
viii
Chapter 4
Chemokine Secretion by Mast Cells Eotaxin Results Discussion References
35 36 37 40 44
Regulation and Dysregulation of Mast Cell Survival and Apoptosis
51
Karin Hartmann and Dean D. Metcalfe Introduction Regulation of Mast Cell Survival and Apoptosis by Growth Factors Regulation of Mast Cell Survival and Apoptosis by Death Receptors Regulation of Mast Cell Survival and Apoptosis by Perforin, Nitric Oxide and Bacterial Toxins Regulation of Mast Cell Survival and Apoptosis by Irradiation and Chemical Agents Perspective: Apoptosis and Mast Cell Disease References
51 52 54 56 57 57 58
Section Two PHENOTYPIC AND ULTRASTRUCTURAL FEATURES OF MAST CELLS AND BASOPHILS Chapter 5
Ultrastructural Features of Human Basophil and Mast Cell Secretory Function
63
Ann M. Dvorak
Chapter 6
Introduction Mechanism(s) of Histamine and CLC-P Secretion from Human Basophils, of Histamine Secretion from Human Mast Cells In Vitro and of TNF-o~ and Chymase Secretion from Rat Peritoneal Cells Histamine Secretion from Human Mast Cells In Vivo Heparin Secretion from Human Mast Cells In Vitro The Vesiculovacuolar Organelle, a New Endothelial Permeability Structure Acknowledgements References
65 72 75 78 83 83
Human Dendritic Mast Cells
89
63
Henrik H. Jacobi and Olle Johansson Introduction The Morphology of Human Dendritic Mast Cells Functional Aspects and Future Lines of Research Concluding Remarks References Chapter 7
89 89 93 94 94
The Phenotypic Similarities and Differences Between Human Basophils and Mast Cells 97 L. Li, S. W. Reddel and S. A. Krilis Introduction Morphology Membrane Receptors
97 98 98
CONTENTS
Chapter 8
ix
Cytoplasmic Contents Mast Cell Phenotypes in Tissues The Involvement of Mast Cells and Basophils in Asthma and Drug Reactions Acknowledgements References
101 104 105 107 107
Interactions Between Nerves and Mast Cells in Amphibians
117
G. Chieffi Baccari, S. Minucci, A. de Paulis and A. de Santis Introduction Morphology of Frog Mast Cells Frog Mast Cells and Peripheral Nervous System Occurrence of Mast Cells in the Central and Peripheral Nervous Systems of Mammals Concluding Remarks References
117 117 120 127 127 128
Section Three SIGNAL TRANSDUCTION IN MAST CELLS AND BASOPHILS Chapter 9
Sequential Protein Kinase Activation and the Regulation of Mast Cell Cytokine Production
133
Erwin W. Gelfand and Gary L. Johnson Introduction Signalling Through Mast Cell Surface Receptors MAPK Family Members Transcriptional Regulation of TNF-ct Production Stem Cell Factor Receptor (c-kit) Differentiation Signalling and Function of Mast Cells Derived from Bone Marrow and Embryonic Stem Cells Identification of a Critical Role for MEKK2 in JNK Activation and Cytokine Production Summary Acknowledgements References Chapter 10 Fc~RI-mediated Induction of TNF-o~ Gene Expression in Mast Cell Lines
133 133 135 138 139 141 142 142 143 143 149
Ulrich Blank and Nadine Varin-Blank Introduction Chromosomal Location and Gene Structure of TNF-~ Regulation of TNF-~ Gene Expression in Non-mast Cell Lines Fc~RI-dependent Regulation of TNF-cz Production Concluding Remarks References Chapter 11 Regulation of Mast Cell Degranulation by SHIP
149 150 152 155 160 162 169
Michael Huber, Jacqueline E. Damen, Mark Ware, Michael Hughes, Cheryl D. Helgason, R. Keith Humphries and Gerald Krystal Introduction Structure and Binding Partners of SHIP
169 170
X
CONTENTS Biological Properties of SHIP Properties of the SHIP Knockout Mouse The Role of SHIP in Fc~RI-induced Degranulation of Mast Cells The Role of SHIP in Steel Factor-induced Signalling in Mast Cells The Role of SHIP in Thapsigargin-induced Signalling in Mast Cells A Model of IgE-induced Degranulation Major Questions Remaining Summary and Conclusions Acknowledgements References
171 172 173 175 176 177 178 179 179 179
Section Four REGULATION OF MAST CELL AND BASOPHIL SIGNALLING AND SECRETION Chapter 12 Immunoreceptor Tyrosine-based Inhibition Motif-dependent Negative
Regulation of Mast Cell Activation and Proliferation
185
Marc Da6ron, Odile Malbec, H~l~ne Li(nard, Pierre Bruhns and Wolf H. Fridman Introduction SIRP-~ can Negatively Regulate Fc~RI-dependent Mast Cell Activation FcvRIIB can Negatively Regulate c-kit-dependent Mast Call Proliferation Conclusion Acknowledgements References
185 187 188 189 190 190
Chapter 13 Perspectives on the Regulation of Secretion from Human Basophils
and Mast Cells
195
Donald MacGlashan Jr, Sandra Lavens-Phillips and Katsushi Miura Introduction Regulation of Fc~RI Expression Desensitization Modification of Basophil Function by IL-3 Summary References Chapter 14 Interactions between Secretory IgA and Human Basophils
195 195 198 201 204 204
209
Koichi Hirai, Motoyasu Iikura, Misato Miyamasu and Masao Yamaguchi Introduction Structure and Metabolism of sIgA Pathophysiology of sIgA sIgA-mediated Basophil Activation Receptors for sIgA Clinical Relevance of sIgA-mediated Basophil Activation Concluding Remarks Acknowledgements References
209 210 212 212 214 216 217 217 217
CONTENTS Chapter 15 Regulation of Mast Cell Secretion by Interferon-~/and Nitric Oxide
xi 221
John W. Coleman Introduction Interferon and Mast Cells Do Mast Cells Produce Interferon-T? Nitric Oxide and Nitric Oxide Synthases Nitric Oxide Effects on Mast Cells Do Mast Cells Produce Nitric Oxide? How does Nitric Oxide Regulate Mast Cells? Nitric Oxide and Mast Cells In Vivo- Clinical Implications Conclusion: Mast Cells, Interferon-y and Nitric Oxide in Cell Interactions and Disease Acknowledgements References
221 221 224 224 225 226 227 228 229 230 230
Section Five STRUCTURE AND FUNCTION OF MAST CELL PROTEASES Chapter 16 Human and Mouse Mast Cell Tryptases
235
Richard L. Stevens Introduction Identification and Cloning of Human Tryptase Genes Identification and Cloning of Mouse Tryptase Genes Biochemical Features of Human and Mouse Tryptases Expression of Mouse and Human Tryptases in Cells and Tissues Function of Human and Mouse Tryptases Tryptase Metabolism Concluding Remarks References
235 236 237 238 242 244 247 248 249
Chapter 17 Expression, Function and Regulation of Mast Cell Granule Chymases
During Mucosal Allergic Responses
257
Pamela A. Knight, Steven H. Wright, Elisabeth M. Thornton, Jeremy Brown and Hugh R. P Miller Introduction Investigating the Response of mMCP- 1 - / - Mice to Gastrointestinal Nematodes Regulation of the Expression of mMCP- 1 in mBMMC Discussion Acknowledgements References Chapter 18 Structure and Function of Human Chymase
257 258 263 268 271 271
275
Norman M. Schechter, Pedro Jos~ Barbosa Pereira and Stefan Strobl Introduction General Properties X-ray Crystal Structure of rHC The Extended Substrate-binding Site of Human Chymase Modelling of the Human Chymase-angiotensin I Interaction
275 275 279 281 283
xii
CONTENTS
Summary Acknowledgements References Chapter 19 Structure and Function of Human Mast Cell Tryptase
286 287 287
291
Andrew E Walls Introduction Distribution and Secretion in Disease Structure and Physicochemical Properties Non-human Tryptases Regulation of Tryptase Activity Peptide Substrates Protein Substrates Actions on Cells and Tissues Cellular Receptors for Tryptase Tryptase as a Therapeutic Target Acknowledgements References
291 291 294 295 296 296 297 298 300 301 302 302
Section Six
NERVE-MAST CELL INTERACTIONS: PHYSIOLOGY AND PATHOLOGY
Chapter 20 Mast Cell-Nerve Interactions: Possible Significance of Nerve Growth Factor
313
John Bienenstock Evidence for Mast Cell-Nerve Interactions Possible Role of NGF Acknowledgement References Chapter 21 Nerve Growth Factor, Mast Cells and Allergic Inflammation
314 317 320 320
325
Luigi Aloe, Alessandra Micera and Sergio Bonini Nerve Growth Factor: Early Discovery and Emerging Data NGF and the Nervous System NGF and the Endocrine System NGF and the Immune System NGF and Mast Cells NGF and Inflammation NGF and Allergic Responses Behavioural Influence on NGF Levels and Allergic Responses Possible Future Directions Acknowledgements References
325 326 327 327 328 331 332 334 335 336 336
Chapter 22 Interactions Between Neurotrophins and Mast Cells
341
Beate M. Henz, Barbara Hermes and Pia Welker Definition and Basic Aspects of Neurotrophins Mast Cells as a Source of Neurotrophic Factors
341 343
CONTENTS Effects of Neurotrophins on Mast Cells Evidence that NGF is also a Human Mast Cell Growth Factor Neurotrophin Receptors on Mast Cells Clinical Findings Suggesting Mast Cell and Neurotrophin Activity Mast Cells and Neurotrophins: Open Issues Acknowledgement References
xiii 343 344 347 348 349 350 350
Chapter 23 Modulation of Peripheral Neurotransmission Associated with
Mast Cell Activation
355
Bradley J. Undem, Radhika Kajekar and Allen C. Myers Sensory (Afferent) Nervous System Enteric Nervous System Sympathetic Nervous System Parasympathetic Nervous System Summary References
356 359 360 361 362 364
Chapter 24 Regulation of Gastrointestinal Mucin Production by Nerve-Mast Cell
Interactions
367
Charalabos Pothoulakis Introduction Neuronal Mediation of Mucin Secretion Effects of Stress on Colonic Mucin and Prostaglandin Release Role of Corticotropin-releasing Factor in Stress-induced Colonic Mucin Secretion Neurotensin is an Important Mediator of Colonic Stress Responses Mast Cells as a Major Link of Stress-mediated Mucin Secretion CRF and NT as Mediators of Intestinal Mast Cell Activation During Stress Clinical Implications References
367 368 368 370 370 371 373 374 375
Section Seven MAST CELLS AND BASOPHILS IN HOMEOSTASIS AND HOST DEFENCE Chapter 25 Mast Cell-Enterobacteria Interactions during Infection
381
Soman N. Abraham and Ravi Malaviya Introduction Protective Role of Mast Cells Against Bacterial Infection Mast Cell Phagocytosis of Bacteria Molecular Basis for Mast Cell-Enterobacteria Recognition Mast Cell Activation Via CD48 Interactions of Human Mast Cells with Enterobacteria Final Thoughts Acknowledgements References
381 382 383 385 391 392 392 394 394
xiv
CONTENTS
Chapter 26 Human Mast Cells and Basophils in Immune Responses to
Infectious Agents
397
Vincenzo Patella, Giovanni Florio, Alfonso Oriente, Giuseppe Spadaro, Virginia Forte, Arturo Genovese and Gianni Marone Introduction Mast Cells in Host Defence Against Bacterial Infections Mast Cells and Basophils in Helicobacterpylori Infection Leukotrienes in the Defence against Bacterial and Viral Infections Activation of Human Basophils and Mast Cells by Protein A Activation of Human Basophils and Mast Cells by Protein L Activation of Human Basophils by Pepstatin A Endogenous Superallergen Protein Fv in Viral Hepatitis Activation of Human Basophils and Mast Cells by HIV- 1 Glycoprotein gp 120 The 'Three Faces' of Mast Cells and Basophils in the Immune Response to Infectious Agents Acknowledgements References
397 398 399 399 400 402 404 406 408 410 411 411
Chapter 27 Differential Regulation of Mast Cell Mediator Secretion by Bacterial
Products
419
Tong-Jun Lin, Fu-Gang Zhu and Jean S. Marshall Introduction Receptors for Bacteria on Mast Cells Selective Mast Cell Responses to Specific Bacterial Products Combined Signals Alter and Enhance Mast Cell Responses Bacteria- and Bacterial Product-mediated Signalling Events in Mast Cells Conclusions References
419 419 421 426 430 432 432
Chapter 28 The Role of Mast Cells, Basophils and Interleukin-3 (IL-3) in Immune
Responses to Parasites: Studies with Mast Cell- and IL-3-Deficient Mice 439
Chris S. Lantz and Stephen J. Galli Introduction Studies of Parasite Infection in Genetically Mast Cell-deficient Mice Assessing the Role of IL-3 in Host Responses to Nematodes using IL-3 - / - Mice KitW/Kitwv, IL-3 - / - Mice Exhibit a Profound Impairment of Basophilia, Mucosal Mast Cell Development and Immunity During Infection with
Strongyloides venezuelensis Summary Acknowledgements References
439 440 443
445 447 449 449
CONTENTS
XV
Section Eight
MAST CELLS IN ATHEROSCLEROSIS AND CARDIAC DISEASES Chapter 29 Human Heart Mast Cells: Immunological Characterization In Situ and In Vitro 455
Gianni Marone, Gennaro de Crescenzo, Vincenzo Patella, Francescopaolo Granata, Laura Verga, Eloisa Arbustini and Arturo Genovese Introduction Isolation of HHMC and their Characterization In Situ Histamine, Proteolytic Enzymes and Proteoglycans Synthesized by HHMC Prostaglandins and Cysteinyl Leukotrienes Synthesized De Novo by HMMC Immunological and Non-immunological Stimuli that Activate HHMC In Vitro Mast Cells and Regulation of Coagulation and Fibrinogenolysis HHMC in Systemic and Cardiac Anaphylaxis and in Anaphylactoid Reactions HHMC and Atherosclerosis HHMC in Patients with Myocarditis and Hyper-eosinophilia HHMC and Angiogenesis in the Heart HHMC and Myocardial Ischaemia HHMC in Idiopathic and Ischaemic Cardiomyopathy Perspective and Conclusions Acknowledgements References
Chapter 30 Mast Cells in Atherosclerotic Human Coronary Arteries: Implications for Coronary Fatty Streak Formation, Plaque Ulceration and Control of Local Haemostatic Balance
455 456 459 460 462 464 465 465 467 467 468 468 469 470 470
479
Petri T. Kovanen Introduction Atherosclerosis is a Disorder of Lipid Metabolism in the Arterial Intima with a Strong Inflammatory Component Circulating Mast Cell Progenitors also find their way in to the Arterial Intima Immunohistochemical Observations on Mast Cells in the Human Coronary Arterial Intima Potential Mechanisms by Which Mast Cells may Play a Role in Atherogenesis Conclusion and Future Directions Acknowledgements References
479 480 481 482 486 492 493 493
Chapter 31 Role of Mast Cells in Endogenous Fibrinolysis and Related
(Patho)physiological Processes
497
Peter Valent Introduction Contribution of Mast Cells to Fibrinogen Extravasation and Fibrin Formation Mast Cell-dependent Fibrinolysis: Role of Tryptase and Chymase The Mast Cell as Site of tPA Expression Human Mast Cells Express the Urokinase Receptor (uPAR, CD87) Functional Significance of MC-tPA: Mast Cells are 'Pro-fibrinolytic' Cells Molecular Basis of Mast Cell Dependent Fibrinolysis: Role of Inhibitors (PAIs) Fibrin-independent Plasminogen Activation Clinical Significance
497 498 498 499 500 500 501 501 501
xvi
CONTENTS Mast Cells Accumulate at the Site of Thrombosis SCF Regulates Expression and Release of tPA in Mast Cells Concluding Remarks and Future Directions Acknowledgement References
Chapter 32 Mast Cells in Myocardial Ischaemia and Reperfusion
502 502 503 503 503
507
Nikolaos G. Frangogiannis and Mark L. Entman Introduction Mast Cells in Normal Hearts The Mast Cell as a Source of Cytokines Mast Cell Degranulation Following Myocardial Ischaemia Mast Cells in Healing Myocardial Infarcts Mast Cell Precursors Infiltrate the Healing Heart SCF Induction Following Myocardial Ischaemia/Reperfusion Macrophages are the Main Source of SCF Following Myocardial Ischaemia Potential Role of Mast Cells in Healing The Mast Cell in Myocardial Ischaemia/Reperfusion: Friend or Foe? Acknowledgement References
507 508 509 511 513 514 515 516 517 517 518 518
Section Nine LEUKOTRIENES, CYTOKINES AND CHEMOKINES IN ALLERGIC DISORDERS Chapter 33 Lipid Mediators from Mast Cells and Basophils in Allergic Diseases
525
Massimo Triggiani, Cristiana Palumbo, Marco Gentile, Francescopaolo Granata, Cecilia Calabrese and Gianni Marone Introduction Arachidonic Acid Pools in Human Mast Cells and Basophils Phospholipase A 2in Human Mast Cells and Basophils Extracellular Effects of Mast Cell-derived Secretory PLA 2 PAF and Related Phospholipids Concluding Remarks Acknowledgements References
Chapter 34 Regulation and Function of Human Intestinal Mast Cells
525 527 528 529 531 533 533 534
541
Stephan C. Bischoff Introduction Effector Functions of Human Intestinal Mast Cells Regulation of Human Intestinal Mast Cell Functions Clinical Implications Future Directions References
541 543 548 550 557 557
CONTENTS
xvii
Chapter 35 Differential Regulation of Basophil Functions by Chemokines
567
Clemens A. Dahinden Basophil Phenotype and Functions Chemokines Acknowledgement References Chapter 36 Chemokine Receptors on Human Mast Cells
567 570 575 575
579
Paola Romagnani, Amato de Paulis, Chiara Beltrame, Gianni Marone and Sergio Romagnani Chemokines Mast Cells Chemokine Receptors on MC Concluding Remarks Acknowledgement References Chapter 37 Release and Cleavage of Stem Cell Factor by Human Mast Cells
579 586 588 591 591 591
597
Amato de Paulis, Giuseppina Minopoli, Eloisa Arbustini, Gennaro de Crescenzo, Fabrizio dal Piaz, Piero Pucci, Tommaso Russo and Gianni Marone Introduction Stem Cell Factor Expression in Human Mast Cells Stem Cell Factor-Protease Interactions Biological Effects of S C F 1-166 and S C F 1-159 Oil HLMC and HSMC Conclusions Acknowledgements References
597 598 600 602 603 604 604
Chapter 38 SCF-Induced Chemokine Production, Allergic Airway Inflammation
and Airway Hyper-reactivity
609
Nicholas W. Lukacs, Sandra H. P. Oliveira and Cory M. Hogaboam Introduction SCF-Induced Mast Cell Activation, Inflammation and Airway Hyper-reactivity Regulation of SCF Production Initiation of Cytokine/Chemokine Production by SCF in Mast Cells and Eosinophils Structural Cell-derived SCF Contributes to Disease Progression: Differential Activation of Mast Cells by Soluble versus Membrane SCF Summary References
609 610 612 613 615 616 617
Section Ten CLINICAL IMPLICATIONS OF HISTAMINE H1 RECEPTORANTAGONISTS Chapter 39 Pharmacological Profile of Mizolastine, a Novel Histamine H1
Receptor Antagonist
625
N. Selve, Ph. Pichat, J. Goldhill, 11. Depoortere and S. Arbilla Histamine and its Receptor Subtypes Specificity and Selectivity of Mizolastine for H~ Histamine Receptor Subtypes
625 626
xviii
CONTENTS
Antihistaminergic Effects of Mizolastine Allergic Reaction Anti-anaphylactic Properties of Mizolastine Immune System-mediated Inflammatory Reaction in Allergy Anti-allergic Effects of Mizolastine Other Pharmacological Effects of Mizolastine Conclusion Acknowledgement References
628 629 630 631 633 635 638 638 639
Chapter 40 Adenosine-Induced Enhancement of Mast Cell Mediator Release in
Asthma and COPD
641
Stephen T. Holgate, Riccardo Polosa, William R. Coward and Martin K. Church Introduction The Bronchoconstrictor Effect of Adenosine in Asthma The Airway Response to Adenosine in COPD Adenosine Receptors on Mast Cells Concluding Comments References Chapter 41 Neural Activation and Inflammation in Allergic Rhinitis
641 642 644 644 645 647
651
Alvin M. Sanico and Alkis Togias Introduction Neurogenic Inflammation Neural Hyper-responsiveness Nerve Growth Factor Summary and Conclusion References
651 652 654 658 659 660
Chapter 42 Antihistaminic and Anti-inflammatory Effects of Mizolastine
665
Massimo Triggiani, Cristiana Palumbo, Marco Gentile, Francescopaolo Granata and Gianni Marone Introduction Pharmacokinetics of Mizolastine Clinical Efficacy of Mizolastine Anti-inflammatory effects of Mizolastine Concluding Remarks References
665 666 666 667 669 669
Chapter 43 Electrophysiological and Molecular Basis for the Adverse
Cardiovascular Effects of Histamine H, Receptor Antagonists 673 Maurizio Taglialatela, Anna Pannaccione, Pasqualina Castaldo, Giovanna Giorgio and Lucio Annunziato Introduction Cardiotoxicity of Second-generation Antihistamines Conclusions Acknowledgements References
673 674 684 684 684
INDEX
689
P L A T E SECTION APPEARS B E T W E E N PAGES
292
AND
293
Contributors Numbers in parentheses indicate the pages on which the authors' contributions begin. An asterisk (*) indicates the author to whom correspondence should be addressed.
S. N. ABRAHAM* (3 81), Department of Pathology and Microbiology, Duke University Medical Center, Durham, NC27710, U.S.A., Tel: (919) 684-3630; Fax: (919) 684-2021. L. ALOE * (325), Institute of Neurobiology, CNR, Viale Marx 15, 1-00137, Rome, Italy, Tel: 39/06/8682592; Fax: 39/06/86090370; e-mail:
[email protected] L. ANNUNZIATO(673), Section of Pharmacology, Dept. of Neuroscience, School of Medicine, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. S. ARBILLA (625), Synth61abo Recherche, 10 rue des Carribres, 92500 Rueil Malmaison, France. E. ARBUSTINI (455,597), Department of Pathology, University of Pavia, Pavia, Italy. G. C. BACCARI* (117), Stazione Zoologica 'A. Dohrn', ltaly, Tel: 39-081-5665840; Fax: 39081-5665820; e-mail: gchieffi @unina.it P. J. BARBOSA PEREIRA (275), Departamento de Biologia Molecular y Celular Instituto de Biologia Molecular de Barcelona (IBMB) Jordi Girona, 18-26 08034 Barcelona, Spain, Tel: 34-93-400 6100, ext. 269; Fax: 34-93-204 5904; e-mail: pbpcri@ alcor.cid.csic.es C. BELTRAME (579), Department of Internal Medicine, Section of Clinical Immunology, Allergy, and Respiratory Diseases, University of Florence, Florence, Italy. J. BIENENSTOCK* (313), Departments of Medicine, Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, HSC-3N26, Hamilton, Ontario, L8N 3Z5, Canada, Tel: 905/525-9140, ext. 22017; Fax: 905/522-4936; e-mail: bienens@ fhs.csu.mcmaster.ca S. C. BISCHOFF* (541), Department of Gastroenterology & Hepatology, Medical School of Hannover, D-30623 Hannover, Germany, Tel: 49 511 532 3305; Fax: 49 511 532 4896; e-mail:
[email protected] N. V-BLANK (149), Unit6 INSERM 363, ICGM H6pital Cochin, 27 rue du Faubourg St Jacques, 75014 Paris, France, Tel: 33 1 46 33 64 40; Fax: 33 1 46 33 92 97; e-mail: varin @cochin.inserm, fr U. BLANK* (149), Unit6 d'Immuno-Allergie, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, Tel: 33 1 40 61 32 64; Fax: 33 140 61 33 83; e-mail:
[email protected] S. BONINI (325), Department of Allergy and Clinical Immunology, Second University of Naples, Italy. J. BROWN (257), Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Veterinary Centre, Easter Bush, Roslin, Midlothian EH25 9RG, U.K.
xx
CONTRIBUTORS
P. BRuI-INS (185), Laboratoire d'lmmunologie Cellulaire et Clinique, INSERM U.2555, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. C. CALABRESE (525), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5,1-80131 Naples, Italy. P. CASTALDO (673), Section of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. M. K. CHURCH (641), Allergy and Inflammation Division, Southampton General Hospital, Southampton, S016 6YD, U.K. J. W. COLEMAN* (221), Department of Pharmacology, University of Liverpool, Ashton Street, Liverpool, L69 3BX, UK, Tel: (144) 151 794 5551; Fax: (44)151794 5540; e-mail: coleman@ liv.ac.uk W. R COWARD (641), Allergy and Inflammation Division, Southampton General Hospital, Southampton, SO16 6YD, U.K. M. DACRON* (185), Laboratoire d'lmmunologie Cellulaire et Clinique, INSERM U.2555, Institut Curie, 26 rue d'Ulm, 75005 Paris, France, Tel: (33)1-4432-4223; Fax: (33)1-40510420; e-mail: Marc.Daeroncurie.fr C. A. DAHINDEN* (567), Institute of Immunology and Allergology Inselspital, University Hospital Bern, CH-3010 Bern, Switzerland. F. DAL PIAZ (597), International Mass Spectrometry Facility Center, University of Naples Federico II, Via S. Pansini 5, 80131, Naples, Italy. J. E. DAMEN (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. G. DE CRESCENZO (455, 597), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5,80131 Naples, Italy. A. DE PAULIS* (117, 579, 597), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy, Tel: 39-081-7462218; Fax: 39081-7462271; e-mail: depaulis @unina.it H. DEI~OORTERE(625), 31 avenue Paul Vaillant Couturier, 92220 Bagneux, France. A. DE SANTIS (117), Stazione Zoologica 'A. Dohrn', Naples, Italy. A. M. DVORAK* (63), Department of Pathology, East Campus, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, U.S.A., Tel: 617 667 3692; Fax: 617 667 2943. M. L. ENTMAN* (507), Department of Medicine, Cardiovascular Sciences, Baylor College of Medicine, One Baylor Plaza, M/S F-602, Houston, TX 77030-3498, U.S.A. G. FLORIO (397), Divisione di Immunologia Clinica e Allergologia, University of Naples Federico II, Via S. Pansini, 5, 80131 Naples, Italy. V. FORTE (397), Divisione di Immunologia Clinica e Allergologia, University of Naples Federico II, Via S. Pansini, 5, 80131 Naples, Italy. N. G. FRANGOGIANNIS (507), Department of Medicine, Cardiovascular Sciences, Baylor College of Medicine, One Baylor Plaza, M/S F-602, Houston, TX 77030-3498, U.S.A. W. H. FRIDMAN (185), Laboratoire d'lmmunologie Cellulaire et Clinique, INSERM U.2555, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. S. J. GALLI* (3, 439), Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, U.S.A., Tel: (650) 723-7975; Fax: (650) 725-6902; e-mail: sgalli @leland.stanford.edu
CONTRIBUTORS
xxi
E. W. GELFAND* (133), Division of Basic Sciences, Department of Pediatrics, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, U.S.A. A. GENOVESE (397, 455), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. M. GENTILE (525, 665), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy. G. GIORGIO (673), Section of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. J. GOLDI~ILI~(625), Synth61abo Recherche, 10 rue des Carri~res, 92500 Rueil Malmaison, France. F. GRANATA (455, 525, 665), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. J.-C. GUTIERREZ-RAMOS (31), Millennium Pharmaceuticals, Inc., 4575 Sydney Street, Cambridge, MA 02139, U.S.A., Tel: 617-679-7262; Fax: 617-551-8910. K. HARTMANN (51), Department of Dermatology, University of Cologne, Joseph-StelzmannStr. 9, 50931 Cologne, Germany. C. D. HELGASON (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. B. M. HENZ* (341), Exp. Dermatology, Charit6, Campus Virchow Clinic, AugustenburgerPlatz 1, D 13344 Berlin, Germany, Tel: 49-30-450- 65001; Fax: 49-30-450 65900; e-mail: magdalena.fuchs @charite.de B. HERMES (341 ), Krankenhaus Neuk611n, Berlin, Germany. K. HIRAI* (209), Department of Bioregulatory Function, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. S. HIROTA (21), Department of Pathology, Osaka University Medical School, Yamada-oka 22, Suita, Osaka 565-0871, Japan. C. M. HOGABOAM (609), University of Michigan Medical School, Department of Pathology, Ann Arbor, M148109-0602, U.S.A. S. T. HOLGATE* (641), Adult Respiratory and Molecular Sciences Research, Southampton General Hospital, Southampton, SO16 6YD, U.K. M. HtJBER (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. M. HucI-IES (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. R. K, HUMPHRIES (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. M. IIKURA (209), Department of Allergy and Rheumatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. H. H. JACOBI* (89), Allergy Unit 7511, National University Hospital, Tagensvej 20, DK 2200 Copenhagen N, Denmark. O. JOHANSSON (89), Experimental Dermatology Unit, Department of Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden. G. L. JOHNSON ( 13 3), Division of Basic Sciences, Department of Pediatrics, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, U.S.A. R. KAJEKAR (35 5), Johns Hopkins Asthma and Allergy Center, 501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. Y. KITAMURA* (21), Department of Pathology, Osaka University Medical School, Yamada-
xxii
CONTRIBUTORS
oka 2-2, Suita, Osaka 565-0871, Japan, Fax: 81-6-6879-3729; e-mail: kitamura@ patho.med.osaka-u.acjp P. A. KNIGHT (257), Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Veterinary Centre, Easter Bush, Roslin, Midlothian EH25 9RG, U.K. P. T. KOVANEN* (479), Wihuri Research Institute, Kalliolinnantie 4, 00140 Helsinki, Finland, Tel: 358-9-637 572; Fax: 358-9-637 476; e-mail:
[email protected] S. A. ~ I S * (97), The University of New South Wales, Department of Immunology, Allergy and Infectious Disease, St George Hospital, Kogarah, New South Wales, 2217, Australia, Tel: 612-93502955; Fax: 61-2-93503981; e-mail:
[email protected] G. KRYSTAL* (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. C. S. LANTZ (3, 439), Department of Biology, James Madison University, Harrisonburg, VA 22807, U.S.A. S. LAVENS-PHILLIPS (195), Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. L. LI (97), The University of New South Wales, Department of Immunology, Allergy and Infectious Disease, St. George Hospital, Kogarah, New South Wales, 2217, Australia. H. LII~NARD (185), Laboratoire d'lmmunologie Cellulaire et Clinique, INSERM U.2555, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. T.-J. LIN* (419), Departments of Pathology and Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, B3H 1E2, Canada. N. W. LUKACS* (609), University of Michigan Medical School, Department of Pathology, Ann Arbor, MI 48109-0602, U.S.A., Tel: 734-764-51 35; Fax: 734-764-2397; e-mail: nlukacs @umich.edu D. MACGLASHAN JR* (195), Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. R. MALAVIYA(381), Hughes Institute, 2665 Longlake Road, St Paul, MN 55113, U.S.A. O. MALBEC (185), Laboratoire d'lmmunologie Cellulaire et Clinique, INSERM U.2555, Institut Curie, 26 rue d' Ulm, 75005 Paris, France. G. MARONE (*397, *455, 525, 579, 597, 665), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy, Tel: 39081-7707492, Fax: 39-081-7462271; e-mail:
[email protected] J. S. MARSHALL (419), Departments of Pathology and Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, B3H 1E2, Canada. D. D. METCALFE* (51), Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institute of Health, Building l0, Room 11C205, 10 Center Drive MSC 1881, Bethesda, MD 20892-1881, U.S.A. A. MICERA (325), Institute of Neurobiology, CNR, Viale Marx 15,1-00137, Rome, Italy. H. R. P. MILLER* (257), Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Veterinary Centre, Easter Bush, Roslin, Midlothian EH25 9RG, U.K., Tel: 0131650 6102; Fax: 0131650 6588; e-mail: Hugh.Miller@ ed.ac.uk G. MINOPOLI (597), Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
CONTRIBUTORS
xxi i i
S. MINUCCI (117), Dipartimento di Fisiologia Umana e Funzioni Biologiche Integrate "E Bottazzi", Seconda Universit~ di Napoli, Naples, Italy. K. MIURA (195), Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. M. MIYAMASU (209), Department of Allergy and Rheumatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E. MORII (21), Department of Pathology, Osaka University Medical School, Yamada-oka 2-2, Suita, Osaka 565-0871, Japan. A. C. MYERS (355), Johns Hopkins Asthma and Allergy Center, 501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. T. NISHIDA (21), Department of Pathology, Osaka University Medical School, Yamada-oka 22, Suita, Osaka 565-0871, Japan. S. H. P. OLIVEIRA (609), University of Michigan Medical School, Department of Pathology, Ann Arbor, M148109-0602, U.S.A. A. ORIENTE (397), Divisione di Immunologia Clinica e Allergologia, Universit~ di Napoli Federico II, Via S. Pansini 5, 80131 Naples, Italy. C. PALUMBO(525, 665), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. A. PANNACCIONE (673), Section of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. g. PATELLA(397, 455), Division of Clinical Immunology and Allergy, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. PH. PICHAT(625), Synth61aboRecherche, 10 rue des Carri~res, 92500 Rueil Malmaison, France. R. POLOSA (641 ), Adult Respiratory and Molecular Sciences Research, Southampton General Hospital, Southampton, S016 6YD, U.K. C. POTHOULAKIS* (367), Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, U.S.A., Tel: (617) 667-1246; Fax: (617) 975-5071; e-mail: cpothoul @caregroup.harvard.edu P. Pucci (597), International Mass Spectrometry Facility Center, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy. E. J. QUACKENBUSH* (31), Clinical Genetics, Children's Hospital, Harvard Medical School, and the Center for Blood Research, 200 Longwood Avenue, Boston, MA 02115, U.S.A., Tel: 617-278-3240; Fax: 617-278-3030. S. W. REDDEL (97), The University of New South Wales, Department of Immunology, Allergy and Infectious Disease, St. George Hospital, Kogarah, New South Wales, 2217, Australia. P. ROMAGNANI* (579), Department of Pathophysiology, Endocrinology Unit, University of Florence, Florence, Italy. S. ROMAGNANI (579), Department of Internal Medicine, Section of Clinical Immunology, Allergy, and Respiratory Diseases, University of Florence, Florence, Italy. T. Russo (597), Department of Biochemistry and Medical Biotechnology, University of Naples Federico II, Naples, Italy. A. M. SANICO* (651), Department of Medicine, Division of Clinical Immunology, Johns Hopkins Asthma & Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A., Tel: (410) 550-2191; Fax: (410) 550-2193; e-mail:
[email protected] N. M. SCHECHTER* (27 5), Department of Dermatology, and Department of Biochemistry and Biophysics, University of Pennsylvania, Clinical Research Building, 415 Curie Blvd.,
xxiv
CONTRIBUTORS
Philadelphia, PA 19104-6142, U.S.A., Tel: 215-898-3680; Fax: 215-573-2033; e-mail: schechte @mail.med.upenn.edu N. SELVE* (625), Synth61aboRecherche, 10 rue des Carri~res, 92500 Rueil Malmaison, France. G. SPADARO (397), Divisione di Immunologia Clinica e Allergologia, Universit?a di Napoli Federico II, Via S. Pansini 5,80131 Naples, Italy. R. L. STEVENS* (235), Brigham and Women's Hospital, Department of Medicine, Smith Building, Room 616B, 1 Jimmy Fund Way, Boston, MA 02115 ,U.S.A., Tel: 617-525-1231; Fax: 617-525-1310; e-mail: rstevens @rics.bwh.harvard.edu S. STROBE (275), Abteilung fur Strukturforschung, Max-Planck-Institut ftir Biochemie, D-82152, Planegg-Martinsried, Germany, Tel: 49 89 8578 2827; Fax: 49-89-8578-3516; e-mail: strobl @biochem.mpg.de M. TAGLIALATELA* (673), Section of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy, Tel: 0039-081-7463310; Fax 0039-081-7463323; e-mail:
[email protected] E. M. THORNTON (257), Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Veterinary Centre, Easter Bush, Roslin, Midlothian EH25 9RG, U.K. A. TOGIAS (651), Department of Medicine, Division of Respiratory and Critical Care Medicine, Johns Hopkins Asthma & Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. M. TRIGGIANI* (525, 665), Division of Clinical Immunology and Allergy, University of Naples, Federico II, Via S. Pansini 5, 1-80131 Naples, Italy, Tel: 39 081 7462219; Fax: 39 0817462271; e-mail: triggian @unina.it M. TSAI (3), Department of Pathology, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, U.S.A. B. J. UNDEM* (355), Johns Hopkins Asthma and Allergy Center, 501 Hopkins Bayview Circle, Baltimore, MD 21224, U.S.A. P. VALENT* (497), Department of Internal Medicine I, Division of Hematology & Hemostaseology, The University of Vienna, W~hringer Gfirtel 18-20, A-1090 Vienna, Austria, Tel: 43 140400 6085; Fax: 43 1402 6930. L. VERCA (45 5), Department of Pathology, University of Pavia, Pavia, Italy. A. F. WALLS* (291), Immunopharmacology Group, Mailpoint 837, Level F South Block, Southampton General Hospital, Southampton, SO16 6YD, U.K. Tel: 44 023 8079 6151; Fax: 44 023 8079 6969; e-mail:
[email protected] M. WARE (169), Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. P. WELKER (341), D. Exp. Dermatology, Charit6, Campus Virchow Clinic, AugustenburgerPlatz 1, D 13344 Berlin, Germany. B. K. WERSHIL (31 ), SUNY Health Sciences Center, Brooklyn, New York, NY 11203, U.S.A; Tel: 718-270-3090; Fax: 718-270-1985. S. H. WRIGHT (257), Department of Veterinary Clinical Studies, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Easter Bush Veterinary Centre, Easter Bush, Roslin, Midlothian EH25 9RG, U.K. M. YAMAGUCHI (209), Department of Allergy and Rheumatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. F.-G. Znu (419), Departments of Pathology and Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia, B3H 1E2, Canada.
Preface The histochemical characteristics of human basophils and tissue mast cells were described over a century ago by Paul Ehrlich. At that time, the basophil's and mast cell's distinguishing feature was the affinity of their specific cytoplasmic granules, now known to have distinctive ultrastructure features, for certain basic dyes. Interestingly, the cell's tinctorial properties visible by light microscopy and their granule ultrastructural characteristics have remained the key identifying features of human basophils and mast cells. For several decades, basophils and mast cells and their mediators were considered to play mainly a proinflammatory role in various allergic disorders, and, as a result, in the 1980s mast cells and basophils fell out of favour among some immunologists. However, with the appreciation of these cells as major potential sources of multifunctional cytokines and chemokines, it became evident in the 1990s that mast cells and basophils may actually express immunoregulatory functions, as well as have roles as effector cells, in various immune disorders and protective host responses. This is a wonderful time in mast cell and basophil research. Indeed, the last few years have witnessed unprecedented progress in our understanding of the development and function of mast cells and basophils, and of the roles played by these cells in physiological and pathological processes. To name just a few recent developments, several lines of evidence now indicate that mast cells and basophils not only express critical effector function in classic IgE-associated allergic disorders, but also play important roles in host defence against parasites, bacteria and perhaps even viruses. Indeed, it is now clear that mast cells and basophils can contribute to host defence in the context of either acquired or innate immune-responses. Moreover, these cells can be activated by different HIV-1 proteins (gp 120 and Tat) and thereby represent a potentially important source of Th2 cytokines during HIV-1 infection. Basophils and mast cells can contribute to late phase inflammatory reactions in the skin and lung. Mature basophils and mast cell precursors circulate in peripheral blood at low concentrations. However, one of their characteristics is their capacity to adhere to activated endothelial cells, and to leave the bloodstream and migrate into inflamed tissues. This probably reflects, at least in part, the expression of the chemokine receptor CCR3 on their surface. The latter observation may also help to explain why increased numbers of basophils and mast cells are present at sites of certain inflammatory responses. The spectrum of diseases in which mast cells have been implicated has extended beyond allergic disorders to include several diseases of the cardiovascular and gastrointestinal systems and the joints, as well as the nervous system. In particular, investigations of potential anatomical and functional interactions between mast cells and the nervous system have recently attracted great interest. Mast cells and basophils are
xxvi
PREFACE
now thought to exert critical proinflammatory functions, as well as potential immunoregulatory roles, in various immune disorders through the release of such mediators as histamine, cysteinyl leukotrienes, cytokines and chemokines and neutral proteases (chymase and tryptase). Moreover, our knowledge of the intracellular signalling pathways that control the development of these cells, and the expression of basophil and mast cell functions, has also advanced rapidly, in part due to the use of powerful genetic approaches in mice to explore mast cell and basophil development and function in vivo. Many of the chapters of this volume represent papers that were presented at a meeting that included these topics. This meeting, entitled 'Mast Cells and Basophils in Physiology, Pathology, and Host Defense', took place from 4th to 6th March 1999 at the Accademia Nazionale dei Lincei ['The National Academy of the Lynxes']. The Accademia Nazionale dei Lincei, which is considered the oldest secular scientific academy in Europe (Galileo became a member in 1611), is housed in the sixteenthcentury Corsini Palace in the heart of Rome. This fascinating setting was an especially fitting place for this particular scientific gathering because it honoured the Nobel Laureat and Lycean, Rita Levi-Montalcini, who gave the keynote address. The rapid advances in this field make it difficult to produce a timely reference text. Despite these difficulties, we accepted the challenge to produce what may be the first volume of the third millennium that focuses on the basic and clinically relevant aspects of mast cell and basophil biology. The editors hope that you will enjoy this volume, and that it will convey some of the excitement that enlivens current work in basophil and mast cell biology. We would like to express our sincere appreciation to Sanofi-Synthelabo and in particular to Gianluca Visconti in Milan, whose enthusiastic support made this volume and the meeting on which it is based possible. We also thank all of the scientific contributors, as well as Jean Gilder, for their contributions to this volume. GIANNI MARONE LAWRENCE M. LICHTENSTEIN STEPHEN J. GALLI
Acknowledgements This volume falls within the framework of the international scientific exchange programme between the University of Naples Federico II (Italy) and the Johns Hopkins University of Baltimore (MD, USA). I owe a debt of gratitude to Professor Fulvio Tessitore, Rector of the University of Naples Federico II, and to Edward J. Benz Jr, Chairman of the Department of Medicine of the Johns Hopkins University, both of whom encouraged and made possible this exchange programme. I am also grateful to Professor Luigi Labruna, President of the Italian National Council for the University, for his invaluable support of the scientific event on which this volume is based. GIANNI MARONE
This Page Intentionally Left Blank
SECTION ONE DEVELOPMENT OF MAST CELLS A N D BASOPHILS
Chapter 1
Regulation of Mast Cell and Basophil Development by Stem Cell Factor and Interleukin-3 M. Tsai, C. Lantz and S. J. Galli
Chapter 2
Gain-of-function Mutations of c-kit in Human Diseases Y. Kitamura, S. Hirota, E. Morii and T. Nishida
Chapter 3
Modulation of Mast Cell Development from Embryonic Haematopoietic Progenitors by Eotaxin E. J. Quackenbush, B. K. Wershil and J.-C. Gutierrez-Ramos
Chapter 4
Regulation and Dysregulation of Mast Cell Survival and Apoptosis K. Hartmann and D. D. Metcalfe
This Page Intentionally Left Blank
CHAPTER
1
Regulation of Mast Cell and Basophil Development by Stem Cell Factor and Interleukin-3 M I N D Y TSAI, 1 CHRIS S. LANTZ 2 and STEPHEN J. GALL1.1 ~Department of Pathology, Stanford University Medical Center, Stanford, California and 2Department of Biology, James Madison University, Harrisonburg, Virginia, U.S.A.
INTRODUCTION In this chapter, we review current understanding of the effects of two cytokines, the c-kit ligand (or stem cell factor), and interleukin-3 (IL-3), on mast cell and basophil development, as well as review some of the effects of SCF on mast cell function. We will focus particularly on findings obtained in analyses of the effects of SCF or IL-3 on mast cell and basophil development and function in vivo. In part, this emphasis reflects the fact that recombinant human SCF (rhSCF) is already undergoing clinical testing in humans. Although rhSCF is being developed as an agent to enhance haematopoiesis, and to facilitate the harvesting of haematopoietic progenitors (1, 2), one of the effects of the repetitive treatment of human subjects with rhSCF is the induction of mast cell hyperplasia (3). However, our focus on in vivo findings is also prompted by three other considerations. First, studies of mice with spontaneous or targeted mutations that affect SCF or IL-3 production, or the receptors for these cytokines, have provided information about the actual importance of endogenous SCF or IL-3 in mast cell and basophil development in vivo. Second, a number of studies have analysed the effects of recombinant forms of SCF or IL-3 on mast cell and basophil development in mice and other mammalian species in vivo. Finally, as we illustrate below, in some cases it has not been possible to use even extensive amounts of in vitro data to predict the results obtained when genetic or other approaches are used to analyse the effects of SCF or IL-3 on mast cell or basophil development in vivo.
* Corresponding author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
Copyright 9 2000Academic Press All rights of reproduction in anyform reserved
4
MINDY TSAI et al.
SCF, A LIGAND FOR THE c-kit RECEPTOR
Mice with a double dose of mutations at either W or Sl have long been known to exhibit a hypoplastic, macrocytic anaemia, sterility and a lack of cutaneous melanocytes (reviewed in refs 4, 5). Transplantation and embryo fusion studies employing W or S1 mutant and congenic normal mice, or in vitro analyses employing cells or tissues derived from these animals, indicated that the deficits in the W mutant mice are expressed by the cells in the affected lineages, whereas those in the S1 mutant animals are expressed by microenvironmental cells necessary for the normal development of the affected lineages (4, 5). The complementary nature of the phenotypic abnormalities expressed by W or Sl mutant mice suggest that the W locus might encode a receptor expressed by haematopoietic cells, melanocytes and germ cells, whereas the S1 locus might encode the corresponding ligand (4). The important observations that mutations at W or S1 also profoundly affect mast cell development were made by Kitamura et al. (6) and Kitamura and Go (7). These authors demonstrated that the virtual absence of mast cells in W / W mice, like the anaemia of these animals, reflected an abnormality intrinsic to the affected lineage (6), whereas the mast cell deficiency of S1/Sle mice, which could not be corrected by bone marrow transplantation from the congenic normal (+/+) mice, reflected an abnormality in the microenvironments necessary for normal mast cell development (7). Kitamura's finding that transplantation of bone marrow cells from the congenic +/+ mice or from beige (C57BL/6-bg/bg) mice, whose mast cells can be identified unequivocally because of their giant cytoplasmic granules, repaired the mast cell deficiency of the W / W mice provided clear evidence that mast cells were derived from precursors that reside in the bone marrow. This work also showed that mutations at W had a more profound effect on the mast cell than on any other haematopoietic lineage. Subsequently, two groups reported that the W gene product encodes the c-kit tyrosine kinase receptor (8, 9). Shortly after this discovery, three groups simultaneously reported that Sl encodes the corresponding ligand, which was variously named (in alphabetical order) kit ligand (KL) (10), mast cell growth factor (MGF) (11-13), steel factor (SLF or SF) (14, 15) and stem cell factor (SCF) (16-18). This chapter will use the terms SCF for the ligand and c-kit for the receptor. The gene for SCF encodes two transmembrane proteins of 220 and 248 amino acids, which are generated by alternative splicing; both forms can be proteolytically cleaved to produce soluble forms of the molecule which retain biological activity and which spontaneously form non-covalently linked dimers in solution (reviewed in refs 19-21). While native SCF is glycosylated, the non-glycosylated, Escherichia coli-derived soluble recombinant forms of the extracellular ligand domain of the molecule (rSCF~64), which were used for many of the studies that we review here, have significant biological activity (reviewed in refs 20, 21). Receptor tyrosine kinases can regulate cell survival, proliferation and differentiation by transducing extracellular signals transmitted by their cognate ligands (22). As predicted on the basis of the phenotypic abnormalities expressed by W or S1 mutant mice, SCF has been shown to promote haematopoiesis and mast cell development, as well as melanocyte survival and proliferation, and to influence the survival and proliferation of primordial germ cells (reviewed in refs 20, 21). Other findings, such as the expression of high levels of c-kit or SCF in the central nervous system, or the expression of c-kit on
1.
REGULATION OF MAST CELL AND BASOPHIL DEVELOPMENT
5
lymphocytes, had not been expected, because W or Sl mutant mice were not known to exhibit central nervous system abnormalities and, in general, these mutants have normal numbers of mature lymphocytes and normal B cell and T cell function (reviewed in refs 20, 21). Similarly, it has only recently become apparent that SCF-c-kit interactions have a critical role in the development of the interstitial cells of Cajal, which generate intestinal electrical pacemaker activity (23-25). Moreover, it was recently shown that mature peripheral blood eosinophils can express c-kit and that SCF stimulation of eosinophils can enhance the cells' very late antigen 4-mediated adhesion to fibronectin and the adhesion molecule VCAM-1 (26). This mechanism could, in part, account for a proposed role for SCF in influencing eosinophil recruitment during certain murine models of inflammation (27).
MULTIPLE E F F E C T S OF SCF IN MAST CELL B I O L O G Y SCF can promote the in vitro survival of early haematopoietic progenitor cells and can act synergistically with other haematopoietic growth factors to promote the further differentiation of multiple haematopoietic lineages (1, 2, 19-21, 28-40). However, unlike most other haematopoietic lineages, mast cells retain significant expression of the SCF receptor (c-kit) into maturity, and thus exhibit responsiveness to SCF not only during their development but also, in all likelihood, throughout their mature life span (reviewed in ref. 20). Results of in vitro analyses, which, in many instances, have been confirmed by in vivo studies, indicate that SCF can have many effects in mast cell development and function: it can maintain mast cell survival, promote chemotaxis or haptotaxis of mast cells and their precursors, promote the proliferation of immature or mature mast cells, promote the maturation of mast cell precursors or immature mast cells and alter the phenotype and mediator content of these cells, directly promote the degranulation and secretion of mediators by mast cells, enhance the mast cell's ability to secrete mediators in response to other signals, including IgE and specific antigen, and alter the expression of other receptors, including those for extracellular matrix components and neuropeptides (reviewed in refs 20, 21). However, the specific effects of SCF on mast cell biology that are expressed under individual circumstances can be influenced significantly by other factors. For example, long-term dosing with recombinant rat SCF (rrSCF) can induce mast cell hyperplasia in multiple organs in normal rats (40). However, the pattern of expression of the mast cellassociated proteases (RMCP), RMCP I and II, by these mast cells varied according to the specific anatomical sites analysed (40). Thus, rrSCF promoted the development of mast cells that expressed predominantly RMCP I in the skin and peritoneal cavity, whereas those in the small intestinal mucosa expressed predominantly RMCP II (40). Subsequently, work in mice (28, 29), and later in rats (30), showed that IL-3 represents one of the additional cytokines that can influence the proliferation, and the serine protease phenotype, of mast cells that have been exposed to SCE It should be emphasized that the regulation of mast cell development in mice and humans may differ in important details (20, 31, 32). Moreover, rhSCF is now in clinical testing to determine the extent to which this cytokine, when used together with granulocyte colony-stimulating factor (G-CSF), can enhance the production and harvesting of haematopoietic progenitor cells (2). Thus, it is of particular interest to
6
MINDY TSAI et al.
consider the effects of rhSCF on human mast cell development and function. In vitro studies demonstrated that rhSCF can promote the development of mast cells from various sources of human haematopoietic progenitor cells (33-36). Subsequently, a Phase I study of E. coli-derived rhSCF showed that the administration of rhSCF (at 5-50 ~tg kg -I day -1, subcutaneously, for 14 days) to patients with advanced breast carcinoma resulted in a significant increase, by -~70%, in the numbers of cutaneous mast cells at sites that had not been directly injected with the agent (3, 37, 38). In addition, the patients exhibited increased urinary levels of the major histamine metabolite, methylhistamine (3, 37, 38), and markedly increased (by 100-1220%) serum levels of mast cell ~-tryptase, as detected by an assay that can measure both the cz and 13forms of this protease (3). The latter finding, when taken together with the observation that, in cynomolgus monkeys, rhSCF dosing induced much higher levels of mast cell development in the liver, spleen and lymph nodes than in the skin (39), suggested that the effect of rhSCF dosing on numbers of cutaneous mast cells may have greatly underestimated the effects of the agent on mast cell populations at other anatomical sites. In any event, this work identified rhSCF as the first cytokine that can induce human mast cell hyperplasia in vivo, and also showed that humans may be more sensitive to this action of rhSCF than are cynomolgus monkeys (3, 37-39). Although all of the biological effects of SCF on mast cells are of interest, none of them can be expressed unless the survival of the lineage is maintained. Work in both genetically mast cell-deficient SCF/MGF mutant S1/S1d (MgfS~/MgF -d) mice (17, 40) and cynomolgus monkeys (39) demonstrated that rSCF can promote the survival of the mast cell lineage in vivo. Thus, cessation of rhSCF dosing in cynomolgus monkeys was followed by a rapid decline of tissue mast cell numbers, in some cases to nearly baseline levels (39). Subsequently, three studies established that SCF can promote mast cell survival by suppressing apoptosis, either in vitro (41-43) or in vivo (42). Indeed, the study by Iemura et al. (42) indicated that apoptosis represents a mechanism which can account for striking (up to 50-fold) and rapid reductions in the size of mast cell populations in vivo, apparently without significant associated inflammation. The ability of SCF to protect mast cells from apoptosis is inhibited by the blockade of C a 2+ influx. On the other hand, the protective effects of IL-3 on mast cell apoptosis are not affected by C a 2+ influx inhibitors, indicating that SCF and IL-3 may maintain mast cell survival by distinct mechanisms (44). The increased numbers of mast cells present in mast cell neoplasms or examples of naturally occurring mastocytosis may in part reflect enhanced mast cell survival. Two SCF-c-kit-dependent mechanisms which may account for increased mast cell survival in such settings in vivo have been described: (1) 'gain-of-function' mutations affecting c-kit itself (45-48); and (2) altered production and/or biodistribution of endogenous SCF (49-50). A third mechanism which can enhance c-kit-dependent mast cell development has been defined in recent studies of mice with various combinations of mutations at c-kit and me, which encodes the Src homology 2 domain (SH2) -containing non-transmembrane protein tyrosine phosphatase, SHP1 (51, 52). This work showed that the decrease in dermal mast cell numbers in WTW ~ (KitW-v/Kit w-~) mice was significantly improved by superimposition of the me~me genotype, which results in diminished negative regulation of c-kit signalling (51, 52). In principle, these findings suggest that agents that can interfere with c-kit-dependent signalling in mast cells might be effective in diminishing the size of mast cell populations in vivo. However, c-kit is expressed on haematopoietic progenitor cells, melanocytes,
1.
REGULATION OF MAST CELL AND BASOPHIL DEVELOPMENT
7
germ cells and many other cell types, including certain neurons (reviewed in refs 19-21). Accordingly, the development of effective and safe approaches for manipulating the SCF receptor-ligand interaction to reduce mast cell numbers in vivo will require achieving either adequate target cell selectivity or clinically acceptable control of the agent's bioavailability. For example, in vitro studies and analyses performed in vivo in mice indicate that the ability of glucocorticoids to reduce mast cell populations may reflect the agent's ability to suppress local SCF production (53, 54). However, in humans, glucocorticoid treatment protocols that result in diminished numbers of dermal mast cells can also produce significant cutaneous atrophy (55).
SCF CAN REGULATE MAST CELL FUNCTION I N V I T R O AND I N VIVO Because the cell lineages that are most profoundly affected by W or S1 mutations (affecting c-kit or SCF, respectively) (reviewed in refs 19, 20) ordinarily are essentially missing in the mutant animals, it was not generally suspected that SCF might regulate the secretory function of cells that express c-kit. However, Wershil et al. (56) showed that SCF can induce mouse skin mast cell degranulation in vivo in doses as low as 140 fmol per site and that this response is c-kit-dependent, in that it occurs when dermal mast cells express the wild-type c-kit but not in phorbol 12-myristate 13-acetate (PMA) -induced dermal mast cells in W / W (KitW/Kit w-v) mice that express the Kit w-v mutant receptor. The receptor encoded by Kit w-u has a normal extracellular ligand-binding domain, but a point mutation in the kinase domain results in markedly reduced tyrosine kinase activity upon ligand engagement (57). Subsequently, it was shown that SCF can also induce mediator release in vitro from rat (58) or mouse (59) peritoneal mast cells and from human skin mast cells (60) and cultured human intestinal mast cells (61). At even lower concentrations in vitro, SCF can augment IgE-dependent activation of mouse peritoneal mast cells (59) or human lung (62) or skin (60) mast cells. SCF treatment can also enhance the responsiveness of mouse mast cells to the neuropeptides substance P (63) and PACAP (pituitary adenylate cyclase polypeptide) (64) in vitro. These findings suggest that SCF may be able to influence neuroimmune interactions by regulating the expression of neuropeptide receptors on mast cells. The ability of SCF to promote mast cell secretion directly, and to enhance mast cell activation via Fc~RI, prompted experiments to compare the signalling pathways that were activated in mast cells that had been stimulated via c-kit as opposed to Fc~RI (65). This work showed that patterns of activation of MAP (mitogen-activated protein) kinases and pp90 rsk and pp70-S6 kinases were very similar in mouse mast cells that were activated through these structurally distinct receptors (65), and suggested that c-kit or Fc~RIdependent signalling pathways may exhibit more overlap than had previously been suspected (65). It should be emphasized, however, that the effects of SCF on mast cell secretory function are potentially complex and may vary not only according to species and type of mast cell population (reviewed in ref. 20) but also according to duration of exposure to SCF and class of mast cell mediators. For example, in purified mouse peritoneal mast cells, short-term exposure to rrSCF can both induce serotonin release directly and enhance IgE-dependent serotonin release (59). However, in immature mouse mast cells generated in vitro, short-term incubation with recombinant mouse SCF induces little or
8
MINDY TSAI et al.
no mediator release (66). By contrast, longer-term incubation of such cells with recombinant mouse SCF enhances IgE-dependent prostaglandin PGD2 generation, at least in part through effects on haematopoietic PGD2 synthase, but simultaneously diminishes the cells' ability to release the granule-associated mediator ~-hexosaminidase (66). Moreover, in studies employing rrSCF, immature mouse mast cells which had been generated in IL-3-containing medium in vitro secreted IL-6 and, to a lesser extent, tumour necrosis factor (TNF-~) in response to challenge with soluble rrSCF, whereas concentrations of rrSCF that were effective in inducing the release of IL-6 resulted in little or no specific release of serotonin or histamine (67). However, SCF can induce marked degranulation in immature mast cells generated from SH2-containing inositol 5'phosphatase (SHIP) knockout mice (68). Thus, SHIP appears to play an inhibitory role in regulating the ability of SCF to initiate intracellular signalling and degranulation in mast cells in vitro. Although the molecular basis for the differences in responsiveness of various mast cell populations to the effects of SCF on mediator secretion are not completely understood, the diversity of the secretory responses induced in different mast cell populations by challenge with SCF in vitro made it difficult to predict whether administering this cytokine to human subjects in vivo would provoke mast cell degranulation. Nevertheless, in a Phase I study of rhSCF (3, 37, 38), we found that subcutaneous injections of rhSCF at 5-50 gg kg -1 induced a wheal and flare response in each of the ten subjects tested and at each rhSCF injection site, and that these reactions, when examined by transmission electron microscopy, exhibited evidence of extensive, anaphylactic-type, degranulation of dermal mast cells (3, 69). Moreover, a few subjects developed adverse events after rhSCF dosing that were consistent with the induction of systemic activation of mast cell populations (3, 37, 38). These findings strongly suggest that rhSCF can directly induce human mast cell degranulation in vivo, as it can in vitro. It has recently been shown that chymase, a major cytoplasmic granule-associated protease of human cutaneous mast cells, can cleave human SCF at a novel site that results in the release of a soluble, but biologically active, fragment of SCF which is 7 amino acids shorter at the C-terminus than previously characterized soluble SCF (70, 71). Thus, in addition to initiating a local, mast cell-dependent inflammatory response, injection of SCF might also initiate a mast cell chymase-dependent mechanism which results in local changes in the proportion of cell membrane-associated SCF compared with soluble SCE The adverse effects of the mast cell activation that is induced at rhSCF injection sites in vivo can be largely ameliorated by pre-treatment of subjects with H1 and H 2 antihistamines (2, 72). However, a recent study reports that it may be possible to modify SCF in a way that enhances its ability to promote haematopoiesis but does not increase its ability to enhance mast cell mediator secretion (73). Specifically, a soluble disulphidelinked dimer of mouse SCF (murine KL covalent dimer, or KL-CD), in comparison to the native, non-covalently linked KL dimer, exhibited significantly enhanced growthpromoting activity in colony-forming assays of mouse haematopoietic progenitor cells (CFU-GM) and in assays of [3H]thymidine incorporation by immature, IL-3-derived mouse mast cells in vitro, and increased mobilization of CFU-GM in the blood and spleen of mice in vivo, without exhibiting a significant change in its ability to enhance either Fc~RI -dependent release of hexosaminidase from IL-3-derived immature mouse mast cells in vitro or induce degranulation of dermal mast cells in the mouse ear in vivo (73). Whether the same (or other) chemical modification of rhSCF would result in an agent with an enhanced therapeutic profile (i.e. more haematopoietic cell growth-promoting
1.
REGULATIONOF MAST CELL AND BASOPHIL DEVELOPMENT
9
activity, but unchanged or diminished ability to promote mast cell secretion) remains to be seen. Finally, recent evidence suggests that, in some instances, increases in mast cell numbers might actually be beneficial. Mast cells can serve as key effector cells in innate immunity (reviewed in ref. 74). Studies by Maurer et al. (75) showed that repetitive treatment of mice with SCF can markedly improve their survival after caecal ligation and puncture, a model of acute bacterial peritonitis. Experiments using mast cellreconstituted WBB6F~-KitW/Kit w-v mice indicated that the enhanced survival associated with such SCF treatment reflected, at least in part, actions of SCF on mast cells (75).
INTERLEUKIN-3 Interleukin-3 is a 28-kDa glycoprotein that was first characterized as a factor that can induce the expression of 20cz-hydroxysteroid dehydrogenase in the splenocytes of nude mice in vitro (76). It was later shown that this cytokine can promote the in vitro differentiation and proliferation of haematopoietic progenitor cells, leading to the generation of multipotential blast cells, mast cells, basophils, neutrophils, macrophages, eosinophils, erythrocytes, megakaryocytes and dendritic cells (77-79). Indeed, Ihle et al. (80) demonstrated that IL-3 represented the critical factor present in the various 'conditioned media' that were used by different groups to generate populations of immature mast cells from mouse haematopoietic cells in vitro (81-85). This work, and many other in vitro studies, indicated that IL-3 might represent a major mast cell developmental/growth factor in the mouse, as well as a T cell-derived factor that can contribute to the enhanced development of other haematopoietic effector cells during immune responses to pathogens (86). However, studies with human haematopoietic cells indicated that IL-3 promoted the development of basophils in vitro, but had little if any ability, under most circumstances, to induce mast cell development (87-89). The administration of IL-3 in vivo can enhance haematopoiesis in mice (90, 91) and experimental primates (89, 92) and can markedly enhance levels of circulating basophils in Rhesus macaques (89). In addition, widespread cutaneous inflammation developed at sites of recombinant human IL-3 injection in Rhesus macaques, and this was associated with a modest increase in numbers of dermal mast cells at such sites (93). However, in part because of apparently conflicting data on the extent to which human mast cells can express receptors for IL-3 (reviewed in ref. 32), it was not clear whether the ability of IL-3 to influence human mast cell development in vitro (88) or in Rhesus macaques in vivo (93) represented direct or indirect effects of the cytokine. On the other hand, both the demonstration that IL-3 can markedly enhance mast cell development in the intestines of nude mice infected with the nematode Strongyloides ratti (94) and the demonstration that neutralizing antibodies to IL-3 can partially suppress (by -~50%) the mast cell hyperplasia which develops in the intestines of mice infected with the nematode Nippostrongylus brasiliensis (95, 96) supported the hypothesis that IL-3 can contribute to the hyperplasia of mucosal mast cells which occurs in murine rodents during T cell-dependent immune responses to certain parasites. In addition to its effects on the development of mast cells, basophils and other haematopoietic cells, many studies have shown that IL-3 can also enhance antigen presentation for T cell-dependent responses, augment macrophage cytotoxicity and adhesion, and promote the secretory function of eosinophils, basophils and mast cells
10
MINDY TSAI et al.
(95, 97-104). Taken together, these findings supported the hypothesis that IL-3 derived from T cells (and perhaps other sources) represents a critical link between the immune and haematopoietic systems, and may be particularly important for promoting the development, survival and effector function of tissue mast cells and blood basophils. However, the actual importance of such potential functions of IL-3 in vivo remained unclear. For example, mice carrying an inactivating mutation in the c~ chain of the heterodimeric IL-3 receptor are apparently normal, and haematopoiesis can occur in vitro in the absence of IL-3 (105, 106). And even though mouse T lymphocytes and mast cells (107-109) can produce IL-3 in vitro, the conditions in which IL-3 is expressed in vivo, and the sources of this cytokine in these settings, are not fully understood (110).
USING IL-3 - / - MICE TO ASSESS THE ROLE OF IL-3 IN MAST CELL AND BASOPHIL DEVELOPMENT Mice which lack IL-3 were produced using gene targeting in embryonic stem cells (111). IL-3 - / - mice are healthy and, unlike W/W ~(KitW/Kit wv) mice, are fertile. Moreover, like mice that carry an inactivating mutation in the c~ chain of the heterodimeric IL-3 receptor (106) or that lack both IL-3 and the common [3 subunit of the receptors for IL-3, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (112), IL-3 - / - mice exhibit no detectable abnormalities in multiple aspects of haematopoiesis in vitro or in vivo (111). Thus, in comparison to mice with mutations resulting in impaired c-kit or SCF expression or function, the phenotype of IL-3 - / - mice was remarkably normal. On the other hand, we found that IL-3 - / - mice did exhibit abnormalities in mast cell development in vitro and in vivo. In accord with previous work indicating that exogenous IL-3 can augment SCF-dependent mast cell development in vitro (20, 28-30, 113-115), we found that SCF induced fewer mast cells to develop in vitro in suspension cultures of bone marrow cells derived from IL-3 - / - mice as opposed to IL-3 +/+ mice (116). By contrast, substantially higher, and essentially equivalent, numbers of mast cells developed when bone marrow cells from either IL-3 - / - or IL-3 +/+ mice were maintained in vitro in exogenous SCF plus IL-3 (116). These in vitro studies thus showed that endogenous IL-3 can enhance, but is not required for, mast cell development from bone marrow progenitors in the presence of exogenous SCF. To assess the role of IL-3 in mast cell development in vivo, we quantified mast cells in the tissues of IL-3 - / - vs. wild-type mice at baseline or after 21 daily subcutaneous injections of rrSCF (at 100 ~tg kg-~/day -1) or vehicle alone (116). The results of these experiments showed that endogenous IL-3 is not essential for the development of mast cells under physiological conditions in vivo. Indeed, in all sites examined, levels of tissue mast cells at baseline in adult IL-3 - / - mice were very similar to those in the corresponding sites in IL-3 +/+ mice. Moreover, in contrast to our observations in the in vitro system, we found that endogenous IL-3 was not required for rrSCF-induced mast cell hyperplasia in vivo. In fact, in certain tissues, mast cell levels after rrSCF treatment were significantly greater (by up to 140%) in IL-3 - / - mice than in the corresponding wild-type mice (116). However, IL-3 contributed significantly to the increases in mast cell numbers that were observed in the intestines and spleen of mice infected with the nematode Strongyloides venezuelensis, and may have accounted for all of the increases in the bone marrow basophils in these animals (116). These findings strongly support the hypothesis that
1.
R E G U L A T I O N OF M A S T C E L L A N D B A S O P H I L D E V E L O P M E N T
11
Fig. 1 A highly simplified model of mouse mast cell and basophil development. Basophils arise from c-kit + multipotential haematopoietic progenitor cells, but typically mature in the bone marrow before entering the peripheral circulation. Basophils then can be recruited from the blood to sites of inflammatory or immune responses. Both human and mouse basophils generally express little or no c-kit on their surface. Mast cells also arise from multipotential haematopoietic progenitor cells, but complete major parts of their differentiation/ maturation in the peripheral tissues. Unlike basophils, mast cells express high levels of c-kit on their surface throughout their development; such c-kit receptors can interact with either membrane-associated or soluble forms of SCE *A committed precursor of tissue mast cells, the pro-mastocyte, has been identified in mouse fetal blood. Fetal and adult mouse blood also contains multipotential haematopoietic progenitor cells which, under appropriate circumstances, can give rise to mast cells as well as other cell types. Mouse blood, haematopoietic tissues and certain other tissues may also contain unipotential mast cell progenitors that are distinct from the pro-mastocyte (see text). t It is unclear to what extent, either in fetal or adult mouse tissues, immature mast cells that reside in the tissues are derived from pro-mastocytes as opposed to circulating multipotential haematopoietic progenitor cells. ++ Note that the phenotype of mature mast cells can vary considerably in different anatomical sites, based in part on local levels of SCF and other cytokines (e.g., IL-3, -4, -9, -10, etc.), and that the phenotypic characteristics of mast cells may vary (in some cases, reversibly) during the course of immune responses or inflammatory processes. This figure has been modified (with permission) from one that originally appeared in Lantz, C. S. and Galli, S. J., Mast cell and basophil development. In: Hematopoiesis: A DevelopmentalApproach (Zon, L. I., ed.), Oxford University Press, New York, in press.
12
MINDY TSAI et al.
much or all of the basophilia, and a significant fraction of the increases in intestinal and splenic mast cell populations, that occurs during Th2-type responses in mice is IL-3 driven. Our current model of the roles of SCF and IL-3 in mouse mast cell and basophil development is outlined in Fig. 1 and some explanatory notes are provided in the legend. The model specifically refers to the mouse system because the availability of mice that are defective in SCF-c-kit signalling and/or which lack IL-3 permit a direct assessment of the importance of SCF and IL-3 in mast cell and basophil development in this species in vivo. However, in vitro studies, and analyses of the effects of rhSCF in vivo, indicate that many of the major themes of mast cell and basophil development (as shown in Fig. 1) are very similar in mice and humans (20, 31, 32). On the other hand, our understanding of these processes still has significant gaps. For example, the 'pro-mastocyte', which represents the earliest mast cell-committed precursor to be identified during ontogeny, has so far been identified only in the mouse (115). The mouse pro-mastocyte is defined by the phenotype Thy-1 ~~c-Kit hi, contains small numbers of cytoplasmic granules that are very similar (by ultrastructure) to those that had previously been identified in immature mouse mast cells generated in IL-3containing medium in vitro, and expresses mRNAs encoding mouse mast cell-associated proteases (MC-CPA, MMCP-4 and MMCP-2) (115). However, this cell lacks expression, at the mRNA level, of Fc~RI. Purified pro-mastocytes can generate functionally competent mast cells at high frequencies in vitro, but do not exhibit developmental potential for other haematopoietic lineages. The development of mast cells from pro-mastocytes in vitro occurred in cultures that had been supplemented with SCF and IL-3, but not in cultures that had been supplemented with only one of these cytokines. However, given our finding of normal levels of tissue mast cells in IL-3 - / - mice (116), it is likely that cytokines other than IL-3 can function together with SCF to regulate the maturation of pro-mastocytes in vivo. When transferred intraperitoneally, pro-mastocytes can reconstitute the peritoneal mast cell compartment of KitW/Kitw-vmice to wild-type levels; moreover, these pro-mastocytederived peritoneal mast cells exhibit certain phenotypic characteristics of 'mature' peritoneal mast cells. The fetal blood pro-mastocyte population was first detected on day 14.5 of mouse gestation and, on day 15.5 of gestation, pro-mastocytes represented approximately one-fortieth of the CD45 + leukocyte fraction in the peripheral blood of these animals. However, the numbers of pro-mastocytes in the fetal blood declined from day 15.5 until birth. The origin of pro-mastocytes is uncertain; specifically, these cells have not yet been identified in mouse fetal liver in either mid or late gestation. Although a mast cell-committed precursor cell that was functionally or morphologically distinct from multipotent haematopoietic stem cells had not previously been purified from mouse bone marrow or blood (117, 118), prior work had established that mast cell precursor activity could be identified in day 9.5 mouse embryonic yolk sac (119) in adult mouse bone marrow (120) and in adult mouse or rat peripheral blood (118, 120-122), as well as in the mesenteric lymph nodes of Nippostrongylus brasiliensisinfected mice (113, 117). In humans, in vitro analyses indicate that mast cells can arise from a circulating c-kit +, CD34 § Ly-, CD14-, CD17-haematopoietic progenitor cell (123, 124) that lacks detectable expression of Fc~RI (123), but not from basophils or other differentiated haematopoietic lineages (1241). However, it is not known whether an equivalent to the mouse pro-mastocyte exists in humans or, indeed, to what extent pro-mastocytes are present in the blood or other tissues of adult mice. In addition, as indicated in Fig. 1, it is not clear (even in the mouse) whether
1.
REGULATIONOF MAST CELL AND BASOPHIL DEVELOPMENT
13
pro-mastocytes or Thy-1- c-Kit + multipotential haematopoietic progenitor cells (or some other population of mast cell progenitors) represents the most important source of the immature mast cells which are found in the peripheral tissues. For example, assays of mast cell colony formation in vitro indicate that unipotential precursors of mast cells (i.e. colony formation unit-mast, or CFU-Mast) may occur in the blood and other tissues of mice and rats (reviewed in refs 117, 118), but the exact relationship of these cells to the pro-mastocyte (or to the Thy 1- Kit + multipotential haematopoietic progenitor cell) is not yet clear. It is possible that tissue mast cells can be derived from either pro-mastocytes or less differentiated precursors, and that the proportion of tissue mast cells which are derived from these various potential precursor populations varies at different stages of development, or in the context of different inflammatory or immune responses that are associated with changes in numbers of mast cells. Nevertheless, it is clear, both in mice and in humans, that mature mast cells do not ordinarily circulate [mast cells may appear in the circulation after long-term dosing with rSCF (39), or in subjects with mastocytosis or mast cell leukaemia (125)]. Accordingly, in both mice and humans, much of the mast cell differentiation/maturation process occurs in the peripheral tissues; these processes are regulated by SCF and many other cytokines in the mouse and, probably, also in humans. By contrast, the weight of current evidence indicates that basophil maturation is completed (or nearly completed) before the cells are released into the peripheral circulation (20, 72, 126). And, unlike mast cells, basophils do not ordinarily reside in large numbers in peripheral tissues, but can be recruited to sites of inflammatory or immune responses (20, 72).
SUMMARY
SCF and IL-3 have distinct roles in mouse mast cell and basophil development. SCF-ckit interactions are required for physiological mast cell development in mice, as mast cells are ordinarily essentially absent in the tissues of KitW/Kit T M mice. Nevertheless, modest numbers of mast cells (generally, only --3-25% of the numbers in similarly treated congenic +/+ mice) can appear in the gastrointestinal mucosal tissues or spleen of KitW/Kit T M mice that have been infected with various nematodes, and studies in IL-3 - / and KitW/Kit T M IL-3 - / - mice show that IL-3 importantly contributes to this example of 'SCF-independent' mast cell hyperplasia (116). Indeed, this may represent the 'in vivo equivalent' of the mast cell development which occurs when bone marrow cells derived from KitW/Kit T M mice are placed in IL-3-containing medium in vitro (128-130). Nevertheless, limited development of 'mucosal mast cells' occurred in Strongyloides venezuelensis-infected mice that were totally devoid of IL-3, indicating that other cytokines can also promote the development of such mast cells (116). Based primarily on the results of in vitro analyses, as well as a limited number of in vivo experiments, cytokines which may promote the development of certain mast cell populations in mice include IL-4 (131,132), IL-6 (133), IL-9 (134, 135), IL-10 (136), TNF-~ (133) and nerve growth factor (NGF; 137-139). Thus, while SCF may be the most important of the mast cell developmental/growth factors in mice, IL-3 (and perhaps many other cytokines) can also contribute to mast cell development in this species. The finding of essentially normal levels of bone marrow basophils in IL-3 - / - mice indicates that IL-3 is not required for the production of this granulocyte in mice (116). However, virtually all of the basophil hyperplasia which occurred in the bone marrow of
14
M I N D Y TSAI et al.
mice that were infected with Strongyloides venezuelensis was IL-3-dependent (116). This finding confirms a large body of evidence, derived from studies in mice, humans and other species, which indicates that IL-3 probably represents a major (if not the major) cytokine responsible for basophil hyperplasia in vivo.
ACKNOWLEDGEMENTS Some of the work reviewed herein was supported by United States Public Health Service grants (AI-23990, CA-72074 and AI-33372), the Beth Israel Hospital Pathology Foundation, Inc. and AMGEN Inc. S.J.G. performed research funded by, and consults for, AMGEN Inc., under terms that are in accord with Beth Israel Deaconess Medical Center, Harvard Medical School and Stanford University conflict of interest policies.
REFERENCES 1. 2.
3.
4. 5.
6. 7. 8.
9. 10. 11. 12. 13. 14. 15. 16. 17.
Morstyn, G., Brown, S., Gordon, M., et al. Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 51:205-214, 1994. Moskowitz, C. H., Stiff, P., Gordon, M. S., et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a phase I/II trial. Blood 89:3136-3147, 1997. Costa, J. J., Demetri, G. D., Harris, T. J., et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J. Exp. Med. 183:2681-2686, 1996. Russell, E. S. Hereditary anemias of the mouse: a review for geneticists. In: Advances in Genetics (Caspari, E. W., ed.), Vol. 20. Academic Press, New York, 1979. Silvers, W. K. Dominant spotting, patch and rump-white; steel, flexed tail, splotch and varitint waddler. In: The Coat Colors of Mice: A Model f o r Gene Action and Interaction, pp. 206-241. Springer-Verlag, New York, 1979. Kitamura, Y., Go, S. and Hatanaka, K. Decrease of mast cells in W/W v mice and their increase by bone marrow transplantation. Blood 52:447-452, 1978. Kitamura, Y. and Go, S. Decreased production of mast cells in SUSId anemic mice. Blood 53:492-497, 1979. Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P. and Bernstein, A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335:88-89, 1988. Geissler, E. N., Ryan, M. A. and Housman, D. E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55:185-192, 1988. Huang, E., Nocka, K., Beier, D. R., et al. The hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63:225-233, 1990. Anderson, D. M., Lyman, S. D., Baird, A., et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 63:235-243, 1990. Copeland, N. G., Gilbert, D. J., Cho, B. C., et al. Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63:175-183, 1990. Williams, D. E., Eisenman, J., Baird, A., et al. Identification of a ligand for the c-kit proto-oncogene. Cell 63:167-174, 1990. Witte, O. N. Steel locus defines new multipotent growth factor. Cell 63:5-6, 1990. Williams, D. E., de Vries, P., Namen, A. E., Widmer, M. B. and Lyman, S. D. The steel factor. Dev. Biol. 151:368-376, 1992. Martin, T. R., Suggs, S. V., Langley, K. E., et al. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63:203-211, 1990. Zsebo, K. M., Williams, D. A., Geissler, E. N., et al. Stem cell factor (SCF) is encoded at the SI locus of
l.
18.
19. 20. 21. 22. 23. 24. 25. 26.
27.
28. 29.
30.
31.
32.
33. 34.
35.
36.
37.
38.
39.
R E G U L A T I O N OF M A S T CELL AND B A S O P H I L D E V E L O P M E N T
15
the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213-224, 1990. Zsebo, K. M., Wypych, J., McNiece, I. K., et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 63:195-210, 1990. Besmer, E The kit ligand encoded at the murine Steel locus: a pleiotropic growth and differentiation factor. Curr. Opin. Cell Biol. 3:939-946, 1991. Galli, S. J., Zsebo, K. M. and Geissler, E. N. The kit ligand, stem cell factor. Adv. Immunol. 55:1-96, 1994. Broudy, V. C. Stem cell factor and hematopoiesis. Blood 90:1345-1364, 1997. Ullrich, A. and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990. Maeda, H., Yamagata, A., Nishikawa, S., et al. Requirement of c-kit for development of intestinal pacemaker system. Development 116:369-375, 1992. Ward, S., Burns, A., Torihashi, S. and Sanders, K. Mutation in the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythm in murine intestine. J. Physiol. 480:91-97, 1994. Huizinga, J. D., Thuneberg, L., Kluppel, M., Malysz, J., Mikkelsen, H. B. and Bernstein, A. W/Kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373:347-349, 1995. Yuan, Q., Austen, K. E, Friend, D. S., Heidtman, M. and Boyce, J. A. Human peripheral blood eosinophils express a functional c-kit receptor for stem cell factor that stimulates very late antigen 4 (VLA-4) mediated cell adhesion to fibronectin and vascular cell adhesion molecule 1 (VCAM-1). J. Exp. Med. 186:313-323, 1997. Lukacs, N. W., Strieter, R. M., Lincoln, E M., Brownell, E., Pullen, D. M., Schock, H. J., Chensue, S. W., Taub, D. D. and Kunkel, S. L. Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation. J. Immunol. 156:3945-3951, 1996. Tsuji, K., Zsebo, K. M. and Ogawa, M. Murine mast cell colony formation supported by IL-3, IL-4, and recombinant rat stem cell factor, ligand for c-kit. J. Cell. Physiol. 148:362-369, 1991. Gurish, M. E, Ghildyal, N., McNeil, H. E, Austen, K. E, Gillis, S. and Stevens, R. L. Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J. Exp. Med. 175:1003-1012, 1992. Haig, D. M., Huntley, J. E, Mackellar, A., et al. Effects of stem cell factor (kit-ligand) and interleukin-3 on the growth and serine proteinase expression of rat bone marrow-derived or serosal mast cells. Blood 83:72-83, 1994. Galli, S. J. Signals in the regulation of mast cell growth and development: a perspective. In: Signal Transduction in Mast Cells and Basophils (Razin, E., Pecht, I. and Rivera, J. eds), in press. Landes, Georgetown, 1998. Li, L., Zhang, X-T. and Krilis, S. A. Factors that affect human mast cell and basophil growth. In: Signal Transduction in Mast Cells and Basophils (Razin E., Pecht I. and Rivera, J. eds), in press. Landes, Georgetown, 1998. Irani, A-M. A., Nilsson, G., Miettinen, U., et al. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009-3021, 1992. Kirshenbaum, A. S., Goff, J. E, Kessler, S. W., Mican, J. M., Zsebo, K. M. and Metcalfe, D. D. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J. Immunol. 148:772-777, 1992. Valent, E, Spanblochl, E., Sperr, W. R., et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit ligand in long-term culture. Blood 80:2237-2245, 1992. Mitsui, H., Furitsu, T., Dvorak, A. M., et al. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl. Acad. Sci. USA 90:735-739, 1993. Costa, J. J., Demetri, G. D., Hayes, D. E, Merica, E. A., Menchaca, D. M. and Galli, S. J. Increased skin mast cells and urine methyl histamine in patients receiving recombinant methionyl human stem cell factor. Proc. Am. Assoc. Cancer Res. 34:211, 1993 (abstract). Costa, J. J., Demetri, G. D., Harris, T. J., et al. Recombinant human stem cell factor (rhSCF) induces cutaneous mast cell activation and hyperplasia, and hyperpigmentation in humans in vivo. J. Allergy Clin. Immunol. 93:225, 1994 (abstract). Galli, S. J., Iemura, A., Garlick, D. S., Gamba-Vitalo, C., Zsebo, K. M. and Andrews, R. G. Reversible expansion of primate mast cell populations in vivo by stem cell factor. J. Clin. Invest. 91:148-152, 1993.
16 40.
41. 42. 43.
44. 45.
46.
47.
48.
49. 50.
51.
52.
53.
54.
55. 56.
57. 58. 59.
60.
M I N D Y TSAI et al. Tsai, M., Shih, L., Newlands, G. E J., et al. The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype. J. Exp. Med. 174:125-131, 1991. Mekori, Y. A., Oh, C. K. and Metcalfe, D. D. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3: prevention of apoptosis by c-kit ligand. J. Immunol. 151:3775-3784, 1993. Iemura, A., Tsai, M., Ando, A., Wershil, B. K. and Galli, S. J. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am. LL Pathol. 144:321-328, 1994. Yee, N. S., Paek, I. and Besmer, E Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of White Spotting and Steel mutant mice. J. Exp. Med. 179:1777-1787, 1994. Gommerman, J. L. and Berger, S. A. Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. Blood 91:1891-1900, 1998. Furitsu, T., Tsujimura, T., Tono, T., et al. Identification of mutations in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736-1744, 1993. Nagata, H., Worobec, A. S., Oh, C. K, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10560-10564, 1995. Longley Jr., B. J., Tyrrell, L., Lu, S. Z., et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:312-314, 1996. London, C. A., Galli, S. J., Yuuki, T., Hu, Z-Q., Helfand, S. C. and Geissler, E. N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. 27:689-697, 1999. Longley Jr., B. J., Morganroth, G. S., Tyrrell, L., et al. Altered metabolism of mast-cell growth factor (ckit ligand) in cutaneous mastocytosis. N. Engl. J. Med. 328:1302-1307, 1993. Otsuka, H., Kusumi, T., Kanai, S., Koyama, M., Kuno, Y. and Takizawa, R. Stem cell factor mRNA expression and production in human nasal epithelial cells: contribution to the accumulation of mast cells in the nasal epithelium of allergy. J. Allergy Clin. Immunol. 102:757-764, 1998. Lorenz, U., Bergemann, A. D., Steinberg, H. N., et al. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J. Exp. Med. 184:1111-1126, 1996. Paulson, R. E, Vesely, S., Siminovitch, K. A. and Bernstein, A. Signaling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase SHP1. Nat. Genet. 13:309-315, 1996. Finotto, S., Mekori, Y. A. and Metcalfe, D. D. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J. Clin. Invest. 99:1721-1728, 1997. Mekori, Y. A., Hartmann, K. and Metcalfe, D. D. Mast cell apoptosis and its regulation. In: Signal Transduction in Mast Cells and Basophils (Razin, E., Pecht, I. and Rivera, J., eds), in press. Landes, Georgetown, 1998. Lavker, R. M. and Schechter, N. M. Cutaneous mast cell depletion results from topical corticosteroid usage. J. Immunol. 135:2368-2373, 1985. Wershil, B. K., Tsai, M., Geissler, E. N., Zsebo, K. M. and Galli, S. J. The rat c-kit ligand, stem cell factor, induces c-kit receptor-dependent mouse mast cell activation in vivo. Evidence that signaling through the c-kit receptor can induce expression of cellular function. J. Exp. Med. 175:245-255, 1992. Nocka, K., Tan, J. C., Chiu, E., et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W 37, W v, W 41, and W. EMBO J. 9:1805-1813, 1990. Nakajima, K., Hirai, K., Yamaguchi, M., et al. Stem cell factor has histamine releasing activity in rat connective tissue-type mast cells. Biochem. Biophys. Res. Commun. 183:1076-1083, 1992. Coleman, J. W., Holliday, M. R., Kimber, I., Zsebo, K. M. and Galli, S. J. Regulation of mouse peritoneal mast cell secretory function by stem cell factor, IL-3 or IL-4. J. Immunol. 150:556-562, 1993. Columbo, M., Horowitz, E. M., Botana, L. M., et al. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J. Immunol. 149:599-608, 1992.
1. 61.
62. 63.
64.
65.
66.
67. 68.
69.
70. 71.
72.
73. 74. 75.
76. 77.
78.
79.
80.
R E G U L A T I O N OF M A S T CELL AND B A S O P H I L D E V E L O P M E N T
17
B ischoff, S. C., Schwengberg, S., Raab, R. and Manns, M. R Functional properties of human intestinal mast cells cultured in a new culture system: enhancement of IgE receptor-dependent mediator release and response to stem cell factor. J. Immunol. 159:5560-5567, 1997. Bischoff, S. C. and Dahinden, C. A. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J. Exp. Med. 175:237-244, 1992. Wershil, B. K., Lavigne, J. A. and Galli, S. J. Stem cell factor (SCF) can influence neuroimmune interactions: bone marrow-derived mast cells (BMCMC) maintained in SCF acquire the ability to release histamine and tumor necrosis factor-alpha (TNF-tx) in response to substance P (SP). FASEB J. 8:A742, 1994 (abstract). Schmidt-Choudhury, A., Meissner, J., Seebeck, J., et al. Stem cell factor influences neuro-immune interactions: The response of mast cells to pituitary adenylate cyclase activiting polypeptide is altered by stem cell factor. Regul. Pept. 83:73-80, 1999. Tsai, M., Chen, R-H., Tam, S-Y., Blenis, J. and Galli, S. J. Activation of MAP kinases, pp90rsk and pp70 $6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc~RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. Eur. J. Immunol. 23:3286-3291, 1993. Murakami, M., Matsumoto, R., Urade, Y., Austen, K. E and Arm, J. E c-Kit ligand mediates increased expression of cytosolic phospholipase A 2, prostaglandin endoperoxide synthase-1, and hematopoietic prostaglandin D2 synthase and increased IgE-dependent prostaglandin D 2 generation in immature mouse mast cells. J. Biol. Chem. 270:3239-3246, 1995. Gagari, E., Tsai, M., Lantz, C. S., Fox, L. G. and Galli, S. J. Differential release of mast cell interleukin-6 via c-kit. Blood 89:2654-2663, 1997. Huber, M., Helgason, C. D., Scheid, M. E, Duronio, V., Humphries, R. K. and Krystal, G. Targeted disruption of SHIP leads to Steel factor-induced degranulation of mast cells. EMBO J. 17:7311-7319, 1998. Dvorak, A. M., Costa, J. J., Morgan, E. S., Monahan-Earley, R. A. and Galli, S. J. Diamine oxidase-gold ultrastructural localization of histamine in human skin biopsies containing mast cells stimulated to degranulate in vivo by exposure to recombinant human stem cell factor. Blood 90:2893-2900, 1997. Longley, B. J., Tyrrell, L., Ma, Y., et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc. Natl. Acad. Sci. USA 94:9017-9021, 1997. dePaulis, A., Minopoli, G., Dal Piaz, F., Pucci, P., Russo, T. and Marone, G. Novel autocrine and paracrine loops of the stem cell factor/chymase network. Int. Arch. Allergy Immunol. 118:422-425, 1999. Costa, J. J. and Galli, S. J. Mast cells and basophils. In: Clinical Immunology: Principles and Practice (Rich, R., Fleisher, T. A., Schwartz, B. D., Shearer, W. T. and Strober, W., eds), pp. 408-430. Mosby Year Book, St. Louis, 1996. Nocka, K. H., Levine, B. A., Ko, J-L., et al. Increased growth promoting but not mast cell degranulation potential of a covalent dimer of c-kit ligand. Blood 90:3874-3883, 1997. Galli, S. J., Maurer, M. and Lantz, C. S. Mast cells as sentinels of innate immunity. Curr. Opin. Immunol. 11:53-59, 1999. Maurer, M., Echtenacher, B., Htiltner, L., Kollias, G., M~innel, D. N., Langley, K. E. and Galli, S. J. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J. Exp. Med. 188:2343-2348, 1998. Ihle, J. N. and Weinstein, Y. Immunological regulation of hematopoietic/lymphoid stem cell differentiation by interleukin 3. Adv. Immunol. 39:1-50, 1986. Rennick, D. M., Lee, E D., Yokota, T., Arai, K. I., Cantor, H. and Nabel, G. J. A cloned MCGF cDNA encodes a multilineage hematopoietic growth factor: multiple activities of interleukin 3. J. Immunol. 134:910-914, 1985. Suda, T., Suda, J., Spicer, S. S. and Ogawa, M. Proliferation and differentiation in culture of mast cell progenitors derived from mast cell-deficient mice of genotype W/W ~. J. Cell. Physiol. 122:187-192, 1985. Caux, C., Vanbervliet, B., Massacrier, C., Durand, I. and Banchereau, J. Interleukin-3 cooperates with tumor necrosis factor-alpha for the development of human dendritic Langerhans cells from cord blood CD34(+) hematopoietic progenitor cells. Blood 87:2376-2385, 1996. Ihle, J. N., Keller, J., Orsozlan, S., et al. Biological properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, P cell stimulating factor activity and histamine producing factor activity. J. Immunol. 131:282-287, 1983.
18 81. 82. 83.
84.
85. 86. 87. 88.
89.
90. 91.
92. 93.
94. 95.
96.
97.
98. 99.
100.
101. 102.
103.
M I N D Y TSAI et al. Nabel, G. J., Galli, S. J., Dvorak, A. M., Dvorak, H. E and Cantor, H. Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature 291:332-334, 1981. Nagao, K., Yokoro, K. and Aaronson, S. A. Continuous lines of basophil/mast cells derived from normal mouse bone marrow. Science 212:333-335, 1981. Razin, E., Cordon-Cardo, C. and Good, R. A. Growth of a pure population of mast cells in vitro with conditioned medium derived from concanavalin A-stimulated splenocytes. Proc. Natl. Acad. Sci. USA 78:2559-2561, 1981. Schrader, J. W., Lewis, S. J., Clark-Lewis, I. and Culvenor, J. G. The persisting (P) cell: histamine content, regulation by a T cell-derived factor, origin from a bone marrow precursor, and relationship to mast cells. Proc. Natl. Acad. Sci. USA 78:323-327, 1981. Tertian, G., Yung, Y. P., Guy-Grand, D. and Moore, M. A. Long-term in vitro culture of murine mast cells. I. Description of a growth factor-dependent culture technique. J. Immunol. 127:788-794, 1981. Ihle, J. N. Interleukin-3 and hematopoiesis. Chem. Immunol. 51:65-106, 1992. Saito, H., Hatake, K., Dvorak, A. M, et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc. Natl. Acad. Sci. USA 85:2288-2292, 1988. Kirshenbaum, A. S., Goff, J. P., Dreskin, S. C., Irani, A. M., Schwartz, L. B. and Metcalfe, D. D. IL-3dependent growth of basophil-like cells and mast-like cells from human bone marrow. J. lmmunol. 142:2424-2429, 1989. Mayer, P., Valent, P., Schmidt, G., Liehl, E. and Bettelheim, P. The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. Blood 74:613-621, 1989. Kindler, V., Thorens, B., de Kossodo, S., et al. Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3. Proc. Natl. Acad. Sci. USA 83:1001-1005, 1986. Metcalfe, D., Begley, C. G., Johnson, N. A., Nicola, N. A., Lopez, A. E and Williamson, D. J. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 68:46-57, 1986. Donahue, R. E., Seehra, J., Metzger, M., et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241:1820-1823, 1988. Volc-Platzer, B., Valent, P., Radaszkiewicz, T., Mayer, E, Bettelheim, E and Wolff, K. Recombinant human interleukin 3 induces proliferation of inflammatory cells and keratinocytes in vivo. Lab. Invest. 64:557-566, 1991. Abe, T. and Nawa, Y. Worm expulsion and mucosal mast cell response induced by repetitive IL-3 administration in Strongyloides ratti-infected nude mice. Immunology 63:181-185, 1988. Madden, K. B., Urban, J. E, Ziltener, H. J., Schrader, J. W., Finkelman, E D. and Katona, I. M. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J. Immunol. 147:1387-1391, 1991. Finkelman, E D., Madden, K. B., Morris, S. C., et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J. Immunol. 151:1235-1244, 1993. Cannistra, S. A., Vellenga, E., Groshek, P., Rambaldi, A. and Griffin, J. D. Human granulocyte-macrophage colony-stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood 71:672-676, 1988. Hirai, K., Morita, Y., Misaki, Y., et al. Modulation of human basophil histamine release by hemopoietic growth factors. J. Immunol. 141:3958-3964, 1988. Kimoto, M., Kindler, V., Higaki, M., Ody, C., Izui, S. and Vassalli, E Recombinant murine IL-3 fails to stimulate T or B lymphopoiesis in vivo, but enhances immune responses to T cell-dependent antigens. J. Immunol. 140:1889-1894, 1988. Rothenberg, M., Owen, W., Silberstein, D., et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin-3. J. Clin. Invest. 81:1986-1992, 1988. Schleimer, R. E, Derse, C. E, Friedman, B., et al. Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. J. Immunol. 143:1310-1317, 1989. Brunner, T., Heusser, C. H. and Dahinden, C. A. Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation. J. Exp. Med. 177:605-611, 1993. MacGlashan Jr., D. W. and Schroeder, J. T. Basophils as the target and source of cytokines. In: Biological and Molecular Aspects of Mast Cell and Basophil Differentiation and Function (Kitamura,
l.
R E G U L A T I O N OF M A S T C E L L AND B A S O P H I L D E V E L O P M E N T
_]9
Y., Yamamoto, S., Galli, S. J. and Greaves, M. W., eds), pp. 51-63. Raven Press, New York, 1995. 104. Pulaski, B. A., Yeh, K. Y., Shastri, N., et al. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex representation of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc. Natl. Acad. Sci. USA 93:3669-3674, 1996. 105. Li, C. L. and Johnson, G. R. Stimulation of multipotential, erythroid and other murine haematopoietic progenitor cells by adherent cell lines in the absence of detectable multi-CSF (IL-3). Nature 316:633-636, 1985. 106. Ichihara, M., Hara, T., Takagi, M., Cho, L. C., Gorman, D. M. and Miyajima, A. Impaired interleukin-3 (IL-3) response of the A/J mouse is caused by a branch point deletion in the IL-3 receptor a subunit gene. EMBO J. 14:939-950, 1995. 107. Burd, E R., Rogers, H. W., Gordon, J. R., et al. Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J. Exp. Med. 170:245-257, 1989. 108. Plaut, M., Pierce, J. H., Watson, C. J., Hanley-Hyde, J., Nordan, R. E and Paul, W. E. Mast cell lines produce lymphokines in response to cross-linkage of FceRI or to calcium ionophores. Nature 339:64-67, 1989. 109. Wodnar-Filipowicz, A., Heusser, C. H. and Moroni, C. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 339:150-152, 1989. 110. Svetic, A., Madden, K. B., Zhou, X., et al. A primary intestinal helminthic infection rapidly induces a gut-associated elevation of Th2-associated cytokines and IL-3. J. Immunol. 150:3434-3441, 1993. 111. Mach, N., Lantz, C. S., Galli, S. J., et al. Involvement of interleukin-3 in delayed-type hypersensitivity. Blood 91:778-783, 1998. 112. Nishinakamura, R., Miyajima, A., Mee, E J., Tybulewicz, V. L. J. and Murray, R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood 88:2458-2464, 1996. 113. Lantz, C. S. and Huff, T. E Differential responsiveness of purified mouse c-kit+ mast cells and their progenitors to IL-3 and stem cell factor. J. Immunol. 155:4024-4029, 1995. 114. Rennick, D., Hunte, B., Holland, G. and Thompson-Snipes, L. Cofactors are essential for stem cell factor dependent growth and maturation of mast cell progenitors: Comparative effects of interleukin-3 (IL-3), IL-4, IL-10, and fibroblasts. Blood 85:57-65, 1995. 115. Rodewald, H-R., Dessing, M., Dvorak, A. M. and Galli, S. J. Identification of a committed precursor for the mast cell lineage. Science 271:818-822, 1996. 116. Lantz, C. S., Boesiger, J., Song, C. H., et al. Role for interleukin-3 in mast cell and basophil development and parasite immunity. Nature 392:90-93, 1998. 117. Huff, T. E, Lantz, C. S., Ryan, J. J. and Leftwich, J. A. Mast cell-committed progenitors. In: Biological and Molecular Aspects of Mast Cell Differentiation and Function (Kitamura, Y., Yamamoto, S., Galli, S. J., Greaves, M. W., eds), pp. 105-117. Raven Press, New York, 1995. 118. Kasugai, T., Tei, H., Okada, M., et al. Infection with Nippostrongylus brasiliensis induces invasion of mast cell precursors from peripheral blood to small intestine. Blood 85:1334-1340, 1995. 119. Sonoda, T., Hayashi, C. and Kitamura, Y. Presence of mast cell precursors in the yolk sac of mice. Dev. Biol. 97:89-94, 1983. 120. Kitamura, Y., Hatanaka, K., Murakami, M. and Shibata, H. Presence of mast cell precursors in peripheral blood of mice demonstrated by parabiosis. Blood 53:1085-1088, 1979. 121. Zucker-Franklin, D., Grusky, G., Hirayama, N. and Schnipper, E. The presence of mast cell precursors in rat peripheral blood. Blood 58:544-551, 1981. 122. Sonoda, T., Ohno, T. and Kitamura, Y. Concentration of mast-cell progenitors in bone marrow, spleen, and blood of mice determined by limiting dilution analysis. J. Cell. Physiol. 112:136-140, 1982. 123. Rottem, M., Okada, T., Goff, J.E and Metcalfe, D. D. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from CD34+/FceRI-cell populations. Blood 84:2489-2496, 1994. 124. Agis, H., Willheim, M., Sperr, W. R., et al. Monocytes do not make mast cells when cultured in the presence of SCE Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J. Immunol. 151:4221-4227, 1995. 125. Metcalfe, D. D. Classification and diagnosis of mastocytosis: current status. J. Invest. Dermatol. 96:2S-4S, 1991. 126. Seder, R. A., Paul, W. E., Dvorak, A. M., et al. Mouse splenic and bone marrow cell populations that express high-affinity Fc epsilon receptors and produce interleukin 4 are highly enriched in basophils. Proc. Natl. Acad. Sci. USA 88:2835-2839, 1991.
20
M I N D Y TSAI et al.
127. Dvorak, A. M., Seder, R. A., Paul, W. E., Kissell-Rainville, S., Plaut, M. and Galli, S. J. Ultrastructural characteristics of FcaRI positive basophils in the spleen and bone marrow of mice immunized with goat anti-mouse IgD antibody. Lab. Invest. 68:708-715, 1993. 128. Yung, Y.-E and Moore, M. A. S. Long-term in vitro culture of murine mast cells. III. Discrimination of mast cell growth-factor and granulocyte CSE J. lmmunol. 129:1256-1261, 1982. 129. Nakano, T., Sonoda, T., Hayashi, C., et al. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/W ~mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J. Exp. Med. 162:1025-1043, 1985. 130. Suda, T., Suda, J., Ogawa, M. and Ihle, J. N. Permissive role of interleukin 3 (IL-3) in proliferation and differentiation of multipotential hemopoietic progenitors in culture. J. Cell. Physiol. 124:182-190, 1985. 131. Mosmann, T. R., Bond, M. W., Coffman, R. L., Ohara, J. and Paul, W. E. T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA 83:5654-5658, 1986. 132. Smith, C. A. and Rennick, D. M. Characterization of a murine lymphokine distinct from interleukin 2 and interleukin 3 (IL-3) possessing a T-cell growth factor activity and a mast-cell growth factor activity that synergizes with IL-3. Proc. Natl. Acad. Sci. USA 83:1857-1861, 1986. 133. Hu, Z-Q., Kobayashi, K., Zenda, N. and Shimamura, T. Tumor necrosis factor-s- and interleukin-6triggered mast cell development from mouse spleen cells. Blood 89:526-533, 1997. 134. Htiltner, L., Druez, C., Moeller, J., et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur. J. Immunol. 20:1413-1416, 1990. 135. Khalil, R. M., Luz, A., Mailhammer, R., et al. Schistosoma mansoni infection in mice augments the capacity for interleukin 3 (IL-3) and IL-9 production and concurrently enlarges progenitor pools for mast cells and granulocytes-macrophages. Infect. Immun. 64:4960-4966, 1996. 136. Thompson-Snipes, L., Dhar, V., Bond, M. W., Mosmann, T. R., Moore, K. W. and Rennick, D. Interleukin-10: a novel stimulatory factor for mast cells and their progenitors. J. Exp. Med. 173:507-510, 1991. 137. Aloe, L. and Levi-Montalcini, R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res. 133:358-366, 1977. 138. Aloe, L. The effect of nerve growth factor and its antibody on mast cells in vivo. J. Neuroimmunol. 18:1-12, 1988. 139. Matsuda, H., Kannan, Y., Ushio, H., et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J. Exp. Med. 174:7-14, 1991.
CHAPTER 2 Gain-of-function Mutations of c-kit in Human Diseases YUKIHIKO KITAMURA, .1 SEIICHI HIROTA, 1 EIICHI MORII, 1 and TOSHIROU NISHIDA 2 1Department of Pathology and 2Department of Surgery, Osaka University Medical School, Suita, Osaka, Japan
INTRODUCTION The c-kit is the cellular homologue of the oncogene v-kit of the HZ4 feline sarcoma virus and encodes a receptor tyrosine kinase that is structurally similar to the receptors of macrophage colony-stimulating factor (M-CSF), platelet-derived growth factor (PDGF) and vascular endothelial cell growth factor (VEGF) (1-4). These receptor tyrosine kinases have unique features: an extracellular domain made up of five immunoglobulinlike repeats, and a tyrosine kinase domain which is split into two domains by an insert sequence of variable length (2, 3). The structure and amino acid sequence of the c-kit protein are well preserved in humans, mice and rats (2, 3, 5). For many years after the discovery of v-kit it was not clear whether kit functions as a cause of human neoplasms. Recently, we demonstrated that gain-of-function mutations of c-kit result in the development of neoplasms of particular cell types, i.e. mast cells and interstitial cells of Cajal (ICCs).
LOSS-OF-FUNCTION MUTATION OF c-kit The W locus of mice was demonstrated to encode the c-kit gene (6, 7). Many loss-offunction mutants have been reported at the W locus. Mice of W / W genotype are most frequently used. The W mutant allele encodes a truncated c-kit protein without the transmembrane domain, and the W mutant allele is a point mutation at the tyrosine kinase domain, resulting in a marked decrease in the kinase activity (8). Double heterozygous W/W v mice show five abnormalities due to the loss-of-function mutations of c-kit: (i) anaemia due to hypoproduction of erythrocytes (9), (ii) white coat colour due to depletion * Corresponding author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
21
Copyright 9 2000Academic Press All rights of reproduction in anyform reserved
22
YUKIHIKO KITAMURA et al.
of melanocytes (9), (iii) sterility due to lack of germ cells (9), (iv) depletion of mast cells (10), (v) depletion of ICCs (11, 12). The ligand for the c-kit receptor tyrosine kinase (KIT) was identified and named stem cell factor (SCF) (13-15). Since SCF is encoded by the S1 locus of mice, it is reasonable that homozygous or double-heterozygous mutant mice at either the W or Sl locus have the same phenotype. The most frequently used mutant mice of the Sl (SCF) locus are of Sl/Sf genotype. S1/Sf mice show anaemia, white coat colour, sterility and depletion of mast cells and ICCs (9, 16, 17). Both W / W and S1/S1d mice are deficient in mast cells, but the mechanism is different due to the character of proteins, which are encoded by the W locus and the S1 locus, respectively. Mast cell depletion of W / W mice is cured by bone marrow transplantation from normal control (+/+) or S1/Sf mice, but that of Sl/Sf mice is not (10, 16). When skin pieces were grafted from W / W to S1/Sf mice, mast cells developed in the graft. However, mast cells did not develop in the skin pieces grafted from Sl/Sf to +/+ mice (16). On the other hand, the mast cell depletion of S1/Sl d mice is cured by injection of SCF (15). Precursors of mast cells have a defect in W/W' mice, whereas stromal cells supporting the differentiation of mast cells have a defect in Sl/Sf mice. In addition to W and W mutant alleles, many other loss-of-function mutations have been reported in the mouse c-kit locus (9, 18). In particular, many mutations at the tyrosine kinase domain have been reported. When such a mutant c-kit protein is expressed on the surface, a dominant negative phenotype is observed. This is attributed to the fact that the heterodimers composed of normal and mutant c-kit proteins have deficient tyrosine kinase activity (8, 19-21). For example, 14#2/+ mice have an almost white coat, and the number of mast cells in the skin of W42/+ mice is decreased to half that of +/+ mice. In contrast, the coat colour of W/+ mice is not diluted, and the number of mast cells in the skin of W/+ mice is not decreased. Since the c-kit protein encoded by the W mutant allele is not expressed on the surface due to the lack of the transmembrane domain, only normal-type c-kit receptors are expressed on the surface of mast cells in W/+ mice. Although the phenotypes of heterozygous W42/+ and W/+ mice are apparently different, the phenotypes of homozygous W42/W42 and W/W mice are comparable. Both W42/W42 and W/W mice completely lack melanocytes and mast cells (21). We reported first a loss-of-function mutation at the c-kit locus of the rat. Homozygous mutant rats at the newly found 'White spotting (Ws)' locus are anaemic and deficient in mast cells, melanocytes and ICCs (22, 23). Mast cells developed in the skin graft from the Ws/Ws to nude athymic rat. Since this result suggested that the Ws locus of the rat was comparable to the W locus rather than to the Sl locus of the mouse, Tsujimura et al. (5) characterized the c-kit gene of Ws/Ws rats. A deletion of 12 bases was found in the c-kit cDNA of Ws/Ws rats. Four amino acids encoded by the 12 deleted bases were located at two amino acids downstream from the tyrosine autophosphorylation site in KIT. A loss-of-function mutant of the c-kit cDNA has also been found in humans. Piebaldism is known as an autosomal dominant genetic disorder characterized by congenital white patches of skin and hair from which melanocytes are depleted. Since the phenotype of human piebaldism is comparable to that of the heterozygous W/+ mouse, Giebel and Spritz (24) compared the c-kit cDNA between piebaldism and normal individuals of the same family and found a point mutation in the individuals with piebaldism. These individuals are heterozygous and do not show any other symptoms.
2.
GAIN-OF-FUNCTION MUTATIONS OF c-kit IN HUMAN DISEASES
23
STOMACH LESIONS OF W / W v AND S1/S1 d MICE In addition to the discovery of mast cell deficiency in W / W v and SUSl d mice, we found spontaneous development of forestomach papillomas and antral ulcers in W / W and S1/S1d mice (25, 26). The stomach lesions were attributed to spontaneous bile reflux in both W / W v and S1/Sl d mice (25, 26). The bile reflux was also observed in W s / W s c-kit mutant rats (23). At the time of the discovery, we could not understand the mechanism of the bile reflux. However, since the depletion of ICCs was identified as the fifth abnormality of W / W v and Sl/Sl d mice (11, 12, 17) and since ICCs regulate the rhythmical contraction of the gastrointestinal tract (11, 12, 27), the bile reflux was attributed to the depletion of ICCs.
GAIN-OF-FUNCTION MUTATION OF c - k R IN MAST CELL NEOPLASMS Binding of SCF activates KIT and leads to autophosphorylation of KIT on tyrosine and to association of KIT with substrates such as phosphatidylinositol 3-kinase (PI3K) (28). In the human mast cell leukaemia cell line HMC-1, KIT was constitutively phosphorylated on tyrosine, activated, and associated with PI3K without the addition of SCF (29). The ckit gene of HMC-1 cells was found to be composed of normal, wild-type allele and mutant allele with point mutations resulting in amino acid substitutions of Gly-560 for Val and Val-816 for Asp (Fig. 1). Amino acid sequences in the regions of the two mutations are completely conserved in all of mouse, rat and human KIT. In order to determine the causal role of these mutations in the constitutive activation, mutant c-kit genes with Gly-560 or Val-816 were constructed and expressed in a human embryonic kidney cell line, 293T cells. In the transfected cells, KIT with either mutation was abundantly phosphorylated on tyrosine and activated in immune complex kinase reaction in the absence of SCF, whereas tyrosine phosphorylation and activation of transfected wild-type KIT was not detectable (29). Tsujimura et al. (30, 31) found the mutation corresponding to Val-816 of human HMC-1 cell line in the P-815 mouse mastocytoma cell line (Asp-817 to Tyr) and the RBL-2H3 rat mast cell leukaemia cell line (Asp-814 to Tyr). Both P-815 and RBL-2H3 cells show constitutive activation of KIT without the addition of SCF. There is a possibility that this mutation has induced mast cell neoplasms in the above-mentioned three species. In fact, the Asp-816 to Val mutation has been found in various types of mast cell neoplasms of human patients (32, 33). To examine the transformation potential of the c-kit activation mutation, we used the murine interleukin-3 (IL-3)-dependent IC-2 mast cell line as a transfectant. The IC-2 cells did not express KIT on the surface. The Val-814 or Gly-559 murine mutant c-kit gene was introduced into IC-2 cells using a retroviral vector. The mutant KIT proteins expressed in IC-2 cells were constitutively phosphorylated on tyrosine and demonstrated kinase activity in the absence of SCF (34). IC-2 cells expressing either Val-814 or G-559 mutation showed factor-independent growth in suspension culture and produced tumours in nude athymic mice (34). Introduction of the murine c-kit gene with Val-814 or Gly-559 mutation also resulted in the malignant transformation of the IL-3-dependent Ba/F3 murine pro-B cell line (35). Val-814 is a point mutation at the tyrosine kinase domain of the c-kit gene whereas
24
Y U K I H I K O K I T A M U R A et al.
Wild-type
QKPMYEVQWKVVEEING
NNYVYIDPTQLPYDHK
Sporadic G I S T s Case 1
QKPMYEVQWK-
Case2
QK .....
QWK V V EEI NG N NY V Y I D P T Q L P Y D H K
Case3
Q[]'] . . . . .
QWK v v EEI NG N NY V YID PTQ LPYDHK
Case4
Q K P M Y E V Q W K [ ~ ] V E E I NG N NY V Y I D P T Q L P Y D H K
Case5
Q
- EEINGNNYVYIDPTQLPYDHK
v VEEINGN
NY V Y I D P T Q L P Y D H K
Familial G I S T s Q K P M Y E V Q W K V - E E I N G N NY V Y I D P TQ L P Y D H K
HMC-1
Q K PMYEVQWKV[-G-]EEI NG N NY V Y I n P T Q L P Y D H K 548
y
FMA3
560
y
570
y
Q K P M Y E V Q W K V V EEI NG N NY V Y I D P
y K
Fig. 1 Various gain-of-function mutations of c-kit in human mast cell neoplasms and GISTs. Deleted amino acids are shown by dashes (-) and mutated amino acids by boxes. Murine and human KIT are of different lengths, so the amino acid numbering in KIT of the FMA3 cell line is different. SP, signal peptide; EC, extracellular domain; TM, transmembrane domain; JM, juxtamembrane domain; TK1 and TK2, tyrosine kinase domains; KI, kinase insert.
Gly-559 is a point mutation between transmembrane and tyrosine kinase domains (hereafter called juxtamembrane domain) (Fig. 1). Chemical cross-linking analysis showed that a substantial fraction of the phosphorylated KIT with the Gly-559 mutation underwent dimerization even in the absence of SCF, whereas the phosphorylated c-kit with the Val-814 mutation did not, suggesting that distinct mechanisms resulted in the constitutive activation of c-kit by the Gly-559 and Val-814 mutations (35). Tsujimura et al. (36) found another gain-of-function mutation at the juxtamembrane domain of FMA3 murine mastocytoma cells. The c-kit cDNA of FMA3 cells carried an in-frame deletion of 21 base pairs (bp) (Fig. 1). The FMA3-type c-kit cDNA with the 21-bp deletion was introduced into the IC-2 cell line. The FMA3-type KIT was constitutively phosphorylated on tyrosine and activated (36). Moreover, the FMA3-type KIT was dimerized without stimulation by SCE The FMA3-type KIT that spontaneously dimerized without SCF binding was not internalized even though it was activated, as is also the case with the Gly-559 KIT. IC-2 cells expressing the FMA3-type KIT grew in suspension culture without IL-3 and SCF and became leukaemic in nude athymic mice.
2.
GAIN-OF-FUNCTION MUTATIONS OF c-kit IN HUMAN DISEASES
25
Although the Gly-559 mutation and the FMA3-type mutation were different in nature, a point mutation and a 21-bp deletion, respectively, their biological effects appeared comparable. Probably, the normal juxtamembrane domain may inhibit the dimerization of KIT, and mutations at the juxtamembrane domain may induce SCF-independent constitutive dimerization of KIT. In the HMC-1 human mast cell leukaemia cell line, the c-kit mutations were observed in both the tyrosine kinase and juxtamembrane domains. However, only the particular point mutation (Asp-816 to Val) of the tyrosine kinase domain was detectable in mast cell tumours directly obtained from human patients (32, 33). Although mast cell tumours are rare in humans, they are the most common malignant neoplasms in dogs, representing 7-21% of all tumours. London et al. (37) recently found mutations of the c-kit gene in canine mast cell tumours. In contrast to mast cell tumours of humans, the mutations in canine mast cell tumours were located at the juxtamembrane domain. London et al. (37) showed that the mutation was a gain-of-function mutation in at least one of the canine mast cell tumours. The mutation site in the c-kit gene of mast cell tumours may be influenced by the host species.
SPORADIC GASTROINTESTINAL STROMAL TUMOURS Since ICCs express KIT, we examined whether any human mesenchymal tumours in gastrointestinal tract expressed KIT. Authentic leiomyomas and authentic schwannomas did not express KIT, but 94% of gastrointestinal stromal tumours (GIST) expressed KIT (38). Moreover, both GIST cells and ICCs expressed CD34 (38). Although various cells, including haematopoietic stem cells, express both KIT and CD34, ICCs are the only cells that are double-positive for KIT and CD34 in normal gastrointestinal wall of humans (38). This strongly suggests that KIT and CD34 double-positive GISTs may originate from ICCs. The complete coding region of c-kit was obtained from five GISTs and sequenced. Mutations were observed in the juxtamembrane domain (Fig. 1). These mutations were located within an l 1-amino-acid stretch (Lys-550 to Val-560), but at non-identical sites (38). No mutations were detectable in other domains of c-kit cDNA, including the tyrosine kinase domain. We next examined whether the c-kit mutations found in the GISTs resulted in constitutive activation of the c-kit receptor tyrosine kinase by transient introduction of the mutant c-kit cDNAs into 293T human embryonic kidney cell line. The wild-type c-kit cDNA was introduced as a negative control, and c-kit mutants found in the HMC-1 mast cell leukaemia cell line were introduced as a positive control. Wild-type KIT was phosphorylated on tyrosine only when SCF was added to the culture medium. In contrast, the gain-of-function KIT mutations found in HMC-1 cells were phosphorylated on tyrosine without the addition of SCE The magnitude of the constitutive tyrosine phosphorylation was greater in the tyrosine kinase domain mutant than in the juxtamembrane domain mutant. The c-kit mutants found in GISTs also showed the constitutive tyrosine phosphorylation in 293T cells without SCE The constitutive tyrosine phosphorylation of the juxtamembrane mutant of HMC-1 cells was of similar magnitude to that of the juxtamembrane mutants of GISTs (38). In in vitro kinase assay, the c-kit mutants found in the GISTs exhibited constitutive kinase activation that was similar in magnitude to that of the juxtamembrane domain mutant of HMC- 1 cells. To investigate the biological consequences of the mutant c-kit, we introduced the c-kit
26
Y U K I H I K O K I T A M U R A et al.
mutations found in the GISTs into the mouse c-kit cDNA and then stably transfected into the IL-3-dependent Ba/F3 murine pro-B cell line. As a control, mouse wild-type c-kit cDNA was also transfected into Ba/F3 cells. Ba/F3 cells with wild-type murine c-kit grew in the presence of either IL-3 or SCE Ba/F3 cells with the mutated c-kit grew autonomously without IL-3 and SCE Ba/F3 cells with the mutated murine c-kit also grew autonomously in nude mice (38). The constitutive kinase activation of all KIT mutations found in GISTs was confirmed in Ba/F3 cells (38). Some GISTs are typical benign tumours, and most of such GISTs are found incidentally at the time of endoscopic examination as submucosal tumours. In contrast, other GISTs metastasize to the liver and disseminate in the peritoneal cavity. Most of the latter type GISTs do not respond to radiotherapy and/or chemotherapy and ultimately kill the host. Large tumour size, the presence of intratumorous necrosis and frequent mitotic figures are considered to indicate a worse prognosis. The clinical behaviour of GISTs, however, is difficult to predict using conventional prognostic factors. Recently, Taniguchi et al. (39) examined whether the presence of the mutation in the juxtamembrane domain of the c-kit gene was important as a prognostic factor. They studied 124 GIST cases and found that the prognosis of the GISTs with the c-kit mutation was significantly worse than that of GISTs without the mutation.
FAMILIAL GIST
Multiple development of GISTs was found in a 60-year-old Japanese woman (case 1 in Fig. 2). A nephew of case 1 (case 3) also suffered from multiple benign GISTs. Analysis of their family pedigree revealed that many family members suffered from intestinal obstruction that may be attributable to multiple development of GISTs (Fig. 2). Case 2, a niece of case 1, received operations for benign and malignant GISTs (40). The benign GISTs obtained from cases 1, 2 and 3 and the malignant GIST from case 2 expressed KIT. DNA was extracted from paraffin-embedded specimens of the tumours, and mutation was investigated using single-strand conformation polymorphism analysis
Fig. 2 A family with multiple GISTs and mutation of the c-kit gene. Filled symbols indicate family members with either intestinal obstruction or the c-kit mutation or both. Squares, males; circles, females; symbols with a dash, dead case.
2.
G A I N - O F - F U N C T I O N MUTATIONS OF c - k i t IN H U M A N DISEASES
27
(SSCP). SSCP of tumours obtained from cases 1 and 3 showed wild-type and mutant bands at exon 11 that encodes the juxtamembrane domain. Direct sequencing of the mutated bands of exon 11 revealed the deletion of one of two consecutive valines (codons 559 and 560) (Fig. 1). Unfortunately, DNA samples suitable for SSCP and direct sequencing were not obtained from tumours of case 2. Next, we obtained DNAs from peripheral leukocytes of cases 1 and 3 and their family members. Deletion of the valine residue was observed in leukocyte DNAs of cases 1, 3 and 4, but not DNAs from others. Case 4 has not reported any abdominal symptoms, probably due to the younger age. We investigated functions of the mutated KIT by introducing it into mouse c-kit cDNA and then transfecting into Ba/F3 cells. Constitutive phosphorylation and kinase activation of the KIT were found. Ba/F3 cells with the mutated KIT grew autonomously both in culture and in nude mice (40). O'Brien et al. (41) also reported a family with multiple GISTs without examining the c-kit mutation. E1-Omar et al. (42) described a woman with leiomyomatosis and a leiomyosarcoma which arose from a leiomyoma. She also showed hyperpigmentation of the perineal skin. We consider the tumours benign and malignant GISTs. Marshall et al. (43) described a family with multiple gastrointestinal tumours, which appeared to be benign GISTs. The family members with multiple gastrointestinal tumours also suffered from urticaria pigmentosa or systemic mast cell disease. Since KIT plays an essential role in the development of melanocytes and mast cells, the hyperpigmentation and mast cell hyperplasia observed in these families may also be attributable to gain-of-function mutations of the c-kit gene. Familial GIST appears to be a cancer syndrome that might include hyperplasia of melanocytes and neoplasia of mast cells in some families.
CONCLUSION Loss-of-function mutations of c-kit results in depletion of erythrocytes, melanocytes, germ cells, mast cells and ICCs. In contrast, gain-of-function mutations of c-kit induce neoplasms of mast cells and ICCs. The site of mutations is different between human mast cell neoplasms and human GISTs, and the mechanisms remain to be clarified. The mast cell was discovered by Ehrlich (44), and the ICC was discovered by Cajal (45). Although there are no characteristics common to mast cells and ICCs without being discovered by the great scientists of the 19th century, development and oncogenesis of these two types of cells are profoundly influenced by the SCF-KIT system.
REFERENCES 1.
2.
3.
4.
Besmer, R, Murphy, J. E., George, R C., Qiu, E, Bergold, R J., Lederman, L., Snyder, Jr. H.W., Broudeur, D., Zuckerman, E. E. and Hardy, W. D. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 320:415-421, 1986. Qiu, E H., Ray, H. E, Brown, Y., Barker, E E., Jhanwar, S., Ruddle, E H. and Besmer, E Primary structure of c-kit: relationship with the CSF- 1/PDGF receptor kinase family - oncogenic activation of vkit involves deletion of extracellular domain and C terminus. E M B O J. 7:1003-1011, 1988. Yarden, Y., Kuang, W. J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Francke, U. and Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 6:3341-3351, 1988. Sibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H. and Sato, M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the
28 5.
6.
7. 8.
.
10. 11.
12. 13.
14. 15.
16. 17.
18. 19.
20.
21.
22.
23.
24. 25.
26.
Y U K I H I K O K I T A M U R A et al. fms family. Oncogene 5:519-524, 1990. Tsujimura, T., Hirota, S., Nomura, S., Niwa, Y., Yamazaki, M., Tono, T., Morii, E., Kim, H. M., Kondo, K., Nishimune, Y. and Kitamura, Y. Characterization of Ws mutant allele of rats: a 12 base deletion in tyrosine kinase domain of c-kit gene. Blood 78:1942-1946, 1991. Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P. and Bernstein, A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335:88-89, 1988. Geissler, E. N., Ryan, M. A. and Housman, D. E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55:185-192, 1988. Nocka, K., Tan, J. C., Chiu, E., Chu, T. Y., Ray, P., Traktman, P. and Besmer, P. Molecular bases of dominant negative and loss of function mutation at the murine c-kit~white spotting locus: W37, W v, W4~ and W. EMBO J. 9:1805-1813, 1990. Russell, E. S. Hereditary anemias of the mouse: a review for geneticists. Adv. Genet. 20:357-459, 1979. Kitamura, Y., Go, S. and Hatanaka, K. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447--452, 1978. Maeda, H., Yamagata, A., Nishikawa, S., Yoshinaga, K., Kobayashi, S., Nishi, K. and Nishikawa, S.-I. Requirement of c-kit for development of intestinal pacemaker system. Development 116:369-375, 1992. Huizinga, J. D., Thuneberg, L., Kltippel, M., Malysz, J., Mikkelsen, H. B. and Bernstein, A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 373:347-349, 1995. Williams, D. E., Eisenman, J., Baird, A., Rauch, C., Ness, K. V., March, C. J., Park, L. S., Martin, U., Mochizuki, D. Y., Boswell, H. S., Burgess, G. S., Cosman, D. and Lyman, S. D. Identification of a ligand for the c-kit proto-oncogene. Cell 63:167-174, 1990. Flanagan, J. G. and Leder, P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63:185-194, 1990. Zsebo, K. M., Williams, D. A., Geissler, E. N., Broudy, Y. C., Martin, E H., Atkins, H. L., Hsu, R. Y., Birkitt, N. C., Okino, K. H., Murdock, D. C., Jacobson, E W., Langley, K. E., Smith, K. A., Takeishi, T., Cattanach, B. M., Galli, S. J. and Suggs, S. V. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213-224, 1990. Kitamura, Y. and Go, S. Decreased production of mast cells in SI/SId anemic mice. Blood 53:492--497, 1979. Ward, S. M., Burns, A. J., Torihashi, S., Harney, S. C. and Sanders, K. M. Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. Am. J. Physiol. 269:1577-1585, 1995. Silvers, W. K. In: The Coat Color of Mice. A Model for Mammarian Gene Action and Interaction. Springer-Verlag, New York, 1979. Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervone, M., Bernstein, A. and Besmer, P. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice; evidence for an impaired c-kit kinase in mutant mice. Genes Dev. 3:816-826, 1989. Reith, A. D., Rottapel, R., Giddens, E., Brady, C., Forrester, L. and Bernstein, A. W mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the c-kit receptor. Genes Dev. 4:390-400, 1990. Tsujimura, T., Koshimizu, U., Katoh, H., Isozaki, K., Kanakura, Y., Tono, T., Adachi, S., Kasugai, T., Tei, H., Nishimune, Y., Nomura, S. and Kitamura, Y. Mast cell number in the skin of heterozygotes reflects molecular nature of c-kit mutation. Blood 81:2530-2538, 1993. Niwa, Y., Kasugai, T., Ohno, K., Morimoto, M., Yamazaki, M., Dohmae, K., Nishimune, Y., Kondo, K. and Kitamura, Y. Anemia and mast cell depletion in mutant rats that are homozygous at 'White spotting (Ws)' locus. Blood 78:1936-1941, 1991. Isozaki, K., Hirota, S., Nakama, A., Miyagawa, J.-I., Shinomura, Y., Xu, Z., Nomura, S. and Kitamura, Y. Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 109:456-464, 1995. Giebel, L. B. and Spritz, R. A. Mutation of the kit protooncogene in human piebaldism. Proc. Natl. Acad. Sci. USA 88:8696-8699, 1991. Kitamura, Y., Yokoyama, M., Matsuda, H. and Shimada, M. Coincidental development of forestomach papilloma and prepyloric ulcer in nontreated mutant mice of W/W v and S1/Sf genotypes. Cancer Res. 40:3392-3397, 1980. Yokoyama, M., Tatsuta, M., Baba, M. and Kitamura, Y. Bile reflux: a possible cause of stomach ulcer in
2. 27. 28. 29.
30.
31.
32.
33.
34.
35.
36.
37. 38.
39. 40.
41. 42. 43.
44. 45.
G A I N - O F - F U N C T I O N MUTATIONS OF c-kit IN H U M A N DISEASES
29
nontreated mutant mice of W/Wv genotype. Gastroenterology 82:857-863, 1982. Suzuki, N., Prosser, C. L. and Dahms, V. Boundary cells between longitudinal and circular layers: essential for electrical slow waves in cat intestine. Am. J. Physiol. 250:G287-294, 1986. Ullrich, A. and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990. Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., Sugahara, H., Butterfield, J.H., Ashman, L.K., Kanayama, Y., Matsuzawa, Y., Kitamura, Y. and Kanakura, Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92:1736-1744, 1993. Tsujimura, T., Furitsu, T., Morimoto, M., Isozaki, K., Nomura, S., Matsuzawa, Y., Kitamura, Y. and Kanakura, Y. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 83:2619-2626, 1994. Tsujimura, T., Furitsu, T., Morimoto, M., Kanayama, Y., Nomura, S., Matsuzawa, Y., Kitamura, Y. and Kanakura, Y. Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int. Arch. Allergy Immunol. 106:377-385, 1995. Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y. and Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10560-10564, 1995. Longley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y.-S., Langley, K., Ding, T.-G., Duffy, T., Jacobs, P., Tang, L. H. and Modlin, I. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:312-314, 1996. Hashimoto, K., Tsujimura, T., Moriyama, Y., Yamatodani, A., Kimura, M., Tohya, K., Morimoto, M., Kitayama, H., Kanakura, Y. and Kitamura, Y. Transforming and differentiation-inducing potentials of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am. J. Pathol. 148:189-200, 1996. Kitayama, H., Kanakura, Y., Furitsu, T., Tsujimura, T., Oritani, K., Ikeda, H., Sugahara, H., Mitsui, H., Kanayama, Y., Kitamura, Y. and Matsuzawa, Y. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85:790-798, 1995. Tsujimura, T., Morimoto, M., Hashimoto, K., Moriyama, Y., Kitayama, H., Matsuzawa, Y., Kitamura, Y. and Kanakura, Y. Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 87:273-283, 1996. London, C. A., Galli, S. J., Yuuki, T., Hu, Z. Q., Helfand, S. C. and Geissler, E. N. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp. Hematol. (in press). Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Tunio, G. M., Matsuzawa, Y., Kanakura, Y., Shinomura, Y. and Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998. Taniguchi, M., Nishida, T., Hirota, S., Isozaki, K., Ito, T., Nomura, T., Matsuda, H. and Kitamura, Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. (in press). Nishida, T., Hirota, S., Taniguchi, M., Hashimoto, K., Isozaki, K., Nakamura, H., Kanakura, Y., Tanaka, T., Takabayashi, A., Matsuda, H. and Kitamura, Y. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat. Genet. 19:323-324, 1998. O'Brien, P., Kapusta, L., Dardick, I., Axler, J. and Gnidec, A. Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia. Am. J. Surg. Pathol. 23:198-204, 1999. E1-Omar, M., Davies, J., Gupta, S., Ross, H. and Thompson, R. Leiomyosarcoma in leiomyomatosis of the small intestine. Postgrad. Med. J. 70:661-664, 1994. Marshall, J. B., Diaz-Aris, A. A., Bochna, G. S. and Vogele, K. A. Achalasia due to diffuse esophageal leiomyomatosis and inherited as an autosomal dominant disorder; report of a family study. Gastroenterology 98:1358-1365, 1990. Ehrlich, P. Beitrage zur Theorie und Praxis der histologishen Farburg. Doctoral Thesis, University of Leipzig, 1878. Cajal, S. R. Sur les ganglions et plexus nerveux de l'intestin. C. R. Soc. Biol. 45:217-223, 1893.
This Page Intentionally Left Blank
CHAPTER 3
Modulation of Mast Cell Development from Embryonic Haematopoietic Progenitors by Eotaxin ELIZABETH J. QUACKENBUSH,*I BARRY K. WERSHIL2 and JOSE-CARL OS GUTIERREZ-RAMOS3 1Children's Hospital, Harvard Medical School, and the Center for Blood Research, Boston, Massachusetts, 2SUNY Health Sciences Center, Brooklyn, New York, and 3Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, U.S.A.
CHEMOKINES AND THEIR RECEPTORS PLAY DIVERSE ROLES AS MEDIATORS OF INFLAMMATION
Within the immune system, chemoattractants (also known as chemokines) are members of a large superfamily of structurally and functionally related proteins (1, 2). Chemoattractants bind to cell-surface receptors, which leads to a rapid, intracellular signalling event, cytoskeletal arrangements and cell motility, along with other cellular functions (3-5). For example, chemokine-mediated activation of integrins on circulating cells is a central event in the immune system's response to injury, inflammation or infection. Subsequently, activated cells undergo firm arrest on the vessel wall and diapedesis (6). Chemokines are structurally classified into four subfamilies, based on highly conserved, N-terminal cysteine residues that are arranged into characteristic motifs: C, CC, CXC or CX3C (1). New chemokines and their receptors are discovered yearly, and evidence suggests that there may be as many as 50 human chemokines (1). The functionally diverse 13chemokines (containing the CC motif) make up the largest family, with nearly twenty members in humans, including macrophage inflammatory proteins (e.g. MIP-lt~; 3), eotaxin (7, 8), RANTES ('regulated upon activation, normal T cell expressed and secreted'; 9) and monocyte chemotactic proteins (MCP)-I-5 (2, 10-12, 85). The C and CX3C motifs define two chemokine subfamilies that contain only one member each. Lymphotactin has a lone C in the N-terminal domain (13) and is a potent chemoattractant for T cells, while neurotactin (also known as fractalkine) has three amino acids intervening between the first two cysteines (14, 15). The CXC (o0 chemokine subfamily is further subdivided by the presence or absence of an amino acid motif, ELR (glutamate-leucine-arginine), between the N-terminus and the * C o r r e s p o n d i n g author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
31
Copyright 9 2000Academic Press All rights of reproduction in anyform reserved
32
ELIZABETH J. QUACKENBUSH et al.
first cysteine (16). The ELR-containing CXC chemokines are uniformly potent neutrophil chemoattractants, and the prototypic human CXC chemokine, interleukin-8 (IL-8), also stimulates histamine release from basophils (17, 18). All chemokine receptors described thus far are seven-transmembrane-spanning, G protein coupled receptors, whose antagonists include Bordetella pertussis toxin (3, 4). The four major classes of chemokine receptors are based on ligand specificity and have been defined as 'specific', 'shared', 'viral' and 'promiscuous'. Specific receptors only bind one ligand. Shared receptors, the largest subset, can bind more than one chemokine, but the chemokines must be members of the same family. Promiscuous receptors can bind to ligands from either family. We now know that haematopoietic chemokines and their receptors function in processes more diverse than cell migration. For example, select chemokines can inhibit angiogenesis (19), stimulate B cell development (20) and aid human immunodeficiency virus (HIV) entry (21).
CHEMOKINES PARTICIPATE IN MULTIPLE MAST CELL AND BASOPHIL FUNCTIONS Basophils and mast cells accumulate in allergic reactions, and their migration, differentiation and activation are required for propagation of inflammatory responses, such as allergic rhinitis, asthma and atopic dermatitis. When activated, they release multiple mediators such as histamine, IL-4, IL-13 and chemokines (22, 23). They also bear a variety of chemokine receptors that can bind multiple chemokines (Table I). In general, less is known about the role of chemokines in mast cell and basophil development, activation and migration. Functional studies have focused on their role in the regulation of migration, cytokine expression, leukotriene formation and histamine release (Table I). Despite similar signal transduction pathways that use pertussissensitive G protein coupled receptors, there is remarkable variation in the ability of individual chemokines to mediate basophil and mast cell exocytosis and chemotaxis. Chemokine receptors on basophils induce chemotaxis and mediator release
In many early studies examining chemokine-induced responses of basophils and mast cells, the ligand-binding receptor was not identified. More recently, the chemokine receptors CCR1, CCR2, CCR3, CCR5, CXCR1, CXCR2 and CXCR4 have been shown to be expressed on basophils and mast cells by mRNA and/or protein analysis (Table I). CCR1, whose mRNA is weakly and constitutively expressed in human basophils, binds multiple CC chemokines, including RANTES, MIP-1 cz and MCP-3. This receptor is not expected to play a major role in basophil chemotaxis, however, as RANTES (a primary ligand) appears to induce basophil chemotaxis through CCR3 (12). Its function on basophils remains unknown, but it may mediate exocytosis rather than migration, since antibodies to CCR3 did not abrogate MIP-1 ~z- or MCP-3-induced histamine release from human basophils. MCP-1, which binds only to CCR2, is a weak chemoattractant of basophils but a potent stimulus of exocytosis (24). MCP-1 and MCP-3 strongly induce histamine release from human basophils, and they, along with MCP-4, readily compete for binding to CCR2 (12). The affinity of MCP-1 is approximately ten-fold higher than that of MCP-3
3.
M O D U L A T I O N OF M A S T C E L L D E V E L O P M E N T BY E O T A X I N
33
TABLE I Chemokine Receptors Expressed by Basophils and Mast Cells Chemokine receptor
Ligands
Expression pattern (receptor)
Function*
CCR1
MIP- 1~; RANTES" MCP-3
Human basophils (low level mRNA)
MIP- 1~: + CTX; + exocytosis
CCR2
MCP-1-4
Human basophils (low level mRNA); rat mast cells
MCP-1" + CTX; ++ exocytosis MCP-2: + CTX; ++ exocytosis MCP-3" ++ CTX; ++ exocytosis
CCR3
Exotaxin-1/2; MCP-2-4; RANTES
Human/rodentt mast cells; human/rodent basophils
Eotaxin/MCP-4: ++ CTX; + exocytosis RANTES: ++ CTX; + exocytosis
CCR5
MIP- 1~; MIP- 1~; RANTES
Human mast cell progenitors
Unknown
CXCR1
IL-8
Human basophils
+/- CTX; + exocytosis
CXCR2
IL-8; NAP-2
Human basophils" human mast cell progenitors
+/-CTX
CXCR4
SDF- 1~
Human mast cell progenitors
+CTX
* CTX, chemotaxis" + indicates strength of activity. t MCP- 1, RANTES and MIP- 1c~ induce histamine release from rat mast cells but not from murine or human mast cells.
and MCP-4. MCP-1 can strongly stimulate histamine release from basophils without the need for IL-3 pre-treatment (24), however, priming with IL-3 allows basophils to respond to even lower concentrations of MCP-1 (25). Eotaxin, eotaxin-2, MCP-3 and MCP-4, all ligands for CCR3, are potent chemoattractants for human basophils, and the activity found with each chemokine was comparable to that seen with eosinophils (12, 86). Anti-CCR3 completely abrogated eotaxin- and RANTES-induced migration, as did pertussis toxin, while MCP-3-induced migration was only minimally inhibited. Migration towards an MCP-4 gradient was also markedly inhibited, but only at MCP-4 concentrations less than 100 nm. Binding experiments show that MCP-4 has a 40-fold higher affinity for CCR3 than MCP-3 has (12). RANTES can also bind to CCR1 and CCR4, but the nearly complete inhibition with anti-CCR3 antibodies of RANTES-induced migration suggests that this is the primary receptor on basophils through which this ligand acts. On human basophils the mRNA levels of CCR3 and CCR2 are similar, and CCR3 is strongly expressed on the surface, based upon flow cytometry data (23). The chemokines eotaxin, RANTES, MCP-4, MCP-3 and MCP-1 rank from low to high in order of efficiency of histamine release from basophils (12). These four chemokines also induced leukotriene C4 production in human basophils, after IL-3 priming, with the same degree of efficiency. Anti-CCR3 treatment eliminated histamine
34
ELIZABETH J. QUACKENBUSH et al.
release induced by eotaxin, while decreasing the effect found with RANTES. Mediator release induced by MCP-1, MIP-1 ~ and IL-8 was not affected by anti-CCR3 antibodies. Hartmann et al. (26) also demonstrated that RANTES, MCP-1, MCP-2, MCP-3, MIP1c~ and MIP-1 [3 were able to induce histamine release from human basophils but none of them induced histamine release from human skin mast cells. By flow cytometry, human basophils express intermediate levels of the IL-8 receptors, CXCR1 and CXCR2, in comparison to the high level of CCR3 found on the surface (23). Surprisingly, the IL-8 analogue, neutrophil-activating peptide 2 (NAP-2), which reacts with CXCR2, induced only a weak chemotactic response and had no effect on exocytosis or cytokine expression, despite a moderate level of CXCR2 surface expression (87). CXCR1 was able to induce both migration and formation of leukotriene C4, but only from IL-3-primed basophils.
Chemokine-induced mast cell exocytosis and migration Despite being multifunctional, secretory immune cells that originate from a common haematopoietic progenitor, basophils and mast cells respond differently to activating stimuli. Basophils respond to IL-3, IL-5 and granulocyte-macrophage colonystimulating factor (GM-CSF), while human mast cells cannot be activated by these factors. SCF is a specific mediator of granule release from mast cells and promotes mast cell differentiation. In contrast to basophils, human mast cells release histamine in response to stem cell factor (SCF) (27), but their response to chemokines depends upon the source of mast cells used. In one study using human mast cells isolated from lung, skin, tonsils and uterus, none of the chemokines tested (MCP- 1, RANTES, MIP- 1~, MIP- 1~, GRO (growth-regulated oncozine) IP-10 and IL-8) induced histamine release (25). A second study by Petersen et al. (27) confirmed that MCP-1, RANTES and MIP-1 ~ are unable to induce histamine release from human skin mast cells. Furthermore, eotaxin did not enhance anti-IgE-stimulated histamine release from CCR3 § human lung mast cells (28). However, murine skin and peritoneal mast cells degranulated in response to MIP-1 ~ and, to a lesser degree, to MCP-1 (29). MCP-1 (but not MIP-1 cz, eotaxin, or MCP-3) directly induced pulmonary murine mast cell degranulation, in vitro, and caused prolonged airway hyper-reactivity and histamine release, in vivo, using a cockroach allergen to induce inflammation (30). MCP-I's activity was mediated through CCR2, as mice lacking CCR2 had a significantly attenuated response to the chemokine. Taub et al. (31) found no degranulation of murine bone marrow mast cells or mast cell lines to MIP-1 ~, MIP-1 [3, RANTES, MCP-1, IL-8, or IP-10. They also did not confirm previous results showing that MIP-I~ induces histamine release from purified murine peritoneal mast cells. Several chemokines also induce mast cell chemotaxis in vitro. Unstimulated murine mast cells will migrate to MCP-1 and RANTES on surfaces coated with extracellular matrix proteins (vitronectin, fibronectin and laminin), while IgE-stimulated mast cells will also migrate to RANTES, MCP-1 and M I P - I ~ (31). RANTES injected subcutaneously into the sole of rat paws caused mast cell accumulation that was inhibited by an anti-RANTES antibody (32). SCF and IL-3 induce the migration of resting and activated mast cells, as well (31), and the level of response is similar to that seen with MCP-1. It is intriguing that mast cells can enhance their migratory response to certain chemokines after antigen or IgE activation. This enhancement may be unique to mast cells and crucial to optimizing migration into
3.
MODULATION OF MAST CELL DEVELOPMENT BY EOTAXIN
35
sites of antigen deposition in pathological situations, such as parasitic infections and allergies. Nilsson et al. (33) investigated the response of the human mast cell line, HMC-1, to different chemokines by calcium flux measurements. Only CXC chemokines with the ELR tripeptide motif, such as IL-8, GRO
CHEMOKINE SECRETION BY MAST CELLS Several cytokines are known to be secreted by these immunoregulatory cells. For example, mast cells activated by topical dinitrofluorobenzene migrate to lymph nodes, where they become an abundant source of the T cell-recruiting chemokine, MIP-1 ~ (35). Likewise, ENA-78 and MCP-5 are produced by mast cells during allergic airway inflammation (11, 36), and RANTES is secreted by mast cells during allergen-induced rhinitis (37). Using HMC-1 as a source of RNA, MCP-1 and RANTES transcripts were detected at moderate and low levels in unstimulated cells, respectively, by northern blotting (38). Following phorbol ester treatment, MCP-1 and RANTES transcripts were upregulated and MIP-1 a, MIP-113 and IL-8 transcripts were newly detected. MCP-1 secretion was confirmed by immunoprecipitation from supernatants of unstimulated and stimulated cells. Secretion of MIP-1 (x was further increased by IgE treatment (39). Lymphotactin (Ltn) gene expression was induced in human mast cells, human basophils, HMC-1 and murine bone marrow mast cells by Fc~RI aggregation (40). Transforming growth factor-13 (TGF-[3) enhanced Fc~RI-induced Ltn mRNA expression, and both MIP-I(z and Ltn were upregulated in response to IL-4 following Fc~RI aggregation. As with MCP-1, lymphotactin was identified in supernatants by western blotting. Eosinophils contain eotaxin within their intracellular granules and respond to exogenous eotaxin by chemotaxis (41). Quantification of cell-associated eotaxin in different leukocyte subsets revealed that eosinophils are the principal source of this chemokine. However, murine bone marrow mast cells grown in SCF, but not in IL-3containing conditioned medium, also secrete eotaxin when exposed to substance P (42). Eotaxin protein was not detected when these cells were stimulated by IgE and antigen. Thus, both murine mast cells and eosinophils can secrete and respond to eotaxin, likely through CCR3. Not all sources of mast cells react accordingly, as mast cells isolated from guinea pig lung (challenged and unchallenged) did not express eotaxin by northern blot analysis (43). Airway epithelial cells appeared to be the major source of eotaxin in the guinea pig pulmonary system.
36
ELIZABETH J. QUACKENBUSH et al.
EOTAXIN Eotaxin is a potent chemoattractant for eosinophils. It is a member of the CC chemokine family and, by northern blot analysis, is constitutively expressed only in adult intestine, thymus and skin (7, 8, 88). Eotaxin does not induce the in vitro chemotaxis of neutrophils, monocytes, macrophages or mast cells in adult mice (8). Human skin mast cells express CCR3 and will migrate to both eotaxin and RANTES with similar efficiency (28). Eotaxin will also induce chemotaxis of T cells, but only after they have been stimulated by IL-2 and IL-4 to express CCR3 (44). Furthermore, eotaxin upregulated ICAM-1, CD29 and CD49a and CD49b on T cells, suggesting that T cell adhesiveness to endothelium is also promoted by eotaxin (44). Conflicting reports on mast cell responses to eotaxin may be explained, in part, by the observation that CCR3 (in humans) is preferentially associated with connective tissue mast cells rather than with mucosal mast cells (28). The biological significance of eotaxin has been most frequently examined in animal models of inflammation. Asthma-associated airway inflammation and bronchial hyperreactivity are characterized by massive infiltration of eosinophils, mediated in part by chemoattractants, such as eotaxin (8, 89). We and others have identified and characterized the kinetics of eotaxin expression and eosinophil infiltration in a murine model of ovalbumin-induced lung inflammation. However, the contribution of eotaxin-triggered mast cell responses (and of mast cell-released eotaxin) to lung inflammation remains poorly understood. In general, asthmatic patients have high levels of eotaxin in their bronchioalveolar fluid and increased expression of eotaxin mRNA in airway epithelial cells (45). Eotaxin injected intraperitoneally into mice can induce a maximum dose-dependent influx of eosinophils in 1-2 h; however, in mast cell-deficient mice the influx is delayed and reduced in numbers (46). Inhibitors of lipoxygenase also caused a reduction in the number of eosinophils in peritoneal lavages. These findings suggest that leukotrienes and mast cells contribute to eotaxin-induced eosinophilia. In other studies, pre-treatment of mice with histamine or serotonin antagonists reduced eosinophil influx into the peritoneum in response to intraperitoneal eotaxin injections (47). The role of constitutively expressed eotaxin may be to control baseline trafficking of eosinophils into non-haematopoietic tissue (88). For example, wild-type mice express eotaxin mRNA in the lamina propria of their jejunum, and eosinophils are readily detected there as well. In eotaxin-deficient mice, there is a large reduction in the number of detectable eosinophils in the lamina propria of the jejunum, as well as in the thymus. We have found by immunostaining significant amounts of eotaxin in the thymic medullary regions and along the underside of the capsule (data not shown), but the significance of this expression pattern is unknown. A second human chemoattractant for eosinophils has been described and named eotaxin-2 (48). Despite their names, eotaxin and eotaxin-2 share only 39% identical amino acids and differ nearly completely in the N-terminal region, a region of particular importance for inducing chemotaxis. Eotaxin-2 induces chemotaxis of basophils, as well as histamine and leukotriene C4 release, post-priming with IL-3 (48). Given the evidence that chemokines participate in mast and basophil exocytosis and migration, we examined the function of eotaxin in mast cell differentiation. We used progenitors isolated from fetal tissues, as circulating mast cell progenitors are prevalent
3.
MODULATION OF MAST CELL DEVELOPMENT BY EOTAXIN
37
and actively differentiating during haematopoietic development in utero. Committed fetal mast cell progenitors are identified by Thy-1%-kit hi expression and mRNA for mast cell-associated proteases. They are present in the fetal blood at mid to late stages of gestation (49). It is presumed that these circulating cells are released from the fetal liver. Until very recently, haematopoietic stem cells in mice were thought to originate in the yolk sac, despite an overwhelming body of evidence from other species that the earliest precursors were located within the body of the embryo proper (50). Recent evidence shows that the greatest number of murine stem cells are obtained from the aorta-gonad-mesonephros (AGM) region, an area around the endoderm of the developing gut in the abdomen (51, 90). Stem cells from this region are thought to migrate to the fetal liver and subsequently to colonize the developing thymus and bone marrow (51). In our studies we used single cell suspensions of fetal liver, fetal blood and yolk sac as sources of progenitors.
RESULTS Eotaxin modulates myelopoiesis and mast cell development from embryonic haematopoietic progenitors Several studies showed previously that SCE a mast cell growth factor, acts as a potent comitogen for multiple types of progenitor cells when combined with other cytokines, including IL-3, IL-6 and IL-1 (52). It also acts as a chemoattractant for progenitor cells (53). Thus, we initially examined the effect of SCF combined with eotaxin on haematopoietic colony formation in methylcellulose cultures. Equal numbers of cells were plated in methylcellulose in the presence of SCF alone (20 ng ml-~), eotaxin alone (50 ng m1-1) and SCF combined with eotaxin. The receptor for SCF, c-kit, has been shown by others to be expressed on progenitor cells isolated from the yolk sac (54) and fetal liver (55). At 11 days post coitum (dpc), we found that 35% of liver cells, 3.8% of yolk sac cells and 3.2% of fetal blood cells expressed c-kit. Eotaxin combined with SCF produced a synergistic response in the total number and size of colonies grown from fetal liver (Fig. 1, A), while an additive effect was seen with yolk sac and fetal blood-derived colonies (data not shown). The synergistic effect of these factors was not always represented by the colony count, but was seen when the total numbers of cells produced in methylcellulose cultures were harvested and counted. Cell counts were decreased by 52%, and colony counts by 30%, when pertussis toxin was added to fetal blood cultures induced with the combination of eotaxin and SCF (data not shown).
Macrophage and mast cell colonies are preferentially induced with SCF and eotaxin Three types of methylcellulose colonies, CFU-erythroid (CFU-E), CFU-MIX and CFUmacrophage (CFU-M), were quantitated (Fig. 1, B, left graph). Colony type was determined by preparing cytospun preparations of individual colonies. CFU-MIX contained cells of varying size, nuclear shape and granulation, and the majority of cells were macrophages, mast cells and undefined mononuclear, weakly granulated cells. Similar patterns of CFU type were obtained with fetal liver and yolk sac. CFU-MIX are most prevalent and additively increase in number with the addition of eotaxin to SCF, as
38
E L I Z A B E T H J. Q U A C K E N B U S H et al.
A Fetal Liver
C
SCF
Eo taxin
SCF § Eotaxin
Colony Count:
187 + 13
200 +_21
364+44
Cell Count: 11 dpc FL" 11 dpc FL" 12 dpc FL:
67,340 38,560 15,750
117,580 54,920 40,440
298,100 160,060 94,410
% OF MAC-I + CELLS
Fetal Liver
Fetal Blood
Yolk Sac SCF
EOTAXIN
BOTH
SCF
EOTAXIN
BOTH
SCF
EOTAXIN
BOTH
I~xp 1
12.7
12.1
15.2
2.1
6.9
14.8
17.4
24.8
34.3
Exp 2
7.7
8.3
34.2
6.8
5.8
22.0
10.5
32.4
47.2
Fig. 1 Eotaxin influences fetal haematopoietic cell differentiation. In A, the total number of fetal liver colonies and progeny cells induced (in three separate experiments) by SCF alone, eotaxin alone, or both factors combined is shown. In B (left graph), the three types of colonies induced with SCF and/or eotaxin are plotted: CFU-erythroid (CFU-E), CFU-MIX (containing cells of varying size, granulation and nuclear shape/size, with and without erythrocytes) and CFU-macrophage (CFU-M). Colony type was confirmed by preparing cytospun preparations from individual colonies with distinct morphological characteristics, after 14 days of culture. Standard error bars are shown, and statistical analysis was performed using the Friedman test: **p<0.001, *p<0.01. The right graph in section B shows the percentage of more differentiated mast cells identified on cytospins stained with modified Giemsa, based on granular content. The percentage of heavily granulated (mature) cells was determined by counting the number of these cells (in 25 or 100 fields at 400x magnification) on cytospun preparations made by harvesting all colony progeny induced in methylcellulose, after 14 days. Total cell counts ranged from 84 to 964. The inset in the right graph shows a mature mast cell generated after 10 days in culture with eotaxin and SCF, stained with toluidine blue (TB+). Colony progeny were harvested and immunofluorescently stained with a monoclonal antibody to Mac-1. The percentage of Mac- 1+ cells, after background subtraction, is shown in C.
3.
MODULATION OF MAST CELL DEVELOPMENT BY EOTAXIN
39
did CFU-M, while CFU-E are not induced by eotaxin alone (in any tissue type). The one exception to this pattern was seen with yolk sac, where the numbers of CFU-M were similar for each growth condition tested. Phenotypic analysis of colony progeny was performed with the lineage markers GR-1, Mac-l, TER-119, Thy-1 and B220, and we found a synergistic increase of 1.63 times (_+0.4) in the number of Mac- 1+ cells from colonies grown in the presence of both factors (Fig. 1, C). This increase was identical to the synergistic increase in the total number of cells induced by eotaxin and SCF combined. The total percentage of lineage-positive cells ranged from 15% to 51%, and progenitors (based upon replating experiments), stromal cells and mast cells were included among the lineage-negative population. Significant numbers of yolk sac- and fetal blood-derived progeny were positive for c-kit (data not shown).
Eotaxin influences mast cell development from embryonic progenitors A unique subpopulation of heavily granulated cells was identified on cytospun preparations of yolk sac- and fetal blood-derived colonies induced with both factors (Fig. 1, B, right graph). These granulated cells were not obtained from cultures grown in eotaxin alone or in SCF alone at low concentrations. However, cultures of progenitor cells in SCF alone at concentrations of > 50 ng ml -~ gave rise to cells with the same morphological characteristics. Acidified toluidine blue (a specific stain for mast cells) and chloroacetate esterase (an enzyme found in mast cells, but not in eosinophils or basophils) both stained the granules of these cells. The number of granules per cell, cell size and nuclear profile (both mononuclear and multinucleated cells were seen) were characteristic of mature mast cell populations derived in vitro. The percentage of mature mast cells obtained from 11dpc fetal blood colonies grown in SCF and eotaxin was 8 _+ 3%, while cells with similar morphology obtained from yolk sac cultures represented 2.8 _+ 1.7% of the total cells produced in methylcellulose after 14 days of culture (Fig. 1, B, right graph). Toluidine blue-positive cells expressing c-kit were identified by immunohistological staining of colony progeny derived from 11 dpc yolk sac and fetal blood (data not shown). We also performed reverse transcriptase-polymerase chain reaction (RT-PCR) analysis for the expression of serine proteases specific for mast cells, in order to confirm that the heavily granulated cells obtained in methylcellulose cultures with SCF and eotaxin were mast cells. Mast cells derived from murine bone marrow cells cultured in spleen cell-conditioned medium are immature mast cells expressing murine mast cell protease 2 (mMCP-2) and murine mast cell carboxypeptidase A (mMC-CPA), while mast cells cultured in medium with SCF alone expressed RNA for mMCP-2, mMC-CPA and mMCP-4 (Fig. 2). Colonies grown from l ldpc fetal blood in SCF alone expressed mMCP-2 and mMC-CPA mRNA but not mMCP-4 mRNA. However, mMCP-2, mMCCPA and mMCP-4 mRNA were expressed by progenitors grown in SCF in combination with eotaxin.
Mature mast cells are more prevalent in haematopoietic colonies derived from fetal blood than from fetal liver progenitors When the relative number of mature mast cells in fetal blood and fetal liver cultured in SCF and eotaxin was examined, we found an increased number in fetal blood (8 _+ 3%) compared with fetal liver (<1%) at 11dpc. In contrast, there are approximately ten times
40
ELIZABETH J. QUACKENBUSH et al.
Fig. 2 Eotaxinis required for the differentiation of mast cell progenitors expressing mMCP-4. RT-PCR was used to determine the pattern of mast cell proteases (carboxypeptidase A, mMC-CPA; cellular protease 2, mMCP-2; cellular protease 4, mMCP-4) expressed in fetal blood colonies. Lanes 1 and 2 represent bone marrow mast cells (BMMC) derived from BALB/c mice, in SCF alone (lane 1) or concanavalin A stimulated conditioned medium (CM; lane 2). Lanes 3-6 represent fetal blood-derived colonies (11dpc). more multipotent progenitors in fetal liver at l ldpc than in fetal blood. In our assay system, 2-4 times more total colonies were produced from fetal liver in the presence of SCF and eotaxin than from fetal blood and yolk sac, despite using five-fold fewer fetal liver cells to seed the cultures. The mean number of total blood and fetal liver cells per organism at 1 ldpc was 8.5 _+ 5.4 x 105 (n = 8) and 3.7 + 2.6 x 105 (n = 5), respectively, which compares favourably with reported estimates. Thus, the estimated number of fetal blood cells at l ldpc responsive to SCF in combination with eotaxin was --500 fetal blood-derived progenitors per embryo and --1600 fetal liver-derived progenitors per embryo, on average.
DISCUSSION Our study showed that eotaxin in combination with SCF synergistically induced from embryonic progenitors the differentiation of granulated cells with morphological features characteristic of mature mast cells, in vitro. These cells were definitively identified as mast cells by their expression pattern of mast cell-specific proteases and by immunohistochemical staining. There are several possible explanations for this observation. Eotaxin, acting through CCR-3 or another receptor, could induce the secretion of additional SCF or other cytokines that accelerate mast cell proliferation,
3.
MODULATIONOF MAST CELL DEVELOPMENT BY EOTAXIN
41
differentiation and/or survival. SCF produced by fibroblasts is known to promote mast cell survival by suppressing apoptosis (56) and to promote mast cell adherence to fibronectin and other interstitial cell types (57). Co-incubation of mast cells with fibroblasts also induces mast cell proliferation and activation (58), and both cell populations can produce significant amounts of eotaxin (59). Hogaboam (91) demonstrated a novel role of transmembrane SCF in murine mast cell activation and eotaxin production mediated by the interaction of mast cells and fibroblasts. Bone marrow-derived mast cell-fibroblast co-cultures were established with and without direct contact, and histamine release and chemokine production were quantitated. Direct contact allows mast cells to bind both transmembrane and soluble SCE In their study, adult mast cells were induced to produce histamine and eotaxin by transmembrane SCE They proposed that SCF activation of mast cells could also have induced IL-4 release simultaneously, which induces eotaxin production by fibroblasts (60). IL-4 promotes murine mast cell proliferation and protease expression but is reported to have an inhibitory effect on the proliferation of human fetal liver-derived mast cell progenitors, by downregulating c-kit expression (61). In contrast, IL-4 and IgE synergistically induced Fc~RI expression and mediator release in human umbilical cordderived mast cells (which may represent circulating mast cells), as well as in murine peritoneal mast cells (62). Ogasawara et al. (63) reported that mouse bone marrow (BM)-derived mast cells initially grown in IL-3 undergo exocytosis and cytokine expression in response to G-protein-activating polybasic compounds, after co-culture with fibroblasts and soluble c-kit ligand. These responses were suppressed by pertussis toxin; furthermore, they were not seen when BM-derived mast cells were cultured with soluble SCF or with fibroblasts alone. The BM mast cells co-cultured with SCF and fibroblasts expressed mMCP-4, suggesting that a fibroblast-derived mast cell maturation factor acted synergistically with SCF to mediate differentiation of B M-derived mast cells to connective tissue-type mast cells that respond to polybasic compounds. This unknown factor may be fibroblastderived eotaxin, since it similarly aids SCF in promoting or maintaining mast cell differentiation towards an mMCP-4-expressing mast cell. This suggestion correlates well with the observation that CCR-3 is preferentially expressed on human connective tissue mast cells, which express mMCP-4 (28). Co-operative induction of chemokine signalling by SCF has been demonstrated for haematopoietic progenitors (53). SDF-l~-mediated chemotaxis of the progenitor cell line, CTS, and of CD34 + bone marrow cells was enhanced by co-incubation of cells with SCE Treatment with SCF in combination with SDF- 1c~-induced phosphorylation of focal adhesion molecules, such as paxillin, and activation of p44/42 mitogen-activated kinase. While eotaxin has not been shown to induce the migration of mature (murine) mast cells, theoretically, downstream targets may also be co-operatively phosphorylated by CCR-3 and c-kit receptors, leading to mast cell activation, granule release and/or proliferation. Ftireder et al. (25) reported no promotion by six chemokines of SCF-induced mast cell or IL-3-induced basophil differentiation, although eotaxin was not tested. They used healthy human peripheral blood mononuclear cells as a source of mast cells. Very little is known about mast cell progenitor development during gestation. Murine mast cell precursors have been detected in the yolk sac as early as 9.5dpc by an in vivo limiting dilution method (64). At 9.5dpc, the concentration of mast cells in the yolk sac was 30 times greater than that found within the embryo body. The concentration peaked in the yolk sac at lldpc, then rapidly declined at 13dpc. Simultaneously, the number of
42
ELIZABETH J. QUACKENBUSH
et al.
fetal liver mast cell precursors rose from 1ldpc until 15dpc, reaching a concentration at 15dpc that was comparable to that seen in yolk sac at 11dpc. Mast cell precursors from yolk sac at 10dpc and fetal liver at 12dpc responded better to SCF alone than to IL-3 combined with IL-1 (65), which may reflect acquisition of IL-3 and IL-1 receptors during development. In contrast, the number of mast cell colonies derived from adult bone marrow was slightly higher in the presence of IL-3 plus IL-1, compared with SCF alone. We found very low numbers of mature mast cells arising in our cultures from 1ldpc fetal liver cells grown with both factors, which correlates with data that the proportion of mast cell precursors in fetal liver is low at 11dpc, despite the large number of multipotent progenitors present. We do not suggest that mast cell progenitors were absent from fetal liver at 1l dpc, but rather that their responses to cytokines or chemokines may be age- and/or site-specific, as well as dependent on receptor expression and signalling patterns. Fetal liver-derived, but not yolk sac-derived, mast cell progenitors could replenish mast cell numbers in the mast cell-depleted murine strain WBB6F1-W/Wv mice, suggesting that definite (i.e. adult) mast cell stem cells were not present in the yolk sac (64). The effect of eotaxin on the differentiation of committed human mast cell progenitors isolated from cord blood was recently reported (66). Committed progenitors were cultured with SCF, IL-6 and IL-10 for 9 weeks. After 4 weeks, cultured cells were still phenotypically committed progenitors, and they expressed four chemokine receptors: CXCR-2, CCR-3, CXCR-4 and CCR5. These receptors mediated transient calcium fluxes in response to their respective ligands; furthermore, eotaxin and SDF-1 cz elicited chemotaxis of the committed progenitors (as did MIP-I~ and IL-8). By week 9, all progenitors had differentiated into mature mast cells and only CCR3 expression was retained. Interestingly, eotaxin now mediated a sustained calcium flux, but could no longer induce chemotaxis. In this study, eotaxin (either alone or in combination with SCF) was not mitogenic. We also examined the effect of eotaxin on embryonic progenitors older than 11dpc and found that eotaxin's ability to induce colony formation in combination with SCF was greatest for progenitors at l ldpc but then declined sharply at 12dpc, with no or few colonies induced from progenitors at 13-14dpc (data not shown). This was true for all three tissues tested, although the decline in the number of fetal liver-derived colonies after 11dpc was not nearly as sharp or as complete as with fetal blood and yolk sac tissues. The reduced effect after 1l dpc may reflect a decrease in the number of responsive progenitors, or a relative reduction secondary to a dilutional effect from the expansion of other cell types, or simply the result of migration out of a developmental compartment. Between 10 and 12dpc, the number of multipotent haematopoietic cells increases linearly in the circulation and exponentially in the fetal liver (67). Significant levels of acidified toluidine blue-positive mast cells (<7%) are found in the circulation of fetal blood from 15dpc until birth, and by day 10, postnatally, they are undetectable on peripheral smears (B. Quackenbush, unpublished observation). Agranular precursors committed to mast cell development are also present in human cord blood mononuclear cell populations (68). Thus, there appears to be a window of time perinatally during which mast cells (presumably) acquire the proper adhesion molecule repertoire needed for transmigration from the vasculature into target tissues. This hypothesis correlates with data obtained on tissue mast cell numbers in human fetal skin and airways at 24 weeks of gestation (69). Their numbers increased gradually during gestation, and then rose dramatically in the early post-natal period. Developmental
3.
MODULATIONOF MAST CELL DEVELOPMENT BY EOTAXIN
43
switches in the use of adhesion molecules necessary for lymphocyte trafficking have been reported to occur between birth and 48 h, postnatally (70), but perinatal changes in mast cell expression patterns have not been examined. These observations raise the questions as to why mast cell progenitors are so prevalent in the circulation prenatally and what is their role as a circulating cell. Mast cells and basophils may play early, key roles in newborn immune defence, as significantly greater levels of spontaneous and anti-IgE-induced histamine are released from cord blood basophils than from adult blood basophils (71). In addition to their role in allergic responses, mast cells and basophils also participate in the host defence against bacterial and viral infections (72), pathogens encountered in utero, along with parasites. Mast cells are selectively found at sites of bacterial entry, such as skin and mucosa, and mast celldeficient mice clear enterobacteria less efficiently than their wild-type littermates (73). Likewise, viral proteins, such as protein Fv, can trigger mediator release from human basophils and mast cells (74). In adult mice, eotaxin in combination with SCF also functions as a granulocyte macrophage colony stimulating factor (GM-CSF) (75). Peled et al. (75) cultured BM progenitors for 7 days with both factors and found a large increase in Gr-1 § cells. GR-1 expression is restricted to band and mature neutrophils (76). Mature neutrophils were not found in our cultures; however, day 12 yolk sac and splanchnopleural cultures could not support the growth of GR- 1+ cells in culture (77). The increase in Mac- 1 may be due to its upregulated expression on macrophages, stem cells or committed progenitors, given that it is co-expressed with c-kit and CD34 on stem/progenitor cells in fetal liver and the AGM region, but not on mature mast cells. Furthermore, our time of colony analysis (at 14 days), as well as the source of progenitors, may in part explain the appearance of mature mast cells and the lack of GR-1 + cells in our experiments, as mast cells would be lateappearing cells in methylcellulose cultures. Human mast cell progenitors from cord blood retained their potential to differentiate into mature mast cells after prolonged culture (3 weeks) with GM-CSF alone. Mature mast cells emerged in culture only after subsequent transfer into SCF-containing medium (78). Fewer mature mast cells were produced compared to cultures grown with SCF alone, suggesting that at least a subset of mast cell progenitors were resistant to the lineage-determining effect of GM-CSE Interestingly, the adhesion molecule VLA-4 was downregulated on colony progeny induced with SCF and eotaxin, and pertussis toxin upregulated VLA-4 (c~413~)expression when it was combined with SCF and eotaxin (data not shown). The expression pattern of VLA-4 on murine BM mast cells during differentiation has been investigated by others (79). VLA-4 levels on IL-3-supported mast cells peaked at 3 weeks and then declined to undetectable levels by 12 weeks of culture, when mature mast cells predominated. The observed inverse correlation between VLA-4 and terminal differentiation of mast cells is analogous to VLA-5 expression during keratinocyte differentiation (80). We found red blood cells, mast cells and Mac-1 § cells (primarily macrophages, based on morphology) in our methylcellulose cultures. SCF alone can induce extensive proliferation of human erythroid progenitors (81), but chemokine-induced proliferation has not been studied. In our system, eotaxin alone has minimal effect on induction of CFU-E. Thus, the progenitor we expand may be capable of multipotency or we are simultaneously expanding different committed progenitors. In human fetuses at 23-34 weeks of gestation, blood obtained by percutaneous umbilical cord sampling had a surprisingly large proportion of eosinophils (42 + 26%) (82). Eotaxin may, thus, play a
44
E L I Z A B E T H J. Q U A C K E N B U S H et al.
role in the expansion of multiple granulocytic subsets during fetal development, in the absence of inflammation or infection. The yolk sac at 9-10dpc contains committed progenitors, mainly erythroid and myeloid, that migrate to the fetal liver as part of the first wave of migrating cells. We have not analysed yolk sac from 9dpc, but our peak of colony-forming activity with SCF and eotaxin (11-12dpc) correlated better temporally with a second wave of progenitors into the fetal liver. This wave includes multipotent progenitors and long-term repopulating cells from the AGM and yolk sac. The fact that adult BM progenitors lacking mature lineage markers can also be synergistically induced with SCF and eotaxin implies that a definitive progenitor is responding (75). Two independent groups generated eotaxin-deficient mice and the number of circulating eosinophils, as well as the number of eosinophils recruited into ovalbumintreated, inflamed airways, differed between the two groups. Rothenberg et al. (83) reported that the number of circulating eosinophils, as well as eosinophil recruitment into ovalbumin-treated inflamed airways, was reduced, while Yang et al. (84) found that the lack of eotaxin did not reduce circulating eosinophil levels or lung eosinophilia induced by aerosolized ovalbumin. The differences found may be due to the genetic backgrounds of the mice used. In summary, our study shows that eotaxin can modulate granulopoiesis, specifically mast cell differentiation, from fetal progenitors and suggests that the study of chemokines during development is a novel and unique approach to understanding many pathological processes in the adult, as well. We propose that eotaxin production and use by activated mast cells contributes to allergic or inflammatory responses, such as antigen-induced lung inflammation, by promoting cellular activation, leukocyte recruitment and tissue damage.
REFERENCES 1. 2. 3. 4. 5. 6. 7.
8.
9.
Rollins, B. J. Chemokines. Blood 90:909-928, 1997. Miller, M. D. and Krangel, M. S. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. Crit. Rev. Immunol. 12:17-46, 1992. Bokoch, G. M. Chemoattractant signaling and leukocyte activation. Blood 86:1649-1660, 1995. Bargatze, R. E and Butcher, E. C. Rapid G protein-regulated activation event involved in lymphocyte binding to high endothelial venules. J. Exp. Med. 178:367-372, 1993. Murphy, P. M. The molecular biology of leukocyte chemoattractant receptors. Annu. Rev. Immunol. 12:593-633, 1994. Springer, T. A. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol. 57:827-872, 1995. Rothenberg, M. E., Luster, A. D. and Leder, P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc. Natl. Acad. Sci. USA 92:8690-8694, 1995. Gonzalo, J-A., Jia, G.-Q., Aguirre, V., Friend, D., Coyle, A. J., Jenkins, N. A., Lin, G.-S., Katz, H., Lichtman, A., Copeland, N., Kopf, M. and Guti6rrez-Ramos, J.-C. Mouse eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. Immunity 4:1-14, 1996. Rot, A., Krieger, M., Brunner, T., Bischoff, S. C., Schall, T. J. and Dahinden, C. A. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J. Exp. Med. 176:1489-1495, 1992.
3. 10.
11.
12.
13.
14.
15.
16.
17.
18. 19.
20. 21.
22.
23.
24. 25.
26.
27.
M O D U L A T I O N OF MAST CELL D E V E L O P M E N T BY EOTAXIN
45
Van Damme, J., Proost E, Lenaerts, J. E and Opdenakker, G. Structural and functional identification of two human, tumor-derived monocyte chemotactic proteins (MCP-2 and MCP-3) belonging to the chemokine family. J. Exp. Med. 176:59-65, 1992. Jia, G.-Q., Gonzalo, J. A., Lloyd, C., Kremer, L., Lu, L., Martinez-A. C., Wershil, B. K. and GutierrezRamos, J.-C. Distinct expression and function of the novel mouse chemokine monocyte chemotactic protein-5 in lung allergic inflammation. J. Exp. Med. 184:1939-1951, 1996. Uguccioni, M., Mackay, C. R., Ochensberger, B., Loetscher, E, Rhis, S., LaRosa, G. J., Rao, E, Ponath, E D., Baggiolini, M. and Dahinden, C. A. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J. Clin. Invest. 100:1137-1143, 1997. Kelner, G. S., Kennedy, J., Bacon, K. B., Kleyensteuber, S., Largaspada, D. A., Jenkins, N. A., Copeland, N. G., Bazan, J. E, Moore, K. W., Schall, T. J. and Zlotnik, A. Lymphotactin: a cytokine that represents a new class of chemokine. Science 266:1395-1399, 1994. Bazan, J. E, Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A. and Schall, T. J. A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640-644, 1997. Pan, Y., Lloyd, C., Zhou, H., Dolich, S., Deeds, J., Gonzalo, J. A., Vath, J., Gosselin, M., Ma, J., Dussault, B., Woolf, E., Alperin, G., Culpepper, J., Gutierrez-Ramos, J.-C. and Gearing, D. Neurotactin: a membrane-anchored chemokine upregulated in brain inflammation. Nature 387:611-617, 1997. Clark-Lewis, I., Schumacher, S., Baggiolini, M. and Moser, B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs: critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J. Biol. Chem. 226:23128-23134, 1991. Dahinden, C. A., Kurimoto, Y., De Weck, A. L., Lindsey, I., Dewald, B. and Baggolini, M. The neutrophil activating peptide NAF/NAP-1 induces histamine and leukotriene release by interleukin 3primed basophils. J. Exp. Med. 170:1787-1792, 1989. White, M. V., Yoshimura, T., Hook, W., Kaliner, M. and Leonard, E. J. Neutrophil attractant/activation protein (NAP- 1) causes human basophil histamine release. Immunol. Lett. 22:151-154, 1989. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. E and Sharpe, R. J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77-79, 1990. Nagasawa, T., Kikutani, H. and Kishimoto, T. Molecular cloning and structure of a pre-B-cell growthstimulating factor. Proc. Natl. Acad. Sci. USA 91:2305-2309, 1994. Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodrowski, J. and Springer, T. A. The lymphocyte chemoattractant SDF-lt~ is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382:829-833, 1996. Gibbs, B. E, Haas, H., Falcone, E H., Albrecht, C., Volrath, I. B., Noll, T., Wolff, H. H. and Amon, U. Purified human peripheral blood basophils release interleukin-13 and pre-formed interleukin-4 following immunological activation. Eur. J. Immunol. 26:2493-2498, 1996. Ochensberger, B., Tassera, L., Bifare, D., Rihs, S. and Dahinden, C. A. Regulation of cytokine expression and leukotriene formation in human basophils by growth factors, chemokines and chemotactic agents. Eur. J. Immunol. 29:11-22, 1999. Bischoff, S. C., Kreiger, M., Brunner, T. and Dahinden, C. A. Monocyte chemoattractant protein- 1 is a potent activator of human basophils. J. Exp. Med. 175:1271-1275, 1992. Ftireder, W., Agis, H., Semper, H., Keil, E, Maier, U., Mtiller, M. R., Czerwenka, K., HOfler, H., Lechner, K. and Valent, E Differential response of human basophils and mast cells to recombinant chemokines. Ann. Hematol. 70:251-258, 1995. Hartmann, K., Beiglbock, E, Czarnetzki, B. M. and Zuberbier, T. Effect of CC chemokines on mediator release from human skin mast cells and basophils. Int. Arch. Allergy Immunol. 108:224-230, 1995. Petersen, L. J., Brasso, K., Pryds, M. and Skov, E S. Histamine release in intact human skin by monocyte chemoattractant factor-1, RANTES, macrophage inflammatory protein-1 t~, stem cell factor, anti-IgE and codeine as determined by an ex vivo skin microdialysis technique. J. Allergy Clin. Immunol. 98: 790-796, 1996.
46 28.
29. 30.
31.
32.
33.
34.
35.
36.
37.
38. 39.
40. 41.
42. 43.
44.
45.
46.
E L I Z A B E T H J. Q U A C K E N B U S H et al. Romagnani, E, De Paulis, A., Beltrame, C., Annuziato, E, Dente, V., Maggi, E., Romagnani, S. and Marone G. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am. J. Pathol. 155:1195-1204, 1999. Alam, R., Forsythe, P. A., Stafford, S., Lett-Brown, M. A. and Grant, J. A. Macrophage inflammatory protein-lo~ activates basophils and mast cells. J. Exp. Med. 176:781-786, 1992. Campbell, E. M., Charo, I. K., Kunkel, S. L., Strieter, R. M., Boring, L., Gosling, J. and Lukacs, N. W. Monocyte chemoattractant protein- 1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. J. lmmunol. 163:2160-2167, 1999. Taub, D., Dastych, J., Inamura, N., Upton, J., Kelvin, D., Metcalfe, D. D. and Oppenheim, J. Bone marrow-derived murine mast cells migrate, but do not degranulate, in response to chemokines. J. Immunol. 154:2393-2402, 1995. Conti, P., Reale, M., Barbacane, R. C., Felaco, M., Grilli, A. and Theoharides, T. C. Mast cell recruitment after subcutaneous injection of RANTES in the sole of the rat paw. Br. J. Haematol. 103:798-803, 1998. Nilsson, G., Mikovits, J. A., Metcalfe, D. D. and Taub, D. D. Mast cell migratory response to interleukin-8 is mediated through interaction with chemokine receptor CXCR2/interleukin-8RB. Blood 93:2791-2797, 1999. Lippert, U., Artuc, M., Grutzkau, A., Moller, A., Kenderessy-Szabo, A., Schadendorf, D., Norgauer, J., Hartmann, K., Schweitzer-Stenner, R., Zuberbier, T., Henz, B. M. and Kruger-Krasagakes, S. Expression and functional activity of the IL-8 receptor type CXCR 1 and CXCR2 on human mast cells. J. Immunol. 161:2600-2608, 1998. Wang, H. W., Tedla, N., Lloyd, A. R., Wakefield, D. and McNeil, E H. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J. Clin. Invest. 102:1617-1626, 1998. Lukacs, N. W., Hogaboam, C. M., Kunkel, S. L., Chensue, S. W., Burdick, M. D., Evanoff, H. L. and Strieter, R. M. Mast cells produce ENA-78, which can function as a potent neutrophil chemoattractant during allergic airway inflammation. J. Leukoc. Biol. 63:746-751, 1998. Rajakulasingam, K., Hamid, Q., O'Brien, E, Shotman, E., Jose, E J., Williams, T. J., Jacobson, M., Barkans, J. and Durham, S. R. RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am. J. Respir. Crit. Care Med. 155:696-703, 1997. Selvan, R. S., Butterfield, J. H. and Krangel, M. S. Expression of multiple chemokine genes by a human mast cell leukemia. J. Biol. Chem. 269:13893-13898, 1994. Yano, K., Yamaguchi, M., de Mora, E, Lantz, C. S., Butterfield, J. H., Costa, J. J. and Galli, S. J. Production of macrophage inflammatory protein-lalpha by human mast cells: increased anti-IgEdependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab. Invest. 77:185-193, 1997. Ramsaeng, V., Vliagoftis, H., Oh, C. K. and Metcalfe, D. D. Lymphotactin gene expression in mast cells following Fce receptor I aggregation. J. lmmunol. 158:1353-1360, 1997. Nakajima, T., Yamada, H., Iikura, M., Miyamasu, M., Izumi, S., Shida, H., Ohta, K., Imai, T., Yoshie, O., Mochizuki, M., Schroder, J. M., Morita, Y., Yamamoto, K. and Hirai, K. Intracellular localization and release of eotaxin from normal eosinophils. FEBS Lett, 434:226-230, 1998. Lu, L. and Wershil, B. K. Substance P induces eotaxin production by murine mast cells grown in stem cell factor. FASEB J. 12:A881, 1998. Cook, E. B., Stahl, J. L., Lilly, C. M., Haley, K. J., Sanchez, H., Luster, A. D., Graziano, E M. and Rothenberg, M. E. Epithelial cells are a major source of the chemokine eotaxin in the guinea pig lung. Allergy Asthma Proc. 19:15-22, 1998. Jinquan, T., Quan, S., Feili, G., Larsen, C. G. and Thestrup-Pedersen, K. Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. J. Immunol. 162:4285-4292, 1999. Lamkhioused, B., Renzi, E M., Abi-Younes, S., Garcia-Zepada, E. A., Allakhverdi, Z., Ghaffer, O., Rothenberg, M. D., Luster, A. D. and Hamid Q. Increased expression of eotaxin in bronchioalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J. Immunol. 159:4593-4601, 1997. Harris, R. R., Komater, V. A., Marett, R. A., Wilcox, D. M. and Bell, R. L. Effect of mast cell deficiency
3.
M O D U L A T I O N OF M A S T CELL D E V E L O P M E N T BY E OT AXIN
47
and leukotriene inhibition on the influx of eosinophils induced by eotaxin. J. Leukoc. Biol. 62:688-691, 1997. 47. Das, A. M., Flower, R. J. and Perritti, M. Resident mast cells are important for eotaxin-induced eosinophil accumulation in vivo. J. Leukoc. Biol. 64:156-162, 1998. 48. Forssmann, U., Uguccioni, M., Loetscher, E, Dahinden, C. A., Langen, H., Thelen, M. and Baggiolini, M. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J. Exp. Med. 185:2171-2176, 1997. 49. Rodewald, H.-R., Dessing, M., Dvorak, A. M. and Galli, S. J. Identification of a committed precursor for the mast cell lineage. Science 217:818-822, 1997. 50. Martin, C., Beaupain, D. and Dieterlen-Lievre, E A study of the development of the hemopoietic system using quail-chick chimeras obtained by blastoderm recombination. Dev. Biol. 75:303-314, 1980. 51. Dzierzak, E. and Medvinsky, A. Mouse embryonic hematopoiesis. Trends Genet. 11:359-366, 1995. 52. Ikuta, K. and Weissman, I. L. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc. Natl. Acad. Sci. USA 89:1502-1506, 1992. 53. Dutt, P., Wang, J. F. and Groopman, J. E. Stromal cell-derived factor-1 alpha and stem cell factor&it ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis. J. Immunol. 161:3652-3658, 1998. 54. Yoder, M. C., Hiatt, K., Dutt, P., Mukherjee, P., Bodine, D. M. and Orlic, D. Characterization of definitive lymphohematopoietic stem cells in the day 9 murine yolk sac. Immunity 7:335-344, 1997. 55. S~nchez, M.-J., Holmes, A., Miles, C. and Dzierzak, E. Characterization of the first definitive hematopoietic stem cells in the AGM and liver of the embryo. Immunity 5:513-525, 1996. 56. Iemura A., Tsai, M., Ando, A., Wershil, B. K. and Galli, S. J. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am. J. Pathol. 144:321-328, 1994. 57. Dastych, J. and Metcalfe, D. D. Stem cell factor induces mast cell adhesion to fibronectin. J. Immunol. 152:213-219, 1994. 58. Levi-Schaffer, E and Rubinchik, E. Activated mast cells are fibrogenic for 3T3 fibroblasts. J. Invest. Dermatol. 104:999-1003, 1995. 59. Bartels, J., Schluter, C., Richter, E., Noso, N., Kulke, R., Christophers, E. and Schroder, J. M. Human dermal fibroblasts express eotaxin: molecular cloning, mRNA expression and identification of eotaxin sequence variants. Biochem. Biophys. Res. Commun. 225:1045-1051, 1996. 60. Mochizuki, M., Bartels, J. and Mallet, A. I. IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160:60-68, 1998. 61. Nilsson, G., Miettinen, U., Ishizaka, T., Ashman, L. K., Irani, A. M. and Schwartz, L. B. Interleukin-4 inhibits the expression of kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 84:1519-1527, 1994. 62. Yamaguchi, M., Sayama, K., Yano, K., Lantz, C. S., Noben-Trauth, N., Ra, C., Costa, J. J. and Galli, S. J. IgE enhances Fc epsilon receptor I expression and IgE-dependent release of histamine and lipid mediators from human umbilical cord blood-derived mast cells: synergistic effect of IL-4 and IgE on human mast cell Fc epsilon receptor I expression and mediator release. J. Immunol. 162:5455-5465, 1999. 63. Ogasawara, T., Murakami, M., Suzuki-Nishimura, T., Uchida, M. K. and Kudo, I. Mouse bone marrowderived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand. J. Immunol. 158:393-404, 1997. 64. Sonoda, T., Hayashi, C. and Kitamura, Y. Presence of mast cell precursors in the yolk sac of mice. Dev. Biol. 97, 89-94, 1983. 65. Keller, G., Kennedy, M., Papayannopoulou, T. and Wiles, M. V. Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol. Cell. Biol. 13:473-486, 1993. 66. Ochi, H., Hirani, W. M., Yuan, Q., Friend, D. S., Austen, E K. and Boyce, J. A. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J. Exp. Med. 190:267-280, 1999. 67. Delassus, S. and Cumano, A. Circulation of hematopoietic progenitors in the mouse embryo. Immunity 4:97-106, 1996.
48 68.
69. 70.
71.
72. 73. 74. 75.
76.
77. 78.
79.
80.
81.
82. 83.
84. 85.
86.
87.
E L I Z A B E T H J. Q U A C K E N B U S H et al. Dvorak, A. M., Furitsu, T. and Ishizaka, T. Ultrastructural morphology of human mast cell progenitors in sequential cocultures of cord blood and fibroblasts. Int. Arch. Allergy Immunol. 100:219-229, 1993. Omi, T., Kawanami, O., Honda, M. and Akamatsu, H. Human mast cells under development of the skin and airways.Aerugi 40:1407-1414, 1991. Mebius, R. E., Streeter, E R., Michie, S., Butcher, E. C. and Weissman, I. L. A developmental switch in lymphocyte homing receptor and endothelial vascular addressin expression regulates lymphocyte homing and permits CD4+CD3 - cells to colonize lymph nodes. Proc. Natl. Acad. Sci. USA 93:11109-11024, 1996. Damsgaard, T. E., Nielsen, B. W., Henriques, U., Hansen, B., Herlin, T. and Schiotz, E O. Histamine releasing cells of the newborn. Mast cells from the umbilical cord matrix and basophils from cord blood. Pediatr. Allergy Immunol. 7:83-90, 1996. Marone, G., Casolaro, V., Patella V., Florio G. and Triggiani, M. Molecular and cellular biology of mast cells and basophils. Int. Arch. Allergy Immunol. 114:207-217, 1997. Echtenacher, B., Mannel, D. N. and Hultner, L. Critical protective effect of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996. Patella, V., Bouvet, J.-E and Marone, G. Protein Fv produced during viral hepatitis is a novel activator of human basophils and mast cells. J. Immunol. 151:5685-5698, 1993. Peled, A., Gonzalo, J.-A., Lloyd, C. and Gutierrez-Ramos, J.-C. The chemotactic cytokine eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung development. Blood 91:1909-1916, 1998. Fleming, T. J., Fleming, M. L. and Malek, T. R. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAB to granulocyte differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151:2399-2408, 1993. Cumano, A., Dieterlen-Lievre, E and Godin, I. Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. Cell 86:907-916, 1996. Hjertson, M., Sundstrom, C., Nilsson, K. and Nilsson, G. The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with fit3 ligand, interleukin-3 or granulocyte-macrophage colony stimulating factor. Br. J. Haematol. 104:516-522, 1999. Fehlner-Gardiner, C. C., Uniyal, S., von Ballestrem, C. G. and Chan, B. M. C. Differential utilization of VLA-4 (o~4~1) and -5 (od[31) integrins during the development of mouse bone marrow-derived mast cells. Differentiation 60:317-325, 1996. Adams, J. C. and Watt, E M. Changes in keratinocyte adhesion during terminal differentiation: reduction in fibronectin binding preceded o~5131 integrin loss from the cell surface. Cell 63:425-435, 1990. Olweus, J., Terstappen, L. W. M. M., Thompson, E A. and Lund-Johansen E Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitors cells. Blood 88:1594-1607, 1996. Smith, J. B. and Tabsh, K. M. Fetal neutrophils and eosinophils express normal levels of L-selectin. Pediatr. Res. 34:253-257, 1993. Rothenberg, M. E., MacLean, J. A., Pearlman, E., Luster, A. D. and Leder, E Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J. Exp. Med. 185:785-790, 1997. Yang, Y., Loy, J., Ryseck, R. E, Carrasco, D. and Bravo, R. Antigen-induced eosinophilic lung inflammation develops in mice deficient in chemokine eotaxin. Blood 92:3912-3923, 1998. Garcia-Zepeda, E. A., Combadiere, C., Rothenberg, M. E., Sarafi, M. N., Lavigne, E, Hamid, Q., Murphy, E M. and Luster A. D. Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. J. Immunol. 157:5613-5626, 1996. Yamada, H., Hirai, K., Miyamasu, M., Iikura, M., Misaki, Y., Shoji, S., Takaishi, T., Kasahara, T., Morita, Y. and Ito, K. Eotaxin is a potent chemokine for human basophils. Biochem. Biophys. Res. Commun. 231:365-368, 1997. Krieger, M., Brunner, T., Bischoff, S. C., Tschainer, V., Walz, A., Moser, B., Baggiolini, M. and Dahinden, C. A. Activation of human basophils through the interleukin receptor. J. Immunol.
3. 88.
89.
90. 91.
M O D U L A T I O N OF M A S T C E L L D E V E L O P M E N T BY E O T A X I N
49
8:2662-2667, 1992. Matthews, A. N., Friend, D. S., Zimmermann, N., Sarafi, M. N., Luster, A. D., Pearlman, E., Wert, S. E., Rothenberg, M. E. Eotaxin is required for the baseline level of tissue eosinophils. Proc. Natl. Acad. Sci. USA. 95:6273-6278, 1998. Gonzalo, J-A., Lloyd, C. M., Wen, D., Albar, J. P., Wells, T. N., Proudfoot, A., Martinez-A. C., Dorf, M., Bjerke, T., Coyle, A. J. and Gutierrez-Ramos, J.-C. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188:157-167, 1998. Medvinsky, A. and Dzierzak, E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 86:897-906, 1996. Hogaboam, C., Kunkel, S. L., Strieter, R. M., Taub, D. D., Lincoln, P., Standiford, T. J., Lukacs, N. W. Novel role of transmembrane SCF for mast cell activation and eotaxin production in mast cellfibroblast interactions. J. Immunol. 160:6166-6171, 1998.
This Page Intentionally Left Blank
CHAPTER 4
Regulation and Dysregulation of Mast Cell Survival and Apoptosis KARIN H A R T M A N N 1 and D E A N D. METCALFE *e 1Department of Dermatology, University of Cologne, Germany and 2Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, U.S.A.
INTRODUCTION Mast cells are long-living cells. In contrast to other inflammatory cells such as eosinophils and neutrophils, mast cells live for several months (1). This prolonged survival of mast cells appears to depend upon intrinsic mast cell regulators as well as upon local factors in the tissues where mast cells reside. Other than stem cell factor (SCF), which appears to be the most important survival factor for murine and human mast cells (2, 3), additional requirements for the survival of mast cells are not well characterized. It is likely that a complex interplay between mast cells and surrounding cells, mediators and extracellular matrix proteins ensures the prolonged survival of tissue mast cells (4). Development and survival of metazoans require a balance between cell proliferation and cell death. Physiologically, most cells are terminated by a genetically programmed, active form of cell death termed 'apoptosis' (5). Apoptosis is now known to be a highly regulated, complex biological event. It is closely linked to other biological processes, including proliferation and differentiation. Apoptotic cells are morphologically characterized by vacuolization of the cytoplasm, blebbing of the cell membrane, loss of microvilli, condensation of chromatin and fragmentation of the nucleus. Extracellular mechanisms that induce apoptosis include deprivation of growth factors (6), stimulation of so-called 'death receptors' on the cell surface, perforin, nitric oxide, bacterial toxins, ultraviolet and y-irradiation and chemical agents. Apoptosis induced by deprivation of growth factors may be prevented by the addition of other growth factors or by adhesion to extracellular matrix proteins (7, 8). Death receptors include CD95/Fas/APO-1, two TRAIL/APO-2 receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) and one receptor for tumour necrosis factor-a (TNFc~-R1/p55/CD 120a) (9). * Corresponding author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
51
Copyright 9 2000Academic Press All rights of reproductionin anyform reserved
52
KARIN HARTMANN AND DEAN D. METCALFE
Induction of apoptosis by the different extracellular mechanisms is tightly regulated by intracellular proteins. Of these, the Bcl-2 family of proteins has been identified as among the most important intracellular regulators of apoptosis (10, 11). Members of the Bcl-2 family include apoptosis-inhibiting, anti-apoptotic molecules such as Bcl-2, Bcl-XL and Mcl-1, as well as apoptosis-inducing, pro-apoptotic molecules such as Bax and Bad (12, 13). Bcl-2 proteins regulate different forms of apoptosis induction downstream. These include the apoptotic pathway induced by deprivation of growth factors or by stimulation of CD95. Bcl-2 proteins do not appear to participate in all forms of apoptotic signalling. Anti-apoptotic Bcl-2 proteins that are localized in the outer membrane of mitochondria inhibit the action of caspases, another group of intracellular proteins that mediate apoptosis (14). In contrast, the pro-apoptotic cytosolic Bax forms heterodimers with Bcl2 or Bcl-XL that form ion channels in the outer mitochondrial membrane (15). Through these ion channels, cytochrome c and other apoptosis-inducing mitochondrial molecules may be released. Other well-described intracellular modulators of apoptosis include the tumour suppressor p53, the oncogen c-Myc and the nuclear factor NF-vd3. The gene product of p53 induces apoptosis in transformed or virus-infected cells. Accordingly, in many tumours, inactivation of p53 by point mutations has been observed, c-Myc also acts in a pro-apoptotic manner. Overexpression of Myc enhances induction of apoptosis secondary to deprivation of growth factors. In contrast, NF-~B inhibits apoptosis induction by CD95 ligand, TRAIL or TNF-~. Phagocytotic cells recognize apoptotic cells by altered expression of cell surface molecules such as thrombospondin and phosphatidyl serine, and phagocytose these cells which become small 'apoptotic bodies'. The membrane of these apoptotic bodies is mainly intact. This assures that, during apoptosis, in contrast to necrosis, there is little if any release of mediators into the microenvironment. As recently demonstrated, mast cells that contain large amounts of cytotoxic enzymes and cytokines also do not release inflammatory mediators during apoptosis (16). Recent research has revealed that many diseases are associated with dysregulation of apoptosis (17). Diseases with a primary deficiency of apoptosis include autoimmune diseases, graft rejection, viral infections and tumours (18). In contrast, a primary excess of apoptosis has been observed in neurodegenerative disorders and diseases of the myocardium.
REGULATION OF MAST CELL SURVIVAL AND APOPTOSIS BY GROWTH FACTORS Apoptosis of mast cells has been demonstrated in vivo. In one study, an increase of mast cells in mouse skin and spleen was first induced by subcutaneous injections of SCF (19). After cessation of SCF treatment, mast cell numbers rapidly declined. Remaining mast cells showed typical morphological findings of apoptosis, thus confirming in vitro data that SCF-dependent mast cells undergo apoptosis after deprivation of SCE In another series of experiments, the mechanism by which corticosteroids decrease mast cell numbers was investigated (20). Corticosteroids were shown to decrease local SCF production by fibroblasts in association with enhanced apoptosis of mast cells. Since glucocorticoids did not affect mast cell survival in vitro directly, these data suggest that glucocorticoids indirectly induce mast cell apoptosis in tissues by downregulating SCF production in the microenvironment.
4.
MAST CELL SURVIVALAND APOPTOSIS
53
The regulation of murine mast cell survival by growth factors has been defined in vitro. Murine interleukin-3 (IL-3)-dependent bone marrow-cultured mast cells (BMCMC) undergo apoptosis after deprivation of IL-3 (6, 19, 21). The addition of SCF prevents apoptosis of BMCMC after IL-3 withdrawal when added until up to 1 h after growth factor deprivation (6). Similarly, SCF-dependent BMCMC underwent apoptosis after removal of SCF, and IL-3 was then capable of protecting the SCF-starved BMCMC from apoptosis (21). Since SCF failed to inhibit apoptotic changes in BMCMC cultured from c-kit-mutated W/Wv mice, it was concluded that SCF prevents apoptosis via binding to ckit (6). In addition, SCF prevents apoptosis directly and not through the release of other cytokines, because dexamethasone and cyclosporin A failed to inhibit the apoptosis protection by SCE Although transforming growth factor-~ (TGF-I]), which is known to induce apoptosis in many other cell types, does not induce apoptosis of BMCMC, it prevents the rescue effect of SCF after IL-3 deprivation (22). This effect of TGF-~ is believed to be mediated by downregulation of c-kit expression (23). In immature BMCMC cultured for 10-15 days in IL-3, insulin-like growth factor I (IGF-I) has additionally been found to prevent apoptosis after IL-3 removal (24). Thus, growth factor-dependent survival of murine BMCMC, as currently understood, is regulated by SCF, IL-3, TGF-~ and IGF-I. A recent study demonstrated differences between SCF- and IL-3-mediated protection from apoptosis in mouse mast cells in relation to the regulation of these protective mechanisms by calcium influx (25). Inhibition of calcium influx by econazole or ketotifen abrogated the SCF-dependent survival of BMCMC but did not affect IL-3dependent survival. These observations suggested that calcium influx is necessary only for SCF-mediated rescue from apoptosis in BMCMC. Accordingly, the murine growth factor-independent mastocytoma cell line P815, which expresses a mutated, constitutively active c-kit, underwent apoptosis in response to calcium influx inhibitors without SCF being present. Experiments with cycloheximide, a known inhibitor of protein synthesis, revealed that active protein synthesis is an additional prerequisite for SCF-mediated suppression of apoptosis in BMCMC (21). Moreover, herbimycin, a known inhibitor of tyrosine kinases, has been reported to inhibit SCF-dependent protection of BMCMC from death, indicating that tyrosine kinases also take part in SCFmediated survival (6). An interesting recent study showed that SCF-mediated survival as well as proliferation of BMCMC additionally depends on phosphatidyl-3'-kinase (PI 3kinase) and Src kinases (26). To induce SCF-dependent proliferation, but not survival, PI 3-kinase and Src kinase pathways in turn also activated the small G protein Rac 1 and protein kinase JNK (c-jun N-terminal kinase), thus dissecting different signalling pathways for SCF-induced proliferation and suppression of apoptosis. Moreover, IL-3-mediated survival of murine mast cells has been found to depend upon Bcl-2. In SCF-dependent BMCMC, IL-3 added after deprivation of SCF significantly induced Bcl-2 gene expression (21). In contrast, inhibition of apoptosis by SCF failed to induce Bcl-2 expression in BMCMC, but correlated with an enhanced expression of Bax RNA. In agreement with this observation, another study found that apoptosis of the IL-3dependent murine mast cell line CFTL-15 in response to IL-3 deprivation was associated with a decrease of Bcl-2 mRNA (27). In addition, transfection of CFTL-15 cells with Bcl2 cDNA prolonged survival of CFTL-15 cells after removal of IL-3. In comparison with Bcl-2 family proteins, p53 does not seem to play a major role in the regulation of SCFdependent survival of BMCMC. This is indicated by experiments in which p53-deficient BMCMC from p53-mutated mice showed a similar induction of apoptosis in response to
54
KARIN HARTMANN AND DEAN D. METCALFE
SCF withdrawal compared with wild-type BMCMC with functional p53 (21). Thus, different signalling pathways modulated by calcium influx, tyrosine kinases, PI 3-kinase, Src kinases and Bcl-2 family proteins have been implicated in the regulation of IL-3dependent versus SCF-dependent survival as well as SCF-mediated proliferation versus survival of murine mast cells. Nerve growth factor (NGF) has also been shown to prevent apoptosis of rat peritoneal mast cells (28). Whereas SCF also induced proliferation of rat peritoneal mast cells, NGF had no effect on proliferation. This observation suggests that SCF and NGF promote mast cell survival by different mechanisms (29). The ability of NFG to rescue mast cells from apoptosis was dependent on the density of cells (28) as well as on binding to the p140 'rk NGF receptor. Tyrosine kinase inhibitors thus blocked phosphorylation of the p140 'r~ tyrosine kinase (29). NGF has also been reported to cause an increase in mRNA expression for IL-3, IL-4, IL-10, TNF-o~ and granulocyte-macrophage colonystimulating factor (GM-CSF) (30). Cyclosporin A inhibited both the induction of cytokines and NGF-dependent survival, but not survival dependent on SCF or IL-3. It is therefore likely that NGF prevents apoptosis of rat mast cells indirectly in an autocrine fashion via release of cytokines that promote viability. NGF, SCF and IL-3 all induced expression of Bcl-2 mRNA in rat mast cells. However, they had no effect on the mRNA expression of Bax, Bcl-XL, Bcl-Xs, caspase-1 and caspase-3. These observations on the intracellular regulation of apoptosis in rat peritoneal mast cells suggest that SCFdependent survival of mouse BMCMC and rat peritoneal mast cells might be regulated in a different manner. In contrast to murine mast cells, less is known about the regulation of human mast cell viability. Primary human mast cells cultured from cord blood mononuclear cells in SCF and IL-6 underwent apoptosis over a period of 5 days after withdrawal of SCF and IL-6 (31). SCF alone was able to fully prevent apoptosis, whereas IL-6 alone only gradually inhibited the apoptotic process. IL-3, IL-4, IL-5 and interferon- 7 (INF-y) have also been reported to enhance survival of cord blood-derived human mast cells (31, 32). In contrast to previous reports examining human lung mast cells (33), cord blood-derived human mast cells were said to express IL-3 receptors (31). The survival-promoting effect of INFy was comparable at different cell densities, suggesting that this effect was induced directly by INF-y without the involvement of autocrine factors (32). In contrast, IFN-y has been reported to inhibit mast cell development in SCF-dependent human bone marrow cell cultures (33). Other cytokines tested, such as IL-2, IL-9, IL-10, IL-11, TNFa, TGF[3, NGF and M-CSF, failed to enhance the viability of cord blood-derived mast cells (31). Taken together, SCF, IL-3, IL-4, IL-5, IL-6, and possibly INF-y promote survival of human mast cells depending on their derivation.
REGULATION OF MAST CELL SURVIVAL AND APOPTOSIS BY DEATH RECEPTORS
Surface expression of CD95/Fas has been described on murine BMCMC and peritoneal mast cells, on the murine mast cell lines C57 and MCP-5 (34), on the murine mastocytoma line P815 and on the human mast cell line HMC-1 (35). Stimulation of CD95 with anti-CD95 monoclonal antibody (mAb) or a Fas ligand-bearing T cell line demonstrated a different sensitivity toward CD95-induced apoptosis in the different murine mast cell types, suggesting a more complex regulation of this apoptotic pathway
4.
M A S T C E L L SURVIVAL A N D A P O P T O S I S
55
Fig. 1 Apoptosis of murine BMCMC after incubation with anti-Fas mAb and actinomycin D. (A) Giemsa staining of control BMCMB incubated with an isotype mAb. A normal morphology and dense cytoplasmatic granules are observed. (B) After treatment with anti-Fas mAb and actinomycin D for 48 h, apoptotic BMCMC are characterized by a decrease in size and an irregular shape. (C) Ultrastructure of control BMCMC incubated with an isotype mAb. A corrugated cell surface and regularly distributed nuclear chromatin are apparent. (D) After incubation with anti-Fas mAb and actinomycin D, the surface folds disappear. The cytoplasm is characterized by vacuolization, and the nuclear chromatin begins to condense.
that also appears to be independent of the amount of CD95 surface expression (34). C57 and P815 cells were highly susceptible to CD95 cross-linking and clearly underwent apoptosis after 24--48 h of stimulation with anti-CD95 mAb (34, 36). By contrast, BMCMC were at first resistant to CD95 stimulation. They underwent apoptosis only after the addition of the protein synthesis inhibitor actinomycin D (Fig. 1), thus suggesting a
56
KARIN HARTMANN AND DEAN D. METCALFE
functional CD95 pathway which might be tightly regulated by inhibiting intracellular proteins (34). In fact, experiments in which P815 cells were transfected with Bcl-2 cDNA demonstrated that overexpression of Bcl-2 protein inhibited CD95-mediated apoptosis (36). In contrast to BMCMC, the virus-transfected cell line MCP-5 was also resistant to CD95 stimulation in the presence of actinomycin D, suggesting yet another regulatory mechanism of the CD95 pathway in transfected mast cell lines (34). In addition, SCF, TGF-~I and Fc~RI aggregation enhanced CD95 expression on BMCMC, and SCF as well as TGF-[3 was shown to partially protect BMCMC against CD95-mediated apoptosis. In P815 cells, growth arrest at the G~ phase by thymidine or aphidicolin increased the susceptibility of these cells to CD95-mediated apoptosis (37). A recent study found that murine BMCMC also express CD95/Fas ligand (38). However, expression of CD95 ligand was restricted to an intracellular expression, as demonstrated by polymerase chain reaction (PCR), western blotting and flow cytometry. There was no CD95 ligand expression on the cell surface. Further, BMCMC were unable to kill CD95-expressing Jurkat cells. Additional experiments are necessary to determine whether certain stimuli lead to a surface expression of CD95 ligand and whether mast cell numbers might also be controlled by autocrine CD95-mediated apoptosis.
REGULATION OF MAST CELL SURVIVAL AND APOPTOSIS BY PERFORIN, NITRIC OXIDE AND BACTERIAL TOXINS Cytotoxic T cells kill their target cells via several independent pathways. In addition to killing induced by an interaction between death ligands, such as CD95 ligand on cytotoxic cells with CD95 receptors on target cells, cytotoxic cells also use a perforinmediated pathway. In this apoptotic pathway, the pore-forming protein perforin acts together with the degranulation of proteases (i.e. granzymes), which finally leads to target cell death. The murine mastocytoma line P815 has been indirectly shown to be sensitive to perforin-mediated apoptosis (36). Cytotoxic T cells from CD95 ligand-defective gld mice, in which only the perforin pathway is believed to be functional, still reduced the viability of P815 cells. Bcl-2-transfected P815 cells were somewhat more resistant to perforin-mediated killing, thus suggesting common regulation of the CD95- and perforin-mediated apoptotic pathways regarding Bcl-2 family proteins. In contrast to CD95-mediated apoptosis, growth arrest at the G~ phase of the cell cycle inhibited the susceptibility of P815 cells to perforin-induced lysis (37). Another stimulus that is well known to cause apoptosis in different cell types is nitric oxide, which is synthesized by nitric oxide synthase in most cell types (39). Low concentrations of nitric oxide have homeostatic roles in the circulation and nervous system, whereas high concentrations are cytocidal and have immunomodulatory roles. One study reports that nitric oxide secreted from fibroblasts induces apoptosis of murine IL-3-dependent BMCMC when fibroblasts and BMCMC are co-cultured (40). This apoptosis was blocked by a specific nitric oxide synthase inhibitor. SCF was also able to inhibit the induction of apoptosis by nitric oxide in BMCMC. In rat peritoneal mast cells, toxin A from Clostridium difficile has been reported to induce apoptosis at higher concentrations (41). After 4 h of treatment with toxin A, rat peritoneal mast cells exhibited typical features of apoptosis as assessed by electron microscopy and gel electrophoresis.
4.
MAST CELL SURVIVAL AND APOPTOSIS
57
REGULATION OF MAST CELL SURVIVAL AND APOPTOSIS BY IRRADIATION AND CHEMICAL AGENTS In murine BMCMC, y-irradiation has been demonstrated to induce apoptosis in vitro (21). Irradiation with 2500 rads rapidly induced apoptosis of the majority of BMCMC within 12 h. SCF was able to protect BMCMC from irradition-induced apoptosis. SCF was still effective in suppressing apoptosis when added to the BMCMC cultures until up to 1 h after irradiation and before the cells became irreversibly committed to apoptosis. The ability of SCF to suppress apoptosis was independent of the cell cycle phase in which BMCMC were irradiated (21) and dependent on activation of both PI 3-kinase and Src kinases (26). Since SCF is known to protect mice from lethal y-irradiation (42), it is possible that SCF exerts its radioprotective effect in vivo through inhibition of irradiation-induced apoptosis of stem cells. It has been reported that the protein synthesis inhibitor cycloheximide prevents apoptosis of BMCMC induced by irradiation. This observation demonstrates that irradiation-induced apoptosis requires active protein synthesis (21). p53 has been identified as one of the proteins regulating irradiation-induced apoptosis. This is based on the observation that BMCMC from p53-mutated mice were far less sensitive to irradiation than were wild-type BMCMC. We have recently shown that the protein synthesis inhibitor actinomycin D is effective in reducing survival of BMCMC and two murine mast cell lines (34). Concentrations of actinomycin D as low as 10 ng/ml clearly reduced the viability of BMCMC and the cell lines after 48 h. In line with this observation, another chemical agent, the protein kinase C inhibitor calphostin C, has recently been reported to induce apoptosis of the human mast cell line HMC-1 (43). Calphostin C-mediated apoptosis of HMC-1 cells was enhanced by adhesion to collagen type III and not affected by adhesion to fibronectin or laminin. This report thus demonstrates a direct influence of extracellular matrix proteins on mast cell apoptosis, as has been described for other cell types (8). Since murine BMCMC have been shown to proliferate in response to vitronectin (44), it is likely that extracellular matrix proteins may also contribute to the regulation of mast cell apoptosis. As noted, corticosteroids failed to affect survival of murine BMCMC. This is in contrast to other cell types such as T cells that rapidly undergo apoptosis in response to corticosteroids (20). Similarly, the human mast cell line HMC-1 also appears resistant to corticosteroid-mediated apoptosis (unpublished data). In another study, the effects of cyclosporin A and FK-506 were examined on the growth of SCF-dependent human tissue mast cells (45). Unexpectedly, cyclosporin A and FK-506 not only failed to suppress, but appeared to enhance, the SCF-dependent growth of human tissue mast cells. Whether human mast cells are truly resistant to immunosuppressive drugs or whether SCF induces the resistance in these mast cells systems remains to be investigated.
PERSPECTIVE: APOPTOSIS AND MAST CELL DISEASE Over the last several years, various diseases have been reported to be associated with a dysregulation of apoptosis (17, 18). We therefore hypothesize that dysregulation of mast cell apoptosis may also take part in the pathogenesis of mast cell disease. Thus, in several tumours and haematological diseases, mutations of different apoptosis genes as well as
58
KARIN H A R T M A N N AND D E A N D. M E T C A L F E
an altered expression of apoptosis-regulating proteins have been observed. Tumours with mutations in the p53 gene or its regulators such as mdm2 are in general more aggressive than comparable tumours without these mutations (46). Melanoma cells have been found to escape the attack of immune effector cells by the expression of CD95 ligand. This leads to induction of apoptosis in CD95-sensitive attacking cells (47). A specific overexpression of the apoptosis-inhibiting Bcl-XL promotes neoplastic proliferation in polycythaemia vera (48) and multiple myeloma (49). In the majority of patients with mastocytosis, somatic mutations of c-kit have been identified that lead to an autonomous proliferation of mast cells (50, 51). These mutations increase aggregation of c-kit, and are thus referred to as activating mutations. The most common of these is Asp816Val. It could thus be speculated that this autonomous growth in mastocytosis is the result of both enhanced proliferation as well as inhibition of apoptosis. Dysregulation of apoptosis may also play an important role in inflammatory processes (52). A recent study demonstrated that tissue eosinophilia in nasal polyps is associated with the expression of the eosinophilic growth factor IL-5 and delayed apoptosis of eosinophils (53). Inhibition of mast cell apoptosis may therefore also take part in the secondary increase of mast cells in inflammatory diseases. Thus, a better understanding of the regulation of mast cell apoptosis may also lead to new therapeutic approaches for patients with mast cell disorders.
REFERENCES 1.
2. 3. 4. 5.
6. 7. 8. 9. 10. 11. 12. 13.
14. 15.
Fodinger, M., Fritsch, G., Winkler, K., Emminger, W., Mitterbauer, G., Gadner, H., Valent, R and Mannhalter, C. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogenic bone marrow transplantation. Blood 84:2954-2959, 1994. Flanagan, J. G. and Leder, E The c-kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 63:185-194, 1990. Martin, E H., Suggs, S. V. and Langley, K. E. Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63:203-211, 1990. Metcalfe, D.D.,Baram, D. andMekori, Y.A. Mastcells. Physiol. Rev. 77:1033-1079, 1997. Kerr, J. E, Wyllie, A. H. and Currie A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239-257, 1972. Mekori, Y. A., Oh, C. K. and Metcalfe, D. D. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand. J. Immunol. 151:3775-3784, 1993. Meredith, J. E., Fazeli, B. and Schwartz, M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell 4:953-961, 1993. Anwar, A. R., Moqbel, R., Walsh, G. M., Kay, A. B. and Wardlaw, A. J. Adhesion to fibronectin prolongs eosinophil survival. J. Exp. Med. 177, 839-843, 1993. Ashkenazi, A. and Dixit, V. M. Death receptors: signaling and modulation. Science 281:1305-1308, 1998. Korsmeyer, S. J. Bcl-2: a repressor of lymphocyte death. Immunol. Today 13:285-288, 1992. Adams, J. M. and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326, 1998. Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nunez, G. and Thompson, C. B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1993. Thornberry, N.A. and Lazebnik, Y. Caspases: enemies within. Science 281:1312-1316, 1998. Yang, J., Liu, X., Bhalla, K., Kim, C. N., Ibrado, A. M., Cai, J., Peng, T. I., Jones, D. E and Wang, X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science
4. 16.
17. 18. 19. 20.
21.
22. 23.
24. 25. 26.
27.
28. 29.
30. 31.
32.
33.
34. 35.
36.
37. 38.
M A S T C E L L SURVIVAL AND A P O P T O S I S
59
275:1129-1132, 1997. Maurer, M. and Galli, S.J. Rapid reduction in the size of mouse cutaneous mast cell populations by apoptosis after cessation of treatment with SCF does not result in skin inflammation. J. Invest. Dermatol. 110:634, 1998 (abstract). Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1146, 1995. Hetts, S. W. To die or not to die. An overview of apoptosis and its role in disease. JAMA 279:300-307, 1998. Iemura, A., Tsai, M., Ando, A., Wershil, B. K. and Galli, S. J. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am. J. Pathol. 144:321-328, 1994. Finotto, S., Mekori, Y. A. and Metcalfe, D. D. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J. Clin. Invest. 99:1721-1728, 1997. Yee, N. S., Paek, I. and Besmer, E Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice. J. Exp. Med. 179:1777-1787, 1994. Mekori, Y. A. and Metcalfe, D. D. Transforming growth factor-beta prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL-3 deprivation. J. Immunol. 153:2194-2203, 1994. Dubois, C. M., Ruscetti, E W., Stankova, J. and Keller, J. R. Transforming growth factor-[3 regulates ckit message stability and cell-surface protein expression in hematopoietic progenitors. Blood 83:3138-3145, 1994. Rodriguez-Tarduchy, G., Collins, M. K. L., Garcia, I. and Lopez-Rivas, A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J. Immunol. 149:535-540, 1992. Gommerman, J. L. and Berger S. A. Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. Blood 91:1891-1900, 1998. Timokhina, I., Kissel, H., Stella, G. and Besmer, E Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Racl and JNK activation in mast cell proliferation. EMBO J. 17:6250-6262, 1998. Mekori, Y. A., Oh, C. K., Dastych, J., Goff, J. E, Adachi, S., Bianchine, P. J., Worobec, A., Semere, T., Pierce, J. H. and Metcalfe, D.D. Characterization of a mast cell line that lacks the extracellular domain of membrane c-kit. Immunology 90:518-525, 1997. Horigome, K., Bullock, E. D. and Johnson, E. M. Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J. Biol. Chem. 269:2695-2702, 1994. Kawamoto, K., Okada, T., Kannan, Y., Ushio, H., Matsumoto, M. and Matsuda, H. Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. Blood 86:4638-4644, 1995. Bullock, E. D. and Johnson, E. M. Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J. Biol. Chem. 271:27500-27508, 1996. Yanagida, M., Fukamachi, H., Ohgami, K., Kuwaki, T., Ishii, H., Uzumaki, H., Amano, K., Tokiwa, T., Mitsui, H., Saito, H., Iikura, Y., Ishizaka, T. and Nakahata, T. Effect of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86:3705-3714, 1995. Yanagida, M., Fukamachi, H., Takei, M., Hagiwara, T., Uzumaki, H., Tokiwa, T., Saito, H., Iikura, Y. and Nakahata, T. Interferon-gamma promotes the survival and Fc epsilon RI-mediated histamine release in cultured human mast cells. Immunology 89:547-552, 1996. Kirshenbaum, A. S., Worobec, A. S., Davis, T. A., Ceoff, J. E, Semere, T. and Metcalfe, D. D. Inhibition of human mast cell growth and differentiation by interferon gamma-l[3. Exp. Hematol. 26:245-251, 1998. Hartmann, K., Wagelie-Steffen, A. L., v. Stebut, E. and Metcalfe, D. D. Fas (CD95, APO-1) antigen expression and function in murine mast cells. J. Immunol. 159:4006-4014, 1997. Hartmann, K., Worobec, A. S., Bianchine, E J., Mekori, Y. A. and Metcalfe, D. D. Expression of Fas antigen on a human and on murine mast cell lines: antibody to Fas antigen induces mast cell apoptosis. J. Allergy Clin. Immunol. 97:261, 1996 (abstract). Schroter, M., Lowin, B., Borner, C. and Tschopp, J. Regulation of Fas(Apo-1/CD95)- and perforinmediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene bcl-2. Eur. J. Immunol. 25:3509-3519, 1995. De Leon, M., Jackson, K. M., Cavanaugh, J. R., Mbangkollo, D. and Verret, C. R. Arrest of the cell cycle reduces susceptibility of target cells to perforin-mediated lysis. J. Cell Biochem. 69:425-435, 1998. Wagelie-Steffen, A. L., Hartmann, K., Vliagoftis, H. and Metcalfe, D. D. Fas ligand (FasL, CD95L,
60
K A R I N H A R T M A N N AND D E A N D. M E T C A L F E
APO-1L) expression in murine mast cells. Immunology 94:569-574, 1998. Weller, R. Nitric oxide - a newly discovered chemical transmitter in human skin. Br. J. Dermatol. 137:665-672, 1997. 40. Park, S., Jun, C., Choi, B., Lee, E., Kim, H., Cho, H. and Chung, H. Stem cell factor protects bone marrow-derived cultured mast cells (BMCMC) from cytocidal effect of nitric oxide secreted by fibroblasts in murine BMCMC-fibroblasts coculture. Biochem. Mol. Biol. Int. 40:721-729, 1996. 41. Calderon, G. M., Torrez-Lopez, J., Lin, T., Chavez, B., Hemandez, M., Munoz, O., Befus, A. D. and Enciso, J. A. Effects of toxin A from Clostridium difficile on mast cell activation and survival. Infect. Immun. 66:2755-2761, 1998. 42. Zsebo, K. M., Smith, K. A., Hartley, C. A., Greenblatt, M., Cooke, K., Rich, W. and McNiece, I. K. Radioprotection of mice by recombinant rat stem cell factor. Proc. Natl. Acad. Sci. USA 89:9464-9468, 1992. 43. Brauer, G., Kruger-Krasagakes, S., v. d. Ohe M., Zhang, J., Henz, B. M. and Grutzkau, A. Extracellular matrix components modulate calphostin C-induced apoptosis in the human mast cell line-1. J. Invest. Dermatol. 110:596, 1998 (abstract). 44. Bianchine, P. J., Burd, P. R. and Metcalfe, D. D. IL-3-dependent mast cells attach to plate-bound vitronectin. Demonstration of augmented proliferation in response to signals transduced via cell surface vitronectin receptors. J. Immunol. 149:3665-3671, 1992. 45. Sperr, W. R., Agis, H., Czerwenka, K., Virgolini, I., Bankl, H. C., Muller, M. R., Zsebo, K., Lechner, K. and Valent, P. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J. Allergy Clin. Immunol. 98:389-399, 1996. 46. Campbell, C., Quinn, A. G., Ro, Y. S., Angus, B. and Rees, J. L. P53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J. Invest. Dermatol. 100:746-748, 1993. 47. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. and Tschopp, J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363-1366, 1996. 48. Silva, M., Richard, C., Benito, A., Sanz, C., Olalla, I. and Femandez-Luna, J. L. Expression of Bcl-X in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 338:564-571, 1998. 49. Tu, Y., Renner, S., Xu, E, Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., Krajewski, S., Reed, J. C. and Lichtenstein, A. Bcl-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 58:256-262, 1998. 50. Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y. and Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. USA 92:10560-10564, 1995. 51. Longley, B. J., Metcalfe, D. D., Thaw, M., Wang, X., Tyrrell, L., Lu, S., Heitjan, D. and Ma, Y. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA. 92:1609-1614, 1999. 52. Simon, H. U. and Blaser, K. Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol. Today 16:53-55, 1995. 53. Simon, H. U., Yousefi, S., Schranz, C., Schapowal, A., Bachert, C. and Blaser, K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J. Immunol. 158:3902-3908, 1997. 39.
SECTION TWO PHENOTYPIC AND ULTRASTRUCTURAL FEATURES OF MAST CELLS AND BASOPHILS
Chapter 5
Ultrastructural Features of Human Basophil and Mast Cell Secretory Function A. M. Dvorak
Chapter 6
Human Dendritic Mast Cells H. H. Jacobi and O. Johansson
Chapter 7
The Phenotypic Similarities and Differences between Human Basophils and Mast Cells L. Li, S. W. Reddel and S. A. Krilis
Chapter 8
Interactions Between Nerves and Mast Cells in Amphibians G. Chieffi Baccari, S. Minucci, A. de Paulis and A. de Santis
This Page Intentionally Left Blank
CHAPTER 5 Ultrastructural Features of Human Basophil and Mast Cell Secretory Function ANN M. DVORAK Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, U.S.A.
INTRODUCTION Mast cells and basophils are critical effector cells in IgE-dependent immediate hypersensitivity responses (1-4). During such reactions, exposure to specific multivalent antigen results in the bridging of IgE molecules which are bound to Fc~RI on the mast cell and/or basophil surface, initiating a series of biochemical and ultrastructural alterations, termed anaphylactic degranulation (AND), which culminate in fusion of cytoplasmic granule membranes with the plasma membrane (2, 3, 5-7). This in turn permits the release of the granule contents to the extracellular milieu. The rapid and massive release of mast cell and basophil mediators, which occurs during acute IgE-dependent reactions, leads to a number of pathophysiological consequences, prominent among which is markedly augmented vascular permeability. Persistent increased vascular permeability, which is associated with basophil and mast cell activation in many other disease processes, suggests that basophils or mast cells may be able to release mediators slowly over long periods of time, by a process distinct from AND, a process termed piecemeal degranulation (PMD), and that the extravasation of fluid and macromolecules at sites of augmented vascular permeability persists. Using electron microscopy, we found that basophils which infiltrated certain delayedtype hypersensitivity responses in man and in experimental animals underwent a progressive loss of cytoplasmic granule contents but exhibited little or no evidence of AND (2, 8, 9). These basophils contained numerous small cytoplasmic vesicles, some of them fused to granule or plasma membranes. Similar changes were observed in tissue mast cells at sites of many disease processes or inflammatory responses, both in man and in experimental animals (2, 8, 9). These and other findings prompted us to propose a general model of basophil and mast cell degranulation that can account for varied rates of
MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
63
Copyright 9 2000 Academic Press All rights of reproduction in any form reserved
64
ANN M. DVORAK
granule substance release occurring under a variety of physiological and pathological conditions (10). This model holds that loss of granule contents occurs under nonanaphylactic conditions by means of exocytotic vesicles which bud from the granule membrane, carrying with them small amounts of granule material. Upon fusion with the plasma membrane, these vesicles discharge their contents into the extracellular space. This vesicle-mediated release of granule contents is termed PMD. Because the size of cytoplasmic granules and basophils undergoing PMD appeared unchanged, we postulated that membrane lost by these cytoplasmic granules in the form of vesicles moving to the surface of the cell was replenished by a flow of vesicles from plasma membrane to cytoplasmic granules. The model proposed that the rate of vesicle flow from the plasma membrane to the granule membrane (and, in turn, from the granule to the plasma membrane) might be regulated by signals acting at the surface of basophils, including those which, at high concentrations, can also stimulate AND. According to this aspect of the model, when the rate of vesicle production induced by stimulation at the cell surface exceeds a critical level, vesicles become sufficiently numerous to promote fusion of the granule membranes with each other and then with the plasma membrane. Thus, PMD and AND might represent different points along a continuous spectrum of cellular secretory activity (11). Earlier, we used electron-dense tracers to confirm that certain aspects of the PMD model, such as the movement of cytoplasmic vesicles from the plasma membrane to cytoplasmic granules, occurred (reviewed in ref. 2). More recently, we developed a new diamine oxidase-gold (DAOG) method (12) which localized a granule mediator, histamine, to basophil and mast cell granules and vesicles (13-23), to identify and quantify the vesicular transport of histamine in basophils and mast cells undergoing PMD (14, 15, 21, 23). DAOG (12) and another enzyme-affinity method, RNase-gold (RG) (based on the inhibition of ribonuclease by heparin), which images heparin (24), were used to assess subcellular sites of histamine and heparin in human mast cells undergoing AND (20, 25). Immunogold analyses of tumour necrosis factor-o~ (TNF-c~), chymase, and the Charcot-Leyden crystal protein (CLC-P) in rat mast cells and human basophils, respectively, also were effective probes for determining secretory granule density and vesicular transport of these proteins in stimulated cells (26-31). An analysis of the ultrastructural features of basophil and mast cell secretion includes the ultrastructural analysis of the basis for the development of enhanced vascular permeability stimulated by vasoactive mediators that are released from basophils and mast cells (32). These changes take place in the microcirculation. Recent ultrastructural studies have documented the role of a new endothelial cell organelle, termed the vesiculo-vacuolar organelle (VVO) (33, 34), in enhanced vascular permeability in allergic inflammation (32, 35). The microcirculation functions to provide rapid exchange of nutrients and waste products between the blood and tissues. In normal tissues, this exchange occurs primarily across capillaries, which are the most abundant of the microvessels and which have the greatest surface area. Electron microscopy has been used to describe continuous, fenestrated and discontinuous capillaries (36, 37). While small molecules freely traverse most capillary endothelia, the passage of circulating macromolecules such as plasma proteins is severely restricted. Physiologists have postulated the existence of small and large endothelial cell pores to explain microvascular permeability (38). The anatomic basis for these pores has been much debated. It is likely that very small hydrophilic molecules (<3 nm) pass through endothelial cells, through intact inter-endothelial cell
5.
BASOPHIL AND MAST CELL SECRETION
65
junctions, or, if lipid-soluble, exit vessels by diffusion in endothelial cell plasma membranes. Other small molecules cross the endothelial cell barrier by specific transport mechanisms. Large molecules such as plasma proteins exit most capillaries at low rates and reportedly (36, 38, 39) by two routes: (i) vesicular transport via the shuttling of 50-70-nm cytoplasmic vesicles present in endothelial cell cytoplasm (or by interconnected vesicles that form transendothelial cell channels), and (ii) interendothelial cell gaps. We recently identified a new endothelial cell cytoplasmic organelle, which we have termed the VVO, which provides the major route of extravasation of macromolecules at sites of augmented vascular permeability in venules associated with experimental tumours (33, 34). We also found evidence for prominent VVOs in association with extensive PMD of local mast cells in the inflamed eyelid lesions of transgenic mice which overexpress interleukin (IL)-4 (40). Using serial ultrathin sections and three-dimensional reconstructions, we found that VVOs spanned tall venular endothelium in normal vessels and that VVOs, often comprising 100 vesicular and vacuolar components, functioned as a permeability organelle in response to exposure to mast cell and basophil mediators (histamine, serotonin, VPF/VEGF) injected into their tissue vicinity (35). Morphometric (32, 35), morphologic (34) and immunocytochemical (41) studies suggest that these structures are formed by fusion of caveolae (39, 41-47) to form large structures which span the venular endothelium. Enzyme-affinity-gold studies labelled histamine within VVOs in the presence of PMD of adjacent mast cells (40), and immunoperoxidase electron microscopic labelling localized the tumour-derived cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) (48-50) within VVOs in tumour vessels (51). VPF/VEGF (52) mRNA and protein have recently been identified in human mast cells by light-microscopic in situ hybridization and by biochemical assays of supernatants from stimulated cells (53, 54).
MECHANISM(S) OF HISTAMINE AND CLC-P SECRETION FROM HUMAN BASOPHILS, OF HISTAMINE SECRETION FROM HUMAN MAST CELLS IN VITRO AND OF TNF-o~AND CHYMASE SECRETION FROM RAT PERITONEAL MAST CELLS
Electron microscopic morphometric studies were used to analyse the role of vesicular transport as a mechanism for effecting secretion by PMD and/or AND in human basophils stimulated with five different secretagogues [tetradecanoyl-phorbol acetate (TPA) (55), formyl-methionyl-leucyl-phenylalanine (FMLP) (11), recombinant histamine-releasing factor (rHRF) (56), monocyte chemotactic protein (MCP)-I, antiIgE (56, 57)] and of isolated human mast cells stimulated with anti-IgE (58, 59). DAOG was used to image histamine (12-15, 17-21, 60-63) in human basophils and human mast cells and an immunogold method to image CLC-P in human basophils (15, 29-31, 61, 63). Morphometric electron microscopic studies that imaged chymase (28) and TNF-c~ (26, 27) by immunogold in rat mast cells were also done. These probes allowed us to show that basophil and mast cell secretory granules and transport vesicles contained histamine (Figs 1-3) (15, 17, 18, 20, 21, 61, 63), CLC-P (Figs 2, 4) (15, 29-31, 61, 63), TNF-o~ (26, 27) and chymase (28). Because the probe label was a discrete gold particle of defined size, we could quantify the density of particles per unit area. These studies showed that, as the dense contents of granules decreased (as in PMD) in stimulated cells (in the
66
ANN M. DVORAK
Fig. 1 Human mast cell granule prepared with DAOG shows gold-labelled histamine, x83,000 (before enlargement). (Reproduced with permission from J. Histochem. Cytochem. 41:787-800, 1993.)
Fig. 2 CLC-P (A-C) and histamine (D-F) localization in human basophil granules. CLC-P resides in CLCs (C) and in the particulate matrix (A, B). Histamine resides in the particulate matrix only (D, E). Nonparticulate primary granules are heavily labelled for CLC-P in (C) but not for histamine in (F). Bars: (A, E) 0.1 gm; (B-D, F) 0.2 ~tm. (Reproduced with permission from Histol. Histopathol. 11:711-728, 1996.)
5.
BASOPHIL AND MAST CELL SECRETION
67
Fig. 3 TPA-stimulated human basophils prepared with DAOG after 2 min show histamine in a granule (G in A) and in electron-dense (A) and electron-lucent (B) vesicles. (A) x117,300; (B) x69,000 (before reduction). (Reproduced with permission from Blood 88:4090-410 l, 1996.)
Fig. 4 FMLP-stimulated human basophil granules and vesicles prepared to detect CLC-P after 20 sec show label in electron-lucent vesicles adjacent to an unaltered granule (A) and to a partially depleted granule in basophils undergoing PMD (B). (A) x46,000; (B) x43,000 (before reduction). (Reproduced with permission from Int. Arch. Allergy Immunol. 113:465-477, 1997.)
68
ANN M. D V O R A K
TABLE I Density of DAOG Labelling in Human Basophil Granules Indicating Histamine During Secretion and Recovery Phase
Dense granules
Altered granules
Background
Secretion Recovery
30.77* +_16.1 (10) 33.49qt _+4.21 (10)
4.08 _+2.97 (10)
3.88t _+0.9 (20) 5.25 _+1.24 (10)
Density is expressed as number of gold particles per ~tm2 _+SE. Numbers in parentheses indicate number of granules or Epon backgrounds counted. * p < 0.05 (compared with altered granules). ~fp < 0.001 (compared with dense granules). :I:p < 0.05 (compared with altered granules or background). Reproduced with permission from Blood 86:3560-3566, 1995.
Fig. 5 %VG/V in human basophils either unstimulated (UN) or stimulated with FMLP (A, C) or TPA (B, D), recovered for electron microscopy at the indicated times and prepared to detect histamine (A, B) or CLC-P (C, D). Asterisks indicate significant values compared to UN. (Modified and reproduced with permission from Blood88:4090-4101, 1996; Lab. Invest. 74:967-974, 1996; Int. Arch. Allergy Immunol. 113:465-477, 1997.)
5.
BASOPHIL AND MAST CELL SECRETION
69
absence of exocytotic extrusion of granules), the emptying granule containers released their labelled content of histamine (18) (Table I), CLC-P (29-31), chymase (28) and TNF- c~ (27). We quantified histamine and CLC-P discharge from human basophils in kinetic electron microscopic morphometric studies. This was done by calculating the proportion of gold-labelled cytoplasmic vesicles (VG) to the total vesicle (V) population (%VG/V) in unstimulated cells or cells stimulated with FMLP or TPA that were collected at appropriate time intervals to span the known kinetics of rapid (FMLP) or slow (TPA) histamine release (Fig. 5). Histamine secretion was biochemically verified in supernatants of stimulated cells (15, 21, 29, 31). Significantly larger numbers of total vesicles were gold-loaded in the FMLP-triggered cells than in the TPA-triggered cells (p<0.001 for 0 time and 1-, 2- and 5- min samples, and p<0.01 for the 10-min samples). Thus, a secretagogue that rapidly induced the anatomic continuum of PMD ~ AND recovery (FMLP) also induced more histamine-loaded vesicles, compared to similar times after stimulation, than a secretagogue that slowly induced PMD, persisting to involve --50% of the cells by 45 min and showing only minor amounts of AND and no morphological evidence of recovery (TPA). These studies established for the first time that an important pro-inflammatory mediator, histamine, traffics from secretory granules to the extracellular milieu in small cytoplasmic vesicles in stimulated human basophils (15, 21). The association of this process with the electron microscopic release reaction defined as PMD (Table II) primarily produced by TPA and, in part, by FMLP, established vesicular transport as the TABLE II Human Basophil Piecemeal Degranulation Condition/circumstance
Reference(s)
Contact allergy, skin biopsies Delayed hypersensitivityto microbial antigens Basophil leukaemia, peripheral blood Lymphoma Vernal conjunctivitis Skin grafts Crohn's disease, ileum and peripheral blood Bullous pemphigoid Dialysis fluid Adenocarcinoma of the lung Recombinant human IL-3stimulated cord blood basophils FMLP-stimulated peripheral blood basophils TPA-stimulated peripheral blood basophils Ulcerative colitis, ileum S6zary's syndrome
90-92 90, 92 93 2, 94-97 98 99, 100 101-103 104 105 2, 95-97 106 11, 21, 30, 31 21, 29, 55 71 107
Reproduced with permission from Dvorak, A. M. Ultrastructural analysis of anaphylactic and piecemeal degranulation of human mast cells and basophils. In: Immunopharmacology of Mast Cells and Basophils (Foreman, J. C., ed.), pp. 89-113. Academic Press, London, 1993.
70
ANN M. DVORAK
Fig. 6 %VG/Vof CLC-Pin formed CLCs at variable locations in humanbasophils stimulated with FMLPor unstimulated (UN), analysed by time. G, granule; EC, extracellular; Cyto, cytoplasmic; channel, degranulation channel. (Reproducedwith permission from Int. Arch. Allergy Immunol. 113:465-477, 1997.) mechanism for effecting this type of regulated secretion. Vesicular transport of histamine was also significant in the more complex stimulated secretory and recovery model produced by exposure of human basophils to the bacterial peptide, FMLP. Comparison of the %VG/V for histamine or CLC-P between two unique secretagogues for human basophils showed that FMLP (an extremely rapid secretagogue) induced simultaneous peaks of vesicles loaded with CLC-P or histamine - values that return to zero, in the case of CLC-P, at early recovery (10 min) (Fig. 5). This coincides with reconstitution of formed CLCs within granules at 10 minutes (30, 31) (Fig. 6). The %VG/V for histamine, however, did not return to baseline, but at 10 min was still elevated over that for unstimulated cells (Fig. 5). Thus, the behaviour of vesicle transport for these two cellular products differed considerably in FMLP-stimulated cells over a 10min interval. The elevated %VG/V for histamine at 10 min most likely represents a combination of uptake and synthesis, since histamine release (measured biochemically) is essentially complete much earlier than 10 min post-stimulation with FMLP (64). TPA (a slow secretagogue with morphological criteria indicating extensive and continuing PMD by 45 min, little evidence of AND, and none of recovery) achieved peak values of %VG/V for CLC-P and histamine between 10 and 15 min, also corresponding to peak histamine release times for this trigger (65, 66). As for FMLP, the %VG/V for CLC-P dropped extensively by 45 min, but the %VG/V for histamine remained high. Since there was no morphological evidence for recovery (and, therefore, synthesis) in TPA-stimulated basophils at 45 min (and little evidence of AND), the elevated vesicular traffic for histamine likely reflects ongoing PMD. These findings are consistent with electron microscopic evaluation of granule contents at 45 min after TPA. For example, granule number is not reduced, and nearly 50% of the granules are empty and represented only by their granule-sized containers; furthermore, neither particle-filled nor empty containers
5.
71
BASOPHIL AND MAST CELL SECRETION
have residual formed CLCs. Thus, a granule source for histamine continued to exist at 45 min post-stimulation, but one for CLC-P was virtually absent. Morphometric electron microscopic comparative studies to anti-IgE, a stimulus known to induce AND (15, 56, 57) were done using two new human basophil stimuli (Fig. 7, Table III). These studies identified important relationships between the percentage of granule-vesicle attachments (GVAs) and the incidence of PMD or AND in the stimulated samples. Thus, GVAs were found to occur soon after anti-IgE and to TABLE III Electron Microscopy of Human Basophils Stimulated with Anti-IgE, rHRF or MCP-1 Stimulant
Time
% GVA
% PMD
% AND
Control Control Anti-IgE Anti-IgE rHRF rHRF MCP-1 MCP- 1
30 sec 7 min 2 min 7 min 2 min 7 min 5 sec 30 sec
14 9 40 2 19 21 32 47
9 18 40 12 25 9 55 28
0 0 13 67 0 16 0 33
Modified and reproduced with permission from J. Allergy Clin. Immunol. 98:355-370, 1996.
Fig. 7 Human basophils after stimulation for 2 min with anti-IgE (A) and 30 sec with MCP-1 (B) show a particle-filled granule devoid of its membrane, which has been extruded to the cell surface, in AND (curved arrow, A) and two glycogen-enveloped vesicles (arrows) attached to a granule in PMD (B). (A) x50,000; (B) x54,500 (before reduction). (Reproduced with permission from J. Allergy Clin. Immunol. 98:355-370, 1996.)
72
ANN M. DVORAK
Fig. 8 Humanlung mast cells at 5 min (A) and 20 min (B) post-stimulationwith anti-IgE show degranulation channels (D) that either are electron-lucent and devoid of histamine (A) or contain a few residual wisps of electron-dense matrix with some DAOG label (B). The degranulation channel in (B) is open to the cell surface (arrowhead). The unaltered granules remaining in each cell are heavily labelled for histamine. (A, B) x32,000 (before reduction). (Reproduced with permission from J. Leukoc. Biol. 59:824-834, 1996.)
diminish as AND prevailed; also, a cytokine (rHRF) and a chemokine (MCP-1) each rapidly stimulated large numbers of GVAs, concomitant with both rapid histamine release and expression of PMD. The ultrastructural trafficking of histamine in IgE-dependent AND of isolated human mast cells and recovery from secretion in short-term cultures was examined with DAOG to detect histamine (20) (Fig. 8). This study showed that electron-dense granules in unstimulated human mast cells, maintained up to 24 h in culture, and in responding antiIgE-stimulated human mast cells, over the same time period in vitro, contained histamine. Alteration of granules, resulting in decreased electron density of their contents, was associated with decreased label for histamine. Electron-lucent intracytoplasmic degranulation chambers were devoid of histamine (Fig. 8). Recovering human mast cells developed new granule stores of histamine by a mixture of conservation, synthetic and endocytotic mechanisms.
HISTAMINE SECRETION F R O M HUMAN MAST CELLS IN VIVO PMD of human mast cells has been imaged in vivo by electron microscopy in a wide variety of circumstances (Table IV); AND of human mast cells in vivo, on the other hand, has not been so frequently captured in electron micrographs (67-69). We used the new
5.
BASOPHIL AND MAST CELL SECRETION
73
TABLE IV Human Mast Cell Piecemeal Degranulation Circumstance
Reference(s)
Urticaria pigmentosa Chronic glomerulonephritis and pyelonephritis Delayed hypersensitivity to microbial antigens Contact allergy Crohn's disease, ileum Melanoma, skin Bullous pemphigoid Whipple's disease, small intestine Renal adenoma Cold and mechanical stimulation, skin Metastatic adenocarcinomato lymph nodes Maxillary sinus mucosa, chronic inflammation Ulcerative colitis, ileum Familial polyposis coli, ileum Interstitial fibrosis, lung Primary and metastatic tumors
108 109 90-92 90-92 101, 103, 110-114 115 104, 116 117 118 119 2, 95-97 116 71 71 120 A.M. Dvorak, (unpublished data)
Reproduced with permission from Dvorak, A. M. Ultrastructural analysis of anaphylactic and piecemeal degranulation of human mast cells and basophils. In: Immunopharmacology of Mast Cells and Basophils (Foreman, J. C., ed.), pp. 89-113. Academic Press, London, 1993. enzyme-affinity-gold method for histamine to document histamine stores and secretion in vivo by human mast cells displaying each of these secretory paths (22, 23).
Histamine Secretion from Human Mast Cells Undergoing PMD In Vivo in Inflammatory Bowel Disease (IBD) Earlier, we determined that 60% of 117 biopsies, obtained from patients with IBD, exhibited evidence of human mast cell PMD; rare instances of AND also occurred (70, 71). We used DAOG to detect histamine to show that the partially empty to completely empty granule containers in PMD were also partially or completely devoid of histamine (23) (Fig. 9). This was the first demonstration of histamine secretion in vivo during PMD of human mast cells. Analogous studies done earlier were also the first to demonstrate histamine secretion in vivo during PMD of transgenic IL-4 mouse mast cells in animals with inflammatory eye disease (IED) (40).
Histamine Secretion from Human Mast Cells Undergoing Stem Cell Factor (SCF)Induced AND In Vivo in Skin Biopsies We participated in a multi-institutional study of patients with advanced breast cancer who were receiving rhSCF (67). We used DAOG to evaluate skin biopsy samples in which human mast cells were elicited and degranulated in vivo in these patients (22, 69). SCF has a role in the regulation of mast cell development and function (72-74) and is known
74
ANN M. D V O R A K Fig. 9 (A) Secretory granules in human ileal mast cells undergoing PMD show gold label for histamine in electron-dense granules (1), gold label associated with residual electron-dense material in a partially empty granule (2), and no label in an entirely empty granule (3) in a cell undergoing PMD. (B) Absorption of DAOG reagent with histamine-agarose before staining abrogates all mast cell granule label. (C) Residual electron-dense reticular arrays contain small amounts of gold label for histamine in otherwise electron-lucent, empty, histaminefree granules of a mast cell undergoing PMD. (A) x48,000; (B) x39,500; (C) x42,000 (before reduction). (Reproduced with permission from J. Allergy Clin. Immunol. 99:812-820, 1997.)
Fig. 10 Skin biopsies from sites that had been injected with rhSCF, obtained from patients who had received rhSCF for 13 days (A) or 1 day (B, C), respectively. The biopsy in (A) was obtained 1 h 45 min after the subcutaneous injection of 5 lag/kg of rhSCF, whereas the biopsy in (B, C) was obtained 1 h 40 min after the subcutaneous injection of 25 gg/kg of rhSCE DAOG label is present on the electrondense contents of cytoplasmic granules in the mast cell in (A) (solid arrowheads); the cell exhibits evidence of secretory activity, and an extruded, non-membrane-bound granule with altered matrix (which is located external to the plasma membrane) retains very little DAOG label for histamine (open arrowhead). However, DAOG heavily labels adjacent collagen fibres, which are seen in cross-section (arrows). In (B), multiple extruded, membranefree mast cell granules (G), which exhibit altered matrix materials, are present in the interstitium near the degranulated mast cell; these extruded granules exhibit relatively little DAOG labelling for histamine, except in regions of the granules that contain the most electron-dense matrix material (solid arrowheads). In (C), the DAOG was absorbed with solid-phase histamine before being used to stain the specimen. Nearly all DAOG staining of intracellular mast cell granules (arrowhead), as well as of the extruded, membrane-free granules (G), was abolished by this specificity control. (A) x52,500; (B) x28,000; (C) x46,500 (before reduction). (Reproduced with permission from Blood 90:2893-2900, 1997.)
5.
B ASOPHIL AND MAST CELL SECRETION
75
to promote mediator release from partially purified populations of human skin mast cells in vitro (75). In the new studies, we documented that rhSCF-elicited wheal and flare skin reactions contained mast cells undergoing regulated secretion by granule extrusion analogous to AND (67, 69). The DAOG method detected histamine in electron-dense granules of mast cells in control and injected skin biopsies; however, the altered matrix of membrane-free, extruded mast cell granules was largely non-reactive with DAOG (Fig. 10). These findings are the first morphological evidence of histamine secretion by classical granule exocytosis in human mast cells in vivo (22). In summary, the new DAOG method for the detection of histamine in electron microscopic samples (12) allowed us to document cellular mechanisms of histamine secretion in human mast cells in vivo by PMD and AND for the first time.
HEPARIN SECRETION FROM HUMAN MAST CELLS IN VITRO
We evaluated an enzyme-affinity-gold electron microscopic method designed to identify RNA-rich structures, based on an RG probe, in human mast cells (24). As expected, the RG technique labelled RNA-containing ribosomes and nucleoli in human mast cells and in a wide variety of samples of human tissues (76). The heparin-rich secretory granules in human mast cells were also labelled (Fig. 11). Extensive studies revealed that human mast cells, isolated from lung or skin and sustained in short-term cultures, derived de novo in growth factor-supplemented cord blood cell cultures or present in vivo in multiple sites, all shared this property. We performed a large number of controls designed to examine the human mast cell granule-binding characteristics of gold alone, of irrelevant protein-gold or enzyme-gold reagents, of the role of charge and enzyme activity after various enzyme digestions, after blocking with macromolecules, after exposure to inhibitors of RNase, of heparin, or to irrelevant enzyme inhibitors, including staining of
Fig. 11 Human lung mast cell ex vivo, stained with RG, shows labelled cytoplasmic granules and nuclei. Several large osmiophilic lipid bodies (open arrowhead) and an intragranular lipid deposit (closed arrowhead) are not labelled. Bar: 1 ktm. (Reproduced with permission from J. Histochem. Cytochem. 46:695-706, 1998.)
76
ANN M. DVORAK
macromolecule-containing test agar blocks and a variety of combined absorption and digestion experiments of the binding of RG to human mast cell granules (24). These studies established that the RG method detected heparin in this site in conventionally prepared, well-preserved electron microscopic samples. These findings demonstrate a new use for the enzyme-affinity-gold technique in mast cell biology, based on the known property of heparin as an inhibitor of RNase (24). The RG reagent is red and is thus visible when passaged over beads to which it binds. Electron microscopic sections containing human mast cells were stained with the fluid reagent after passage over beads and the number of gold particles per granule area was calculated for each of six conditions (Fig. 12). The results show that RG did not bind to Sepharose and that it subsequently stained granules (Fig. 12A, 554 gold particles ~m2). In contrast, RG bound to heparin-agarose beads, turning them red, and the subsequent granule label was significantly reduced (Fig. 12B; 17 ~m2; p<0.001). A reduction in granule label that did not achieve statistical significance was seen when RG was blocked in solution with RNA and passaged over Sepharose (Fig. 12C; 55 ~tm2); the beads remained unstained. When RG was blocked in solution with RNA prior to passage over heparin-agarose, the beads turned red, binding RG; granule gold label was significantly reduced (Fig. 12D; 25 ILtm2; p<0.001). In contrast, RG, incubated in solution with heparin and then passaged over Sepharose, did not bind to the beads, leaving them white, and a significant reduction in granule gold label occurred (Fig. 12E; 18 ~tm2; p<0.001). Finally, a double absorption of RG with heparin, first in solution, followed by heparin-agarose, resulted in red beads and abrogation of granule label (Fig. 12F; 3~m2; p<0.001). Altogether, the absorption
Fig. 12 Human mast cell granules labelled with RG after bead absorptions (see text). Bars: (A) 110 nm; (B, D) 130 nm; (C) 200 nm; (E) 150 nm; (F) 190 nm. (Reproduced with permission from Clin. Exp. Allergy 29:1118-1128, 1999.)
5.
B A S O P H I L AND M A S T C E L L S E C R E T I O N
77
experiments indicated that RG bound to human mast cell granule heparin, based on the known property of heparin as an inhibitor of the enzyme, RNase (24, 25). We used the newly defined electron microscopic method for heparin (24) to follow the subcellular distribution of heparin in actively secreting and recovering human mast cells in vitro (25) (Figs 13, 14). We found that heparin was labelled by RG in electron-dense granules within non-secretory human mast cells, in electron-dense granules that persisted in secretory human mast cells at the time of maximum histamine secretion, and in electron-dense granules within recovering human mast cells. Heparin stores were absent in newly formed, electron-lucent, intracytoplasmic degranulation channels in secretory human mast cells. Electron-dense granule matrices in the process of extrusion to the cell exterior still retained heparin at the instant of cellular secretion. Non-granule heparin stores bound RG in recovering human mast cells. These locations included resolving degranulation channels (as newly emergent granules partitioned and condensed within them), and electron-dense content-containing vesicles and pro-granules within synthetic human mast cells. Ultimately, all electron microscopic patterns of human mast cell granules developed in recovering cells, and each of them contained heparin. We concluded that heparin was secreted from human mast cells which were stimulated by
Fig. 13 Secretory mast cells, 20 min (A, B) or 6 h (C) after stimulation with anti-IgE, stained with RG, show large intracytoplasmic degranulation channels (C) devoid of electron-dense material and heparin in (A). Cytoplasmic granules that are not altered contain heparin (A, C). Extruded granules with variable electron density and heparin are present at 20 min (B) and 6 h (C) after stimulation. Note that RG label is bound to extruded, electron-dense, membrane-free granule materials at the cell surface (arrow) in the 20-min sample (B) but that two extruded granules (G) that persist in the extracellular location at 6 h are devoid of heparin. (A) x35,000; (B) x37,000; (C) x24,000 (before reduction). (Reproduced with permission from Clin. Exp. Allergy 29:1118-1128, 1999.)
78
A N N M. D V O R A K
Fig. 14 Secretory mast cells, 6 h after anti-IgE stimulation and stained with RG, show degranulation channel condensation (121) as a recovery process. Unaltered granules in each cell contain heparin but lipid bodies (arrows) do not. The large degranulation channel with minor amounts of electron-dense material in (A) is devoid of heparin; the smaller, condensing degranulation channel with electron-dense granule domains in (B) contains heparin. (A) x33,000; (B) x36,000 (before reduction). (Reproduced with permission from Clin. Exp. Allergy 29:1118-1128, 1999.)
anti-IgE, and heparin was recovered by a combination of conservative and synthetic mechanisms in human mast cells after a secretory event (25).
THE VESICULO-VACUOLAR ORGANELLE, A N E W E N D O T H E L I A L P E R M E A B I L I T Y STRUCTURE
VPF/VEGF was originally discovered in the late 1970s because of its capacity to increase the permeability of microvessels to plasma (77). A potent vascular permeabilizing protein in tumour culture supernatants (77) was purified and named VPF (52). Subsequently, endothelial cell mitogenic activity was found to be mediated by the same molecule, resulting in the designation of VPF/VEGF (78-81). The permeabilizing cytokine, VPF/VEGF, is among the most potent vascular permeabilizing agents known, having a potency some 50,000 times that of the mast cell- and basophil-derived mediator, histamine (49, 50, 82, 83). We now know that mast cells also synthesize and store VPF/VEGF (53, 54); thus, secretory stimuli might enhance vascular permeability by several mediators released from mast cells. We observed (33) that the predominant pathway for electron-dense tracers to leak into the subcutis from the blood vascular space in vessels in tumours secreting VPF/VEGF was by way of VVOs (Fig. 15) (34). VVOs also occurred in the venules of the normal subcutis of animals not bearing tumours, and these structures represented the predominant pathway by which tracers exited these
5.
BASOPHIL AND MAST CELL SECRETION
79
normal vessels. However, both VVO labelling and tracer extravasation were much greater in tumour vessels than in control vessels. Vessels associated with a mouse ovarian tumour had numbers of VVOs which were not significantly different from those of control vessels; the number of ferritin-containing vesicles and vacuoles/VVO, however, was more than twice as great in tumour vessels compared with control vessels (p<0.001), and the number of extravasated ferritin particles per ~tm of vessel perimeter was more than four times as great in tumour vessels compared with control vessels (p<0.001). Ferritin entered VVOs from the lumen within seconds after intravenous injection, passed from vesicle to vesicle via open stomata, then, upon reaching the abluminal surface, spilled into underlying basal lamina. Classical inter-endothelial cell gaps were not observed (Fig. 15), nor did ferritin pass between intact inter-endothelial cell junctions.
Fig. 15 Tumour vessel endothelial cell VVO at 10 sec after injecting horse radish peroxidase (HRP) intravenously. Continuity of the VVO with the vascular lumen (L) is made evident by HRP which also extends to the basal lamina (B) focally. The inter-endothelial celljunction does not contain HRP (arrowhead). Bar: 260 nm. (Reproduced with permission from J. Leukoc. Biology. 59:100-115, 1996.) Quantification of the individual vesicle and vacuoles that comprise VVOs in tumour compared with normal endothelial cells showed that the perimeters and areas of tumour vessel vesicles and vacuoles significantly exceeded that of normal endothelial cells (Fig. 16). Morphometry revealed that VVOs were enormous cytoplasmic structures (median area 0.12-0.14 ~m 2 in a single electron micrograph). Specimen tilting provided evidence that individual VVO vesicles and vacuoles communicated with each other and with the plasma membrane of endothelial cells by stomata, some of which were closed by diaphragms composed of a single membrane. High magnification images with two tracers, ferritin (Fig. 17) and horseradish peroxidase (HRP) (Fig. 18), revealed that passage of macromolecules through VVOs occurred through stomata and was regulated at the level of stomatal diaphragms, thereby demonstrating a mechanism for controlling the passage of macromolecules across endothelial cells. Compared with tumour endothelial cells, little circulating ferritin and HRP entered the VVOs of normal endothelial cells because stomata joining vesicles and vacuoles to each other and to the lumen and ablumen were closed. These findings indicate that VVOs provide a major pathway for the extravasation of circulating macromolecules across endothelial cells taller than capillary endothelial cells,
80
A N N M. D V O R A K
Fig. 16 A total of 521 vesicles and vacuoles from tumour endothelial cells and 487 from control endothelial cells were measured. The mean areas and perimeters of tumour endothelial cell vesicles-vacuoles were significantly larger than in normal endothelial cells.
Fig. 17 Tumour vessel endothelial cell VVO vesicle shows a central stoma filled with ferritin at the basal lamina front (BL). The vesicle chamber contains little ferritin and is connected to the underlying plasma membrane by a narrow neck (arrows). Bar 63 nm. (Reproduced with permission from J. Leukoc. Biology. 59:100-115, 1996.)
Fig. 18 Tumour endothelial cell VVO, connected to the abluminal surface, shows an open, HRPcontaining stoma of a vesicle. The abluminal surface of the endothelial cell plasma membrane is focally stained with HRP beneath this vesicle; the basal lamina (BL) remains unstained. Bar: 80 nm. (Reproduced with permission from J. Leukoc. Biology. 59:100-115, 1996.)
5.
B ASOPHIL AND MAST CELL SECRETION
81[
Fig. 19 Diagram showing two VVOs within an endothelial cell. The complex transcytoplasmic pathway linking the vascular lumen with the endothelial cell basal lamina is illustrated in both; one (left) opens to the inter-endothelial cell junction above its narrow mid portion. Small circular structures within vesicles and vacuoles are stomata. (Reproduced with permission from J. Leukoc. Biology. 59:100-115, 1996.)
and suggest that upregulated VVO function accounts for the well-known hyperpermeability of tumour blood vessels (Fig. 19). By morphological analysis (34), the smaller vesicles found in VVOs are similar in size and structure to the well-known plasmalemmal vesicles or caveolae that line plasma membranes in endothelial cells (84, 85). Given the obvious similarities between caveolae and VVO vesicles and vacuoles, we considered the possibility that VVOs might form from the linking together of individual caveolae. We also hypothesized that the larger vesicles and vacuoles of VVOs might form from the fusion of two or more caveola-sized vesicles. A similar fusion mechanism has been proposed in the generation of several types of cytoplasmic secretory granules in which small progranules of unit size fuse with each other in varying combinations to form larger mature granules whose volumes represent multiples of the volume of the unit pro-granule (58, 86-89). If this hypothesis is correct, then the volumes of the various VVO vesicles and vacuoles would not be expected to fall on a continuum but instead would represent multiples of the volume of smaller unit vesicles. We used a morphometric approach that has been successfully employed to demonstrate that the volumes of the cytoplasmic granules of both mast cells and pancreatic acinar cells have a periodic distribution (58, 86-89). The results make two points: (i) the size of VVO vesicles and vacuoles is heterogeneous; (ii) the volumes of individual VVO vesicles and vacuoles do not fall on a continuum but instead exhibit a modal distribution (32). The most frequent vesicle-vacuole had a unit volume of --0.00015 ~tm3; this value corresponds to a spheroid of a diameter of--60nm, i.e. the size of typical capillary caveolae. Vacuoles corresponding to the fusion of as many as ten unit vesicles were detected. The data, therefore, are consistent with the hypothesis that larger VVO vesicles and vacuoles arise from the fusion of different numbers of caveola-sized unit vesicles. Additional evidence that VVOs are constructed from the fusion of caveolae is the presence of caveolin within VVOs (41). VPF/VEGF is a cytokine secreted by many animal and human tumours, activated macrophages, keratinocytes, rheumatoid synovial cells, embryonic tissues and by
82
ANN M. DVORAK
Fig. 20 Tumourendothelial cells, stained with antibody to VPF/VEGF (A-C, F), with an irrelevant antibody control (D), or with VPF/VEGF-absorbed specific antibody (E). Individual vesicle stomata within the VVO and the abluminal cell surface contain VPF in (A). (B) illustrates portions of a single VVO at mid cytoplasm. The stomata interconnecting individual vesicle components are positive for VPF; the surrounding chamber of the VVO is not. (C) One stoma of a VVO contains VPF/VEGE The remainder of this VVO and the one adjacent to it near the luminal surface do not stain for VPF/VEGF. Note the central lucent spot within the VPFpositive stoma. This spot corresponds to a stomatal structure that has been termed a knob (84, 85), as described for caveolae. It does not stain for VPF/VEGE Knobs are visible within the stomata of the adjacent VPF/VEGF-negative VVO. The two controls (D, E) show abluminal (D) and mid cytoplasmic (E) VVOs that are not positive. The large, round multivesicular body (F) does not contain VPF/VEGE Bars: (A, B, E, F) 90 nm; (C) 104 nm; (D) 112 nm. (Reproduced with permission from J. Histochem. Cytochem. 43:381-389, 1995.) cultured epithelial and mesenchymal cell lines. It acts selectively on endothelial cells to increase their permeability to circulating macromolecules and to stimulate their replication. Although not detectably expressed by normal endothelial cells in the human and animal tumours we have studied, V P F / V E G F accumulates in the microvessels supplying tumours and certain inflammatory reactions in which V P F / V E G F is overexpressed. We used a pre-embedding immunocytochemical method to localize V P F / V E G F by electron microscopy in mouse tumour blood vessels. V P F / V E G F was observed on the abluminal plasma membrane and in V V O s of endothelial cells (Fig. 20). Earlier, we determined that VVOs equivalent to those in hyperpermeable tumour vessels are present in normal venules that do not leak substantial amounts of plasma protein (33). To explain these findings, we hypothesized that V P F / V E G F increased the permeability of tumour blood vessels by increasing V V O function and that the V V O s of normal venules were relatively impermeable in the absence of exposure to V P F / V E G E To test this hypothesis, V P F / V E G F was injected intradermally in normal animals after intravenous injection of a soluble macromolecular tracer, ferritin, whose extravasation could be followed by electron microscopy. V P F / V E G F caused normal venules to leak ferritin, and ferritin extravasated by way of VVOs, just as in hyperpermeable tumour endothelial cells (35). Like VPF/VEGF, histamine and serotonin also stimulated ferritin extravasation across venules by way of V V O s (35). Together, these data establish V V O s
5.
B A S O P H I L AND M A S T C E L L S E C R E T I O N
83
as the major pathway by which soluble plasma proteins exit venules in response to several mediators that increase venular hyperpermeability in allergic inflammation when mast cells undergo secretion.
ACKNOWLEDGEMENTS
Supported by NIH Grant AI-33372. I thank Peter K. Gardner for assistance in the preparation of the manuscript.
REFERENCES 1. Ishizaka, T. Mechanisms of IgE-mediated hypersensitivity. In: Allergy. Principles and Practice, Vol. I (Middleton, E. Jr., Reed, C. E., Ellis, E. E, Adkinson, N. F. Jr. and Yunginger, J. W., eds), pp. 71-93. C. V. Mosby, St. Louis, 1988. 2. Dvorak, A. M., ed. Basophil and Mast Cell Degranulation and Recovery. Blood Cell Biochemistry, Vol. 4 (Harris, J. R., ed.). Plenum Press, New York, 1991. 3. Galli, S. J. New concepts about the mast cell. N. Engl. J. Med. 328:257-265, 1993. 4. Costa, J. J., Weller, E E and Galli, S. J. The cells of the allergic response. Mast cells, basophils and eosinophils. JAMA 278:1815-1822, 1997. 5. Kinet, J.-E The gamma-zeta dimers of Fc receptors as connectors to signal transduction. Curr. Opin. Immunol. 4:43-48, 1992. 6. Beaven, M. A. and Metzger, H. Signal transduction by Fc receptor: the Fc epsilon RI case. Immunol. Today 14:222-226, 1993. 7. Schwartz, L. and Huff, T. Biology of mast cells and basophils. In: Allergy: Principles and Practice, (Middleton, E. Jr., Reed, C. E., Ellis, E. F., Adkinson, N. E Jr, Yunginger, J. W. and Busse, W. W., eds), pp. 135-168. C. V. Mosby, St. Louis, 1993. 8. Dvorak, A. M. Basophils and mast cells: piecemeal degranulation in situ and ex vivo: a possible mechanism for cytokine-induced function in disease. In: Granulocyte Responses to Cytokines. Basic and Clinical Research (Coffey, R. G., ed.), pp. 169-271. Marcel Dekker, New York, 1992. 9. Galli, S. J., Dvorak, A. M. and Dvorak, H. E Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. In: Mast Cell Activation and Mediator Release, (Ishizaka, K., ed.), pp. 1-141. Karger, Basel, 1984. 10. Dvorak, H. E and Dvorak, A. M. Basophilic leucocytes: structure, function and role in disease. Clin. Haematol. 4:651-683, 1975. 11. Dvorak, A. M., Warner, J. A., Kissell, S., Lichtenstein, L. M. and MacGlashan, D. W. Jr. F-Met peptideinduced degranulation of human basophils. Lab. Invest. 64:234-253, 1991. 12. Dvorak, A. M., Morgan, E. S., Schleimer, R. E and Lichtenstein, L. M. Diamine oxidase-gold labels histamine in human mast-cell granules: a new enzyme-affinity ultrastructural method. J. Histochem. Cytochem. 41:787-800, 1993. 13. Dvorak, A. M. Ultrastructural localization of histamine in human basophils and mast cells; changes associated with anaphylactic degranulation and recovery demonstrated with a diamine oxidase-gold probe. Allergy 52 (Supp134): 14-24, 1997. 14. Dvorak, A. M. Histamine content and secretion in basophils and mast cells. In: Progress in Histochemistry and Cytochemistry, (Graumann, W., Bendayan, M., Bosman, E T., Heitz, E U., Larsson, L.-I., Ramaekers, F. C. and Schumacher, U., eds), pp. 169-350. Gustav Fischer Verlag, Jena, 1998. 15. Dvorak, A. M. Cell biology of the basophil. Int. Rev. Cytol. 180:87-236, 1998. 16. Dvorak, A. M. and Morgan, E. S. Ultrastructural detection of histamine in human mast cells developing from cord blood cells cultured with human or murine recombinant c-kit ligands. Int. Arch. Allergy Immunol. 111:238-244, 1996. 17. Dvorak, A. M., Morgan, E. S., Lichtenstein, L. M. and MacGlashan, D. W. Jr. Activated human basophils contain histamine in cytoplasmic vesicles. Int. Arch. Allergy Immunol. 105:8-11, 1994. 18. Dvorak, A. M., MacGlashan, D. W. Jr., Morgan, E. S. and Lichtenstein, L. M. Histamine distribution in human basophil secretory granules undergoing FMLP-stimulated secretion and recovery. Blood 86:3560-3566,1995.
84
A N N M. D V O R A K
19. Dvorak, A. M., Morgan, E. S., Monahan-Earley, R. A., Estrella, P., Schleimer, R. E, Weller, E E, Tepper, R. I., Lichtenstein, L. M. and Galli, S. J. Analysis of mast cell activation using diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Int. Arch. Allergy Immunol. 107:87-89, 1995. 20. Dvorak, A. M., Morgan, E. S., Schleimer, R. E and Lichtenstein, L. M. Diamine oxidase-gold ultrastructural localization of histamine in isolated human lung mast cells stimulated to undergo anaphylactic degranulation and recovery in vitro. J. Leukoc. Biol. 59:824-834, 1996. 21. Dvorak, A. M., MacGlashan, D. W. Jr., Morgan, E. S. and Lichtenstein, L. M. Vesicular transport of histamine in stimulated human basophils. Blood 88:4090-4101, 1996. 22. Dvorak, A. M., Costa, J. J., Morgan, E. S., Monahan-Earley, R. A. and Galli, S. J. Diamine oxidase-gold ultrastructural localization of histamine in human skin biopsies containing mast cells stimulated to degranulate in vivo by exposure to recombinant human stem cell factor. Blood 90:2893-2900, 1997. 23. Dvorak, A. M. and Morgan, E. S. Diamine oxidase-gold enzyme-affinity ultrastructural demonstration that human gut mucosal mast cells secrete histamine by piecemeal degranulation in vivo. J. Allergy Clin. Immunol. 99:812-820, 1997. 24. Dvorak, A. M. and Morgan, E. S. Ribonuclease-gold labels heparin in human mast cell granules: new use for an ultrastructural enzyme affinity technique. J. Histochem. Cytochem. 46:695-706, 1998. 25. Dvorak, A. M. and Morgan, E. S. Ribonuclease-gold ultrastructural localization of heparin in isolated human lung mast cells stimulated to undergo anaphylactic degranulation and recovery in vitro. Clin. Exp. Allergy 29:1118-1128, 1999. 26. Beil, W. J., Login, G. R., Galli, S. J. and Dvorak, A. M. Ultrastructural immunogold localization of tumor necrosis factor-~ to the cytoplasmic granules of rat peritoneal mast cells with rapid microwave fixation. J. Allergy Clin. Immunol. 94:531-536, 1994. 27. Beil, W. J., Login, G. R., Aoki, M., Lunardi, L. O., Morgan, E. S., Galli, S. J. and Dvorak, A. M. Tumor necrosis factor alpha immunoreactivity of rat peritoneal mast cell granules decreases during early secretion induced by 48/80: an ultrastructural immunogold morphometric analysis. Int. Arch. Allergy Immunol. 109:383-389, 1996. 28. Login, G. R., Aoki, M., Yamakawa, M., Lunardi, L. O., Digenis, E. C., Tanda, N., Schwartz, L. B. and Dvorak, A. M. Immunocytochemical localization of chymase to cytoplasmic vesicles after rat peritoneal mast cell stimulation by compound 48/80. J. Histochem. Cytochem. 45:1379-1391, 1997. 29. Dvorak, A. M., Ackerman, S. J., Letourneau, L., Morgan, E. S., Lichtenstein, L. M. and MacGlashan, D. W. Jr. Vesicular transport of Charcot-Leyden crystal protein in tumor-promoting phorbol diesterstimulated human basophils. Lab. Invest. 74:967-974, 1996. 30. Dvorak, A. M., MacGlashan, D. W. Jr., Warner, J. A., Letourneau, L., Morgan, E. S., Lichtenstein, L. M. and Ackerman, S. J. Localization of Charcot-Leyden crystal protein in individual morphologic phenotypes of human basophils stimulated by f-Met peptide. Clin. Exp. Allergy 27:452-474, 1997. 31. Dvorak, A. M., MacGlashan, D. W. Jr., Warner, J. A., Letourneau, L., Morgan, E. S., Lichtenstein, L. M. and Ackerman, S. J. Vesicular transport of Charcot-Leyden crystal protein in f-Met peptide-stimulated human basophils. Int. Arch. Allergy Immunol. 113:465-477, 1997. 32. Feng, D., Nagy, J. A., Pyne, K., Hammel, I., Dvorak, H. E and Dvorak, A. M. Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 6:23-44, 1999. 33. Kohn, S., Nagy, J. A., Dvorak, H. E and Dvorak, A. M. Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab. Invest. 67:596-607, 1992. 34. Dvorak, A. M., Kohn, S., Morgan, E. S., Fox, E, Nagy, J. A. and Dvorak, H. E The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J. Leukoc. Biol. 59:100-115, 1996. 35. Feng, D., Nagy, J. A., Hipp, J., Dvorak, H. E and Dvorak, A. M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine and serotonin. J. Exp. Med. 183:1981-1986, 1996. 36. Granger, D. N. and Perry, M. A. Permeability characteristics of the microcirculation. In: The Physiology and Pharmacology of the Microcirculation, Vol. 1 (Martmortillaro, N. A., ed.), pp. 157-208. Academic Press, New York, 1983. 37. Simionescu, N. Cellular aspects of transcapillary exchange. Physiol. Rev. 63:1536-1579, 1983. 38. Renkin, E. M. Capillary transport of macromolecules. Pores and other endothelial pathways. J. Appl. Physiol. 5:315-325, 1985. 39. Schnitzer, J. E. Update on the cellular and molecular basis of capillary permeability. Trends Cardiovasc. Med. 3:124-130, 1993.
5.
B ASOPHIL AND MAST CELL SECRETION
85
40. Dvorak, A. M., Tepper, R. I., Weller, E E, Morgan, E. S., Estrella, E, Monahan-Earley, R. A. and Galli, S. J. Piecemeal degranulation of mast cells in the inflammatory eyelid lesions of interleukin-4 transgenic mice. Evidence of mast cell histamine release in vivo by diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. Blood 83:3600-3612, 1994. 41. Vasile, E., Qu-Hong, Dvorak, H. E and Dvorak, A. M. Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating matrigel-collagen gels. J. Histochem. Cytochem. 47:159-167, 1999. 42. Parton, R. G. Caveolae and caveolins. Curr. Opin. Cell Biol. 8:542-548, 1996. 43. Parton, R. G., Joggerst, B. and Simons, K. Regulated internalization of caveolae. J. Cell Biol. 127:1199-1215, 1994. 44. Anderson, R. G. W. Plasmalemmal caveolae and GPI-anchored membrane proteins. Curr. Opin. Cell Biol. 5:647-652, 1993. 45. Anderson, R. G. W. Caveolae: where incoming and outgoing messengers meet. Proc. Natl. Acad. Sci. USA 90:10909-10913, 1993. 46. Schnitzer, J. E., Oh, E, Jacobson, B. S. and Dvorak, A. M. Caveolae from luminal plasmalemma of rat lung endothelium: Microdomains enriched in caveolin, Ca++-ATPase, and inositol triphosphate receptor. Proc. Natl. Acad. Sci. USA 92:1759-1763, 1995. 47. Schnitzer, J. E., McIntosh, D. E, Dvorak, A. M., Liu, J. and Oh, E Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 269:1435-1439, 1995. 48. Dvorak, H. E, Brown, L. E, Detmar, M. and Dvorak, A. M. Vascular permeability factor/vascular endothelial cell growth factor, microvascular hyperpermeability and angiogenesis. Am. J. Pathol. 146:1029-1039, 1995. 49. Dvorak, H. E, Nagy, J. A., Feng, D., Brown, L. E and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237:97-132, 1999. 50. Brown, L. E, Detmar, M., Claffey, K., Nagy, J. A., Feng, D., Dvorak, A. M. and Dvorak, H. E Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In: Regulation ofAngiogenesis (Goldberg, I. D. and Rosen, E. M., eds), pp. 233-269. Birkh~iuser Publishing, Basel, 1997. 51. Qu-Hong, Nagy, J. A., Senger, D. R., Dvorak, H. E and Dvorak, A. M. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J. Histochem. Cytochem. 43:381-389, 1995. 52. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. E Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983. 53. Boesiger, J., Tsai, M., Maurer, M., Yamaguchi, M., Brown, L. E, Claffey, K. E, Dvorak, H. E and Galli, S. J. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fc~ receptor I expression. J. Exp. Med. 188:1135-1145, 1998. 54. Grtitzkau, A., Krtiger-Krasagakes, S., Baumeister, H., Schwartz, C., K6gel, H., Welker, E, Lippert, U., Henz, B. M. and Moller, A. Synthesis, storage, and release of vascular endothelial cell growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206.Mol. Biol. Cell 9:875-884, 1998. 55. Dvorak, A. M., Warner, J. A., Morgan, E., Kissell-Rainville, S., Lichtenstein, L. M. and MacGlashan, D. W. Jr. An ultrastructural analysis of tumor-promoting phorbol diester-induced degranulation of human basophils. Am. J. Path. 141:1309-1322, 1992. 56. Dvorak, A. M., Schroeder, J. T., MacGlashan, D. W. Jr., Bryan, K. E, Morgan, E. S., Lichtenstein, L. M. and MacDonald, S. M. Comparative ultrastructural morphology of human basophils stimulated to release histamine by anti-IgE, recombinant IgE-dependent histamine-releasing factor, or monocyte chemotactic protein-1. J. Allergy Clin. Immunol. 98:355-370, 1996. 57. Dvorak, A. M., Newball, H. H., Dvorak, H. E and Lichtenstein, L. M. Antigen-induced IgE-mediated degranulation of human basophils. Lab. Invest. 43:126-139, 1980. 58. Dvorak, A. M., Hammel, I., Schulman, E. S., Peters, S. E, MacGlashan, D. W. Jr., Schleimer, R. E, Newball, H. H., Pyne, K., Dvorak, H. E, Lichtenstein, L. M. and Galli, S.J. Differences in the behavior of cytoplasmic granules and lipid bodies during human lung mast cell degranulation. J. Cell Biol. 99:1678-1687, 1984. 59. Dvorak, A. M., Schulman, E. S., Peters, S. E, MacGlashan, D. W. Jr., Newball, H. H., Schleimer, R. E
86
60. 61.
62. 63. 64.
65.
66.
67.
68.
69.
70.
71.
72. 73.
74.
75.
76. 77.
78.
A N N M. D V O R A K and Lichtenstein, L. M. Immunoglobulin E-mediated degranulation of isolated human lung mast cells. Lab. Invest. 53:45-56, 1985. Dvorak, A. M. Ultrastructural analysis of human mast cells and basophils. In: Human Basophils and Mast Cells. BiologicaIAspects, (Marone, G., ed.), pp. 1-33. Karger, Basel, 1995. Dvorak, A. M. Human basophil recovery from secretion. A review emphasizing the distribution of Charcot-Leyden crystal protein in cells stained with the electron-dense tracer, cationized ferritin. Histol. Histopathol. 11:711-728, 1996. Dvorak, A. M. New aspects of mast cell biology. Int. Arch. Allergy Immunol. 114:1-9, 1997. Dvorak, A. M. A role for vesicles in human basophil secretion. Cell Tissue Res. 293:1-22, 1998. Warner, J. A., Peters, S. P., Lichtenstein, L. M., Hubbard, W., Yancey, K. B., Stevenson, H. C., Miller, P. J. and MacGlashan, D. W. Jr. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J. Leukoc. Biol. 45:558-571, 1989. Schleimer, R. P., Gillespie, E. and Lichtenstein, L. M. Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. I. Characterization of the response. J. Immunol. 126:570-574, 1981. Schleimer, R. P., Gillespie, E., Daiuta, R. and Lichtenstein, L. M. Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. II. Interaction with other stimuli. J. Immunol. 128:136-140, 1982. Costa, J. J., Demetri, G. D., Harrist, T. J., Dvorak, A. M., Hayes, D. E, Merica, E. A., Menchaca, D. M., Gringeri, A. J., Schwartz, L. B. and Galli, S. J. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J. Exp. Med. 183:2681-2686, 1996. Dvorak, A. M. Human mast cells. Ultrastructural observations of in situ, ex vivo, and in vitro sites, sources, and systems. In: The Mast Cell in Health and Disease, (Kaliner, M. A. and Metcalfe, D. D., eds), pp. 1-90. Marcel Dekker, New York, 1992. Dvorak, A. M., Costa, J. J., Monahan-Earley, R. A., Fox, P. and Galli, S. J. Ultrastructural analysis of human skin biopsy specimens from patients receiving recombinant human stem cell factor: subcutaneous injection of rhSCF induces dermal mast cell degranulation and granulocyte recruitment at the injection site. J. Allergy Clin. Immunol. 101:793-806, 1998. Dvorak, A. M., McLeod, R. S., Onderdonk, A. B., Monahan-Earley, R. A., Cullen, J. B., Antonioli, D. A., Morgan, E., Blair, J. E., Estrella, P., Cisneros, R. L., Cohen, Z. and Silen, W. Human gut mucosal mast cells: ultrastructural observations and anatomic variation in mast cell-nerve associations in vivo. Int. Arch. Allergy Immunol. 98:158-168, 1992. Dvorak, A. M., McLeod, R. S., Onderdonk, A., Monahan-Earley, R. A., Cullen, J. B., Antonioli, D. A., Morgan, E., Blair, J. E., Estrella, P., Cisneros, R. L., Silen, W. and Cohen, Z. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. Int. Arch. Allergy Immunol. 99:74-83, 1992. Galli, S. J., Zsebo, K. M. and Geissler, E. N. The kit ligand, stem cell factor. Adv. Immunol. 55:1-96, 1994. Mitsui, H., Furitsu, T., Dvorak, A. M., Irani, A.-M. A., Schwartz, L. B., Inagaki, N., Takei, M., Ishizaka, K., Zsebo, K. M., Gillis, S. and Ishizaka, T. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl. Acad. Sci. USA 90:735-739, 1993. Furitsu, T., Saito, H., Dvorak, A. M., Schwartz, L. B., Irani, A.-M. A., Burdick, J. E, Ishizaka, K. and Ishizaka, T. Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989. Columbo, M., Horowitz, E. M., Botana, L. M., MacGlashan, Jr., D. W., Bochner, B. S., Gillis, S., Zsebo, K. M., Galli, S.J. and Lichtenstein, L.M. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J. Immunol. 149:599-608, 1992. Dvorak, A. M. and Morgan, E. S. Ribonuclease-gold labels proteoglycan-containing cytoplasmic granules and ribonucleic acid-containing organelles- a survey. Histol. Histopatho114:597-626, 1999. Dvorak, H. F., Dvorak, A. M., Manseau, E. J., Wiberg, L. and Churchill, W. H. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J. Nat. Cancer Inst. 62:1459-1472, 1979. Ferrara, N. and Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor
5.
B A S O P H I L AND M A S T C E L L S E C R E T I O N
87
specific for vascular endothelial cells. Biochem. Biophys. Res. Comm. 161:851-858, 1989. 79. Ferrara, N., Houck, K., Jakeman, L. and Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endoc. Rev. 13:18-32, 1992. 80. Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V. and Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989. 81. Gospodarowicz, D., Abraham, J. A. and Schilling, J. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculostellate cells. Proc. Natl. Acad. Sci. USA 86:7311-7315, 1989. 82. Dvorak, H. E, Nagy, J. A., Berse, B., Brown, L. E, Yeo, K.-T., Yeo, T.-K., Dvorak, A. M., Van De Water, L., Sioussat, T. M. and Senger, D. R. Vascular permeability factor, fibrin and the pathogenesis of tumor stroma formation.Ann. N. Y. A cad. Sci. 667:101-111, 1992. 83. Senger, D. R., Van De Water, L., Brown, L. E, Nagy, J. A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W., Dvorak, A. M. and Dvorak, H. E Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303-324, 1993. 84. Palade, G. E. and Bruns, R. R. Structural modulations of plasmalemmal vesicles. J. Cell Biol. 37:633-649, 1968. 85. Bruns, R. R. and Palade, G. E. Studies on blood capillaries. I. General organization of blood capillaries in muscle. J. Cell Biol. 37:244-276, 1968. 86. Hammel, I., Lagunoff, D., Bauza, M. and Chi, E. Periodic, multimodal distribution of granule volumes in mast cells. Cell Tissue Res. 228:51-59, 1983. 87. Hammel, I., Dvorak, A. M., Peters, S. E, Schulman, E. S., Dvorak, H. E, Lichtenstein, L. M. and Galli, S. J. Differences in the volume distributions of human lung mast cell granules and lipid bodies: evidence that the size of these organelles is regulated by distinct mechanisms. J. Cell Biol. 100:1488-1492, 1985. 88. Hammel, I., Lagunoff, D. and Wysolmerski, R. Theoretical considerations on the formation of secretory granules in the rat pancreas. Exp. Cell Res. 204:1-5, 1993. 89. Hammel, I., Dvorak, A. M., Fox, E, Shimoni, E. and Galli, S. J. Defective cytoplasmic granule formation. II. Differences in patterns of radiolabeling of secretory granules in beige versus normal mouse pancreatic acinar cells after [3H]-glycine administration in vivo. Cell Tissue Res. 293:445-452, 1998. 90. Dvorak, H. E, Mihm, M. C. Jr., Dvorak, A. M., Johnson, R. A., Manseau, E. J., Morgan, E. and Colvin, R. B. Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab. Invest. 31:111-130, 1974. 91. Dvorak, H. E, Mihm, M. C. Jr. and Dvorak, A. M. Morphology of delayed-type hypersensitivity reactions in man. J. Invest. Dermatol. 67:391-401, 1976. 92. Dvorak, A. M., Mihm, M. C. Jr. and Dvorak, H. E Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab. Invest. 34:179-191, 1976. 93. Dvorak, A. M., Dickersin, G. R., Connell, A., Carey, R. W. and Dvorak, H. E Degranulation mechanisms in human leukemic basophils. Clin. Immunol. Immunopathol. 5:235-246, 1976. 94. Glasser, L., Corrigan, J. J. Jr. and Payne, C. Basophilic meningitis secondary to lymphoma. Neurology 26:899-902, 1976. 95. Dvorak, A. M. Morphologic and immunologic characterization of human basophils, 1879 to 1985. Riv. Immunol. Immunofarmacol. 8:50-83, 1988. 96. Dvorak, A. M. The fine structure of human basophils and mast cells. In: Mast Cells, Mediators and Disease (Holgate, S. T., ed.), pp. 29-97. Kluwer, Dordrecht, 1988. 97. Dvorak, A. M., ed. Human Mast Cells. Advances in Anatomy, Embryology, and Cell Biology, Vol. 114 (Beck, E, Hild, W., Kriz, W., Ortmann, R., Pauly J. E. and Schiebler, T. H., series eds). Springer-Verlag, Berlin, 1989. 98. Collin, H. B. and Allansmith, M. R. Basophils in vernal conjunctivitis in humans: an electron microscopic study. Invest. Ophthalmol. Vis. Sci. 16:858-864, 1977. 99. Dvorak, H. E, Mihm, M. C. Jr., Dvorak, A. M., Barnes, B. A., Manseau, E. J. and Galli, S. J. Rejection of first-set skin allografts in man. The microvasculature is the critical target of the immune response. J. Exp. Med. 150:322-337, 1979. 100. Dvorak, H. E, Mihm, M. C. Jr., Dvorak, A. M., Barnes, B. A. and Galli, S. J. The microvasculature is the critical target of the immune response in vascularized skin allograft rejection. J. Invest. Dermatol. 74:280-284, 1980. 101. Dvorak, A. M., Monahan, R. A., Osage, J. E. and Dickersin, G. R. Crohn's disease: transmission electron microscopic studies. II. Immunologic inflammatory response. Alterations of mast cells, basophils, eosinophils, and the microvasculature. Hum. Pathol. 11:606-619, 1980.
88
ANN M. D V O R A K
102. Dvorak, A. M. and Monahan, R. A. Crohn's disease. Ultrastructural studies showing basophil leukocyte granule changes and lymphocyte parallel tubular arrays in peripheral blood. Arch. Pathol. Lab. Med. 106:145-149, 1982. 103. Dvorak, A. M. and Monahan, R. A. Chronic abdominal pain, malaise, constipation and diarrhea in a forty year old woman: Crohn's disease. Norelco Rep. 31:18-44, 1984. 104. Dvorak, A. M., Mihm, M. C. Jr., Osage, J. E., Kwan, T. H., Austen, K. E and Wintroub, B. U. Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J. Invest. Dermatol. 78:91-101, 1982. 105. Fox, C. C., Dvorak, A. M., MacGlashan, D. W. Jr. and Lichtenstein, L. M. Histamine-containing cells in human peritoneal fluid. J. Immunol. 132:2177-2179, 1984. 106. Dvorak, A. M., Saito, H., Estrella, P., Kissell, S., Arai, N. and Ishizaka, T. Ultrastructure of eosinophils and basophils stimulated to develop in human cord blood mononuclear cell cultures containing recombinant human interleukin-5 or interleukin-3. Lab. Invest. 61:116-132, 1989. 107. Dvorak, A. M. and Monahan-Earley, R. A. Case 39: Soft tissue mass and lytic lesion of the scapula in a 55-year-old man with a 16-year history of eczema. Primary T cell lymphoma of the skin (Mycosis fungoides and Sezary's syndrome). Diagnostic Ultrastructural Pathology L A Text-Atlas of Case Studies Illustrating the Correlative Clinical-Ultrastructural Pathologic Approach to Diagnosis, pp. 327-346. CRC Press, Boca Raton, FL, 1992. 108. Asboe-Hansen, G. Mast cells and the skin. In Monographs in Pathology, Vol. 10 (Helwig, E. B. and Mostofi, F. K., eds) pp. 83-111. Williams & Wilkins, Baltimore, 1971. 109. Colvin, R. B., Dvorak, A. M. and Dvorak, H. F. Mast cells in the cortical tubular epithelium and interstitium in human renal disease. Hum. Pathol. 5:315-326, 1974. 110. Dvorak, A. M. Mast-cell hyperplasia and degranulation in Crohn's disease. In: The Mast Cell. Its Role in Health and Disease (Pepys, J. and Edwards, A. M., eds), pp. 657-662. Pitman Medical, Kent, 1979. 111. Dvorak, A. M. Ultrastructural pathology of Crohn's disease. In: Inflammatory Bowel Diseases - Basic Research and Clinical Implications (Goebell, H., Peskar, B. M. and Malchow, H., eds), pp. 3-4 1. MTP Press, Lancaster, 1988. 112. Dvorak, A. M. and Monahan-Earley, R. A. Diagnostic Ultrastructural Pathology. L A Text-Atlas of Case Studies Illustrating the Correlative Clinical-Ultrastructural Pathologic Approach to Diagnosis. CRC Press, Boca Raton, FL, 1992. 113. Dvorak, A. M. and Silen, W. Differentiation between Crohn's disease and other inflammatory conditions by electron microscopy.Ann. Surg. 201:53-63, 1985. 114. Dvorak, A. M., Monahan, R. A., Osage, J. E. and Dickersin, G. R. Mast-cell degranulation in Crohn's disease. Lancet i:498, 1978 (letter). 115. Dvorak, A. M., Mihm, M. C. Jr., Osage, J. E. and Dvorak, H. E Melanoma. An ultrastructural study of the host inflammatory and vascular responses. J. Invest. DermatoL 75:388-393, 1980. 116. Dvorak, A. M. and Kissell, S. Granule changes of human skin mast cells characteristic of piecemeal degranulation and associated with recovery during wound healing in situ. J. Leukoc. BioL 49:197-210, 1991. 117. Dvorak, A. M. and Monahan-Earley, R. A. Case 5: Weight loss, fatigue, diarrhea, fever and lymphadenopathy in a 48-year-old male industrial engineer. Whipple's disease. Diagnostic Ultrastructural Pathology L A Text-Atlas of Case Studies Illustrating the Correlative ClinicalUltrastructural Pathologic Approach to Diagnosis, pp. 34-45. CRC Press, Boca Raton, FL, 1992. 118. Dvorak, A. M. and Monahan, R. A. Abdominal pain, hepatomegaly and weight loss in a fifty four year old man: renal cell carcinoma and adenoma. Norelco Rep. 32:61-66, 1985. 119. Murphy, G. E, Austen, K. F., Fonferko, E. and Sheffer, A. L. Morphologically distinctive forms of cutaneous mast cell degranulation induced by cold and mechanical stimuli: an ultrastructural study. J. Allergy Clin. Immunol. 80:603-611, 1987. 120. Dvorak, A. M. and Monahan-Earley, R. A. Case 10: Progressive cough and shortness of breath in a 34year-old man. Diffuse interstitial fibrosis and mast cell hyperplasia of the lung consistent with hypersensitivity pneumonitis. Diagnostic Ultrastructural Pathology. II. A Text-Atlas of Case Studies Emphasizing Respiratory and Nervous Systems, pp. 142-163. CRC Press, Boca Raton, FL, 1995. 121. Dvorak, A. M., Schleimer, R. P., Schulman, E. S. and Lichtenstein, L. M. Human mast cells use conservation and condensation mechanisms during recovery from degranulation. In vitro studies with mast cells purified from human lungs. Lab. Invest. 54:663-678, 1986.
CHAPTER
6
Human Dendritic Mast Cells HENRIK H. JACOB1.1 and OLLE JOHANSSON2 1Allergy Unit 7511, National University Hospital, Copenhagen, Denmark and 2Experimental Dermatology Unit, Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
INTRODUCTION In recent years, it has become evident that human mast cells comprise different subtypes that display variations in their morphological (1-3), biochemical (4-7) and functional (8-12) properties. However, the identification and classification of such mast cell subtypes is still in its beginning. In this chapter we describe a subpopulation of human mast cells with dendrite-like cellular processes. The existence of such dendritic cells, side by side with ordinary round or elongated mast cells, clearly illustrates the marked heterogeneity of human mast cells. The chapter focuses on the morphology of the human dendritic mast cells. However, we also discuss some functional aspects that may be of particular relevance to these cells.
THE M O R P H O L O G Y OF HUMAN DENDRITIC MAST CELLS Mast cells are characteristic tissue cells with a single round or oval nucleus and numerous cytoplasmic granules that stain metachromatically with thiazine dyes such as toluidine blue, and also show characteristic orthochromatic staining with phthalocyanin dyes such as Alcian blue. The size and shape of mast cells show considerable variation, but human mast cells are usually described as round or elongated cells with a diameter ranging between 8 and 20 ~tm depending on the organ examined (1-3). The description of human mast cells as being round or elongated is, however, not entirely adequate because some mast cells may also have dendrite-like cellular processes (Fig. 1). Such dendritic mast cells have been observed in the human nasal mucosa (13), skin (14) and gastrointestinal system (unpublished data). * C o r r e s p o n d i n g author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
89
Copyright 9 2000 Academic Press All rights of reproduction in anyform reserved
90
HENRIK H. JACOBI AND OLLE JOHANSSON
Fig. 1 Dendritic mast cell in the human skin. The cell has been labelled for histamine using the indirect immunofluorescence technique. Small second- and third-level branches are visible on the distal part of the cellular process. Bar: 25 ~m. (Modified with permission from J. Cutan. Pathol. 25:189-198, 1998.) The study of human dendritic mast cells is dependent on the availability of sensitive and specific methods for the identification of mast cells in human tissues. Although conventional staining methods, using toluidine blue or Alcian blue, occasionally may reveal mast cells with an apparent dendritic morphology (15), these methods are not sensitive enough to detect the small second- or third-level branches that may be present on some of the dendrite-like cellular processes (13). In contrast, immunostaining using antibodies against mast cell mediators such as histamine, tryptase or chymase results in excellent labelling of small cellular processes; the next section will describe some of the immunohistochemical methods that we have used to study dendritic mast cells in human tissues.
lmmunostaining of Mast Cells Mast cells contain significant amounts of histamine and neutral serine proteases, and human mast cells can easily be identified in tissue sections using immunohistochemistry for histamine, tryptase or chymase (4, 16, 17). Furthermore, such immunohistochemical methods seem to be superior to conventional staining methods using toluidine blue or Alcian blue (13, 18). To stain human mast cells for histamine, biopsies are fixed in phosphate-buffered saline (PBS) with 4% 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (CDI) for 2 h at 4~ After fixation, the biopsies are immersed in PBS with 10% sucrose for 24 h before sectioning in a cryostat. The sections are then stained with antihistamine antibodies raised against histamine conjugated to different carrier proteins with CDI (19). Tryptase and chymase immunohistochemistry can also be performed on CDI-fixed biopsies if the proper antitryptase and antichymase antibodies are selected (13). Alternatively, biopsies can be fixed in 4% paraformaldehyde for 2 h at 4~ and then processed as described above. The latter approach results in excellent staining with many antitryptase and
6.
HUMAN DENDRITIC MAST CELLS
91
antichymase antibodies (14), but completely abolishes staining with the antihistamine antibodies (17). Although the choice of fixation procedure and primary antibodies is important for the optimal immunostaining of mast cells in tissue sections, the thickness of the tissue sections is equally important when studying mast cell subpopulations with dendrite-like cellular processes. The cellular processes bend and curve through the tissue, and it is obvious that, if the tissue sections are cut too thin, one will also reduce the likelihood that the entire length of the cellular processes will be contained within a given tissue section. We find that tissue sections with a thickness of 14-15 ~tm are optimal for most lightmicroscopy studies. For confocal microscopy, even thicker tissue sections are preferable. Dendritic Mast Cells in the Human Nose
It is now clear that mast cells in the human nasal mucosa may have dendrite-like cellular processes (13). Such dendritic mast cells have been identified by immunostaining of nasal mucosa biopsies using the methods described above. In one study, biopsies were taken from the lower or middle nasal turbinates of healthy controls and symptom-free atopic patients. The biopsies were fixed in CDI and tissue sections were subsequently triple-stained for histamine, tryptase and chymase. In addition, tissue sections already immunostained for mast cell mediators were restained using Alcian blue. These procedures revealed both ordinary round and elongated mast cells as well as mast cells with thin, branching, dendrite-like cellular processes (13). Figure 2 demonstrates the typical morphology of dendritic mast cells in the human nasal mucosa. The cell bodies of the dendritic mast cells are usually positive for both tryptase and chymase, demonstrating that these cells are MCTc mast cells. As for the cellular processes, some of these are positive for both tryptase and chymase, whereas others are positive for histamine but seem to be negative for mast cell proteases. The dendritic mast cells are primarily localized in the subepithelial connective tissue without any obvious relationship to blood vessels or glands. Some cells have only one slender process, whereas other cells have several processes extending from different parts of the cell body. Some of the cellular processes divide into two or three terminal branches and some processes have small histamine-positive swellings along their course. As described above, dendritic mast cells can be detected in nasal mucosa biopsies from both healthy subjects and symptom-free atopic patients. The number of cells shows considerable variation from subject to subject without any obvious differences between healthy subjects and symptom-free atopic patients. In most subjects, the dendritic mast cells are few and account for less than 5% of the mast cells in the subepithelial connective tissue (13). Dendritic Mast Cells in the Human Skin
Dendritic mast cells in normal human skin were first detected using histamine immunohistochemistry (17, 18). In these studies, punch biopsies were taken from the palm or forearm of healthy subjects. The biopsies were fixed in CDI and tissue sections were subsequently immunostained for histamine. This procedure revealed round and elongated cells as well as dendritic histamine-positive cells. The identity of the dendritic histamine-positive cells was later confirmed using tryptase and chymase immunohistochemistry, demonstrating that these cells are MCTc mast cells (14, 20).
92
H E N R I K H. J A C O B I AND O L L E J O H A N S S O N
Fig. 2 Dendritic mast cells in the human nasal mucosa. (a, b) Biopsy from an allergic patient. Double-labelling for histamine (a) and tryptase (b) using the indirect immunofluorescence technique. The round cell to the right is an ordinary mast cell without cellular processes. (c, d) Biopsy from a healthy subject. Double-labelling for histamine (c) and chymase (d). (e, f) Biopsy from a healthy subject. Double-labelling for histamine (e) and tryptase (f). The arrows point to small histamine-positive swellings along the course of the cellular process. Bar: 10 ~tm. (Reproduced with permission from Lab. Invest. 78:1179-1184, 1998.)
Although only few dendritic mast cells are present in normal skin, the relative number of these cells is increased in prurigo nodularis skin (14). Figure 3 demonstrates dendritic mast cells in prurigo nodularis skin. Dendritic mast cells are found both in the reticular and in the papillary dermis with no obvious relationship to dermal structures such as glands or vessels. The cells usually have a large cell body and the cellular processes may be quite long (>50 ~trn) with second- or third-level branches. At the ultrastructural level, dendritic mast cells often have a large cell body but contain relatively few granules in the cytoplasm, especially within the dendrites (14).
6. HUMAN DENDRITIC MAST CELLS
93
Fig. 3 Dendritic mast cells in prurigo nodularis lesional skin. Double-labelling for tryptase (a, c, e) and chymase (b, d, f) using the indirect immunofluorescencetechnique. Bar: 50 ~tm.(Reproduced with permission from Eur. J. Dermatol. 9:297-299, 1999.)
F U N C T I O N A L ASPECTS AND FUTURE LINES OF R E S E A R C H Little is known about the function and differentiation pathways of the human dendritic mast cells. The increased number of these cells in prurigo nodularis skin (14) and at sites of allergic inflammation (unpublished data) indicate that: (i) ordinary mast cells may transform into the dendritic phenotype during an inflammatory response; and/or (ii) dendritic mast cells are selectively recruited to sites of inflammation. The presence of dendrite-like cellular processes may simply reflect that the mast cells are migrating in the tissue. However, a similar change in shape has not been reported for other types of migrating cells. Alternatively, the cellular processes may be specialized structures with particular efferent and/or afferent functions. In this context it is interesting that, in addition to their role in immediate hypersensitivity reactions, mast cells have been implicated in conditions as diverse as antigen presentation (21, 22), host defence (23-25), tissue remodelling (26-28) and angiogenesis (29, 30). Whether the dendritic phenotype is associated with any of these functions remains to be established. An important question to address in future studies will be whether the cellular processes are directed toward particular cell types in the tissue. This latter question can be answered by double-staining experiments using specific markers of resident tissue cells and inflammatory cells. In the human nose and skin we have not been able to detect any obvious relationship between the dendritic mast cells and blood vessels or glands. The relationship to nerve fibres has not been studied systematically but such studies are now in progress.
94
H E N R I K H. J A C O B I AND O L L E J O H A N S S O N
Other important questions will be whether the cellular processes express particular proteins and whether the cellular processes terminate as free endings in the extracellular space or make direct cell-to-cell contacts with the surrounding cells. In this context it is interesting that mast cells (at least in the murine system) may express connexins on their cytoplasmic membrane, indicating that mast cells have the potential to communicate with other cells through gap junctions (31).
CONCLUDING REMARKS It is now clear that a subpopulation of human MCTc cells have dendrite-like cellular processes. Some cells have only one slender process, whereas other cells have several processes extending from different parts of the cell body. Furthermore, the cellular processes may be quite long with second- or third-level branches, and some processes have small histamine-positive swellings along their course. The dendritic MCTc cells have been observed in the human nasal mucosa and skin as well as in other organs, and their numbers seem to increase at inflammatory sites. However, the study of these cells is only in its beginning and further studies will be necessary to reveal the functional significance of the human dendritic mast cells.
REFERENCES 1. Schulman, E. S., Kagey-Sobotka, A., MacGlashan, D. W., Adkinson, N. E, Peters, S. R, Schleimer, R. E and Lichtenstein L. M. Heterogeneity of human mast cells. J. Immunol. 131:1936-1941, 1983. 2. Galli, S. J., Dvorak, A. M. and Dvorak, H. E Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog. Allergy 34:1-141, 1984. 3. Lee,T. D. G., Swieter, M., Bienenstock, J. and Befus, A. D. Heterogeneity in mast cell populations. Clin. Immunol. Rev. 4:143-199, 1985. 4. Irani, A. A., Schechter, N. M., Craig, S. S., DeBlois, G. and Schwartz, L. B. Two types of human mast cells that have distinct neutral protease compositions. Proc. Natl. Acad. Sci. USA 83:4464-4468, 1986. 5. Schechter, N. M., Irani, A.-M. A., Sprows, J. L., Abernethy, J., Wintroub, B. U. and Schwartz, L. B. Identification of cathepsin G-like proteinase in the MCTc type of human mast cell. J. Immunol. 145:2652-2661, 1990. 6. Irani, A.-M. A., Goldstein, S. M., Wintroub, B. U., Bradford, T. and Schwartz, L. B. Human mast cell carboxypeptidase. Selective localization to MCTc cells. J. Immunol. 147:247-253, 1991. 7. Bradding, E, Okayama, Y., Howarth, E H., Church, M. K. and Holgate, S. T. Heterogeneity of human mast cells based on cytokine content. J. Immunol. 155:297-307, 1995. 8. Church, M. K., Pao, G. J.-K. and Holgate, S. T. Characterization of histamine secretion from mechanically dispersed human lung mast cells: effects of anti-IgE, calcium ionophore A23187, compound 48/80, and basic polypeptides. J. Immunol. 129:2116-2121, 1982. 9. Schulman, E. S., MacGlashan, D. W., Peters, S. E, Schleimer, R. E, Newball, H. E. I. and Lichtenstein, L. M. Human lung mast cells: purification and characterization. J. Immunol. 129:2662-2667, 1982. 10. Benyon, R. C., Lowman, M. A. and Church, M. K. Human skin mast cells: their dispersion, purification, and secretory characterization. J. Immunol. 138:861-867, 1987. 11. Lawrence, I. D., Warner, J. A., Cohan, V. L., Hubbard, W. C., Kagey-Sobotka, A. and Lichtenstein, L. M. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J. Immunol. 139:3062-3069, 1987. 12. Patella, V., Marinb, I., Lamp~rter, B., Arbustini, E., Adt, M. and Marone, G. Human heart mast cells. J. Immunol. 154:2855-2865, 1995. 13. Jacobi, H. H., Liang, Y., Tingsgaard, E K., Larsen, E L., Poulsen, L. K., Skov, E S., Haak-Frendscho, M., Niles, A. L. and Johansson, O. Dendritic mast cells in the human nasal mucosa. Lab. Invest. 78:1179-1184, 1998.
6.
HUMAN DENDRITIC MAST CELLS
95
14. Liang, Y., Jacobi, H. H., Marcusson, J. A., Haak-Frendscho, M. and Johansson, O. Dendritic mast cells in prurigo nodularis skin. Eur. J. Dermatol. 9:297-299, 1999. 15. Trotter, C. M., Carney, A. S. and Wilson, J. A. Mast cell distribution and morphology in human nasal turbinates following decalcification. Rhinology 27:81-89, 1989. 16. Irani, A.-M. A., Bradford, T. R., Kepley, C. L., Schechter, N. M. and Schwartz, L. B. Detection of MCT and MCTc types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J. Histochem. Cytochem. 37:1509-1515, 1989. 17. Johansson, O., Virtanen, M., Hilliges, M. and Yang, Q. Histamine immunohistochemistry: a new and highly sensitive method for studying cutaneous mast cells. Histochem. J. 24:283-287, 1992. 18. Johansson, O., Virtanen, M., Hilliges, M. and Yang, Q. Histamine immunohistochemistry is superior to the conventional heparin-based routine staining methodology for investigations of human skin mast cells. Histochem. J. 26:424-430, 1994. 19. Panula, P., Happola, O., Airaksinen, M. S., Auvinen, S. and Virkamaki, A. Carbodiimide as a tissue fixative in histamine immunohistochemistry and its application in developmental neurobiology. J. Histochem. Cytochem. 36:259-269, 1988. 20. Liang, Y., Marcusson, J. A., Jacobi, H. H., Haak-Frendscho, M. and Johansson, O. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in pruligo nodularis: a reappraisal. J. Cutan. Pathol. 25:189-198, 1998. 21. Malaviya, R., Twesten, N. J., Ross E. A., Abraham, S. N. and Pfeifer, J. D. Mast cells process bacterial Ags through a phagocytic route for class I MHC presentation to T cells. J. Immunol. 156: 1490-1496, 1996. 22. Frandji, P., Tkaczyk, C., Oskeritzian, B., David, B., Desaymard, C. and Mecheri, S. Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes. Eur. J. Immunol. 26:2517-2528, 1996. 23. Matsuda, H., Watanabe, N., Kiso, Y., Hirota, S., Ushio, H., Kannan, Y., Azuma, M., Koyama, H. and Kitamura, Y. Necessity of IgE antibodies and mast cells for manifestation of resistance against larval Haemophysalis longicornis ticks in mice. J. Immunol. 144:259-262, 1990. 24. Echtenacher, B., M~innel, D.N. and Htiltner, L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996. 25. Malaviya, R., Ikeda, T., Ross, E. and Abraham, S. N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-~. Nature 381:77-80, 1996. 26. Cairns, J. A. and Walls, A. E Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts. J. Clin. Invest. 99:1313-1321, 1997. 27. Gruber, B. L., Kew, R. R., Jelaska, A., Marchese, M. J., Garlick, J., Ren, S., Schwartz L. B. and Korn, J. H. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol. 158:2310-2317, 1997. 28. Kofford, M. W., Schwartz, L. B., Schechter, N. M., Yager, D. R., Diegelman, R. F. and Graham, M. E Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997. 29. Marks, R. M., Roche, W. R., Czerniecki, M., Penny, R. and Nelson, D. S. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab. Invest. 55:289-294, 1986. 30. Blair, R. J., Meng, H., Marchese, M. J., Ren, S., Schwartz, L. B., Tonnesen, M. G. and Gruber B. L. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J. Clin. Invest. 99:2691-2700, 1997. 31. Vliagoftis, H., Hutson, A. M., Mahmudi-Azer, S., Kim, H., Rumsaeng, V., Oh, C. K., Moqbel, R. and Metcalfe, D. D. Mast cells express connexins on their cytoplasmic membrane. J. Allergy Clin. Immunol. 103:656-662, 1999.
This Page Intentionally Left Blank
CHAPTER 7 The Phenotypic Similarities and Differences Between Human Basophils and Mast Cells L. LI, S. W. REDDEL and S. A. KRILIS* Department of Medicine, The University of New South Wales, Department of lmmunology, Allergy and Infectious Disease, St George Hospital, Kogarah, New South Wales, Australia
INTRODUCTION Mast cells and basophils are well known as the primary effector cells in allergic inflammation and they represent a major source of inflammatory mediators. A number of studies support the belief that human mast cells play a unique role in a wide variety of processes, including inflammation (1), host defence (2, 3), tissue remodelling (4-6) and angiogenesis (7), whereas human basophils are important for allergic inflammation, especially in chronic disease (8). Whether mast cells and basophils are two distinct cell types or different states of a single cell lineage is not fully understood. It is apparent that mast cells and basophils share many constitutive properties but they also have differences in respect of their development, functions, morphology, secretory granular contents and cell surface molecules. The traditional view is that mast cells arise from mast cell committed precursors in the bone marrow, circulate as agranular cells, then traverse the vascular space and enter the tissues where they complete their development. Differentiation and maturation of mast cells are most likely regulated by local micro-environmental factors (9-12). Mast cells are found in almost all of the major organs and tissues of the body, particularly in association with connective tissue structures such as blood vessels, lymphatic vessels and nerves, and in proximity to surfaces that interface the external environment such as those of the respiratory and gastrointestinal systems and the skin. In contrast, basophils differentiate and mature in the bone marrow, circulate in the blood and comprise less than 1% of total leukocytes. Normally basophils are not found in human tissue sites. However, there is increasing evidence that basophils are also involved in hypersensitivity reactions in inflamed tissue (13, 14). In this review the respective phenotypic features of basophils in blood and mast cells in tissues are examined with a discussion of their differences and similarities. * Corresponding author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
97
Copyright 9 2000Academic Press All rights of reproduction in anyform reserved
98
L. LI et al.
MORPHOLOGY
Mast cells and basophils were first identified by a characteristic influence of solvent and pH on the metachromatic staining reaction, which was found to be an effect on the binding of the dyes to heparin (15, 16). It is now clear that a large number of compounds stain metachromatically, in particular sulphated mucopolysaccharides and heparin, which are found in both mast cells and basophils (17, 18). Mast cells and basophils can be distinguished on morphological grounds. It has been revealed that mast cells from most human tissue sites have a similar appearance. Analysis in a number of light- and electron-microscopic studies shows that mast cells appear as cells with a non-segmented monolobed nucleus, a surface architecture composed of narrow, elongated folds and numerous smaller and very typical cytoplasmic granules (19). Basophils, on the other hand, are typically a round cell with a few short blunt projections. The nucleus shows a polymorphonuclear morphology with marked chromatin condensation. In comparison to mast cells, basophils contain fewer and larger electron-dense granules which lack the patterns associated with mast cells (20-22). In vitro studies have lead to a different morphological view of the nuclear profile of the mast cell. In many cases, differentiated mast cells possessing multilobular nuclei have been found occasionally in cultured mouse (23-26) and human mast cells (27-31). The findings were strongly supported by the histopathological results from rodent studies by Gurish et al. (32). They demonstrated clearly that mast cells with multilobular nuclei can be found occasionally in the skeletal muscle of normal mice as well as in the jejunum of helminth-infected mice and in various tissues of the V3 mastocytosis mouse (32). The patterns of the granules in mast cells and basophils have also been examined. The results from Craig et al. indicate that only granules with the chymase protease exhibit a grating or lattice substructure whereas regions lacking this protease show a scroll pattern (33-35). The ultrastructural study by Weidner and Austen confirmed that mast cells from lung and bowel mucosa generally stained only for tryptase (MCT) and that their granules were rich in scrolls; however, they emphasized the finding of significant granule morphological heterogeneity both amongst tryptose-chymase positive mast cells (MCTc) found in any particular tissue site and between the individual granules of single mast cells (both MCTc and MCT) identified within a range of tissues (36). Ultrastructurally immature mast cell granules with the tryptase protease show a scroll pattern, as do their mature counterparts. Immature mast cell granules containing both tryptase and chymase proteases have an amorphous electron-dense core rather than a grating or lattice pattern (34). Basophil granules are rather uniform compared with those of the mast cell. Most granules in basophils contain electron-dense particles with neither scroll nor lattice patterns. The protein forming the Charcot-Leyden crystal, previously thought to be eosinophil-specific, has also been seen in some basophil granules (37, 38).
MEMBRANE RECEPTORS
The major aspects of mast cell activation may be initiated upon cross-linking of the highaffinity receptor Fc~RI which is expressed on the cell surface. This occurs when multiple specific IgE antibody molecules both bind to a multivalent antigen and are also bound at their Fc region by Fc~RI. The three subunits of the IgE receptor : (cz, [3 and 7) have now all
7. PHENOTYPICCOMPARISON OF HUMAN BASOPHILS AND MAST CELLS
99
Fig. 1 Phenotypiccharacteristics of human mast cells and basophils. T, tryptase; C, chymase; IgERI, highaffinity IgE receptor; CPA, carboxypeptidaseA; Bsp-1, basophil specificprotein 1. References: Castells, 1987 (105); Fureder, 1994(161); Furitsu, 1989 (192); Irani, 1987(132); Irani, 1992 (79); Irani, 1994(134);Li, 1995 (29); Li, 1996 (30); Li, 1996 (31); Mitsui, 1993 (82); Nilsson, 1993 (137); Rottem, 1994 (28); Saito, 1996 (193); Sillaber, 1992 (195); Valent, 1989 (194);Weidner, 1993 (133).
been cloned and sequenced (39-41). The c~ chain is mainly external, having only a short tail extending into the cytoplasm via one transmembrane (hydrophobic) domain. The chain and each of the two disulphide-linked ~/chains are predominantly cytoplasmic and have four and one transmembrane domains, respectively (41). The ~ and "f chains show substantial interspecies homology whereas the ]3 chains are different between humans and rodents. Human basophils also express Fc~RI as well as the low-affinity receptor FcvRII (42-44) and may also be activated by cross-linkage of IgE receptors. In an elegant study it has been suggested that activation of basophils from atopic subjects may also occur by anti-IgG through IgG-IgE immune complexes acting on Fc~RI (45). The expression of the Fc~RI was once thought to be a unique characteristic of mast cells and basophils (46). However, it is also found on several potential effector cells such as Langerhan's cells in tissue (47, 48), eosinophils (49), monocytes (50) and peripheral blood dendritic cells (51). The mRNA transcripts for the cz and 7 chains were detected on highly purified Langerhan's cells using polymerase chain reaction (PCR) technology, but transcripts for the [3 chain were found only in a minority of individuals without correlation with atopic status (49). It seems that the [~chain is necessary in effector cells of anaphylaxis and in cells containing pre-formed mediators packed in granules. The cluster-of-differentiation (CD) features specific for discriminating mast cells and basophils have not yet been defined, although several studies have made the suggestion that mast cells could be isolated by using a particular pattern of differentiation antigens that are more commonly expressed on mast cells than on basophils (52, 53). It also appears that mast cells express many leukocyte antigens that are not found on basophils.
1 O0
L. LI et
al.
Common antigens found on both mast cells and basophils include CD45, CD55, CD59, CD63, histamine H2 and prostaglandin D2 receptors (54-58). Adhesion molecules play a major role in cellular binding to other cells and to extracellular matrix glycoproteins. Integrins, which are the best known of them, are a family of non-covalently linked heterodimers of ~ and 13 subunits that mediate cell binding activity (59, 60). Both mast cells isolated by collagenase digestion from tissues and blood basophils express 13~ integrins (CD29, CD49d, CD49e) and low levels of intercellular adhesion molecule 1 (ICAM- 1) (61), whereas 132integrins (CD 18, CD 11a, CD 1lb, CD1 lc), [33 integrins (CD61/CD51) and vascular cell adhesion molecule 1 (VCAM-1) were only identified on basophils (62-64). Activation of basophils or mast cells results in enhanced expression of adhesion molecules and/or increased adherence to other cells and to extracellular matrix glycoproteins (65-69). A recent study showed that the cross-linking of surface expressed [3~ integrins on the basophils of asthmatic patients by antibody or fibronectin can trigger a significant release of histamine, but not in the case of basophils of normals or of human lung mast cells (70). Haematopoietic cytokines play a potent role in cell differentiation and proliferation in both mouse and human. Intense studies over the years have demonstrated differences in cytokine-promoted development between mast cells and basophils, and between humans and rodents. Interleukins IL-3 and IL-5, and granulocyte-macrophage colonystimulating factor (GM-CSF) which affect mouse mast cell growth are differentiation factors for human basophils but not for human mast cells (71, 72). It is noteworthy that human basophils, like eosinophils, express receptors for IL-3 (CD123), IL-5 (CD115) and GM-CSF (CDll6) (57, 73), whereas the lack of receptors for IL-3, IL-5 and GMCSF on tissue mast cells may explain why they do not respond to these cytokines alone. However, studies from cultured human mast cells showed that mRNAs for IL-3, IL-4, IL5 and IL-6 receptors and binding sites for IL-3 can be detected (74). The expression by mast cells but not basophils of c-kit (CD 117), the receptor for kit ligand (variously stem cell factor, mast cell growth factor, steel factor) (75), is taken to be a key feature of distinction between the two cell types although we (see below) (31) and indirect evidence from others (76) have shown that this is not the case in all circumstances. The expression of c-kit on the mast cell surface is very important to the cell for differentiation, proliferation and survival (29, 75). Kit ligand (KL) is one of the major growth factors for mast cells and also for other haematopoietic cells (22, 29, 77-83). The expression of urokinase receptors (CD87) on mast cells may also have implications for specific mast cell-dependent microvascular processes such as fibrinolysis, migration, or local tissue repair (84). IL-8, a neutrophil chemotactic agent, is involved in a large number of neutrophildriven acute and chronic inflammatory diseases. Its receptors are found on neutrophils, T lymphocytes, monocytes and keratinocytes. However, IL-8 is also involved in mast cell and basophil activation. Binding and competition studies with ~25I-labelled IL-8 revealed specific IL-8 receptors on basophils from normal individuals, and it was suggested that IL-8 activates human basophils by a receptor-mediated mechanism similar to that operating in neutrophils (85). Two subunits of IL-8 receptors called CXCR1 and CXCR2 have been identified (86, 87). Interestingly, in human mast cells, CXCR1 is expressed on the cell surface, whereas the CXCR2 receptor is located intracellularly in specific mast cell granules on immunoelectron microscopy (88). One of the significant advances is the derivation of the IgM monoclonal bsp-1
7.
PHENOTYPICCOMPARISON OF HUMAN BASOPHILS AND MAST CELLS 1 0 1
antibody, which is used for purifying and isolating human basophils from blood (89, 90). It was also shown that bsp-1 is a cell surface-expressed protein and is found on the basophil but not on mast cells. Another integral membrane protein found on basophils is the 48-kDa CD40 marker which is also expressed on B cells, T cells, dendritic cells, monocytes and epithelial cells (91). Since CD40 has been clustered as a member of the nerve growth factor/tumour necrosis factor (NGF/TNF) receptor superfamily, the presence of CD40 receptor may influence cellular activation via signalling with CD40 ligand which amongst others is secreted by both basophils and mast cells. A number of studies have searched for markers of the human mast cell progenitor. In 1991, Kirshenbaum et al. (92) demonstrated that both mast cell and basophil progenitors were from CD34 + cells. CD34 + cells cultured with recombinant human IL-3 (rhlL-3) gave rise to basophils, whereas CD34 + cells co-cultured with 3T3 fibroblasts in the presence of rhIL-3 gave rise to mast cells (92). Further studies investigated additional markers such as c-kit, CD 14 and CD 17. The results showed that the clone which marked as CD34 +, c-kit +, CD 14- and CD 17- and that separated from lymphocytes on counter flow centrifugation developed into mast cells (93). More recently, cells expressing CD34 and CD38 but without HLA-DR were found to be more likely to be human mast cellcommitted progenitors (94) when single cells were cultured in a broth of various lineage promoting factors. The CD38 molecule is found on mature granulocytes, some CD34 + myeloid cells and some lymphocytes. Interestingly, there were relatively few co-colonies developing from these single cells, suggesting quite an early differentiation given a stochastic model of lineage determination.
CYTOPLASMIC CONTENTS Histamine and Heparin One of the distinctive features of mast cells and basophils that was found in early studies is that they contain substantial amounts of histamine in their granules. Under normal conditions the content of histamine in mast cells is slightly higher than that in basophils. Exposure of human basophils to antigen or anti-IgE leads to a histamine release on average of 1 pg per cell (95), whereas lung, skin and synovial mast cells release approximately 4 pg per cell (96-98). The basophil histamine release requires 20-30 min for completion in comparison to about 10 min for mast cells (99). Studies by Stevens et al. (100) and Thompson et al. (101) have shown that human lung mast cells contain a mixture of both heparin and chondroitin sulphate E, whereas Metcalfe et al. (102) showed that chondroitin sulphate A is the dominant proteoglycan in basophils. The presence of highly sulphated proteoglycans in the secretory granules of mast cells and basophils results in metachromasia which is visible by toluidine blue stain. The release of histamine and heparin could enhance neo-vascularization and endothelial cell proliferation in tissues (103, 104).
Proteolytic Enzymes The two major proteases found in mast cell granules are chymase and tryptase. At the present time these proteases are considered to be the most selective markers for mast cells, as basophils from normal individuals contain only negligible amounts of tryptase protein and no detectable chymase protein (105). Immunohistochemical staining using
102
L. LI et al.
antibodies to tryptase and chymase can be utilized to distinguish mast cells from basophils and other cells (106, 107). The most predominant of the proteins comprising mast cell granules is tryptase. It has been purified from nearly all mast cells, including dispersed human lung mast cells (108), isolated skin mast cells (109) and pituitary tissue mast cells (110). It has been estimated that there is a concentration of 12-35 pg per lung or skin mast cell (111) but only 0.04 pg of tryptase per basophil which normally is not able to be detected by immunohistoreaction (105). Four highly conserved forms of tryptase (designated tryptase I, II/[3, III and ct) have been described, all with a 30-amino-acid leader sequence followed by a catalytic portion of 27.4 kDa (112-115). Tryptase is bound to a proteoglycan complex in the granules that is smaller than those binding other proteases (116). The presence of histamine seems to be necessary to stabilize tryptase activity (117). According to Sakai et al. (118), only [~tryptase is processed to a functional form or active enzyme within the mast cells in vivo. However, recent findings by Stevens' group demonstrate that both ct- and ~-tryptase are active in vitro (119). Chymase is the second major human mast cell protease (120-123) and is found at high levels in connective tissues such as the skin and submucosa of the gut and at low levels in the lung. Only one human chymase gene has been identified so far. However, the investigation carried out by McEuen et al. (124) showed that there are two different forms of human skin chymase by heparin-agarose chromatography. The activities of these two forms were similar in substrate specificity but the inhibitor profile was distinctly different from other chymotryptic enzymes. The study also revealed that there were different levels of expression for these two forms of chymase in the tissues (124). Two other proteases, carboxypeptidase A (CPA) and cathepsin G, have been associated with mast cells with a chymase-expressing phenotype. Carboxypeptidase is a unique 36kDa protease and is encoded by a single gene localized to chromosome 3 (125-127). The results of sequenced CPA cDNA sequences from both human skin and lung suggest only a single CPA gene in humans (128). Cathepsin G is a 26-kDa serine protease and a chymotryptic enzyme with a structure seemingly identical to that of neutrophil and monocyte cathepsin G (129). Cathepsin G and CPA are selectively present in the tryptasepositive/chymase-positive mast cell phenotype (130, 131). Like T cells, mast cells exhibit substantial phenotypic and sometimes ultrastructural variation in humans. The most widely adopted classification is descriptive and based on granule protease expression. Mast cells that express tryptase along with chymase, CPA and a cathepsin G-like protease are named MCTc and are found predominantly in connective tissue of skin, submucosa of stomach, submucosa of intestine, submucosa of colon and breast parenchyma, lymph nodes, conjunctiva and synovium (132-134). At human cardiac explantation the mast cells are mainly MCTc and are located primarily in the appendage of the atrium (135). Mast cells with tryptase alone are designated MCT; these cells predominate in the intestinal mucosa, nasal mucosa and lung (132-134). In the uterus most mast cells are limited to the inner half of the myometrium with equal proportions of MCv and MCTc. There are fewer mast cells, mostly MCTc, in the outer half of the myometrium and cervix, and in the endometrium, where they are mostly MCT (136). There is also a third type of mast cell, MCc; these express chymase without tryptase and reside mainly in the submucosa and mucosa of the stomach, small intestinal submucosa and colonic mucosa (132-134).
7.
PHENOTYPICCOMPARISON OF HUMAN BASOPHILS AND MAST CELLS 1 0 3
Certain mast cell phenotypes can also be promoted in vitro. Cultures of haematopoietic progenitor cells in the presence of KL alone result in selective differentiation to mast cells of MCT phenotype. Mast cells derived from fetal liver by culture with rhKL were predominantly of the MCT phenotype, as were mast cells derived by co-culture of human fetal liver cells with mouse 3T3 fibroblasts (79, 137). The conditioned media obtained from a cell strain from the bone marrow of a mastocytosis patient can influence mast cell phenotypes. Li et al. (30) were able to show that using this conditioned media preferential MCTc and MCc phenotypes developed from unseparated bone marrow cells. Furthermore, the conditioned media with added rhKL also upregulated MCc and MCTc and downregulated MCT phenotypes from umbilical cord blood (30).
Lipid-derived Mediators In addition to histamine and tryptase, cross-linking of IgE on human lung mast cells also leads to the synthesis of substantial amounts of arachidonic acid metabolites, including prostaglandin D2 (PGD2), leukotriene C4 (LTC4), platelet-activating factor (PAF) and some LTB4 (138-140). It has been noted that lung, heart and gut mast cells contain more LTC4 and PGD2 whereas skin mast cells synthesize more PGD2 and much less or no LTC4 (97, 141). In comparison, human basophils generate LTC4 and little or no PGD 2 (139, 141). Mast cells also synthesize PGE2, which may contribute to the inflammation which characterizes the late-phase response (141). PAF is another newly synthesized lipidderived mediator with the ability to influence a range of different aspects of inflammation. PAF is synthesized by both human lung mast cells and basophils (142, 143). The release of PAF either from mast cells or basophils amplifies the inflammatory response, leading to the activation and recruitment of neutrophils and eosinophils.
Cytokines In a similar fashion to that found in Th2 cells, the activation of mast cells and basophils leads to the de novo synthesis of several cytokines, although the mechanism has not yet been completely clarified. Basophils have a more restricted armamentarium of cytokines than mast cells do. Since cytokines play an important role in cell regulation, the recognition that mast cells produce a large number of cytokines suggests that mast cells may influence other cells within the microenvironment or play a more central role in subacute and chronic inflammatory processes. Two cytokines have so far been shown to be produced following basophil activation: IL-4 is synthesized over a period of hours following IgE cross-linking (144, 145); the related IL-13 has also been found to be released at increasing levels over 24 h after basophil activation where it can be immunolocalized to the granules (146). It has been shown that human mast cells can secrete a greater number of cytokines than basophils. The first demonstration of mast cell cytokine production was of IL-3 and TNF-t~ by peritoneal mast cells (147) using immunohistostaining, but now at least nine different cytokines have been shown to be produced by tissue mast cells including TNF-ct, IL-1, IL-4, IL-5, IL-6, IL-8, IL-13, NGF and KL. Human skin mast cells contain TNF-t~ protein and mRNA which is responsible for the upregulation of the endothelial cell adhesion molecule (ELAM- 1) (148). Under allergic conditions, cutaneous mast cells also produce significant amounts of IL- 1 that may contribute to lymphocytic infiltration (149).
104
L. LI et al.
Freshly purified human lung mast cells release IL-4, essential for the triggering of Th2 lymphocytes that themselves produce IL-4 to initiate inflammatory cell accumulation and B lymphocyte immunoglobulin class switching to IgE (150, 151). Other cytokines involved in mast cells found in normals and in the asthmatic airway are IL-5 and IL-6 which together with IL-4 and TNF-cz are detected by immunostaining and would indicate that mast cells may play an important role in initiating and maintaining the inflammatory response in asthma (151). A study on human skin mast cells showed that the capability of mast cells to generate IL-8 may contribute to neutrophil recruitment (152). On activation, human lung mast cells produce IL-13 with a secretion pattern that is comparable to the IL-13 release from peripheral blood Th2 cells (153). More recently, it was found that human mast cells express NGF (154) and also IL-16, a chemoattractant factor, which is another newly found cytokine from lung and bone marrow cultured mast cells and may suggest that mast cells induce the accumulation of CD4 + T cells in the inflammatory process (155). Mast cells express the c-kit receptor which is essential for mast cell proliferation and some aspects of maturation. Recent experiments have demonstrated that mast cells from the heart (156), skin and lung (157) are also able to synthesize the mRNA of KL and secrete the protein. In addition to IL-4 and IL-13, lung mast cells and blood basophils share the ability to express CD40 ligand. CD40 ligand shares significant amino acid homology with members of the NGF/TNF family and is viewed as a member of the NGF/TNF superfamily. The interaction between CD40 ligand as expressed by mast cells and CD40 on B cells, along with the binding of IL-4 to IL-4 receptor on B cells, satisfies the minimum requisite stimulus for immunoglobulin class switching to IgE (158) and may also have effects on B cell growth and transcriptional regulation (159). It suggests that mast cells and basophils play a key role in allergy, not only by producing inflammatory mediators, but also by directly regulating IgE production independently of T cells (158, 160). MAST CELL PHENOTYPES IN TISSUES Although mast cells from most human tissue sites have a similar ultrastructural appearance, they are slightly distinct in their surface markers, protease content, cytokine release and response to some external stimuli. Mast cells from adult skin and foreskin, but generally not elsewhere, express the additional marker CD88/C5aR, which also appears on the surface of the blood basophil (57, 58, 161). Uterine mast cells express CD 1l e/CD 18 (64) and both uterine and cutaneous mast cells also exhibit CD32 marker. In patients with rheumatoid arthritis significant amounts of C5aR (CD88) was detected on synovial mast cells (162). Using antibody to cross-link IgE to stimulate mast cells from skin, heart and lung researchers were able to demonstrate that the tryptase content in skin mast cells was much higher than that of heart and lung mast cells, whereas the release of tryptase in lung mast cells was the lowest of the three tissues examined. Heart mast cells isolated from the explanted diseased heart obtained at transplant were stimulated in vitro. The de novo synthesized mediators LTC4 and P G D 2 w e r e released from these mast cells, whereas PGD2 with only a little LTC4 was released from skin mast cells. Moreover, mast cells from skin seem to be very sensitive to stimulation, with C5a, substance P, compound 48/80 and morphine all leading to histamine release, whereas heart mast cells only
7.
PHENOTYPICCOMPARISON OF HUMAN BASOPHILS AND MAST CELLS 1_0 5
reacted to C5a and compound 48/80 and lung mast cells failed to respond to C5a (163). High chymase-like enzymatic activity was also detected in skin, uterus and stomach tissues, whereas lower levels of chymase enzymatic activity were present in lung, tonsil, colon and liver (164). In comparison to skin mast cells, uterine mast cells do not react to substance P but respond strongly with anti-IgE to release a significant amount of LTC4 and in fact produce similar arachidonic acid metabolites to lung mast cells. Ultrastructurally, however, there are no differences between the mast cells from skin, lung and uterus (165, 166). The results from examining the protease profile of mast cells with their differences in neutral protease composition suggest that the different mast cell phenotypes could serve differing biological and pathological roles. By examining mast cells for their specific cytokine contents, Bradding et al. (167) demonstrated that MCT express IL-5, IL-6 and some IL-4, whereas MCTc preferentially express IL-4 but have very little IL-5 and IL-6 in the tissues of bronchial and nasal mucosae from normal, asthmatic and allergic rhinitis patients. They found a similar predominant IL-4 pattern in skin mast cells which contain both tryptase and chymase (MCTc) (167). However, there is no significant difference between MCvc from skin and MCT from lung tissue in terms of their release of KL (157). Mast cells migrate to tissue sites with different microenvironments where they develop distinct phenotypes with different expression of serine proteases. A recent study by Longley et al. (12) clearly demonstrated that the microenvironment of tissues does influence mast cell phenotypic development, even if, ultrastructurally, they appear similar. Examination of mast cells of patients with urticaria pigmentosa and aggressive systemic mastocytosis whose pathological mast cells are monoclonally derived and chronically stimulated by KL, indicates that mast cells in spleen express MCT but that in the skin the majority of mast cells are MCTc. It also suggests that the KL axis does not irrevocably commit mast cells to a chymase-positive phenotype (12). The earlier observation of reduction of MCT numbers when compared to normals in the intestinal mucosa but not MCTc numbers in submucosa was obtained in patients with congenital combined immunodeficiency or acquired immunodeficiency syndrome (132). This suggests that functional T cells or their cytokines are necessary for the phenotypic development of MCT cells in the mucosa, but that in the submucosal microenvironment T cells do not appear to be required for the development of MCTc. In the upper dermis of skin from patients with psoriasis a significantly increased number of MCT cells are found, whereas 99% of mast cells are MCTc in normal skin (168). Nasal epithelium is normally dominated by MCTc; however, MCT phenotypes were consistently increased in allergic rhinitis (169-171). The same alteration of phenotype pattern was also seen in the synovial layer in osteoarthritis and in the bladder epithelium of nephrogenic metaplasia, where in both cases the number of MCT was significantly higher than usual (172, 173). However, in some other pathological states MCTc are the predominant cell type; for example, in atherosclerosis 80-95% of mast cells in the intima of carotid arteries are MCTc. There are similar findings in active vernal conjunctivitis, giant papillary conjunctivitis and allergic conjunctivitis (174, 175).
THE INVOLVEMENT OF MAST CELLS AND BASOPHILS IN A S T H M A A N D DRUG REACTIONS
Allergic asthma is a complex disorder characterized by local and systemic allergic
106
L. LI et al.
inflammation and reversible airway obstruction. There is clearly extensive evidence that mast cells and basophils act as primary effectors of allergic inflammation (176-184). Under normal conditions the level of tryptase in serum or plasma is less than 5 ng ml q (105). There are significant increases after allergen challenge in nasal lavage fluid (185) and in skin chamber fluid overlying the site of exposed dermis in an in vivo blister model in allergic patients for testing the direct exposure of skin mast cells to allergens (186). Redington et al. have stated that mast cells are more likely to be involved in the acute or early phase of the allergic response, whereas basophils are well established as the major effector cells of the chronic or late phase. One of the pieces of supportive evidence for this is that initially there is an elevation of both histamine and PGD2 as found in mast cells, whereas there is only histamine in the second rise of the late-phase response (184). Mast cells and basophils may be involved in drug hypersensitivity reactions. At least one of the groups clinically imitates IgE-mediated reactions, which are probably caused by non-immune mechanisms leading to the degranulation of mast cells and basophils (187, 188). The pathogenesis of the adverse reactions caused by different classes of drugs is complex and still not completely understood. In vitro and in vivo studies indicate that the release of vasoactive mediators, such as histamine and tryptase, from peripheral blood basophils and tissue mast cells plays a crucial role in determining the clinical manifestations (189). More recently, direct evidence has revealed that human blood basophilic cells are able to store or synthesize tryptase and/or chymase and CPA, which may contribute to the level of proteases in allergic conditions (31). This study involved four groups: normals, allergy and asthma patients and those with drug allergies. Mononuclear cells from peripheral blood were prepared for the detection of antigens such as tryptase, chymase, ckit and bsp-1. It showed that bsp-1 § cells were increased from 0.72% to 1.4% (allergy), 1.5% (asthma) and 2.3% (drug allergy), and that nearly 50% of these basophilic cells stained for tryptase or/and chymase. Using in situ hybridization with chymase and t~- and 13-specific tryptase probes, it appeared that in normals the predominant staining was for the t~-tryptase transcript with negligible staining for ~-tryptase and with no detectable staining for chymase. However, both chymase and ~- and ~-tryptase transcripts were upregulated in basophilic cells from individuals with asthma and in those experiencing adverse drug reactions. Four out of eight patients who were exposed to allopurinol, ceftriaxone or penicillin showed significant upregulation of chymase-positive basophilic cells, whereas the other four patients experiencing amlodipidine, isoniazid or ceftriaxone drug reactions appeared to have a predominantly tryptase immunoreactivity with few chymase-positive cells. This is the first time that basophilic cells have been documented in the blood of patients with allergic conditions to show a pattern that normally is seen in mast cells in terms of the neutral protease content. It is not clear at the present time whether mast cells and basophils can reversibly alter the expression of their neutral proteases. Nevertheless, several previous studies from rodent or human systems have shown strong support for this possibility. Friend et al. (190) provided evidence that mast cell subtypes can reversibly alter their expression of serine proteases, and more recently mouse mast cells were found to be able to alter their expression in vivo of multiple members of two distinct families of serine proteases (191). In humans it has been noted that clonal human mast cells differ in terms of their protease pattern or in their chymase and tryptase levels when these mast cells reside in varied tissue sites of a patient with systemic mastocytosis (12). In a study by Li et al. (31), the peripheral blood leukocytes of patients with an allergic
7.
PHENOTYPIC COMPARISON OF HUMAN BASOPHILS AND MAST CELLS 1 0 7
(atopic) disorder, asthma or drug reaction were found to have an increased proportion of metachromatic cells morphologically resembling basophils and expressing bsp-1, as well as in the majority expressing any combination of c-kit, tryptase or chymase. This study clearly demonstrated that: (i) there is an increased number of metachromatic cells in the blood of individuals with an allergic disorder; (ii) those metachromatic cells in patients with allergy, asthma or those experiencing an allergic drug reaction expressed substantial amounts of tryptase and/or chymase and CPA that are considered to be mast cell-specific proteases; (iii) interestingly most of the metachromatic tryptase- and/or chymase-positive cells also reacted to the basophil-specific marker bsp-1 which is not expressed on mast cells under normal conditions; in addition, these cells were generally of small size with multilobed nuclei which are more typical characteristics of basophils. Therefore the presence of metachromatic cells with features of both basophils and mast cells in the peripheral blood of these patients suggests: (i) that human mast cells and basophils may under certain conditions change their contents, including their proteolytic enzymes; (ii) that these cells may accelerate their synthesis of mediators for which mRNA has been encoded; and (iii) that different phenotypes may arise from the same progenitor and the differentiated cells may not be fixed in that state but rather that it may depend upon the microenvironment. Many of the distinctions between mast cells and basophils such as the larger size, larger uncondensed monolobed nucleus and increased cytokine expression of mast cells are not specific for these two cell classes but rather are consistent with a heightened state of cellular activation in mast cells. Likewise, the increased expression of ~2 integrins and VCAM-1 on basophils may be interpreted as reflecting a functional requirement to be able to migrate into tissues rather than a determinant of cell lineage. The metachromatic cells found in the blood of allergic patients (31) do not fit well in the mast cell/basophil dichotomy. It remains unclear whether they are best described as functional mast cells that, rather unusually, are found in the blood, or as basophils expressing supposedly mast cell-specific antigens. This research calls into question the prevailing view that mast cells and basophils are separate lineages.
ACKNOWLEDGEMENTS This work was supported by grants from the National Health and Medical Research Council of Australia and the Clive and Vera Ramaciotti Foundation.
REFERENCES 1. Schwartz, L. B. and Austen, K. E Structure and function of the chemical mediators of mast cells. Prog. Allergy 34:271-321, 1984. 2. Echtenacher, B., Mannel, D. N. and Hultner, L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996. 3. Malaviya, R., Ikeda, T., Ross, E. and Abraham, S. N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381:77-80, 1996. 4. Cairns, J. A. and Walls, A. E Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intercellular adhesion molecule- 1 expression. J. Immunol. 156:275-283, 1996. 5. Gruber, B. L., Kew, R. R., Jelaska, A., Marchese, M. J., Garlick, J., Ren, S., Schwartz, L. B. and Korn, J. H. Human mast cells activate fibroblasts: tryptase is a fibrogenic factor stimulating collagen messenger ribonucleic acid synthesis and fibroblast chemotaxis. J. Immunol. 158:2310-2317, 1997.
108
L. LI et al.
6. Kofford, M. W., Schwartz, L. B., Schechter, N. M., Yager, D. R., Diegelmann, R. E and Graham, M. F. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J. Biol. Chem. 272:7127-7131, 1997. 7. Blair, R. J., Meng, H., Marchese, M. J., Ren, S., Schwartz, L. B., Tonnesen, M. G. and Gruber, B. L. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J. Clin. Invest. 99:2691-2700, 1997. 8. Schroeder, J. T., Kagey-Sobotka, A. and Lichtenstein, L. M. The role of the basophil in allergic inflammation. Allergy 50:463-472, 1995. 9. Levi-Schaffer, E, Austen, K. E, Gravallese, E M. and Stevens, R. L. Coculture of interleukin 3dependent mouse mast cells with fibroblasts results in a phenotypic change of the mast cells. Proc. Natl. Acad. Sci. USA 83:6485-6488, 1986. 10. Ghildyal, N., Friend, D. S., Nicodemus, C. E, Austen, K. E and Stevens, R. L. Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to IL-10. J. Immunol. 151:3206-3214, 1993. 11. Gurish, M. E, Pear, W. S., Stevens, R. L., Scott, M. L., Sokol, K., Ghildyal, N., Webster, M. J., Hu, X., Austen, K. E and Baltimore, D. Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity 3:175-186, 1995. 12. Longley, B. J., Tyrrell, L., Lu, S., Ma, Y., Klump, V. and Murphy, G. E Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironments. J. Invest. Dermatol. 108:792-796, 1997. 13. Liu, M. C., Hubbard, W. C., Proud, D., Stealey, B.A., Galli, S. J., Kagey-Sobotka, A., Bleecker, E. R. and Lichtenstein, L. M. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am. Rev. Respir. Dis. 144:51-58, 1991. 14. Charlesworth, E. N., Kagey-Sobotka, A., Schleimer, R. E, Norman, E S. and Lichtenstein, L. M. Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. J. Immunol. 146:671-676, 1991. 15. Lison, L. Etudes sur la metachromasie colorants metachromatiques et substances chromotropes. Arch. Biol. 46:599-668, 1935. 16. Holmgren, H. and Wilander, O. Beitrag zur Kenntris der Chemie und Funktion der Ehrlichschen Mastzellen. Z Mikrosk. Anat. Forsch. 42:242-278, 1937. 17. Kramer, H. and Windrum, G. M. The metachromatic staining reaction. Cytochemistry 3:227-237, 1955. 18. Ackerman, G. A. Cytochemical properties of the blood basophilic granulocyte. Ann. N. Y. Acad. Sci. 103:376-393, 1963. 19. Dvorak, A. M. Human mast cells.Adv. Anat. Embryol. Cell Biol. 114:1-107, 1989. 20. Eguchi, M. Comparative electron microscopy of basophils and mast cells, in vivo and in vitro. Electron Microsc. Rev. 4:293-318, 1991. 21. Dvorak, A. M. Basophil and mast cell degranulation and recovery. In: Blood Cell Biochemistry (Harris, R. J., ed.), Plenum Press, New York, 1991. 22. Galli, S. J. and Hammel, I. Mast cell and basophil development. Curr. Opin. Hematol. 1:33-39, 1994. 23. Galli, S. J., Dvorak, A. M., Marcum, J. A., Ishizaka, T., Nabel, G., Der Simonian, H., Pyne, K., Goldin, J. M., Rosenberg, R. D., Cantor, H. and Dvorak, H. E Mast cell clones: a model for the analysis of cellular maturation. J. Cell Biol. 95:435-444, 1982. 24. Nakano, T., Sonoda, T., Hayashi, C., Yamatodani, A., Kanayama, Y., Yamamura, T., Asai, H., Yonezawa, T., Kitamura, Y. and Galli, S. J. Fate of bone marrow-derived cultured mast cells after intracutaneous, intraperitoneal, and intravenous transfer into genetically mast cell-deficient W/Wv mice. Evidence that cultured mast cells can give rise to both connective tissue type and mucosal mast cells. J. Exp. Med. 162:1025-1043, 1985. 25. Dvorak, A. M., Wiberg, L., Monahan-Earley, R. A. and Galli, S. J. A simple technique to facilitate the ultrastructural analysis of cells in soft agar culture systems: demonstration of the development in vitro of morphologically mature mast cells and phagocytic macrophages from the bone marrow cells of genetically mast cell-deficient W/Wv or congenic normal mice. Lab. Invest. 62:774-781, 1990. 26. Rottem, M., Goff, J. E, Albert, J. E and Metcalfe, D. D. The effects of stem cell factor on the ultrastructure of Fc epsilon RI+ cells developing in IL-3-dependent murine bone marrow-derived cell cultures. J. Immunol. 151:4950-4963, 1993. 27. Irani, A. M., Nilsson, G., Miettinen, U., Craig, S. S., Ashman, L. K., Ishizaka, T., Zsebo, K. M. and Schwartz, L. B. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009-3021, 1992.
7.
PHENOTYPIC COMPARISON OF HUMAN BASOPHILS AND MAST CELLS ]
09
28. Rottem, M., Okada, T., Goff, J. R and Metcalfe, D. D. Mast cells cultured from the peripheral blood of normal donors and patients with mastocytosis originate from a CD34+/Fc epsilon RI-cell population. Blood 84:2489-2496, 1994. 29. Li, L., Macpherson, J. J., Adelstein, S., Bunn, C. L., Atkinson, K., Phadke, K. and Krilis, S. A. Conditioned media from a cell strain derived from a patient with mastocytosis induces preferential development of cells that possess high affinity IgE receptors and the granule protease phenotype of mature cutaneous mast cells. J. Biol. Chem. 270:2258-2263, 1995. 30. Li, L., Meng, X. W. and Krilis, S. A. Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-kit ligand. J. Immunol. 156: 4839-4844, 1996. 31. Li, L., Li, Y., Reddel, S. W., Cherrian, M., Friend, D. S., Stevens, R. L. and Krilis, S. A. Identification of basophilic cells in the peripheral blood of asthma, allergy, and drug-reactive patients that express mast cell granule protease. J. Immunol. 161:5079-5086, 1998. 32. Gurish, M. E, Friend, D. S., Webster, M., Ghildyal, N., Nicodemus, C. E and Stevens, R. L. Mouse mast cells that possess segmented/multi-lobular nuclei. Blood 90:382-390, 1997. 33. Craig, S. S., Schechter, N. M. and Schwartz, L. B. Ultrastructural analysis of human T and TC mast cells identified by immunoelectron microscopy. Lab. Invest. 58:682-691, 1988. 34. Craig, S. S., Schechter, N. M. and Schwartz, L. B. Ultrastructural analysis of maturing human T and TC mast cells in situ. Lab. Invest. 60:147-157, 1989. 35. Craig, S. S. and Schwartz, L. B. Human MCTC type of mast cell granule: the uncommon occurrence of discrete scrolls associated with focal absence of chymase. Lab. Invest. 63:581-585, 1990. 36. Weidner, N. and Austen, K. E Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J. Invest. Dermatol. 96:26S-31 S, 1991. 37. Ackerman, S. J., Weil, G. J. and Gleich, G. J. Formation of Charcot-Leyden crystals by human basophils. J. Exp. Med. 155:1597-1609, 1982. 38. Dvorak, A. M. and Ackerman, S. J. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to granules and intragranular crystals in mature human basophils. Lab. Invest. 60:557-567, 1989. 39. Kochan, J., Pettine, L. E, Hakimi, J., Kishi, K. and Kinet, J. E Isolation of the gene coding for the alpha subunit of the human high affinity IgE receptor. Nucleic Acids Res. 16:3584, 1988. 40. Kinet, J. E, Blank, U., Ra, C., White, K., Metzger, H. and Kochan, J. Isolation and characterization of cDNAs coding for the beta subunit of the high-affinity receptor for immunoglobulin E. Proc. Natl. Acad. Sci. USA 85:6483-6487, 1988. 41. Blank, U., Ra, C., Miller, L., White, K., Metzger, H. and Kinet, J. E Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 337:187-189, 1989. 42. Ishizaka, T., Sterk, A. R. and Ishizaka, K. Demonstration of Fcgamma receptors on human basophil granulocytes. J. Immunol. 123:578-583, 1979. 43. Anselmino, L. M., Perussia, B. and Thomas, L. L. Human basophils selectively express the Fc gamma RII (CDw32) subtype of IgG receptor. J. Allergy Clin. Immunol. 84:907-914, 1989. 44. Guo, C. B., Liu, M. C., Galli, S. J., Bochner, B. S., Kagey-Sobotka, A. and Lichtenstein, L. M. Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am. J. Respir. Cell Mol. Biol. 10:384-390, 1994. 45. Lichtenstein, L. M., Kagey-Sobotka, A., White, J. M. and Hamilton, R. G. Anti-human IgG causes basophil histamine release by acting on IgG-IgE complexes bound to IgE receptors. J. Immunol. 148:3929-3936, 1992. 46. MacGlashan D. W. Jr, Schleimer, R. E, Peters, S. E, Schulman, E. S., Adams, G. K., Sobotka, A. K., Newball, H. H. and Lichtenstein, L. M. Comparative studies of human basophils and mast cells. Fed. Proc. 42:2504-2509, 1983. 47. Bieber, T., de la Salle, H., Wollenberg, A., Hakimi, J., Chizzonite, R., Ring, J. and Hanau, D. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J. Exp. Med. 175:1285-1290, 1992. 48. Brini, A. T., Schmidt, L., Zbar, B. and Kinet, J. E A dinucleotide repeat polymorphism in the gene for the gamma subunit of the human Fc epsilon receptors (FLER16). Hum. Mol. Genet. 2:619, 1993. 49. Gounni, A. S., Lamkhioued, B., Ochiai, K., Tanaka, Y., Delaporte, E., Capron, A., Kinet, J. E and Capron, M. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 367:183-186, 1994. 50. Sihra, B. S., Kon, O. M., Grant, J.A. and Kay, A. B. Expression of high-affinity IgE receptors (Fc epsilon RI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects:
110
L. LI et al.
relationship to total serum IgE concentrations. J. Allergy Clin. Immunol. 99:699-706, 1997. 51. Maurer, D., Fiebiger, S., Ebner, C., Reininger, B., Fischer, G. E, Wichlas, S., Jouvin, M. H., SchmittEgenolf, M., Kraft, D., Kinet, J. P. and Stingl, G. Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J. Immunol. 157:607-616, 1996. 52. Valent, P. 1995 Mack-Forster Award Lecture. Review. Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes. Eur. J. Clin. h~vest. 25:715-720, 1995. 53. Willheim, M., Agis, H., Sperr, W. R., Koller, M., Bankl, H. C., Kiener, H., Fritsch, G., Fureder, W., Spittler, A. and Graninger, W. Purification of human basophils and mast cells by multistep separation technique and mAb to CDw 17 and CD 117/c-kit. J. Immunol. Methods 182:115-129, 1995. 54. Lichtenstein, L. M. and Gillespie, E. Inhibition of histamine release by histamine controlled by H2 receptor. Nature 244:287-288, 1973. 55. Knol, E. E, Mul, E P., Jansen, H., Calafat, J. and Roos, D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J. Allergy Clin. Immunol. 88:328-338, 1991. 56. Virgolini, I., Li, S., Sillaber, C., Majdic, O., Sinzinger, H., Lechner, K., Bettelheim, P. and Valent, P. Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin El, 12, and a D2 receptor. J. Biol. Chem. 267:12700-12708, 1992. 57. Fureder, W., Agis, H., Willheim, M., Bankl, H. C., Maier, U., Kishi, K., Muller, M. R., Czerwenka, K., Radaszkiewicz, T. and Butterfield, J. H. Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. J. Immunol. 155:3152-3160, 1995. 58. Ghannadan, M., Baghestanian, M., Wimazal, E, Eisenmenger, M., Latal, D., Kargul, G., Walchshofer, S., Sillaber, C., Lechner, K. and Valent, P. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. J. Invest. Dermatol. 111:689-695, 1998. 59. Ruoslahti, E. and Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science 238:491--497, 1987. 60. Buck, C. A. and Horwitz, A. F. Integrin, a transmembrane glycoprotein complex mediating cellsubstratum adhesion. J. Cell Sci. Suppl 8:231-250, 1987. 61. Bochner, B. S., Luscinskas, E W., Gimbrone, M. A. J., Newman, W., Sterbinsky, S. A., Derse-Anthony, C. P., Klunk, D. and Schleimer, R. P. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J. Exp. Med. 173:1553-1557, 1991. 62. Bochner, B. S., MacGlashan D. W. J.r, Marcotte, G. V. and Schleimer, R. P. IgE-dependent regulation of human basophil adherence to vascular endothelium. J. Immunol. 142:3180-3186, 1989. 63. Sperr, W. R., Agis, H., Czerwenka, K., Klepetko, W., Kubista, E., Boltz-Nitulescu, G., Lechner, K. and Valent, P. Differential expression of cell surface integrins on human mast cells and human basophils. Ann. Hematol. 65:10-16, 1992. 64. Guo, C. B., Kagey-Sobotka, A., Lichtenstein, L. M. and Bochner, B. S. Immunophenotyping and functional analysis of purified human uterine mast cells. Blood 79:708-712, 1992. 65. Bochner, B. S., Peachell, P. T., Brown, K. E. and Schleimer, R. P. Adherence of human basophils to cultured umbilical vein endothelial cells. J. Clin. Invest. 81:1355-1364, 1988. 66. Thompson, H. L., Burbelo, P. D., Segui-Real, B., Yamada, Y. and Metcalfe, D. D. Laminin promotes mast cell attachment. J. Immunol. 143:2323-2327, 1989. 67. Bochner, B. S., McKelvey, A. A., Sterbinsky, S. A., Hildreth, J. E., Derse, C. P., Klunk, D. A., Lichtenstein, L. M. and Schleimer, R. P. IL-3 augments adhesiveness for endothelium and CDIlb expression in human basophils but not neutrophils. J. Immunol. 145:1832-1837, 1990. 68. Bochner, B. S. and Sterbinsky, S. A. Altered surface expression of CD11 and Leu 8 during human basophil degranulation. J. Immunol. 146:2367-2373, 1991. 69. Dastych, J., Costa, J. J., Thompson, H. L. and Metcalfe, D. D. Mast cell adhesion to fibronectin. Immunology 73:478-484, 1991. 70. Lavens, S. E., Goldring, K., Thomas, L. H. and Warner, J. A. Effects of integrin clustering on human lung mast cells and basophils. Am. J. Respir. Cell Mol. Biol. 14:95-103, 1996. 71. Denburg, J. A., Silver, J. E. and Abrams, J. S. Interleukin-5 is a human basophilopoietin: induction of histamine content and basophilic differentiation of HL-60 cells and of peripheral blood basophil-eosinophil progenitors. Blood 77:1462-1468, 1991. 72. Tsuda, T., Wong, D., Dolovich, J., Bienenstock, J., Marshall, J. and Denburg, J. A. Synergistic effects of nerve growth factor and granulocyte-macrophage colony-stimulating factor on human basophilic cell differentiation. Blood 77:971-979, 1991.
7.
PHENOTYPIC COMPARISON OF HUMAN BASOPHILS AND MAST CELLS 1 1 1
73. Stain, C., Stockinger, H., Scharf, M., Jager, U., Gossinger, H., Lechner, K. and Bettelheim, E Human blood basophils display a unique phenotype including activation linked membrane structures. Blood 70:1872-1879, 1987. 74. Yanagida, M., Fukamachi, H., Ohgami, K., Kuwaki, T., Ishii, H., Uzumaki, H., Amano, K., Tokiwa, T., Mitsui, H., Saito, H., Likura, Y., Ishizaka, T. and Nakahata, T. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86:3705-3714, 1995. 75. Galli, S. J., Zsebo, K. M. and Geissler, E. N. The kit ligand, stem cell factor. Adv. Immunol. 55:1-96, 1994. 76. Columbo, M., Horowitz, E. M., Botana, L. M., MacGlashan, D. W. Jr, Bochner, B. S., Gillis, S., Zsebo, K. M., Galli, S. J. and Lichtenstein, L. M. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances IgE-dependent mediator release from both skin mast cells and peripheral blood basophils. J. Immunol. 149:599-608, 1992. 77. Zsebo, K. M., Williams, D. A., Geissler, E. N., Broudy, V. C., Martin, E H., Atkins, H. L., Hsu, R. Y., Birkett, N. C., Okino, K. H. and Murdock, D. C. Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213-224, 1990. 78. Lerner, N. B., Nocka, K. H., Cole, S. R., Qiu, E H., Strife, A., Ashman, L. K. and Besmer, E Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood 77:1876-1883, 1991. 79. Irani, A. A., Craig, S. S., Nilsson, G., Ishizaka, T. and Schwartz, L. B. Characterization of human mast cells developed in vitro from fetal liver cells cocultured with murine 3T3 fibroblasts. Immunology 77:136-143, 1992. 80. Irani, A. M., Nilsson, G., Miettinen, U., Craig, S. S., Ashman, L. K., Ishizaka, T., Zsebo, K. M. and Schwartz, L. B. Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 80:3009-3021, 1992. 81. Valent, E, Spanblochl, E., Sperr, W. R., Sillaber, C., Zsebo, K. M., Agis, H., Strobl, H., Geissler, K., Bettelheim, E and Lechner, K. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 80:2237-2245, 1992. 82. Mitsui, H., Furitsu, T., Dvorak, A. M., Irani, A. M., Schwartz, L. B., Inagaki, N., Takei, M., Ishizaka, K., Zsebo, K. M. and Gillis, S. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc. Natl. Acad. Sci. USA 90:735-739, 1993. 83. Nilsson, G., Miettinen, U., Ishizaka, T., Ashman, L. K., Irani, A. M. and Schwartz, L. B. Interleukin-4 inhibits the expression of Kit and tryptase during stem cell factor-dependent development of human mast cells from fetal liver cells. Blood 84:1519-1527, 1994. 84. Sillaber, C., Baghestanian, M., Hofbauer, R., Virgolini, I., Bankl, H. C., Fureder, W., Agis, H., Willheim, M., Leimer, M., Scheiner, O., Binder, B. R., Kiener, H. P., Bevec, D., Fritsch, G., Majdic, O., Kress, H. G., Gadner, H., Lechner, K. and Valent, E Molecular and functional characterization of the urokinase receptor on human mast cells. J. Biol. Chem. 272:7824-7832, 1997. 85. Krieger, M., Brunner, T., Bischoff, S. C., von Tscharner, V., Walz, A., Moser, B., Baggiolini, M. and Dahinden, C. A. Activation of human basophils through the IL-8 receptor. J. Immunol. 149:2662-2667, 1992. 86. Su, S. B., Mukaida, N., Wang, J., Nomura, H. and Matsushima, K. Preparation of specific polyclonal antibodies to a C-C chemokine receptor, CCR1, and determination of CCR1 expression on various types of leukocytes. J. Leukoc. Biol. 60:658-666, 1996. 87. Leong, S. R., Lowman, H. B., Liu, J., Shire, S., Deforge, L. E., Gillece-Castro, B. L., McDowell, R. and Hebert, C. A. IL-8 single-chain homodimers and heterodimers: interactions with chemokine receptors CXCR1, CXCR2, and DARC. Protein Sci. 6:609-617, 1997. 88. Lippert, U., Artuc, M., Grutzkau, A., Moller, A., Kenderessy-Szabo, A., Schadendorf, D., Norgauer, J., Hartmann, K., Schweitzer-Stenner, R., Zuberbier, T., Henz, B. M. and Kruger-Krasagakes, S. Expression and functional activity of the IL-8 receptor type CXCR 1 and CXCR2 on human mast cells. J. Immunol. 161:2600-2608, 1998. 89. Bodger, M. E and Newton, L. A. The purification of human basophils: their immunophenotype and cytochemistry. Br. J. Haematol. 67:281-284, 1987. 90. Bodger, M. E, Mounsey, G. L., Nelson, J. and Fitzgerald, E H. A monoclonal antibody reacting with human basophils. Blood 69:1414-1418, 1987. 91. Valent, E, Majdic, O., Maurer, D., Bodger, M., Muhm, M. and Bettelheim, E Further characterization of surface membrane structures expressed on human basophils and mast cells. Int. Arch. Allergy Appl. Immunol. 91:198-203, 1990.
112
L. LI et al.
92. Kirshenbaum, A. S., Kessler, S. W., Goff, J. P. and Metcalfe, D. D. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J. Immunol. 146:1410-1415, 1991. 93. Agis, H., Willheim, M., Sperr, W. R., Wilting, A., Kromer, E., Kabrna, E., Spanblochl, E., Strobl, H., Geissler, K., Spittler, A., Boltz-Nitulescu, G., Majdic, O., Lechner, K. and Valent, E Monocytes do not make mast cells when cultured in the presence of SCE Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. J. Immunol. 151:4221-4227, 1993. 94. Kempuraj, D., Saito, H., Kaneko, A., Fukagawa, K., Nakayama, M., Toru, H., Tomikawa, M., Tachimoto, H., Ebisawa, M., Akasawa, A., Miyagi, T., Kimura, H., Nakajima, T., Tsuji, K. and Nakahata, T. Characterization of mast cell-committed progenitors present in human umbilical cord blood. Blood 93:3338-3346, 1999. 95. Marone, G., Giugliano, R., Lembo, G. and Ayala, E Human basophil releasability. II. Changes in basophil releasability in patients with atopic dermatitis. J. Invest. Dermatol. 87:19-23, 1986. 96. Peters, S. E, Kagey-Sobotka, A., MacGlashan, D. W. Jr, Siegel, M. I. and Lichtenstein, L. M. The modulation of human basophil histamine release by products of the 5-1ipoxygenase pathway. J. Immunol. 129:797-803, 1982. 97. Lawrence, I. D., Warner, J. A., Cohan, V. L., Hubbard, W. C., Kagey-Sobotka, A. and Lichtenstein, L. M. Purification and characterization of human skin mast cells. Evidence for human mast cell heterogeneity. J. Immunol. 139:3062-3069, 1987. 98. Kopicky-Burd, J. A., Kagey-Sobotka, A., Peters, S. E, Dvorak, A. M., Lennox, D. W., Lichtenstein, L. M. and Wigley, E M. Characterization of human synovial mast cells. J. Rheumatol. 15:1326-1333, 1988. 99. Peters, S. E, Schulman, E. S., Schleimer, R. E, MacGlashan, D. W. Jr, Newball, H. H. and Lichtenstein, L. M. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments.Am. Rev. Respir. Dis. 126:1034-1039, 1982. 100. Stevens, R. L., Fox, C. C., Lichtenstein, L. M. and Austen, K. E Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc. Natl. Acad. Sci. USA 85:2284-2287, 1988. 101. Thompson, H. L., Schulman, E. S. and Metcalfe, D. D. Identification of chondroitin sulfate E in human lung mast cells. J. Immunol. 140:2708-2713, 1988. 102. Metcalfe, D. D., Bland, C. E. and Wasserman, S. I. Biochemical and functional characterization of proteoglycans isolated from basophils of patients with chronic myelogenous leukemia. J. Immunol. 132:1943-1950, 1984. 103. Folkman, J. How is blood vessel growth regulated in normal and neoplastic tissue? G. H. A. Clowes memorial Award lecture. Cancer Res. 46:467-473, 1986. 104. Norrby, K., Jakobsson, A. and Sorbo, J. Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch. B Cell Pathol. 52:195-206, 1986. 105. Castells, M. C., Irani, A. M. and Schwartz, L. B. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J. Immunol. 138:2184-2189, 1987. 106. Schwartz, L. B. Monoclonal antibodies against human mast cell tryptase demonstrate shared antigenic sites on subunits of tryptase and selective localization of the enzyme to mast cells. J. Immunol. 134:526-531, 1985. 107. Irani, A. M., Bradford, T. R., Kepley, C. L., Schechter, N. M. and Schwartz, L. B. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J. Histochem. Cytochem. 37:1509-1515, 1989. 108. Schwartz, L. B., Lewis, R. A. and Austen, K. E Tryptase from human pulmonary mast cells. Purification and characterization. J. Biol. Chem. 256:11939-11943, 1981. 109. Harvima, I. T., Schechter, N. M., Harvima, R. J. and Fraki, J. E. Human skin tryptase: purification, partial characterization and comparison with human lung tryptase. Biochim. Biophys. Acta 957:71-80, 1988. 110. Cromlish, J. A., Seidah, N. G., Marcinkiewicz, M., Hamelin, J., Johnson, D. A. and Chretien, M. Human pituitary tryptase: molecular forms, NH2-terminal sequence, immunocytochemical localization, and specificity with prohormone and fluorogenic substrates. J. Biol. Chem. 262:1363-1373, 1987. 111. Schwartz, L. B., Bradford, T. R., Littman, B. H. and Wintroub, B. U. The fibrinogenolytic activity of purified tryptase from human lung mast cells. J. bnmunol. 135:2762-2767, 1985. 112. Miller, J. S., Westin, E. H. and Schwartz, L. B. Cloning and characterization of complementary DNA for human tryptase. J. Clin. Invest. 84:1188-1195, 1989. 113. Miller, J. S., Moxley, G. and Schwartz, L. B. Cloning and characterization of a second complementary DNA for human tryptase. J. Clin. Invest. 86:864-870, 1990. 114. Vanderslice, E, Ballinger, S. M., Tam, E. K., Goldstein, S. M., Craik, C. S. and Caughey, G. H. Human
7.
PHENOTYPIC COMPARISON OF HUMAN BASOPHILS AND MAST CELLS ]
13
mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family. Proc. Natl. Acad. Sci. USA 87:3811-3815, 1990.
115. Pallaoro, M., Fejzo, M. S., Shayesteh, L., Blount, J. L. and Caughey, G. H. Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3. J. Biol. Chem. 274:3355-3362, 1999. 116. Goldstein, S. M., Leong, J., Schwartz, L. B. and Cooke, D. Protease composition of exocytosed human skin mast cell protease-proteoglycan complexes. Tryptase resides in a complex distinct from chymase and carboxypeptidase. J. Immunol. 148:2475-2482, 1992. 117. Schwartz, L. B. Mast cells: function and contents. Curr. Opin. Immunol. 6:91-97, 1994. 118. Sakai, K., Ren, S. and Schwartz, L. B. A novel heparin-dependent processing pathway for human tryptase. Autocatalysis followed by activation with dipeptidyl peptidase I. J. Clin. Invest. 97:988-995, 1996. 119. Huang, C., Li, L., Krilis, S. A., Chanasyk, K., Tang, Y., Li, Z., Hunt, J. E. and Stevens. R. L. Human tryptase ~ and ~/II are functionally distinct due, in part, to a single amino acid difference in one of the surface loops that forms the substrate-binding cleft. J. Biol. Chem. 274:19670-19676, 1999. 120. Schechter, N. M., Fraki, J. E., Geesin, J. C. and Lazarus, G. S. Human skin chymotryptic proteinase. Isolation and relation to cathepsin G and rat mast cell proteinase I. J. Biol. Chem. 258:2973-2978, 1983. 121. Schechter, N. M., Choi, J. K., Slavin, D. A., Deresienski, D. T., Sayama, S., Dong, G., Lavker, R. M., Proud, D. and Lazarus, G. S. Identification of a chymotrypsin-like proteinase in human mast cells. J. Immunol. 137:962-970, 1986. 122. Caughey, G. H., Zerweck, E. H. and Vanderslice, E Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J. Biol. Chem. 266:12956-12963, 1991. 123. Urata, H., Kinoshita, A., Perez, D. M., Misono, K. S., Bumpus, E M., Graham, R. M. and Husain, A. Cloning of the gene and cDNA for human heart chymase. J. Biol. Chem. 266:17173-17179, 1991. 124. McEuen, A. R., Gaca, M. D., Buckley, M. G., He, S., Gore, M. G. and Walls, A. E Two distinct forms of human mast cell chymase - differences in affinity for heparin and in distribution in skin, heart, and other tissues. Eur. J. Biochem. 256:461-470, 1998. 125. Goldstein, S. M., Kaempfer, C. E., Kealey, J. T. and Wintroub, B. U. Human mast cell carboxypeptidase. Purification and characterization. J. Clin. Invest. 83:1630-1636, 1989. 126. Reynolds, D. S., Stevens, R. L., Gurley, D. S., Lane, W. S., Austen, K. E and Serafin, W. E. Isolation and molecular cloning of mast cell carboxypeptidase A. A novel member of the carboxypeptidase gene family. J. Biol. Chem. 264:20094-20099, 1989. 127. Reynolds, D. S., Gurley, D. S. and Austen, K. F. Cloning and characterization of the novel gene for mast cell carboxypeptidase A. J. Clin. Invest. 89:273-282, 1992. 128. Natsuaki, M., Stewart, C. B., Vanderslice, E, Schwartz, L. B., Wintroub, B. U., Rutter, W. J. and Goldstein, S. M. Human skin mast cell carboxypeptidase: functional characterization, cDNA cloning, and genealogy. J. Invest. Dermatol. 99:138-145, 1992. 129. Hohn, E A., Popescu, N. C., Hanson, R. D., Salvesen, G. and Ley, T. J. Genomic organization and chromosomal localization of the human cathepsin G gene. J. Biol. Chem. 264:13412-13419, 1989. 130. Schechter, N. M., Irani, A. M., Sprows, J. L., Abernethy, J., Wintroub, B. and Schwartz, L. B. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. J. Immunol. 145:2652-2661, 1990. 131. Irani, A. M., Goldstein, S. M., Wintroub, B. U., Bradford, T. and Schwartz, L. B. Human mast cell carboxypeptidase. Selective localization to MCTC cells. J. Immunol. 147:247-253, 1991. 132. Irani, A. M., Craig, S. S., DeBlois, G., Elson, C. O., Schechter, N. M. and Schwartz, L. B. Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function. J. Immunol. 138:4381-4386, 1987. 133. Weidner, N. and Austen, K. F. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol. Res. Pract. 189:156-162, 1993. 134. Irani, A. M. and Schwartz, L. B. Human mast cell heterogeneity. Allergy Proc. 15:303-308, 1994. 135. Sperr, W. R., Bankl, H. C., Mundigler, G., Klappacher, G., Grossschmidt, K., Agis, H., Simon, E, Laufer, E, Imhof, M. and Radaszkiewicz, T. The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. Blood 84:3876-3884, 1994. 136. Mori, A., Zhai, Y. L., Toki, T., Nikaido, T. and Fujii, S. Distribution and heterogeneity of mast cells in the human uterus. Hum. Reprod. 12:368-372, 1997. 137. Nilsson, G., Forsberg, K., Bodger, M. P., Ashman, L. K., Zsebo, K. M., Ishizaka, T., Irani, A. M. and Schwartz, L. B. Phenotypic characterization of stem cell factor-dependent human foetal liver-derived
114
L. LI et al.
mast cells. Immunology 79:325-330, 1993. 138. Lewis, R. A., Soter, N. A., Diamond, E T., Austen, K. E, Oates, J. A. and Roberts, L. J. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129:1627-1631, 1982. 139. Warner, J. A., Peters, S. P., Lichtenstein, L. M., Hubbard, W., Yancey, K. B., Stevenson, H. C., Miller, P. J. and MacGlashan D. W. Jr. Differential release of mediators from human basophils: differences in arachidonic acid metabolism following activation by unrelated stimuli. J. Leukoc. Biol. 45:558-571, 1989. 140. Harvima, I. T., Horsmanheimo, L., Naukkarinen, A. and Horsmanheimo, M. Mast cell proteinases and cytokines in skin inflammation. Arch. Dermatol. Res. 287:61-67, 1994. 141. Peters, S. P., Kagey-Sobotka, A., MacGlashan, D. W. Jr and Lichtenstein, L. M. Effect of prostaglandin D2 in modulating histamine release from human basophils. J. Pharmacol. Exp. Ther. 228:400-406, 1984. 142. Triggiani, M., Schleimer, R. P., Warner, J. A. and Chilton, E H. Differential synthesis of 1-acyl-2-acetylsn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J. Immunol. 147:660-666, 1991. 143. Brunner, T., de Weck, A. L. and Dahinden, C. A. Platelet-activating factor induces mediator release by human basophils primed with IL-3, granulocyte-macrophage colony-stimulating factor, or IL-5. J. Immunol. 147:237-242, 1991. 144. MacGlashan, D. J., White, J. M., Huang, S. K., Ono, S. J., Schroeder, J. T. and Lichtenstein, L. M. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils. J. Immunol. 152:3006-3016, 1994. 145. Schroeder, J. T., MacGlashan D. W. Jr, Kagey-Sobotka, A., White, J. M. and Lichtenstein, L. M. IgEdependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures. J. Immunol. 153:1808-1817, 1994. 146. Li, H., Sim, T. C. and Alam, R. IL-13 released by and localized in human basophils. J. Immunol. 156:4833-4838, 1996. 147. Farram, E. and Nelson, D. S. Mouse mast cells as anti-tumor effector cells. Cell. Immunol. 55:294-301, 1980. 148. Walsh, L. J., Trinchieri, G., Waldorf, H. A., Whitaker, D. and Murphy, G. E Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc. Natl. Acad. Sci. USA 88:4220-4224, 1991. 149. Bochner, B. S., Charlesworth, E. N., Lichtenstein, L. M., Derse, C. P., Gillis, S., Dinarello, C. A. and Schleimer, R. P. Interleukin-1 is released at sites of human cutaneous allergic reactions. J. Allergy Clin. Immunol. 86:830-839, 1990. 150. Bradding, P., Feather, I. H., Wilson, S., Bardin, P. G., Heusser, C. H., Holgate, S. T. and Howarth, P. H. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J. Immunol. 151:3853-3865, 1993. 151. Bradding, P., Roberts, J. A., Britten, K. M., Montefort, S., Djukanovic, R., Mueller, R., Heusser, C. H., Howarth, P. H. and Holgate, S. T. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 10:471-480, 1994. 152. Moiler, A., Lippert, U., Lessmann, D., Kolde, G., Hamann, K., Welker, P., Schadendorf, D., Rosenbach, T., Luger, T. and Czarnetzki, B. M. Human mast cells produce IL-8. J. Immunol. 151:3261-3266, 1993. 153. Jaffe, J. S., Raible, D. G., Post, T. J., Wang, Y., Glaum, M.C., Butterfield, J.H. and Schulman, E.S. Human lung mast cell activation leads to IL-13 mRNA expression and protein release. Am. J. Respir. Cell Mol. Biol. 15:473-481, 1996. 154. Nilsson, G., Forsberg-Nilsson, K., Xiang, Z., Hallbook, E, Nilsson, K. and Metcalfe, D. D. Human mast cells express functional TrkA and are a source of nerve growth factor. Eur. J. Immunol. 27:2295-2301, 1997. 155. Rumsaeng, V., Cruikshank, W. W., Foster, B., Prussin, C., Kirshenbaum, A. S., Davis, T.A., Kornfeld, H., Center, D. M. and Metcalfe, D. D. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL- 16. J. Immunol. 159:2904-2910, 1997. 156. Patella, V., Marino, I., Arbustini, E., Lamparter-Schummert, B., Verga, L., Adt, M. and Marone, G. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation 97:971-978, 1998. 157. Zhang, S., Anderson, D. E, Bradding, P., Coward, W. R., Baddeley, S. M., MacLeod, J. D., McGill, J. I., Church, M. K., Holgate, S. T. and Roche, W. R. Human mast cells express stem cell factor. J. Pathol.
7.
PHENOTYPIC COMPARISON OF HUMAN BASOPHILS AND MAST CELLS 1 1 5
186:59-66, 1998. 158. Gauchat, J. E, Henchoz, S., Mazzei, G., Aubry, J. R, Brunner, T., Blasey, H., Life, R, Talabot, D., FloresRomo, L. and Thompson, J. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340-343, 1993. 159. Kehry, M. R. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J. Immunol. 156:2345-2348, 1996. 160. Gruss, H. J., Herrmann, E, Gattei, V., Gloghini, A., Pinto, A. and Carbone, A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk. Lymphoma 24:393-422, 1997. 161. Fureder, W., Agis, H., Sperr, W. R., Lechner, K. and Valent, R The surface membrane antigen phenotype of human blood basophils. Allergy 49:861-865, 1994. 162. Kiener, H. R, Baghestanian, M., Dominkus, M., Walchshofer, S., Ghannadan, M., Willheim, M., Sillaber, C., Graninger, W. B., Smolen, J. S. and Valent, R Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum. 41:233-245, 1998. 163. Patella, V., de Crescenzo, G., Ciccarelli, A., Marino, I., Adt, M. and Marone, G. Human heart mast cells: a definitive case of mast cell heterogeneity. Int. Arch. Allergy Immunol. 106:386-393, 1995. 164. Urata, H., Strobel, F. and Ganten, D. Widespread tissue distribution of human chymase. J. Hypertens. Supp112:S 17-$22, 1994. 165. Massey, W. A., Guo, C. B., Dvorak, A. M., Hubbard, W. C., Bhagavan, B. S., Cohan, V. L., Warner, J. A., Kagey-Sobotka, A. and Lichtenstein, L. M. Human uterine mast cells. Isolation, purification, characterization, ultrastructure, and pharmacology. J. Immunol. 147:1621-1627, 1991. 166. Tainsh, K. R., Lau, H. Y., Liu, W. L. and Pearce, E L. The human skin mast cell: a comparison with the human lung cell and a novel mast cell type, the uterine mast cell. Agents Actions 33:16-19, 1991. 167. Bradding, R, Okayama, Y., Howarth, R H., Church, M. K. and Holgate, S. T. Heterogeneity of human mast cells based on cytokine content. J. Immunol. 155:297-307, 1995. 168. Harvima, I. T., Naukkarinen, A. Harvima, R. J., Aalto, M. L., Neittaanmaki, H. and Horsmanheimo, M. Quantitative enzyme-histochemical analysis of tryptase- and chymase-containing mast cells in psoriatic skin. Arch. Dermatol. Res. 282:428-433, 1990. 169. Bentley, A. M., Jacobson, M. R., Cumberworth, V., Barkans, J. R., Moqbel, R., Schwartz, L. B., Irani, A. M., Kay, A. B. and Durham, S. R. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J. Allergy Clin. Immunol. 89:877-883, 1992. 170. Otsuka, H., Inaba, M., Fujikura, T. and Kunitomo, M. Histochemical and functional characteristics of metachromatic cells in the nasal epithelium in allergic rhinitis: studies of nasal scrapings and their dispersed cells. J. Allergy Clin. Immunol. 96:528-536, 1995. 171. Juliusson, S., Aldenborg, E and Enerback, L. Proteinase content of mast cells of nasal mucosa: effects of natural allergen exposure and of local corticosteroid treatment. Allergy 50:15-22, 1995. 172. Buckley, M. G., Gallagher, R J. and Walls, A. E Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase-positive, chymase-negative mast cells. J. Pathol. 186:67-74, 1998. 173. Aldenborg, E, Peeker, R., Fall, M., Olofsson, A. and Enerback, L. Metaplastic transformation of urinary bladder epithelium: effect on mast cell recruitment, distribution, and phenotype expression. Am. J. Pathol. 153:149-157, 1998. 174. Irani, A. M., Butrus, S. I., Tabbara, K. E and Schwartz, L. B. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J. Allergy Clin. Immunol. 86:34-40, 1990. 175. Jeziorska, M., McCollum, C. and Woolley, D. E. Mast cell distribution, activation, and phenotype in atherosclerotic lesions of human carotid arteries. J. Pathol. 182:115-122, 1997. 176. Dvorak, H. F: and Mihm, M. C. J. Basophilic leukocytes in allergic contact dermatitis. J. Exp. Med. 135:235-254, i 972. 177. Hastie, R., Heroy, J. H. and Levy, D. A. Basophil leukocytes and mast cells in human nasal secretions and scrapings studied by light microscopy. Lab. Invest. 40:554-561, 1979. 178. Marone, G. The role of basophils and mast cells in the pathogenesis of pulmonary diseases. Int. Arch. Allergy Appl. Immunol. 76 (Suppl 1):70-82, 1985. 179. Bascom, R., Wachs, M., Naclerio, R. M., Pipkorn, U., Galli, S. J. and Lichtenstein, L. M. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J. Allergy Clin. Immunol. 81:580-589, 1988. 180. Charlesworth, E. N., Kagey-Sobotka, A., Norman, R S. and Lichtenstein, L. M. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction. J. Allergy Clin.
116
L. LI et al.
Immunol. 83:905-912, 1989. 181. Charlesworth, E. N., Hood, A. E, Soter, N. A., Kagey-Sobotka, A., Norman, E S. and Lichtenstein, L. M. Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration. J. Clin. Invest. 83:1519-1526, 1989. 182. Bochner, B. S., Undem, B. J. and Lichtenstein, L. M. Immunological aspects of allergic asthma. Annu. Rev. Immunol. 12:295-335, 1994. 183. Warner, J. A. and Kroegel, C. Pulmonary immune cells in health and disease: mast cells and basophils. Eur. Respir. J. 7:1326-1341, 1994. 184. Redington, A. E., Polosa, R., Walls, A. E, Howarth, P. H. and Holgate, S. T. Role of mast cells and basophils in asthma. Chem. Immunol. 62:22-59, 1995. 185. Baumgarten, C. R., Nichols, R. C., Naclerio, R. M., Lichtenstein, L. M., Norman, E S. and Proud, D. Plasma kallikrein during experimentally induced allergic rhinitis: role in kinin formation and contribution to TAME-esterase activity in nasal secretions. J. Immunol. 137:977-982, 1986. 186. Schwartz, L. B., Atkins, E C., Bradford, T. R., Fleekop, E, Shalit, M. and Zweiman, B. Release of tryptase together with histamine during the immediate cutaneous response to allergen. J. Allergy Clin. Immunol. 80:850-855, 1987. 187. Schlumberger, H. D. Pseudo-allergic reactions to drugs and chemicals. Ann. Allergy 51:317-324, 1983. 188. Mathews, K. E Clinical spectrum of allergic and pseudoallergic drug reactions. J. Allergy Clin. Immunol. 74:558-566, 1984. 189. Genovese, A., Stellato, C., Marsella, C. V., Adt, M. and Marone, G. Role of mast cells, basophils and their mediators in adverse reactions to general anesthetics and radiocontrast media. Int. Arch. Allergy Immunol. 110:13-22, 1996. 190. Friend, D. S., Ghildyal, N., Austen, K. E, Gurish, M. E, Matsumoto, R. and Stevens, R.L. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J. Cell Biol. 135:279-290, 1996. 191. Friend, D. S., Ghildyal, N., Gurish, M. E, Hunt, J., Hu, X., Austen, K. E and Stevens, R. L. Reversible expression of tryptases and chymases in the jejunal mast cells of mice infected with Trichinella spiralis. J. Immunol. 160:5537-5545, 1998. 192. Furitsu, T., Saito, H., Dvorak, A. M., Schwartz, L. B., Irani, A. M., Burdick, J. E, Ishizaka, K. and Ishizaka, T. Development of human mast cells in vitro. Proc. Natl. Acad. Sci. USA 86:10039-10043, 1989. 193. Saito, H., Ebisawa, M., Tachimoto, H., Shichijo, M., Fukagawa, K., Matsumoto, K., Iikura, Y., Awaji, T., Tsujimoto, G., Yanagida, M., Uzumaki, H., Takahashi, G., Tsuji, K. and Nakahata, T. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J. Immunol. 157:343-350, 1996. 194. Valent, E, Schmidt, G., Besemer, J., Mayer, E, Zenke, G., Liehl, E., Hinterberger, W., Lechner, K., Maurer, D. and Bettelheim, E Interleukin-3 is a differentiation factor for human basophils. Blood 73:1763-1769, 1989. 195. Sillaber, C., Geissler, K., Scherrer, R., Kaltenbrunner, R., Bettelheim, E, Lechner, K. and Valent, E Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. Blood 80:634-641, 1992.
CHAPTER 8 Interactions Between Nerves and Mast Cells in Amphibians G. CHIEFFI BACCARI, ,1 S. M I N U C C I , 2 A. DE PAULIS3 and A. DE SANTIS 1 1Stazione Zoologica 'A. Dohrn' 2Dipartimento di Fisiologia Umana e Funzioni Biologiche Integrate 'F. Bottazzi ', Seconda Universitgt di Napoli, 3Dtvtstone . . . di Immunologia Clinica e Allergologia, Universitfi di Napoli 'Federico H', Naples, Italy
INTRODUCTION Mast cells are present in the connective tissue of the majority of vertebrates (1). Despite the extensive literature on mammalian mast cells (2-5), few studies have been devoted to the characterization of these cells in non-mammalian vertebrates. This is rather surprising, because mast cells were identified in several tissues of Rana esculenta (1) and Rana pipiens (6, 7) several decades ago and the ultrastructural and immunological characterization of mast cells in amphibians is still at a very early stage (8-11). In this brief review, we provide up-to-date information on the characterization of mast cells that are present in various anatomical sites in the frog Rana esculenta. In particular, we emphasize the close association between mast cells and nerves in frog tissues.
M O R P H O L O G Y OF F R O G MAST CELLS
Histology and Histochemistry Mast cells are widely distributed in all frog tissues that have been examined. They are large cells with a diameter of between 8 and 30 ~tm. Their cytoplasm is packed with secretory granules showing the typical metachromasia originally reported by Paul Ehrlich (12). The metachromatic staining property of frog mast cells differs from that of humans in that the former are stained dark purple and the latter reddish purple (11). The mast cell density varies greatly between different tissues, being highest in the tongue (253 _+ 45 mast cells mm2).Mast cells are also present in the kidney (15.3 _+ 1.4 mast cells mm2), the testis (11, 13), the peripheral nervous system (30 + 5.2 mm 2) and the heart (5.3 _+ 0.4 mm -2), as has been recently reported in humans (3, 14, 15). * C o r r e s p o n d i n g author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
117
Copyright 9 2000 Academic Press All rights of reproduction in any form reserved
118
G. CHIEFFI B A C C A R I et al.
Fig. 1 Paraffin-embedded section of the heart of the frog Rana esculenta. A mast cell (arrow) is closely apposed to a melanocyte (arrowhead). Toluidine blue at pH 4.2. x1250.
Fig. 2 Three elongated mast cells (arrows) in the sciatic nerve of the frog Rana esculenta. Toluidine blue at pH 4.2. x125 (before reduction).
Interestingly, the majority of frog heart mast cells, in contrast to other anatomical sites, are usually round (Fig. 1). This is in sharp contrast to the mast cells present within nerves which are extremely elongated (Fig. 2). The combined Alcian blue-safranin staining method reveals several subtypes of frog mast cells in different anatomical sites. In particular, blue and red granules can be detected in tongue and peritoneal mast cells, whereas heart and kidney mast cells are Alcian blue-negative/safranin-positive. These two staining patterns are characteristic of
8.
N E R V E - M A S T CELL I N T E R A C T I O N S IN A M P H I B I A N S
] 19
connective tissue mast cells (CTMC) in rodents and probably reflect biochemical differences in the granule content. For example, different proteoglycans and/or proteases can underlie these staining properties (16-18). The histochemical properties of mast cells revealed by the Alcian blue-safranin staining method have been used to assess maturational changes in the granules of CTMC (19). It has been postulated that the Alcian blue-safranin reaction differentiates degrees of sulphation, the more highly sulphated the polysaccharide, the greater its affinity for safranin. It was proposed that Alcian bluepositive granules contain a polysaccharide that is poor or totally lacking in N-sulphate, presumably a heparin precursor (19, 20). Similarly, cells that bear safranin-positive granules contain highly N-sulphated polysaccharide, probably heparin (19, 21). More recently, a close correlation between the presence of safranin-positive granules and the amount of rat mast cell protease I has been reported (22). Mast cells in the intestinal lamina propria of frog were Alcian blue-positive/safranin-negative, as previously reported in rodents (16-18). If the staining properties are conferred on the different frog mast cell subtypes by virtue of their proteoglycan content, it is likely that frog mast cells express a certain degree of specialization in proteoglycan synthesis. Ultrastructure
The ultrastructural analysis of frog mast cells in different anatomical sites showed that they contained a single-lobed, central nucleus with peripheral condensation of nuclear chromatin (Fig. 3). Interestingly, the surface of frog mast cells was not adorned with folds as in human mast cells (23). A few mitochondria and free ribosomes were occasionally seen in the cytoplasm. The cytoplasm was packed with numerous membrane-bound secretory granules. These were extremely heterogeneous in s h a p e - ovoid, fusiform or r o u n d - and displayed substructural patterns unique to the different species. Secretory
Fig. 3 Electron micrograph of a mast cell from Rana esculenta tongue surrounded by collagen fibres. The cytoplasm contains numerous heterogeneous, polymorphic granules. V, blood vessel, x 10,000.
120
G. CHIEFFI BACCARI et al.
granules contained an elaborate and heterogeneous substructural architecture. Some had crystal particles in hexagonal arrays, others had fusiform inclusions with a 'sandwichlike' structure and a few partial scrolls, different from those of human mast cells. Again different from human mast cells (14, 23-25), lipid bodies were never observed in frog mast cells.
Subcellular Localization of Histamine in Frog Mast Cells The histamine content of different frog tissues varied markedly, being highest in the heart (Table I) (11). The histamine content of various frog mast cells (-0.1 pg per mast cell) was approximately 30 times lower than that of human mast cells isolated from different anatomical sites (-~3 pg per cell) (14, 23). TABLE I Histamine content of various frog tissues
Tongue Heart Kidney Testis
Histamine content Wet tissue (ng g)
Protein(rag g)
241_+44.5 874_+67.3 586_+146 688_+76.8
3.9_+0.7 35.7_+2.7 7.4+1.8 12.5_+1.4
A monoclonal antihistamine antibody was used to detect histamine in frog mast cells. After immunogold staining of frog tongue, low concentrations of gold particles were present over all the secretory granules in more than 95% of frog mast cells, presumably reflecting the low concentration of histamine in these cells (11).
FROG MAST CELLS AND PERIPHERAL NERVOUS SYSTEM Occurrence of Mast Cells in Different Topographical Areas of Frog Nerves Each vertebrate uni- and multifascicular peripheral nerve has three separate connective tissue sheets. On the outside of each nerve there is a collagenous epineurium and beneath that a perineurium which surrounds each fascicle of nerve fibres. Individual nerve fibres are embedded in the endoneurium, which completely fills the space bounded by the perineurium (26). In our study, mast cells were always detected within the epineurium, endoneurium and perineurium of the frog peripheral nerves (Fig. 4). We therefore focused our attention on the occurrence of mast cells in the large nerves of the frog, such as sciatic and brachial nerves, as well as in the glossopharyngeal and hypoglossal nerve branches which supply the tongue. M a s t cells in the sciatic a n d brachial nerves
In the sciatic and brachial nerves of the frog, mast cells have always been identified on the basis of their typical metachromatic secretory granules. The cytoplasm extends along the longitudinal axis of the nerve fibres (Fig. 2) and is safranin-positive with the combined Alcian blue-safranin method.
8.
N E R V E - M A S T CELL I N T E R A C T I O N S IN A M P H I B I A N S
121
Fig. 4 Electron micrograph of a nervous fascicle from Rana esculenta tongue. Mast cells (arrows) are located within the endoneurium (End) and perineurium (Per). One mast cell is closely associated with the nervous fascicle (arrowhead). Ep, epineurium, x2800 (before reduction).
Fig. 5 (A) Electron micrograph of the longitudinal section of Rana esculenta sciatic nerve. One mast cell (asterisk) is located in the endoneurium z3600 (original magnification). (B) Cross-section of Rana esculenta brachial nerve. An endoneurial mast cell (asterisk) surrounded by collagen fibres is present among myelinic and unmyelinic fibres (arrows). x3600 (original magnification).
122
G. C H I E F F I B A C C A R I et al.
Ultrastructural examination of the sciatic and brachial nerves demonstrates that mast cells are more abundant in the epineurium and endoneurium than in the perineurium. Endoneurial mast cells surrounded by collagen fibres are in close proximity to myelinic (Fig. 5A, B) and amyelinic fibres (Fig. 5B) and are frequently present around blood vessels. Chemical mediators, such as histamine released from mast cells, can stimulate proliferation and increase permeability in endothelial cells from mammalian tissues (27-29). Although the endothelial response to mast cell degranulation is well documented, the response of the neuron is not. However, the close anatomical association between mast cells and nerve fibres suggests the existence of reciprocal and/or feedback interactions between neurons and mast cells brought about by their metabolic products. Interestingly, in vivo administration of nerve growth factor (NGF) can induce mast cell hyperplasia (30). Moreover, mast cells synthesize, store and release NGF (31, 32), and NGF can cause mediator and cytokine release from mast cells (33-35). Thus, it is possible that mast cells exert a paracrine control of neurons. In addition, several neuropeptides, such as substance P, vasoactive intestinal peptide (VIP), calcitonin generelated peptide and neurokinins, locally released from nerve fibres (36), can activate mast cells to release chemical mediators (37-39). Mast cells in the glossopharyngeal and hypoglossal nerve branches The frog tongue receives a dense innervation from the glossopharyngeal and hypoglossal nerves. The former is a sensorimotor nerve, the latter is a motor nerve. Numerous connective type mast cells are present around and within these nerves. Unilateral and prolonged electrical stimulations of the hypoglossal nerve in the frog cause degranulation and changes in the morphology of the mast cells on the stimulated side (Chieffi Baccari et al., unpublished observations). These cells show heterochromatic nuclei and massive intracellular loss of their granules (Fig. 6). Dimitriadu et al. (40) have demonstrated that prolonged or intense stimulation of the trigeminal ganglion in the rat causes degranulation and changes in the histochemical characteristics of the dura mater and tongue mast cells.
Fig. 6 Paraffin-embedded section of Rana esculenta tongue after electrical stimulation ofhypoglossal nerve. Two degranulated mast cells (arrows) with heterochromatic nuclei can be observed in the connective tissue. Toluidine blue, pH 4.2. x1250.
8.
NERVE-MAST CELL INTERACTIONS IN AMPHIBIANS
I23
Fig. 7 Electronmicrographof a large nervous fascicle fromRana esculenta tongue.A mast cell (MC) is seen embedded in the epineurium (Ep) in close associationto the perineurium (Per). • (before reduction).
Ultrastructural study of the large nerve fascicles in the frog tongue shows that mast cells are present in the epineurium (Fig. 7) and endoneurium (Fig. 8A) but not in the perineurium. Figure 8B shows that perineurium consists of various cellular layers linked by tight junctions. Individual perineurial cells are laden with vesicles and caveolae. The epineurial and endoneurial mast cells are always in close association to the perineurial cells (Figs 7 and 8A, B). Figure 8B shows the close anatomical association between mast cells and perineurium. The distance of the plasma membranes of the mast cell and perineural cell is less than 70 nm. Small nerve fascicles lack epineurium, and the perineurium is limited to a few cellular layers. In these nerve fascicles, mast cells are constantly present within the lamellae of the perineurium and appear surrounded by perineurial processes (Fig. 9A, B). The plasma membranes of the two cells are at a distance of 40-100 nm and at some points they seem to be in contact. The close anatomical association between mast cells and perineurial cells is suggestive of paracrine interactions.The perineurium is a tissue-nerve barrier which regulates the endoneurial microenvironment by limiting the passage of substances and protects axons and Schwann cells from antigens, toxins and infectious agents (26). The interaction between mast cells and perineurium may be important near body surfaces (e.g. the tongue) where fascicles of nerve fibres can be exposed to bacteria or parasites. Therefore, mast cells and their mediators could participate in the functions of the tissue-nerve barrier of the perineurium.
124
G. CHIEFFI BACCARI et al.
Fig. 8 (A) Electron micrograph of a nervous fascicle of Rana esculenta tongue. An endoneurial mast cell (MC) is closely associated to the perineurium (Per). End, endoneurium, x6000 (original magnification). (B) High magnification of the frame indicated in (A), showing the close association between the plasma membrane of the mast cell (dark arrow) and the plasma membrane of the perineurium (pale arrow), x22,000 (original magnification).
Fig. 9 (A) Electron micrograph of a small nerve fascicle from Rana esculenta tongue. A mast cell (MC) is embedded within the perineurial cellular layers (Per). SC, Schwann cell nucleus, x4600 (original magnification). (B) High magnification of the frame indicated in (A), showing the close association between the plasma membrane of the mast cell (dark arrow) and the plasma membrane of the perineurial cell (pale arrow), x28,000 (original magnification).
8.
N E R V E - M A S T CELL I N T E R A C T I O N S IN A M P H I B I A N S
125
Development There is little information on the ontogenesis of mast cells in the peripheral nervous system and it is unknown how and when these cells enter the nerves during embryogenesis. Mast cells have been observed in nerves of the eye muscles of rat between days 20 and 21 of intrauterine life. Only occasionally mast cells were seen in the sciatic nerve, spinal ganglia and spinal roots at day 21 of fetal life, but during the first 2 weeks after birth the number of such cells increased considerably (41). Our anatomical and morphological observations (42) showed that the first recognizable mast cells arised in the mesenchyme of the developing tongue (Fig. 10) in tadpole at stage 26 of Witschi's standard tables (43). The mast cells are round in shape and are distinguishable from other mesenchymal cells for the presence of few cytoplasmic granules. Their periodic acid-Schiff (PAS)-positive granules were orthochromatic when stained with toluidine blue at pH 4.2, and Alcian blue-positive when stained with Alcian blue-safranin, suggesting a 'mucosal' phenotype and the absence of heparin (21). At this larval stage no recognizable mast cells were seen within the nerves.
Fig. 10 Paraffin-embedded section of the tongue of Rana esculenta tadpole at stage 26 of the Witschi standard table (see text). Two immature mast cells (arrows), surrounded by mesenchyme, are located symmetrically on both sides of the tongue. Toluidine blue at pH 4.2. x312.
From this stage onwards, the mast cell density significantly increased in all tissues. At stage 29 metachromatic mast cells can be observed within both tongue nerves (hypoglossal and glossopharyngeal branches) and the sciatic nerve. These cells contain granules which bind safranin. This staining suggests the presence of highly N-sulphated glycosaminoglycans such as heparin. These cells contain a few granules that do not yet exhibit their characteristic ultrastructural pattern. In the sciatic nerve, mast cells are
126
G. C H I E F F I B A C C A R I et al.
Fig. 11 Electron micrograph of a nerve fascicle from the Rana esculenta tadpole tongue at metamorphosis stage. A mast cell (MC) is closely associated to one of the perineurial cells (arrows). x3600.
present in the endoneurium and epineurium predominantly in a perivascular location. At metamorphosis (stage 33) the distribution of mast cells within nerves was similar to that in the adult frog. In the sciatic nerve, elongated mast cells showing numerous metachromatic granules similar to those described for mature connective mast cells, are present in the endoneurium along the longitudinal direction of the nerve fibres. In the tongue nerve mast cells are in close association with the perineurial cells (Fig. 11). Interestingly, the mast cell-perineurium anatomical association exists in early phases of nerve development. The perineurial cells appear early and they initially lack a basal lamina, and are not joined by the tight junctions that form a barrier in the adult. In this phase, the perineurial cells probably participate in providing and transporting nutrients to the axons and Schwann cells (44). Mast cells are already present in the first phases of nerve development and are closely associated to perineurial cells (Fig. 11). It has been proposed that factors released by the Schwann cell-axon complex during nerve development may be responsible for perineurial differentiation and organization from the surrounding mesenchyme (45-47). Therefore, it is likely that the same factors in this period are also responsible for differentiation of mast cells which share the same embryological origin with perineurial cells. In fact, today a fibroblastic, mesenchymal origin of the perineurial cells is accepted rather than a Schwann cell derivation (44, 46). The Wallerian degeneration, during which a proliferation of perineurial cells has been shown, is also characterized by a significant perineurial mast cell hyperplasia (48). In this respect, it is likely that both perineurial and mast cells may be influenced locally by the same growth factor. Mast cell proliferation occurs in the rat sciatic nerve undergoing Wallerian degeneration (41, 49). In our investigation, the mast cell density increases early in the
8.
NERVE-MAST CELL INTERACTIONS IN AMPHIBIANS
127
distal part of the injured brachial nerve in the flog, but has still to be established whether the increasing mast cell density is due to their migration or to their multiplication in situ.
OCCURRENCE OF MAST CELLS IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS OF MAMMALS In the last few years, the anatomical association between peripheral nerves and mast cells has been documented in a variety of mammalian tissues, including skin, diaphragm, mesentery and thymus, gastrointestinal and respiratory tracts (50-55). Mast cells have also been described in the central nervous system where they have a predominantly perivascular location (56, 57). Previous studies (41, 58, 59) have documented that mast cells are also present within the large nerve plexa and peripheral nerve trunks of numerous mammals, including man. Their density varies significantly in different species, being numerous in the rat and guinea pig, but rare in the cat. Furthermore, mast cells accumulate in damaged parts of human peripheral neuropathy (41, 49). They may exert important functions in inflammatory demyelinating processes. Mast cells have been localized in multiple sclerosis plaques (60-62) as well as in areas of demyelination in experimental allergic encephalomyelitis (63) or experimental allergic neuritis (64). Myelin basic protein can stimulate mast cell degranulation and induces peripheral (65) and central (66) demyelinization, and myelin proteins are degraded by mast cell proteases. In addition, during experimental allergic neuritis a delayed T cell response may depend on early release of mast cell mediators and T cell products can cause mast cell activation (64, 67, 68).
CONCLUDING REMARKS
Histochemical analysis of frog mast cells in different tissues revealed properties of the connective and mucosal types previously found in rodents (16, 17, 69). Ultrastructural study of the connective-type mast cells showed that the cytoplasmic secretory granules have unique morphological characteristics formerly unrecognized in any human or animal mast cells. The histamine content of these cells in different anatomical sites is lower than that of human mast cells (11). The striking mast cell-nerve association documented in this study is intringuing. In the large nerves, such as sciatic and brachial nerves, mast cells are present in the endoneurium and epineurium where they are in close association with the vasa nervorum and myelinic and amyelinic fibres. In the small nerve fascicles of the tongue (body surface exposed to the external milieu), the mast cells are predominantly located between the perineurial layers, suggesting a role in the tissue-nerve barrier function of the perineurium. Although there is some evidence to support the existence of paracrine interactions between the peripheral nervous system and mast cells, the physiological significance of these relationships remains to be established. Furthermore, the role of mast cells and their mediators in different pathological situations of the nervous system is largely unknown. Furthermore, a better characterization of the embryonal development of mast cells in
128
G. C H I E F F I B A C C A R I et al.
peripheral nerves could contribute to clarifying the origin of mast cells and their increase in different pathological conditions. A comparative study of mast cells might uncover new models for investigating their pathophysiological role, particularly for their widerspread occurrence throughout the body.
REFERENCES 1. Michels, N. A. The mast cells in the lower vertebrates. Cellule 33:339-46 l, 1923. 2. Galli, S. J. Biology of disease. New insights into 'the riddle of the mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab. Invest. 62: 5-33, 1990. 3. Marone, G., (ed.) Human Basophils and Mast Cells: Biological Aspects. Karger, Basel, 1995. 4. Marone, G., Spadaro, G. and Genovese, A. Biology, diagnosis and therapy of mastocytosis. In: Human Basophils and Mast Cells: Clinical Aspects (Marone, G., ed.), pp 1-21. Karger, Basel, 1995. 5. Metcalfe, D. D., Baram, D. and Mekori, Y. A. Mast cells. Physiol. Rev. 77:1033-1079, 1997. 6. Chiu, H. and Lagunoff, D. Histochemical comparison of frog and rat mast cells. J. Histochem. Cytochem. 19:369-375, 1971. 7. Chiu, H. and Lagunoff, D. Histochemical comparison of vertebrate mast cells. Histochem. J. 4:135-144, 1972. 8. Setoguti, T. Electron microscopy study on the newt mast cell, especially its granule-extrusion mechanism. J. Ultrastruct. Res. 27:377-395, 1969. 9. Nakao, T. and Uchinomiya, K. Fine structure of cytoplasmic granules of tadpole mast cells. J. Electron Microsc. 23:57-60, 1974. 10. Vugman, I. Ultrastructure of toad (Bufo paracnemius) mast cells: their alteration by compound 48/80. Anat. Anz. 154:425-432, 1983. 11. Chieffi Baccari, G., de Paulis, A., Di Matteo, L., Gentile, M., Marone, G. and Minucci, S. In situ characterization of mast cells in the frog Rana esculenta. Cell Tissue Res. 292:151-162, 1998. 12. Ehrlich, E Beitr~ige zur Kenntnis der granulierten Bindegewebszellen und der eosinophilen Leukocyten. Arch. Anat. Physiol. 3:166-169, 1879. 13. Minucci, S., Di Matteo, L., Chieffi, E, Pierantoni, R. and Fasano, S. 17[3-Estradiol effects on mast cell number and spermatogonial mitotic index in the testis of the frog, Rana esculenta. J. Exp. Zool. 278:93-100, 1997. 14. Patella, V., Marinb, I., Lampfirter, B., Arbustini, E., Adt, M. and Marone, G. Human mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J. Immunol. 154:2855-2865, 1995. 15. Patella, V., de Crescenzo, G., Marinb, I., Genovese, A., Adt, M., Gleich, G. J. and Marone G. Eosinophil granule proteins activate human heart mast cells. J. Immunol. 157:1219-1225, 1996. 16. Enerbfick, L. Mast cells in rat gastrointestinal mucosa. Effects of fixation. Acta Pathol. Microbiol. Immunol. Scand. 66:289-302, 1966. 17. Enerb~ck, L. Mast cells in rat gastrointestinal mucosa. Dye-binding and metachromatic properties. Acta Pathol. Microbiol. Immunol. Scand. 66:303-312, 1966. 18. Bienenstock, J. An update on mast cell heterogeneity. J. Allergy Clin. Immunol. 81:763-769, 1988. 19. Combs, J. W., Lagunoff, D. and Benditt, E. E Differentiation and proliferation of embryonic mast cells of the rat. J. Cell Biol. 25:577-592, 1965. 20. Spicer, S. S. A correlative study of the histochemical properties of rodent acid mucopolysaccharides. J. Histochem. Cytochem. 8:18-33, 1960. 21. Gaytan, E, Bellido, C., Carrera, G. and Aguilar, E. Differentiation of mast cells during postnatal development of neonatally estrogen-treated rats. Cell Tissue Res. 259:25-31, 1990. 22. Koretou, O. Relationship between the staining property of mast cell granule with alcian blue-safranin O and toluidine blue O, and the content of mast cell protease I in the granule of the rat peritoneal mast cell. Acta Histochem. Cytochem. 21:25-32, 1988. 23. de Paulis, A., Marinb, I., Ciccarelli, A., de Crescenzo, G., Concardi, M., Verga, L., Arbustini, E. and Marone, G. Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization. Arthritis Rheum. 39:1222-1233, 1996. 24. Dvorak, A. M., Hammel, I., Schulman, E. S., Peters, S. E, MacGlashan, D. W. Jr, Schleimer, R. E, Newball, H. H., Pyne, K., Dvorak, H. E, Lichtenstein, L. M. and Galli, S. J. Differences in the behavior
8.
25. 26.
27. 28. 29. 30. 31. 32.
33.
34.
35. 36. 37. 38. 39. 40.
41. 42. 43. 44. 45.
46. 47. 48.
49.
N E R V E - M A S T C E L L I N T E R A C T I O N S IN A M P H I B I A N S
129
of cytoplasmic granules and lipid bodies during human lung mast cell degranulation. J. Cell Biol. 99:1678-1687, 1984. Dvorak, A. M. Basophil and mast cell degranulation and recovery. Blood Cell Biochemistry, Vol. 4. Plenum Press, New York, 1991. Thomas, P. K. and Olsson, Y. Microscopic anatomy and function of the connective tissue components of peripheral nerve. In: Peripheral Neuropathy (Dyck, P. J., Thomas, P. K., Lambert, E. H. and Bunge, R., eds), pp. 168-189. W. B. Saunders, Philadelphia, 1984. Powell, H. C., Myers, R. R. and Costello, M. L. Increased endoneurial fluid pressure following injection of histamine and compound 48/80 into rat peripheral nerves. Lab. Invest. 43:564-572, 1980. Marks, R. M., Roche, W. R., Czerniecki, M., Penny, R. and Nelson, D. S. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab. Invest. 55:289-294, 1986. Norrby, K., Jakobsson, A. and Sorbo, J. Mast-cell-mediated angiogenesis: A novel experimental model using the rat mesentery. Virchows Arch. B Cell Pathol. 52:195-206, 1986. Aloe, L. and Levi-Montalcini, R. Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Res. 133:358-366, 1977. Leon, A., Buriani, A., dal Toso, R., Fabris, M., Romanello, S., Aloe, L. and Levi-Montalcini, R. Mast cells synthesize, store, and release nerve growth factor. Proc. Natl. Acad. Sci. USA 91:3739-3743, 1994. Nilsson, G., Forsberg-Nilsson, K., Xiang, Z., Hallbook, E, Nilsson, K. and Metcalfe, D. D. Human mast cells express functional TrkA and are a source of nerve growth factor. Eur. J. Immunol. 27(9):2295-2301, 1997. Marshall, J. S., Stead, R. H., McSharry, C., Nielsen, L. and Bienenstock, J. The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor. J. hnmunol. 144:1886-1892, 1990. Horigome, K., Pryor, J. C., Bullock, E. D. and Johnson, E. M. Mediator release from mast cells by nerve growth factor. Neurothrophin specificity and receptor mediation. J. Biol. Chem. 268:14881-14887, 1993. Bullock, E. D. and Johnson, E. M. Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. J. Biol. Chem. 271:27500-27508, 1996. Morley, J. E., Kay, N. E., Solomon, G. E and Plotnikoff, N. P. Neuropeptides: conductors of the immune orchestra. Life Sci. 41:527-544, 1987. Benyon, R. C., Lowman, M. A. and Church, M. K. Human skin mast cells: their dispersion, purification and secretory characterization. J. Immunol. 138:861-867, 1987. Lowman, M. A., Benyon, R. C. and Church, M. K. Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br. J. Pharmacol. 95:121-130, 1988. Stellato, C., de Paulis, A., Ciccarelli, A., Cirillo, R., Patella, V., Casolaro, V. and Marone, G. Antiimflammatory effect of cyclosporin A on human skin mast cells. J. Invest. Dermatol. 98:800-804, 1992. Dimitriadu, V., Buzzi, M. G., Moskowitz, M. A. and Theoharides, T. C. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44:97-112, 1991. Olsson, Y. Mast cells in the nervous system. Int. Rev. Cytol. 24:27-70, 1968. Chieffi Baccari, G., Rusciani, A., Di Matteo, L. and Minucci, S. Ontogenesis of the mast cells in the tongue and gastrointestinal tract of the frog, Rana esculenta. Eur. J. Histochem. 39(suppl 1):47, 1995. Witschi, E. Amphibians, normal stages and fate maps. In: Development of Vertebrates (Witschi, E., ed.), pp 78-91. W.B. Saunders, Philadelphia, 1956. du Plessis, D. G., Mouton, Y. M., Muller, C. J. F. and Geiger, D. H. An ultrastructural study of the development of the chicken perineurial sheath. J. Anat. 189:631-641, 1997. Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R. and Sasse, J. Endothelial cellderived basic fibroblast growth factor: synthesis and deposition into sub-endothelial extracellular matrix. Proc. Natl. Acad. Sci. USA 84:2292-2296, 1987. Bunge, M. B., Wood, P. M., Tyan, L. B., Bates, M. L. and Sanes, J. R. Perineurium originates from fibroblasts: demonstration in vitro with a retroviral marker. Science. 243:229-231, 1989. Eccleston, P. A. Regulation of Schwann cell proliferation: mechanisms involved in peripheral nerve development. Exp. Cell Res. 199:1-9, 1992. Latker, C. H., Wadhwani, K. C., Balbo, A. and Rapoport, S. Blood-nerve barrier in the frog during Wallerian degeneration: are axons necessary for maintenance of barrier function? J. Comp. Neurol. 309:650-664, 1991. Olsson, Y. and Sjostrand, J. Proliferation of mast cells in peripheral nerves during Wallerian degeneration: a radioautographic study. Acta Neuropathol. 13:111-121, 1969.
130
G. C H I E F F I B A C C A R I et al.
50. Newson, B., Dahlst6m, A., Enerb~ick, L. and Ahlman, H. Suggestive evidence for a direct innervation of mucosal mast cells. An electron microscopic study. Neuroscience 10:565-570, 1983. 51. Stead, R. H., Tomioka, M., Quinonez, G., Simon, G. T., Felten, S. Y. and Bienenstock, J. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. Proc. Natl. Acad. Sci. USA 84:2975-2979, 1987. 52. Stead, R. H., Dixon, M. E, Bramwell, N. H., Riddell, R. H. and Bienenstock, J. Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. Gastroenterology 97: 575-585, 1989. 53. Arizono, N., Matsuda, S., Hattori, T., Kojima, Y., Maeda, T. and Galli, S. J. Anatomical variation in mast cell nerve associations in the rat small intestine, heart, lung, and skin. Lab. Invest. 62:626-634, 1990. 54. Bienenstock, J., Stead, R. H. and Marshall, J. S. Mast cells and the Nervous System. In: The Mast Cell in Health and Disease (Kaliner, M. A. and Metcalfe, D. D., eds), pp. 687-698. Marcel Dekker, New York, 1993. 55. Blennerhassett, M. G. Nerve and mast cell interaction: cell conflict or information exchange? Progr. Clin. Biol. Res. 390:225-241, 1994. 56. Johnson, D. and Krenger, W. Interactions of mast cells with nervous s y s t e m - recent advances. Neurochem. Res. 17:939-951, 1992. 57. Silver, R., Silverman, A. J., Vitkovic, L. and Lederhendler, I. I. Mast cells in the brain: evidence and functional significance. Trends Neurosci. 19:25-31, 1996. 58. Enerb~ick, L., Olsson, Y. and Sourander, E Mast cells in normal and sectionated peripheral nerve. Z. Zellforsch. 66:596-608, 1965. 59. Olsson, Y. Mast cells in human peripheral nerve. Acta Neurol. Scand. 47:357-368, 1971. 60. Olsson, Y. Mast cells in plaques of multiple sclerosis. Acta Neurol. Scand. 50:611-618, 1974. 61. Prineas J. W. and Wright R. G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 38:409-421, 1978. 62. Toms, R., Weiner, H. L. and Johnson, D. Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. J. Neuroimmunol. 30:169-177, 1990. 63. Dietsch, G. N. and Hinrichs, D. J. The role of mast cells in the elicitation of experimental allergic encephalomyelitis. J. Immunol. 142:1476-1481, 1989. 64. Brosnan, C. E, Lyman, W. D., Tansey, E A. and Carter, T. H. Quantitation of mast cells in experimental allergic neuritis. J. Neuropathol. Exp. Neurol. 44:196-203, 1985. 65. Johnson, D., Seeldrayers, E A. and Weiner, H. L. The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelinic basic protein and P2 can stimulate mast cell degranulation. Brain Res. 444:195-198, 1988. 66. Theoharides, T .C., Dimitriadou, V., Letourneau, R., Rozniecki, J. J., Vliagoftis, H. and Boucher, W. Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain myelin changes resembling early stages of demyelination. Neuroscience 57:861-871, 1993. 67. Askenase, E W. and Van Loveren, H. Delayed-type hypersensitivity: activation of mast cells by antigenspecific-T-cell factors initiates the cascade of cellular interactions. Immunol. Today 4:259-264, 1983. 68. Kaplan, A. E, Reddigari, S., Baeza, M. and Kuna, E Histamine releasing factors and cytokine-dependent activation of basophils and mast cells. Adv. Immunol. 50:237-260, 1991. 69. Tainsh K. R. and Pearce, E L. Mast cell heterogeneity: evidence that mast cells isolated from various connective tissue locations in the rat display markedly graded phenotypes. Int. Arch. Allergy Immunol. 98:26-34, 1992.
SECTION THREE SIGNAL TRANSDUCTION IN MAST CELLS AND BASOPHILS
Chapter 9
Sequential Protein Kinase Activation and the Regulation of Mast Cell Cytokine Production E. W. Gelfand and G. L. Johnson
Chapter 10
FceRI-mediated Induction of TNF-~ Gene Expression in Mast Cell Lines U. Blank and N. Varin-Blank
Chapter 11
Regulation of Mast Cell Degranulation by SHIP M. Huber, J. E. Damen, M. Ware, M. Hughes, C. D. Helgason, R. K. Humphries and G. Krystal
This Page Intentionally Left Blank
CHAPTER 9
Sequential Protein Kinase Activation and the Regulation of Mast Cell Cytokine Production ERWlN W. GELFAND* and GARY L. JOHNSON Division of Basic Sciences, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colorado, U.S.A.
INTRODUCTION Mast cells play a central role in inflammatory and immediate allergic reactions. The binding of multivalent antigens to receptor-bound IgE and the subsequent aggregation of the high-affinity Fc receptors for IgE (Fc~RI) provide the trigger for mast cell activation. The consequences of mast cell activation are the release of pre-formed inflammatory mediators from secretory granules (degranulation) and the synthesis and secretion of a number of pro-inflammatory cytokines. These mast cell responses are regulated by intracellular signal transduction pathways triggered by Fc~RI aggregation. In addition, mast cells express a number of other receptors which are linked to intracellular signalling pathways that are both similar and distinguishable from those triggered through Fc~RI. This review focuses on sequential protein kinase activation in mast cells which culminates in the liberation of pro-inflammatory cytokines.
SIGNALLING THROUGH MAST CELL SURFACE RECEPTORS Among the earliest demonstrable responses to Fc~RI aggregation is the phosphorylation of the receptor itself, priming the receptor for direct interactions with important effector molecules that activate distinct signalling pathways (1). Fc~RI are heterotrimeric or tetrameric complexes comprising an IgE-binding ~ subunit, a 13 subunit and two y subunits (2). The cytoplasmic domains of the ~ and y subunits contain two tyrosine residues located within a conserved consensus sequence (immunoreceptor tyrosine activation motif, ITAM) (3). The presence of ITAMs in both [3 and y subunits implies that they both participate in signals transduced through tetrameric Fc~RI complexes (4, 5) and * Corresponding author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
133
Copyright 9 2000 Academic Press All rights of reproduction in anyform reserved
134
ERWIN W. GELFAND AND GARY L. JOHNSON
phosphorylation of this pair on conserved tyrosines is essential for signal transduction. The extracellular domain of the a subunit is essential to generate the biochemical signals
(6). Activation through Fc~RI is highlighted by the rapid phosphorylation of a set of cellular proteins on tyrosine residues, and is presumed to be mediated by the nontransmembrane protein tyrosine kinases (PTKs), Lyn and Syk (4, 5, 7, 8). Lyn, a Src family PTK, is constitutively associated with Fc~RI, binding to the inactive ~ subunit (5, 9, 10). Syk becomes activated, binding to the phosphorylated ITAMs of the Fc~RI y subunit. Lyn and Syk appear to be activated sequentially: Lyn activation is immediate and transient and appears to send the initiating signal following Fc~RI engagement. Syk activation peaks after Lyn activation and may be dependent on Lyn activation. Syk activation peaks at a time that coincides with maximum tyrosine phosphorylation of the Fc~RI y subunit. The y subunit appears essential for signalling that results in secretion (4, 7, 9), and the [3 subunit may be important for Ras signalling (11). The y dimer functions as an autonomous activating complex, whereas the 13 chain serves as an amplifier that increases Syk activation and C a 2+ mobilization (9). Aggregation of Fc~RI also results in the activation of phospholipase Cy1 (PLC), and is dependent on Syk activation. Fc~RI cross-linking activates the lipid kinase, phosphatidylinositol 3-kinase (PI3K). A number of other proteins also undergo rapid tyrosine phosphorylation following Fc~RI aggregation, including pp60 cSrc,B cell tyrosine kinase (Btk) (7, 12), Spy 75, p95 vav, Nck (13-15) and the focal adhesion proteins, focal adhesion kinase (p125Fak)and paxillin (16, 17). Studies of bone marrow-derived mast cells (BMMC) from genetically deficient mice have revealed some surprising results. Although cross-linking of Fc~RI in Lyn-deficient mast cells failed to induce protein phosphorylation of various substrates and only evoked a slow C a 2+ response, degranulation and cytokine production proceeded normally (18). In contrast to Lyn and Syk, Btk does not physically associate with Fc~RI. Nonetheless, Btk plays an important role in Fc~RI signalling. Btk-deficient mice demonstrate reduced anaphylactic reactions. BMMC from deficient mice also show reduced responses in terms of Fc~RI-induced degranulation and cytokine production under certain circumstances (19) but not in others (unpublished results). In contrast to Lyn and Btk, Syk appears essential, since, in the absence of kinase active Syk, ligation of Fc~RI fails to activate a number of kinases (20), to trigger degranulation (9, 21) or to induce cytokine production (20). The stem cell factor receptor (SCFR, c-Kit) is expressed on immature haematopoietic progenitor cells (22) and mast cells, and stem cell factor (SCF, mast cell growth factor, kit ligand or steel factor) is the ligand for the tyrosine kinase SCFR. In mice, recombinant SCF can promote mast cell hyperplasia, degranulation and mediator release (22, 23). SCFR (CDll7) is a transmembrane protein that is homologous to receptors for polypeptide growth factors such as SCE The receptor consists of an intracellular tyrosine kinase domain, a single transmembrane domain and an extracellular domain that binds SCE Ligation of the SCFR (by SCF) results in SCFR autophosphorylation (24) and binding of PI3K and PLC-y1 to the receptor (25). Although p21Ras is activated, there is no detectable tyrosine phosphorylation of Ras GTPase-activating protein (24).
9.
SEQUENTIAL PROTEIN KINASE ACTIVATION
135
M A P K FAMILY M E M B E R S
An emerging cluster of sequential protein kinase pathways regulated through surface receptors has now been identified involving members of the MAPK (mitogen-activated protein kinase) family in addition to extracellular regulated kinase-1 (ERK-1) and ERK-2 (Fig. 1). These multiple linear MAPK cascades have been identified that operate through sequential activation of cytosolic protein kinases to lead signals from the plasma membrane to their cytosolic and nuclear targets, regulating nuclear transcription factors (26-29). They are characterized as serine/threonine protein kinases activated by dual phosphorylation on both a tyrosine and a threonine (30). The MAPK family includes p42/p44 MAPK (ERK-1 and ERK-2), the c-Jun kinases (JNKs, which are also referred to as stress-activated protein kinases, SAPKs), and p38, the osmotic shock responsive kinase (similar to the yeast Hog 1) (31-33) (Fig. 1). All members of this family are thought to play major roles in transcriptional regulation. Several tiers in these cascades have been identified (Fig. 1). These cascades, in association with other signalling pathways, can differentially alter the phosphorylation status of the transcription machinery. The regulation of these different MAPKs involves their phosphorylation by MKKs (MAPK kinase) including the MEKs (MAPK~_RK kinases, MAPKK) (34) and JNK kinases (JNKK or SEKs, stress/E_RK kinases) (35-37). The MEKs and JNKKs phosphorylate specific MAPK family members on both a tyrosine and a threonine, resulting in MAPK activation (31, 32, 35-37). Moreover, each pathway is downregulated by a variety of phosphatases, which may exhibit different specificities for the different pathways (29). In general, the ERKs are activated by agonists for tyrosine kinase-encoded receptors
Fig. 1 Sequential activation of mitogen activated protein kinase (MAPK) pathways.
136
ERWIN W. GELFAND AND GARY L. JOHNSON
and G protein-coupled receptors, whereas the JNKs and p38 are activated by cellular stress, inflammatory cytokines and, in mast cells, Fc~RI and SCE The ERKs may induce mitogenesis and differentiation whereas the stress-activated kinases (JNK, p38) have been implicated in apoptosis, oncogenic transformation, cytokine production and inflammatory responses in different cell types. The MKKs are in turn regulated by MAPK kinase kinases (MAPKKKs) which form a functional sequential protein kinase module (MKKK-MKK-MAPK). This group of kinases includes the Rafs (Raf- 1, B-Raf, N-Raf) and the recently cloned MEKKs (MEKK 1, 2, 3, 4) (36, 38, 39). The MEKKs have been cloned and characterized (38, 40, 41). Raf kinases preferentially activate the ERK pathway, whereas the MEKKs regulate the JNK pathway. In addition to the MEKKs, germinal centre kinase (GCK), mixed lineage kinase 3 (MLK-3) and tumour progression locus 2 (Tpl-2) kinase have been shown to regulate the JNK pathway as MKKKs (42-50). The JNKs are activated in response to many cellular stresses, including heat shock, UV irradiation (36, 51-53), CD40 ligation of B lymphocytes (54) and CD28 stimulation ofT cells (55). Ten separate JNKs have been identified and are grouped into three families: JNK1, JNK2 and JNK3 (56). The JNKs function to phosphorylate c-Jun at the N-terminal regulatory sites, serine 63 and serine 73, mapping within its transactivation domain, and also result in the transcriptional activation of c-Jun (57). Other substrates of the JNKs are activating transcription factor 2 (ATF-2) (581) and Elk-1 (59). The DNA binding activity of bacterially expressed ATF-2 is increased by phosphorylation in vitro and in vivo (58). ATF-2 is a member of a group of transcription factors that bind to a similar sequence located in the promoters of many genes, including tumour necrosis factor-cz (TNF-cz) (60), indicating a role for the JNK pathway in the transcriptional regulation of many genes. The stress-responsive p38 MAPK isoform has been implicated in the activation of MAPKAP-kinase 2 and the expression of pro-inflammatory cytokines (61). p38 activation is mediated by dual phosphorylation of threonine (180) and tyrosine (182) (25). Activation of p38 results in the phosphorylation and activation of ATF-2, as well as CHOP, a member of the C/EBP family of transcription factors (25, 62). JNK and p38 are often activated in parallel, but independent activation of p38 has also been observed indicating the existence of independent signalling roles for these MAP kinase cascades (36, 37). Cross-talk between the mammalian MAPK pathways also occurs. These separate pathways appear to be functionally independent and are regulated by distinct protein kinase cascades, via the activation of a unique MAPK kinase. One type, MEK1/MEK2, is a strong activator of ERK but does not phosphorylate JNK or p38 (34, 37, 63). Two other MAPK kinases, MKK3 and MKK6, activate p38 (36, 64); MKK4 (JNKK, SEK1) and MKK7 activate JNK (35-37). Upstream of the MKK is an MEKK or other MKKK and the low molecular weight GTP-binding proteins, Cdc42, Racl or Rho (64-66).
Fc~RI Signalling in MC/9 Mast Cells In order to study antigen triggering of mast cells, we generated hybridomas secreting anti-ovalbumin (OVA) IgE (67). In initial studies, we investigated signalling through Fc~RI using the MC/9 murine mast cell line following addition of OVA to OVA-specific IgE-sensitized cells or DNP to DNP-IgE-sensitized cells (68). We showed that following antigen-induced aggregation of Fc~RI, JNK was significantly activated within 5 min and peaked at 15-20 min after addition of OVA (69). Activation by OVA was dose-dependent
9.
SEQUENTIAL PROTEIN KINASE ACTIVATION
137
and specific since OVA did not induce activation of JNK in DNP-IgE-sensitized cells. Anti-mouse IgE antibody activated JNK in both DNP-IgE- and OVA-IgE-sensitized cells. In addition, ERK2 was rapidly activated within 30 sec following addition of OVA. In immunoblots using anti-ERK2 antibody, kinase activation was detected within 1 min and still observed 90 min after OVA stimulation. In these studies, MEKK1 activation preceded the activation of JNK in response to triggering through Fc~RI. MEKK1 activation was detected 30 sec after addition of OVA to IgE-sensitized cells. Maximal MEKK1 activity was achieved by 3 min and was 2.5-3-fold over basal levels. MEKK1 activity decreased over the ensuing 10 min after addition of OVA. Wortmannin is an inhibitor of PI3K with reasonable selectivity when used at concentrations below 1 ~tM (48). Pre-incubation of the cells (for 15 min) with wortmannin inhibited JNK activation in a dose-dependent fashion; kinase activity was almost completely eliminated in the presence of 100 nM wortmannin. In contrast, concentrations of 300 nM wortmannin failed to inhibit ERK2 activation by OVA. These findings demonstrate the role for PI3K in regulating the JNK pathway by a Src family tyrosine kinase-associated receptor. In these mast cells, the regulation of the MEKK1-JNKK-JNK pathway was dependent on the activation of PI3K. Moreover, the results clearly indicated that there was a very early separation in the signal pathways activated through Fc~RI to differentially regulate JNK and ERK2 sequential protein kinase pathways. It is also clear that the third MAPK isoform, p38, is activated by antigen cross-linking of IgE-sensitized MC/9 cells (69). The kinetics of activation are very similar to those of JNK, with detectable activity at 1 min, peaking at 5 min and gradually declining over the ensuing 60 rain. In parallel to the results of wortmannin on JNK activation, the PI3K inhibitor prevented activation of p38 at similar concentrations. However, the inhibition of p38 was never as complete as the inhibition of JNK activation, suggesting that inputs in addition to PI3K are involved in differentially regulating JNK and p38 activities (69). Mast cells have the capacity to enhance many aspects of allergic inflammation in asthma or other allergic disorders via the elaboration of a number of multifunctional cytokines. The first cytokine to be associated with mast cells was TNF-cz, but mast cells represent a source of other cytokines as well, including interleukins IL-3, IL-4, IL-5, IL6, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (6, 70). MC/9 cells are known to transcribe and produce TNF-cz; other cytokines such as IL-4 or IL-6 are not detected in MC/9 cells. These cells, sensitized with anti-OVA IgE, were incubated with OVA, the supernates were harvested and levels of TNF-cz assayed by ELISA. Within the first 30 min after addition of OVA, no TNF-cz was detected, suggesting little pre-formed TNF-cz production in MC/9 cells; TNF-cz production peaked at 2.5-3 h after stimulation of Fc~RI (69). Both cycloheximide and actinomycin D completely prevented TNF-cz production. Addition of wortmannin inhibited TNF-cz production in a dose-dependent manner (69); in contrast, the MEK1 inhibitor PD 98059, at concentrations that inhibited activation of MEK1 and ERK2, failed to impact TNF-cz production (69). These data indicate that signalling through Fc~RI activates three members of the MAPK family: ERK, JNK and p38. Inhibition of MEK1 is associated with the inhibition of ERK activation; inhibition of PI3K is associated with inhibition of JNK and p38 activation. The regulation of TNF-cz production is sensitive to wortmannin but unaffected by inhibition of MEK1. These results imply that specific MAPK signalling pathways are involved in the regulation of mast cell TNF-cz production triggered through Fc~RI.
138
ERWIN W. GELFAND AND GARY L. JOHNSON
TRANSCRIPTIONAL REGULATION OF TNF-o~ PRODUCTION
Little is known about the signal transduction pathways that regulate TNF-~ gene expression in mast cells. In rat basophilic leukaemia (RBL) cells, G~z, a heterotrimeric G protein, appeared to modulate the Fc~RI stimulatory pathway for TNF-~ synthesis (71). Some clues are also evident from the promoter for the TNF-~ gene which encodes NFrd3, AP- 1, AP-2, NFAT, Ets and AP-1/ATF-related regulatory elements. Within the TNF-~ promoter the regulatory elements involve regulation by transcription factors that are substrates for MAPK members, including ERKs, JNKs and p38 MAPK. For example, cJun and ATF-2 transcription factors are strongly implicated in the control of TNF-~ gene expression (72) and are substrates for JNK and p38 (57, 58). MEKK1 has been shown to also regulate the activation of NF-vd3 (55, 63), which has been implicated as being important in controlling TNF-~ gene transcription. In addition, in monocytes, a series of pyridinylimidazole compounds have been shown to block lipopolysaccharide-induced activation of p38; inhibition of p38 MAPK inhibits TNF-c~ synthesis (in monocytes) primarily at the level of translation and expression (73). Thus JNK and p38 kinases appear to be major regulators of TNF-~ gene expression and, in mast cells, are activated in response to ligation of Fc~RI. To test these predictions, MC/9 cells were transiently transfected with the reporter plasmid, pTNF(_~_31~)Luc, having the luciferase gene regulated by the TNF-~ promoter. Passively sensitized, transfected MC/9 cells responded to OVA and Fc~RI aggregation with a 5-6-fold increase in luciferase expression (68). Wortmannin (100 nM) inhibited this response by 40%: in contrast, the ERK inhibitor PD 98059 actually enhanced the expression of luciferase in response to OVA. The results with wortmannin on TNF-~ gene expression were similar to the effects of the inhibitor on protein expression. These results show that a component of the Fc~RI-mediated increase in TNF-c~ gene expression requires PI3K activity and this response appears largely independent of ERK stimulation. Aggregation of Fc~RI stimulated MEKK1 activity in MC/9 cells (69). Expression of an activated form of MEKK1 activated JNK; the activities of ERK and p38 were induced much less, if at all, in these cells (69). Activated MEKK1 expression in these MC/9 cells stimulated an increase in luciferase activity, resulting from activation of the TNF-~ promoter. These data demonstrated that, under these conditions, activated MEKK1 is capable of stimulating TNF-c~ gene transcription. To further define specific control of TNF-cz transcription, MC/9 cells were transfected with an inhibitory JNK2 mutant (JNK2-APF). Transfection of MC/9 cells with this mutant partially inhibited OVAstimulated TNF-cz promoter activity and inhibited MEKKl-stimulated luciferase expression (69). This partial inhibition observed with JNK2-APF may be related to it being a competitive inhibitory mutant; at present strong dominant-negative mutants for JNK or its upstream regulator, JNK kinase, have not been developed and the kinaseinactive mutants behave only as modest competitive inhibitory mutants. The findings suggested that MEKK1 stimulation of TNF-cz promoter-driven luciferase expression requires JNK2. But, more importantly and relevant to subsequent findings, the limited inhibition of Fc~RI-mediated TNF-~ promoter activity indicated that additional MEKKs were more likely to play a dominant role in these OVA-induced responses and this has been confirmed in more recent studies (see below). Four MEKKs with homology in their kinase domains have now been cloned. All four function as MKKKs capable of activating the JNK pathway. Based on the deduced
9.
SEQUENTIAL PROTEIN KINASE ACTIVATION
139
primary sequences of MEKK1, 2, 3 and 4, specific properties related to kinase activation may be predicted for each (Fig. 2 and Table I). To more directly define which MEKKs are involved in Fc~RI-mediated signalling of JNK, kinase-inactive inhibitory mutants (66) of the MEKKs were used. In these experiments, kinase-inactive MEKK2 and MEKK4 inhibited FGRI-stimulated JNK activity by approximately 60% and 80%, respectively, whereas inhibitory mutants of MEKK1 or MEKK3 were without effect (unpublished). Thus, although MEKK1 activation followed Fc~RI aggregation and constitutively activated MEKK1 stimulated JNK, it did not appear essential for JNK activation when Fc~RI was ligated. The immunosuppressants cyclosporin A (CsA) and FK506 are potent inhibitors of TNF-~ production in mast cells. Both CsA and FK506 (but not rapamycin) strongly inhibited FGRI activation of JNK and p38 to a lesser extent (74). Cyclosporin H (CsH) which does not bind to the cyclophilins and does not have immunosuppressive activity, did not inhibit Fc~RI activation of JNK or p38. In addition, incubation of MC/9 cells with CsA did not inhibit FGRI mobilization of calcium or activation of the tyrosine kinase Syk, implying that early signal events triggered by FGRI cross-linking are unaffected by CsA. These data indicate that the likely target for CsA via a cyclophilin complex (or FK506) is calcineurin, and identify a calcineurin-regulated JNK pathway following Fc~RI aggregation of mast cells.
STEM CELL F A C T O R R E C E P T O R (c-KIT) SCFR, the tyrosine kinase encoded receptor for SCF, promotes the growth and differentiation of mast cells. SCF ligation also stimulates the release of mast cell
Fig. 2 Domains of the MAPKKK. Hatched bar, kinase domain; PH, pleckstrin homology domain; PPP, proline-rich domain; CRIB, Cdc42/Rac interacting binding domain. TABLE I Summary of demonstrated regulators of MAPK pathways
MEKK1 MEKK2 MEKK3 MEKK4
ERK
JNK
+ + +
+ + + +
-
p38
140
ERWIN
W.
GELFAND AND
GARY
L.
JOHNSON
inflammatory mediators, including histamine and serotonin, and induces mast cell adherence and chemotaxis. In MC/9 cells, addition of SCF stimulated ERK, JNK and p38 in MC/9 cells (74). The activation of JNK and p38 by SCF was modest compared to signalling through Fc~RI in these cells. Strikingly, SCFR co-stimulation with Fc~RI markedly augmented the activation of JNK. Although SCFR activation alone did not result in measurable increases in TNF-o~ production in MC/9 cells, together with Fc~RI ligation, there was a marked increase in TNF-ot production; co-stimulation with SCF and OVA (Fc~RI) only weakly potentiated p38 or ERK activation, confirming that JNK was differentially regulated by Fc~RI relative to p38 and ERK (74). Substantiating these observations were the findings that wortmannin failed to inhibit the activation of ERK, p38 and JNK in response to SCF in MC/9 cells, in striking contrast to signalling through Fc~RI (74). It should be noted that not every protein kinase pathway activated through Fc~RI and SCFR is differentially inhibited by wortmannin. ERK activation through Fc~RI was unaffected. As a corollary, AKT (PKB), which is activated in response to PI3K stimulation by either Fc~RI or SCFR ligation, was inhibited by wortmannin. Further support for the independence of the Fc~RI and SCFR signalling pathways derives from studies with the immunosuppressant drugs (Table II). CsA (and FK506, but not rapamycin) strongly inhibited Fc~RI activation of JNK and p38, but not ERK (74). In striking contrast, SCFR activation of JNK, p38 and ERK was completely unaffected by the immunosuppressants. Such results clearly document the independence of the signal pathways regulating JNK and p38 activity by Fc~RI and SCFR. The integration of such early signalling events which differ between Fc~RI and SCFR in their control of pathways controlling TNF-c~ production is likely important in overall regulation of cytokine production. TABLE II Functional characterization of three mast cell populations
FceRI SCFR Cytokine production Degranulation Transfection Wortmann sensitivity FceRI JNK FceRI cytokine SCFR JNK FceRI p38 SCFR p38 C s A sensitivity FceRI JNK FceRI cytokine SCFR JNK F c e R I p38 SCFR p38 n.d. -
not done
MC/9
BMMC
ESMC
+
+
+
+
+
+
TNF-(x
TNF-o~, IL-4
TNF-o~, IL-4
-
+
+
Transient/stable
-
Transient/stable
+
+
+
+
+
+
-
+
+
+
+
n.d.
-
-
n.d.
+
+
+
+
+
+
-
-
+
+
n.d.
-
-
n.d.
9.
SEQUENTIAL PROTEIN KINASE ACTIVATION
141
DIFFERENTIATION, SIGNALLING AND FUNCTION OF MAST CELLS DERIVED FROM BONE M A R R O W AND EMBRYONIC STEM CELLS Mast cell development is a complex process that results in the appearance of phenotypically distinct populations of cells in different anatomical sites. Although more likely representative of cytokine-driven differences than specific attributes of the sites, connective tissue mast cells differ from mucosal mast cells primarily in their storage of large amounts of histamine. Bone marrow obtained from the femurs of mice and grown in medium containing IL-3 or IL-3-SCF rapidly differentiates into mast cells (bone marrowderived mast cells, BMMC). Fc~RI is detected within 7-10 days of culture and the cells become granulated within 3-4 weeks, confirming previous observations (75). Cells grown in IL-3-SCF take on the features of connective tissue mast cells as they are larger, contain uniformly electron-dense cytoplasmic granules, have a longer life span and stain positively with Alcian blue, safranin O, berberine sulphate and contain large amounts of histamine (unpublished observations). In contrast, the cells grown in IL-3 alone are smaller, contain cytoplasmic granules that are not uniformly electron-dense, do not stain with the various dyes, and contain less histamine. Despite these phenotypic differences, both cell types express functional Fc~RI: addition of OVA or DNP to passively sensitized cells (anti-OVA or anti-DNP-IgE) leads to rapid increases in cytosolic Ca 2+, p38, JNK and ERK activation, and TNF-c~ and IL-4 production (76). As in the MC/9 cells, JNK activation and cytokine production was both wortmannin-sensitive and CsA-sensitive (Table II). As the BMMC do not express FKBP12, these cells are not inhibited by FK506. Thus, these BMMC have in common most of the features of Fc~RI signalling in MC/9 cells. Further, the responses to SCF are in general the same: addition of SCF augmented JNK activation and cytokine production in these cells and the SCF response was CsA-resistant (Table II). An important feature of the BMMC is that addition of OVA to passively sensitized cells results in degranulation, measured by the release of (tritiated) serotonin or histamine (using an enzyme immunoassay) (76). Signalling through Fc~RI triggers serotonin release that was inhibited by wortmannin and CsA. Moreover, the MEK1 inhibitor also blocked serotonin release. Although BMMC are easily derived in culture and have proven useful to study the regulation of cytokine production and degranulation, genetic manipulation of these cells has proven difficult. To overcome these problems, we have derived mast cells from embryonic stem cell cultures (ESMC). The undifferentiated blast cell colonies were cultured with IL-3 or IL-3-SCF. The kinetics of mast cell differentiation from these colonies were identical to those of the BMMC, with Fc~RI detected on the majority of the cells during the second week in culture and the majority of the cells exhibited cytoplasmic granules by weeks 3-4. Similar to BMMC, the phenotype of the cells was dictated by the cytokine mixture present in the culture medium; as discussed for BMMC, IL-3 alone induced cells with low histamine content ('-20 nM per 106 cells) and IL-3-SCF induced cells with high histamine content (--600 nM per 10 6 cells) (unpublished observations). Importantly, the ESMC exhibited signalling properties similar to those described for BMMC when Fc~RI or SCFR were ligated as well as for the control of cytokine production and the degranulation response (see Table II). The ability to transfect ES cells efficiently serves to make them an important genetically manipulatable system. Inducible expression and targeted disruption of specific genes as well as mast cell differentiation have been possible in this system.
142
ERWIN W. GELFAND AND GARY L. JOHNSON
IDENTIFICATION OF A CRITICAL ROLE FOR MEKK2 IN JNK ACTIVATION AND CYTOKINE PRODUCTION As described above, multiple MEKKs have been shown to function as an MKKK in the signalling module MKKK-MKK-JNK. Initial experiments using passively sensitized MC/9 cells indicated that specific kinase-inactive inhibitory MEKKs could modulate (inhibit) OVA-induced JNK activation. In particular, kinase-inactive MEKK2 and MEKK4 strongly inhibited JNK activation in response to Fc~RI ligation (unpublished observations). Importantly, inhibitory mutants of MEKK1 and MEKK3 had little or no effect in these experiments. Only kinase-inactive MEKK4 appeared to exhibit an inhibitory effect on SCFR signalling; inhibitory MEKK2 did not affect signalling through the SCFR under these conditions. These results confirmed the differential involvement of specific MEKKs in the regulation of Fc~RI and SCFR signalling and ultimately cytokine production. To further and more directly define the role of MEKK2 in regulating MAPK signalling pathways and cytokine production in mast cells, targeted disruption of the MEKK2 gene in mouse embryonic stem cells has been utilized (77). MEKK2 protein was absent in the homozygous-deficient ES cell clones and mast cells were derived from these ES cells. The loss of MEKK2 had no discernible effects on Fc~RI or SCFR expression, growth and differentiation characteristics, morphology or granule content. In the MEKK2 - / - mast cells, the ability of Fc~RI to activate JNK was virtually eliminated. However, activation of JNK in response to stress or UV irradiation was maintained. In contrast, MEKK1 - / mast cells exhibited a normal JNK activation response to Fc~RI aggregation. Thus, the loss of JNK activation in response to Fc~RI ligation appeared specific to the loss of MEKK2 but not MEKK1. Further, in contrast to JNK activation, following ligation of Fc~RI, ERK and p38 activation were unaffected by the loss of MEKK2. Such findings indicate that MKKK, other than MEKK2, regulate receptor activation of ERK and p38 in mast cells and implicate an essential role for MEKK2 for JNK activation following signalling through Fc~RI. The functional consequences of a deficiency of MEKK2 were also identified. Induction of mast cell degranulation following aggregation of Fc~RI in MEKK2 - / - cells was indistinguishable from the response in normal (MEKK2 +/+) mast cells. However, the regulation of cytokine mRNA expression was significantly altered in MEKK2 - / cells. In particular, the expression of mRNA for TNF-~ and IL-4 was significantly reduced following Fc~RI aggregation or the combination of Fc~RI and SCFR signalling. These findings indicate a major role for MEKK2 in the control of JNK (but not ERK or p38) activation in mast cells and that MEKK2-dependent signalling pathways regulate cytokine production in these cells.
SUMMARY Based on these results, a model emerges suggesting that the activation of the MEKK2 (and MEKK4) pathway and calcineurin regulation of NFATp contribute to the induction of TNF-~ and other cytokine gene expression following cross-linking of Fc~RI (Fig. 3). The involvement of the MEKK pathway in regulating the TNF-o~ promoter defines a mechanism for the previously described CRE augmentation of ~:3 regulation of TNF-oc
9.
143
SEQUENTIAL PROTEIN KINASE ACTIVATION
gene expression (72). The regulation of NFATp by calcineurin and transcriptional regulation via ~: regulatory elements that bind NFATp in the TNF-~ promoter also appears pivotal. Predictably, CsA inhibits TNF-c~ and IL-4 production. We have shown that this inhibition is not only the result of interference with activation of NFATp (via inhibition of the CaZ+-calmodulin-dependent phosphatase calcineurin) but CsA also inhibits the activation of JNK following ligation of Fc~RI. In addition, the inhibition of JNK correlates with inhibition of calcineurin as the inactive cyclosporin, CsH fails to do so and FK506 (but not rapamycin) has similar effects. Thus, the immunosuppressant cyclosporins have at least two sites of action involving calcineurin in cytokine production: inhibition of the transcription factor NFAT and inhibition of the JNK pathway. MEKK2 & 4 and PAK1 Regulate TNFcx Synthesis Fc~ RI
Jl•,,, ~
./
99
Kinase Cdc42/Rac
PLCT
MKK3
J
P38
4
~
N~
MEKK
~t
c~,+2
JNKK
/
(MKK4)
Calcineurin ~'~1~ M E K K 2
Nly.AT
~
JNK
PAK1
9
Jun/ATF-2 /
k3
CRE
Fig. 3 Interplay of NFAT and JNK pathways. Ligation and activation of FceRI activates the tyrosine kinases Lyn, Btk and Syk. This results in activation of PLCy, PI3K and the MEKKs. These signalling events appear essential for the activation/regulation of p38s, JNKs, NFAT and NF-~zB. The TNF-c~ promoter (and other cytokine promoters) is activated by NFAT and JNK. p38 may be involved in the post-transcriptional regulation of TNF-c~ synthesis.
ACKNOWLEDGEMENTS We are grateful to Drs T. Ishizuka, A. Oshiba, N. Sakata, N. Terada, E Gerwins, G. Fanger, E. Hamelmann, H. Kawasome, K. Takeda, K. Chayama, T. Garrington and T. Yujiri for their important contributions to this work and to Drs G. Keller and S. Webb for their help in growth and differentiation of mast cells. Supported by the National Institutes of Health (AI-42246).
144
ERWIN W. GELFAND AND GARY L. JOHNSON
REFERENCES 1. Paolini, R., Jouvin, M. H. and Kinet, J. P. Phosphorylation and dephosphorylation of the high affinity receptor for immunoglobulin e immediately after receptor engagement and disengagement. Nature 353:855-858, 1991. 2. Blank, U., Ra, C., Miller, L., White, K., Metzger, H. and Kinet, J. E Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 337:187-189, 1989. 3. Reth, M. Antigen receptor tail clue. Nature 338:383-384, 1989. 4. Jouvin, M. H., Adamczewski, M., Nemerof, R., Letourneur, O., Valle, A. and Kinet, J. E Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin e receptor. J. Biol. Chem. 269:5918-5925, 1994. 5. Kihara, H. and Siraganian, R. E Src homology 2 domains of Syk and Lyn bind to tyrosinephosphorylated subunits of the high affinity IgE receptor. J. Biol. Chem. 269:22427-22432, 1994. 6. Paul, W. E., Seder, R. A. and Plaut, M. Lymphokine and cytokine production by Fc epsilon RI +cells. Adv. Immunol. 53:1-29, 1993. 7. Eiseman, E. and Bolen, J. B. Engagement of the high-affinity IgE receptor activates Src protein-related tyrosine kinases. Nature 355:78-80, 1992. 8. Hutchcroft, J. E., Geahlen, R. L., Deanin, G. G. and Oliver, J. M. FceRI-mediated tyrosine phosphorylation and activation of the 72-kDa protein tyrosine kinase PTK 72 in RBL-2H3 rat tumor mast cells. Proc. Natl. Acad. Sci. USA 89:9107-9111, 1992. 9. Lin, S., Cicala, C., Scharenberg, A. M. and Kinet, J. E The FceRI~ subunit functions as an amplifier of FcERIy-mediated cell activation signals. Cell 85:985-995, 1996. 10. Shiue, L., Green, J., Green, O. M., Karus, J. L., Morgenstern, J. E, Ram, M. K., Zoller, M. J., Zydowsky, L. D., Bolen, J. B. and Brugge, J. S. Interaction of p72Syk with the gamma and beta subunits of the highaffinity receptor for immunoglobulin E, Fc epsilon RI. Mol. Cell. Biol. 15:272-281, 1995. 11. Kimura, T., Kihara, H., Bhattacharyya, S., Sakamoto, H., Appella, E. and Siraganian, R. E Downstream signaling molecules bind to different phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) peptides of the high affinity IgE receptor. J. Biol. Chem. 270:27962-27968, 1996. 12. Kawakami, T., Yao, L., Miura, T., Tsukada, S., Witte, O. W. and Kawakami, T. Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol. Cell. Biol. 14:51085113, 1994. 13. Fukamachi, H., Yamada, N., Miura, T., Kato, T., Ishikawa, M., Gulbins, E., Altman, A., Kawakami, Y. and Kawakami, T. Identification of a protein, SPY75 with repetitive helix-turn-helix motifs and an SH3 domain as a major substrate for protein tyrosine kinase(s) activated by Fc epsilon RI cross-linking. J. Immunol. 152:642-652, 1994. 14. Margolis, B., Hu, E, Katzav, S., Li, W., Oliver, J. M., Ullrich, A., Weiss, A. and Schlessinger, J. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs. Nature 356:71-74, 1992. 15. Li, W., Hu, O., Skolnik, E. Y., Ullrich, A. and Schlessinger, J. The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors. Mol. Cell. Biol. 12:5824-5833, 1992. 16. Hamawy, M. M., Mergenhagen, S. and Siraganian, R. P. Tyrosine phosphorylation of pp125FAK by the aggregation of high affinity immunoglobulin E receptors requires cell adherence. J. Biol. Chem. 268: 6851-6854, 1993. 17. Hamawy, M. M., Swaim, W. D., Minoguchi, K., de Feijter, A. W., Mergenhagen, S. E. and Siraganian, R. E The aggregation of the high affinity IgE receptor induces tyrosine phosphorylation of paxillin, a focal adhesion protein. J. Immunol. 153:4655-4662, 1994. 18. Nishizumi, H. and Yamamoto, T. Impaired tyrosine phosphorylation and C a 2+ mobilization, but not degranulation, in Lyn-deficient bone marrow-derived mast cells. J. Immunol. 158:2350-2355, 1997. 19. Kawakami, Y., Miura, T., Bissonnette, R., Hata, D., Khan, W. N., Kitamura T., Yamamoto, M. M., Hartman, S. E., Yao, L., Alt, E W. and Kawakami, T. Bruton's tyrosine kinase regulated apoptosis and JNK/SAPK kinase activity. Proc. Natl. Acad. Sci. USA 94:3938-3942, 1997. 20. Costello, E, Downward, J. and Tybulewicz, V. L. J. Critical role for the tyrosine kinase Syk in signaling through the high affinity IgE receptor of mast cells. Oncogene 13:2595-2605, 1996. 21. Zhang, J., Berenstein, E. H., Evans, R. L. and Siraganian, R. E Transfection of Syk protein tyrosine reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat
9.
S E Q U E N T I A L P R O T E I N KINASE ACTIVATION
145
basophilic leukemia RBL-2H3 cells. J. Exp. Med. 184:71-79, 1996. 22. Galli, S. J., Zsebo, K. M. and Geissler, E. N. The kit ligand, stem cell factor. Adv. Immunol. 55:1-96, 1994. 23. Galli, S. J., Tsai, M. and Wershil, B. K. The c-Kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. Am. J. Pathol. 142:965-974, 1993. 24. Rottapel, R., Reedijk, M., Williams, D. E., Lyman, S. D., Anderson, D. M., Pawson, T. and Bernstein, A. The steel/w transduction pathway: Kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the steel factor. Mol. Cell. Biol. 11:3043-3051, 1991. 25. Davis, R. J. Transcriptional regulation by MAP kinases (review). Mol. Reprod. Dev. 42:459-467, 1995. 26. Davis, R. J. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556, 1993. 27. Johnson, G. L. and Vaillancourt, R. R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell Biol. 6:230-238, 1994. 28. Blumer, K. J. and Johnson, G. L. Diversity in function and regulation of MAP kinase pathways. Trends Biochem. Sci. 19:236-240, 1994. 29. Waskiewicz, A. J. and Cooper, J. A. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr. Opin. Cell. Biol. 7:798-805, 1995. 30. Ray, L. B. and Sturgill, T. W. Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine in vivo. Proc. Natl. Acad. Sci. USA 85:3753-3757, 1988. 31. Boulton, T. G., Nye, S. H., Robbins, D. J., Radziejewska, N. Y. E., Morgenbesser, S. D., DePinko, R. A., Panayotatos, N., Cobb, M. H. and Yanopoulos, G. D. ERKs: a family of protein serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGE Cell 65: 663-675, 1991. 32. Ahn, N. G., Weiel, J. E., Chan, C. E and Krebs, E. G. Identification of multiple epidermal growth factorstimulated protein serine/threonine kinases from Swiss 3T3 cells. J. Biol. Chem. 265:11487-11494, 1990. 33. Ahn, N. G., Seger, R., Bratlien, R. L., Silty, C. D., Tonks, N. and Krebs, E. G. Multiple components in an epidermal growth factor-stimulated protein kinase cascade. J. Biol. Chem. 266:4220-4227, 1991. 34. Crews, C. M., Alessandrini, A. and Erickson, R. L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258:478-480, 1992. 35. Sanchez, I., Hughes, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M. and Zon, L. I. Role of the SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor cJun. Nature 372:794-798, 1994. 36. Lin, A., Minden, A., Marinetto, H., Lange-Carter, C. A., Johnson, G. L., Mercurio, E and Karin, M. Identification of a dual specificity kinase that activates Jun kinases and p38-Mpk2. Science 268:286-290, 1995. 37. Derijard, B., Rainglaud, J., Barrett, T., Wu, I.-H., Han, J., Ulevitch, R. J. and Davis, R. J. Independent human MAP kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267:682-685, 1995. 38. Blank, J. L., Gerwins, P., Elliott, E. M., Sather, S. and Johnson, G. L. Molecular cloning of MEK kinase (MEKK) 2 and 3: regulation of sequential phosphorylation pathways involving mitogen activated protein kinase and c-Jun kinase. J. Biol. Chem. 271:5361-5368, 1996. 39. Wu, X., Noh, S. J., Zhou, G., Dixon, J. E. and Guan, K. L. Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J. Biol. Chem. 271:3265-3271, 1996. 40. Gerwins, P., Blank, J. L. and Johnson, G. L. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. J. Biol. Chem. 272:8288-8295, 1997. 41. Gerwins, E, Blank, J. L. and Johnson, G. L. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. J. Biol. Chem. 272:8288-8295, 1997. 42. Pombo, C. M., Kehrl, H., Sanchez, E, Katz, J., Avruch, J., Zon, L. I., Woodgett, J. R., Force, T. and Kyrikis, J. M. Activation of the SAPK pathway by the human ST620 homologue germinal center kinase. Nature 337:750-754, 1995. 43. Creasy, C. L. and Chernoff, J. Cloning and characterization of a member of the MST subfamily of Ste20like kinases. Gene 167:303-306, 1995. 44. Doror, D. S., Devereax, L., Dietzsh, E. and De Kretser, T. Identification of a new family of human epithelial protein kinases containing two leucine/isoleucine-zipper bearing domains. Eur. J. Biochem. 213:701-710, 1983.
146
E R W I N W. G E L F A N D AND GARY L. J O H N S O N
45. Ezoe, K., Lee, S., Strunk, K. M. and Spritz, R. A. PTKI: a novel protein kinase required for proliferation of human melanocytes. Oncogene 9:935-938, 1994. 46. Holzman, L. B., Merit, S. E. and Fan, G. Identification, molecular cloning, and characterization of dual leucine-zipper beating kinase. J. Biol. Chem. 269:30808-30817, 1994. 47. Katoh, M., Hirai, M., Sugimura, T. and Terada, M. Cloning and characterization of MST, a novel (putative) serine/threonine kinase with SH3 domain. Oncogene 10:1447-1451, 1995. 48. Reddy, U. R. and Pleasure, D. Cloning of a novel putative protein kinase having a leucine zipper domain from human brain. Biochem. Biophys. Res. Commun. 202:613-620, 1994. 49. Patrios, C., Makris, A., Chernoff, J. and Tsichlis, E N. Tpl-2 acts in concert with Rac and Raf-1 to activate mitogen-activated protein kinase. Proc. Natl. Acad. Sci. USA 91:9755-9759, 1994. 50. Salmeron, A., Ahmad, T. B., Carlile, G. W., Pappin, D., Narsimhan, R. E and Ley, S. C. Activation of MEK-1 and SEK-1 by Tpl-2 protoncoprotein, a novel of MAP-kinase kinase kinase. EMBO J. 15:817-826, 1996. 51. Derijard, B., Hibi, M., Wu, H., Barrett, T., Su, B., Deng, T., Karin, M. and Davis, R. J. JNKI: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037, 1994. 52. Kyriakis, J. M., App, H., Zhang, X.-E, Banerjie, P., Brautigan, D. L., Rapp, U. R. and Avruch, J. Raf-1 activates MAP kinase-kinase. Nature 358:417-421, 1992. 53. Minden, A., Lin, A., McMahon, M., Lange-Carter, C., Derijard, B., Davis, R. J., Johnson, G. L. and Karin, M. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723, 1994. 54. Sakata, N., Patel, H. R., Terada, N., Aruffo, A., Johnson, G. L. and Gelfand, E. W. Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells. J. Biol. Chem. 270:30823-30828, 1995. 55. Su, B., Jacinto, E., Hibi, M., Kallunki, T., Karin, M. and Ben-Neriah, Y. JNK is involved in signal integration during costimulation ofT Iymphocytes. Cell 77:727-736, 1994. 56. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanaugh, J., Sluss, H. K., Derijard, B. and Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2760-2770, 1996. 57. Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, Z. and Woodgett, J. R. Phosphorylation of c-Jun mediated by MAP kinases. Nature 353:670-674, 1991. 58. Gupta, S., Campbell, D., Derijard, B. and Davis, R. J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389-393, 1995. 59. Gille, H., Strahl, T. and Shaw, E E. Activation of ternary complex factor Elk- 1 by stress-activated protein kinases. Curr. Biol. 5:1191-1200, 1995. 60. Tsai, E. Y., Jain, J., Pesavento, P. A., Rao, A. and Goldfeld, A. E. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol. 16:459-467, 1996. 61. Beyaert, R., Cuenda, A., Berghe, W. V., Plaisance, S., Lee, J. C., Haegeman, G., Cohen, E and Fiers, W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor. EMBO J. 15:1914-1923, 1996. 62. Wang, X. Y. and Ron, D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 272:1347-1349, 1996. 63. Zheng, C. E and Guan, K. L. Cloning and characterization of two distinct human extracellular signalregulated kinase activator kinases, MEK1 and MEK2. J. Biol. Chem. 268:11435-11439, 1993. 64. Han, J., Lee, J. D., Jiang, Y., Li, Z., Feng, L. and Ulevitch, R. J. Characterization of the structure and function of a novel MAP kinase kinase (MKK 6). J. Biol. Chem. 271:2886-2891, 1996. 65. Minden, A., Lin A., Claret, E X., Abo, A. and Karin, M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147-1157, 1995. 66. Fanger, G. R., Johnson, N. L. and Johnson, G. L. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J. 16:4961-4972, 1997. 67. Oshiba, A., Hamelmann, E., Takeda, K., Bradley, K., Loader, J. E., Larsen, G. L. and Gelfand, E. W. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific IgE and IgG1 in mice. J. Clin. Invest. 97:1398-1408, 1996. 68. Ishizuka, T., Oshiba, A., Sakata, N., Terada, N., Johnson, G. L. and Gelfand, E. W. Aggregation of the FceRI on mast cells stimulates a wortmannin-sensitive c-Jun amino-terminal kinase (JNK) activity. J. Biol. Chem. 271:12762-12766, 1996. 69. Ishizuka T., Terada N., Gerwins, E, Hamelmann, E., Oshiba, A., Fanger, G. R., Johnson, G. L. and
9.
70.
71. 72. 73.
74.
75.
76.
77.
S E Q U E N T I A L P R O T E I N K I N A S E ACTIVATION
147
Gelfand, E. W. Mast cell TNF-~ production is regulated by MEK kinases. Proc. Natl. Acad. Sci. USA 94:6358-6363, 1997. Bradding, E, Roberts, J. A., Britten, K. M., Montefort, S., Djukanovic, R., Mueller, R., Heusser, C. H., Howarth, E H. and Holgate, S. T. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 10:471-480, 1994. Baumgartner, R. A., Hirasawa, N., Ozawa, K., Gusovsky, E and Beaven, M. A. Enhancement of TNF-~ synthesis by overexpression of Ga2in a mast cell line. J. Immunol. 157:1625-1629, 1996. Rao, A. NFATp: a transcription factor required for the co-ordinate induction of several cytokine genes. Immunol. Today 15:274-281, 1994. Lee, J. C., Laydon, J. T., McDonnell, E C., Gallagher, T. E, Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. E, White, J. R., Adams, J. L. and Youn, E R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746, 1994. Ishizuka, I., Kawasome, H., Terada, N., Takeda, K., Gerwins, E, Keller, G. M., Johnson, G. L. and Gelfand, E. W. Stem cell factor augments FceRI-mediated TNFc~ production and stimulates MAP kinases via a different pathway in MC/9 mast cells. J. Immunol. 161:3624-3630, 1998. Thompson, H. L., Metcalfe, D. D. and Kinet, J. E Early expression of high-affinity receptor for immunoglobulin E (FceRI) during differentiation of mouse mast cells and human basophils. J. Clin. Invest. 85:1227-1233, 1990. Ishizuka, T., Chayama, K., Takeda, K., Terada, N., Keller, G. M., Johnson, G. L. and Gelfand, E. W. MAP kinase activation through FceRI and stem cell factor receptor is differentially regulated by PI3-kinase and calcineurin in mouse bone marrow-derived mast cells. J. Immunol. 162: 2087-2094, 1999. Garrington, T. E, Chayama, K., Webb, S., Yujiri, T., Russell, D. M., Sather, S., Gibson, S., Keller, G., Gelfand, E. W. and Johnson, G. L. MEKK2 gene disruption inhibits IgE and c-Kit ligand stimulated JNK activation and cytokine production in ES cell-derived mast cells. Genes Dev. (submitted 2000).
This Page Intentionally Left Blank
CHAPTER
10
Fc~RI-mediated Induction of TNF-o~ Gene Expression in Mast Cell Lines ULRICH B L A N K *~ and N A D I N E VARIN-BLANK 2 1Unit~ d'lmmuno-Allergie, Institut Pasteur and 2Unit~ INSERM 363, ICGM H6pital Cochin, Paris, France
INTRODUCTION Tumour necrosis factor-~ (TNF-cz) is a multifunctional cytokine that is produced by numerous cell types and plays a central role in various immune and inflammatory responses (1). TNF-a, or cachectin, was originally discovered by its ability to induce tumour regression and to cause wasting syndrome during parasite infections. The cloned cDNA (2, 3) has significant homologies to T cell-derived lymphotoxin-a (Lt-c~), also called TNF-[3, and lymphotoxin-[~ (Lt-[3) (4, 5). Human TNF-~ is synthesized as a 233 amino acid membrane precursor. Secretion requires a specific Zn-dependent metalloprotease which cleaves an unusually long leader peptide to give a major secreted protein of 157 amino acids (6). Secreted TNF-~ forms a trimer which allows TNF-~ to aggregate its receptors on target cells (7). During the 1980s several groups described the presence of a cytotoxic activity comparable to TNF-cz in normal mast cells, cytokine-dependent mast cell cultures and several interleukin (IL)-3-dependent and independent mast cell lines (8-14). Further immunological and molecular studies clearly established TNF-a as a mast cell mediator (15-17). Mast cells are the only cells known to contain significant quantities of TNF-cz pre-stored in cytoplasmic granules that can be released by exocytotic discharge, providing an immediate source upon activation (16, 18, 19). They also respond to stimulation with the new synthesis of bioactive protein, which accounts for the sustained action of the cytokine at the inflammatory site (18). As mast cells are exclusively localized in tissues, the production and action of TNF-a from mast cells is thought to be essentially local. Their preferential distribution close to blood and lymphatic vessels, nerve endings and epithelia could potentialize its action by providing adequate stimuli on target cells. Mast cell-derived TNF-a has been shown to contribute importantly to host defence reactions * C o r r e s p o n d i n g author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
149
Copyright 9 2000 Academic Press All rights of reproduction in any form reserved
150
ULRICH BLANK AND NADINE VARIN-BLANK
during local infections (20, 21). It also plays a detrimental role in allergy and asthma as a mediator of late-phase inflammatory reactions (22-25). In view of its potent and pleiotropic actions, it is fundamental to maintain the biosynthesis and release of TNF-~ under tight control. Evidence has accumulated from different cell types that this regulation takes place at multiple levels, including transcription, translation and secretion. In this chapter we focus on recent advances in our understanding of these mechanisms and then try to summarize what is known for mast cells.
Chromosome 6
LT-[
Centromer
MHC CI. II genes
TNF-a
LT-a
Telomer
MHC CI. I genes
Fig. 1 Localizationand structure of the genes encoding TNF-a, LT-t~and LT-13on human chromosome 6. Exons and introns are marked as black and white boxes respectively. The drawing is not to scale. TNF-txis separated from LT-a and LT-~by approximately 1 and 3 kbp, respectively. C H R O M O S O M A L LOCATION AND GENE S T R U C T U R E OF T N F - a In both humans and mice the TNF-c~ gene is located in a region between the loci encoding MHC class I and class II molecules on chromosomes 6 and 17 respectively and is closely linked to the Lt-o~ and Lt-[3 genes (Fig. 1) (26, 27). The structure of the TNF-(x gene has been determined in several species and allowed extensive sequence comparison (26, 28). In all species known so far the gene presents the same structure, with the coding region consisting of four exons arranged over approximately 3 kb of DNA. As expected, the TNF-~ sequence is highly conserved during evolution both in the coding region (> 60%) and in 3" and 5" untranslated regions (UTRs). Notably, the 3" UTR contains multimers of a characteristic pentanucleotide, AUUUA, which is present in many cytokine mRNAs (29). Analysis of the 5" and 3" flanking region has also shown strong evolutionary conservation. A recent comparison between mouse and human promoter regions shows substantial homology in the whole upstream sequence extending to the Lt-~ gene, the first 220 bp upstream of the transcriptional start site being the most highly conserved sequences (30). Additional high sequence conservation is also apparent further upstream ( n t - 3 5 0 t o - 8 0 0 ) coveting particularly several NF-rd3 and NF-~cB-related (CK-1 and CK-2) sequence elements (26, 31). Figure 2 is a schematic drawing of the promoter region of the rat gene (28) and illustrates the principal regulatory sequence elements. A sequence comparison for the highly conserved r~B elements in the promoter as well as from the 3" flanking region of the gene is separately shown in Fig. 3.
10.
F c e R I - M E D I A T E D I N D U C T I O N OF TNF-o: G E N E E X P R E S S I O N
151
Fig. 2 A schematic representation of the rat TNF-(z promoter region indicating regulatory elements potentially involved in gene transcription. The numbers indicate distance from the transcriptional start site indicated by an arrow (+ 1). Note that the ~cB2 site in rat and mouse promoters is not conserved in the human promoter. The ~:B4/NFAT or kappa3 element has been shown to bind both NFAT and NF-r,B nuclear factors in humans.
CK-1 human porcine rabbit mouse rat
~ACCCCCC
GGA_GATACAGG
GGA_GAC_CCCCT
~AATCCT_T GAGAATCCTT
GTGAATTCCC GTGAATTCCC GTGAATTCCC GTGAATTCCC GTGAATTCCC
~B-3 human porcine rabbit mouse rat
~B-I
~TATCCTT GAAGTATCCC_T GGAGTATCCTT GGA_GTATCCTT GGAGTATCCTT
CRE +
CK-2 GGGGCTGTCC GGGGCTGTCC GGGGCTGTCC GGGGCTGTCC GGGGCTGTCC
w~B4/NFAT (kappa3)
TGAGCTCA~TTTCTGG
TGAGCTCA~TTTCTGG TGAGCTCA~TTTCTGG TGAGA_TCATGGT_TTTCTGG TGAGA_TCATGGT_TTTC TGG
3" flanking human porcine horse
mo u s e
rat
GAATTTCC GGGAATTTCC GGGAATTTCC ~AATTTCC GGGAATTTCC
Fig. 3 Sequence alignment of wB elements conserved between different species. For the v,B4/NFAT the adjacent CRE element is also shown. Differences to the human sequence are underlined. The relative positions of these elements in the rat gene can be seen in Fig. 2. The ~:B site in the 3" flanking region lies 218 bp downstream of the polyadenylation signal in the rat gene.
] 52
ULRICH BLANK AND NADINE VARIN-BLANK
REGULATION OF TNF-~ GENE EXPRESSION IN NON-MAST CELL LINES Regulation at the Level of Transcription Induction of TNF-~ gene expression is initiated by a number of stimuli, including various cytokines, bacterial products, immunological stimuli as well as some non-specific activators (1, 26). Following activation the increase of TNF-~ mRNA steady-state levels is rapid and does not require de novo protein synthesis. Nuclear run-on studies performed on primary macrophages and macrophage cell lines have clearly established a transcriptional induction both by augmenting the initiation and by increasing processivity during the elongation step (32-34). Processivity was independent of protein synthesis whereas initiation of transcription was further increased in the presence of cycloheximide, suggesting the action of short-lived repressors. Several studies have allowed identification of cis-acting elements and nuclear factors involved in the regulation of TNF-~ gene expression. Although there was initially some controversy about differences between human and murine systems (33, 35-37), a functional role for the transcription factor NF-~:B is now clearly established (30, 38). All ~:B sites identified in the promoter region are able to bind NF-rd3 and functionally contribute to the induction of TNF-c~ gene expression. This is further confirmed by studies using pyrrolidine dithiocarbamate PDTC, a pharmacological inhibitor of NF-rd3 activation (39), or more recently the overexpression of the cytosolic inhibitor I-~:BWT or I-r~B ($32,36A), a phosphorylating-deficient mutant form (30). A ~:B element situated approximately 220 bp downstream of the polyadenylation signal site of the TNF-~ gene (see Fig. 3) also mediates lipopolysaccharide (LPS)-induced TNF-c~ gene expression in murine macrophages (37). In rat astrocytes the LPS-induced TNF-~ gene expression was mainly regulated by this element rather than the upstream ~:B sites (40). These observations indicate strong lineage- and tissue-specific regulatory mechanisms. This is further corroborated by studies in T lymphocytes where another factor, NFATp, a member of the nuclear factor of activated T cells (NFAT) family of proteins was required for the strong induction by T cell receptor ligands (41, 42). NFATp bound to the kappa3 (r~B4/NFAT; see Fig. 2) site in the absence of fos/jun (AP-1) family proteins and induced transcriptional activation (42). The simultaneous binding of activating transcription factor 2 (ATF-2) and jun family members to the adjacent cyclic AMP-responsive element (CRE) significantly enhanced the effect (43). In addition to NF-~:B and NFAT and depending on the stimulus and cell type, a variety of other transcription factors have also been implicated in the induction of TNF-c~ gene expression. These include C/EBP~ (or NF-IL6) predominantly expressed in monocytes-macrophages and binding to a site encompassing n t - 7 4 t o - 1 0 0 upstream of the transcription initiation site in humans. C/EBP~ acts synergystically with c-jun in the PMA or LPS induction of the TNF-~ gene in U937 cells (44). Other transcriptional activators identified include a member of the ets family that binds to the highly conserved sequence element immediately adjacent to CRE and also known as the PU. 1 element (45), the Egr-1/Krox-24 transcription factor which binds to a GC-rich sequence (nt -160 and -170) of the huTNF-~ gene (46), as well as the TNF-~ core promoter region immediately upstream (28 bp) of the TATA box containing SP-1 and AP-2 conserved elements (47). In conclusion, the data collected have allowed the identification of a number of transcriptional activators involved in TNF-~ gene transcription. However, our understanding of this process is still sketchy as most of the studies have dealt with the
10. FceRI-MEDIATED INDUCTION OF TNF-~ GENE EXPRESSION
153
independent analysis of a given promoter element under different conditions of stimulation whereas in vivo the co-operative occupancy of the promoter by multiple transcription factors certainly renders the situation more complex (48). So far, we know nothing about the identity of the factors that appear to repress promoter activity, as indicated in one of the studies (49).
Post-transcriptional Regulation Post-transcriptional regulatory mechanisms have been shown to play an important role in gene expression in eukaryotic cells (50). They depend in part on specific sequences present in the 3" UTR. One major class of these regulatory sequences is present in mRNAs encoding growth factors, oncoproteins or cytokines, including TNF-o~, and consists of a conserved AU-rich sequence element (ARE) (29). This sequence is composed of several repeats of the pentanucleotide AUUUA. The ARE has been associated with both an accelerated degradation of mRNA (29) and interference with translation (51, 52). Ample evidence exists demonstrating that the production of TNF-~ is regulated to a considerable extent by such cytoplasmic regulatory mechanisms of mRNA function (53, 54). TNF-t~ mRNA has a very short half-life (39 min) (55). Recent investigations in mice lacking the ARE sequence of the TNF-ct gene have confirmed the role of this element in TNF-o~ message instability in the resting macrophages (56). In LPS-stimulated cells the situation was more complex, as an approximately 4-fold increase in mRNA half-life in A R E - / - mice was opposed to a stimulation-induced stabilization of TNF-o~ mRNA which was at least partially dependent on the ARE. At similar transcription rates the accumulation of mRNA was higher in ARE +/+ mice (90fold) than in A R E - / - mice (46-fold). This accumulation did not seem to be due to an 'induced' splicing mechanism as recently proposed (57) since both the accumulation and disappearance of nuclear pre-mRNA was comparable in both types of mice. It is noteworthy that, even in the absence of ARE, the mRNA was still responsive to LPSmediated stabilization, indicating the importance of other sequences than the ARE. Altogether these data suggest that in stimulated cells AREs mediate both positive and negative regulatory feedback loops. Tristetraprolin, the prototype of CCCH-zinc finger proteins, has recently been identified as an ARE binding protein able to mediate destabilization of the TNF-t~ message in murine macrophages (58). An example of a protein operating at the ARE during the induction/stabilization phase of the response is the ubiquitously expressed embryonic lethal abnormal visual (ELAV) RNA binding protein HuR (59). Besides mRNA stability, earlier studies have also indicated an effect of the ARE element on translation (5 l, 54). The phenotype of A R E - / - mice is characterized by a permissive translation of TNF-ct in non-stimulated cells and the development of chronic inflammatory arthritis and bowel disease (56). In macrophages the 3" UTR of TNF-ct maintains the TNF-tx mRNA in a repressed state and LPS stimulation derepresses this translational silencing (53, 60). A trans-dominant factor expressed constitutively in certain cell lines also overcomes the translational blockade (52). More recently, both the p38-mitogen-activated protein kinase (p38) and the c-Jun Nterminal-stress-activated protein kinase (JNK-SAPK) have been implicated in the signalling pathways leading to translational control of TNF-~. Inhibition of the LPSmediated activation of p38 with a specific pharmacological compound, SB203580, substantially reduced TNF-ct secretion in the absence of any matching effects on TNF-ct mRNA levels (61). The translational block by p38 implicated the downstream MAPKAP
154
ULRICH BLANK AND NADINE VARIN-BLANK
kinase 2 (62). Furthermore, a kinase-defective mutant of SAPK~ blocked translation of TNF-cz and similarly a dexamethasone-induced block of translation was overcome by overexpression of WT SAPK[3 (63). Implication of both kinases was confirmed in ARE - / - mice which were shown to be no longer susceptible to translational modulation by p38 and JNK-SAPK pathways (56). However, the molecular mechanism of the translational blockade remains unclear, but TNF-~ mRNA could remain unbound to the translational machinery in unstimulated cells and shift into polyribosomes upon stimulation (64). Furthermore, an inducible complex could bind to ARE sequences (65). Besides their role in translation, data obtained in a T cell line indicate that p38 and JNK-SAPK together with signal-regulated kinase (erkl/erk2) also play a role in the transcriptional control of TNF-c~ synthesis (66). The relative contribution of the different MAPK cascades is schematically presented in Fig. 4.
Stimulus S r
9
S
I
V
J,~
0
S
r
I S I S I J
T TNF-,a Transcription
9
TNIF-~
Translation
Fig. 4 Proposed signalling pathways of MAPK leading to TNF-(~ biosynthesis according to data obtained in macrophages and T cells (61-63). The diverse members of the MAPK are indicated. The broken arrows indicate mechanisms only shown in T cells.
10.
FceRI-MEDIATEDINDUCTION OF TNF-o~GENE EXPRESSION
155
Regulation at the Level of Secretion TNF-~ is a type II transmembrane protein that contains an unusually long 76 amino acid signal peptide (2). The 26-kDa transmembrane form is transported along the exocytotic pathway to the plasma membrane where it is cleaved by a highly specific membranebound metalloendoprotease, called TACE (6). Although a biologically active membranebound form of 26 kDa has been described on activated monocytes, pulse chase studies demonstrated that the membrane precursor usually decreases with a half-life of around 15-20 rain to yield the 17-kDa secreted form in the medium (67). Experiments using a specific inhibitor of the TNF-~ metalloprotease showed that unprocessed TNF-c~ became sequestered into perinuclear microsomes which co-localize with the Golgi (68). It is not completely clear to what extent secretion of TNF-~ in monocytes and macrophages requires active signalling. LPS-stimulated secretion has been described to be sensitive to B o t u l i n u m toxin type D without affecting intracellular TNF-c~ levels and independently secretion could require phosphokinase C (PKC) activation (67, 69).
FcERI-DEPENDENT REGULATION OF TNF-o~ PRODUCTION Characteristics of FcERI-dependent TNF-or Gene Expression in Mast Cells Mast cells are critical effectors of IgE-dependent immune responses mediated through their high-affinity IgE receptor (Fc~RI). In these cells aggregation of receptor-bound IgE provides a potent stimulus for TNF-cx production first recognized in the RBL-2H3 and PT18 mast cell lines (12, 15, 18, 70, 71). TNF-o~ represents a new class of mast cell mediators that are released from both pre-formed and de novo synthesized pools. This has been very elegantly shown in experiments using the transcriptional inhibitor actinomycin D which does not block degranulation (18). The C1.C57.1 mast cell line, primary IL-3dependent mast cell cultures and purified rat peritoneal mast cells (RPMC) released about 10% of the maximal TNF-~ levels achieved by the Fc~RI-stimulated exocytotic discharge. In most cultured mast cell lines TNF-o~ is, however, not constitutively present in appreciable amounts (16). Yet, like normal mast cells, they respond to stimulation with a rapid induction of TNF-cx mRNA and the secretion of newly synthesized protein (15, 72, 73). The Fc~RI-stimulated TNF-o~ gene expression in mast cells is tightly regulated and follows the roles of an immediate early gene with a rapid induction independent of protein synthesis (16, 73). The low levels of mRNA detected in non-stimulated cells (16, 18, 74) do not lead to a significant release of protein in short-term cultures (11, 16, 18, 74). The protein can nevertheless be accumulated in the medium of certain mast cells after 20 h (75). Upon stimulation through Fc~RI, TNF-~ mRNA steady-state levels rapidly increase with maxima being achieved at around 1 h and then decline (16, 72-74). This is followed by the secretion of newly synthesized protein starting between 30 and 60 rain after addition of stimulus, whereas secretion of pre-formed TNF-c~ is complete within 10 rain (18). Nuclear run-on experiments in C1.MC/C57.1 mast cells as well as studies using the transcriptional inhibitor actinomycin D in C1.MC/C57.1 and RBL-2H3 cells indicate that the increase in TNF-~ mRNA steady-state levels depends on de novo transcription (73, 76). Induction also requires a continuous aggregation of IgE receptors, steady-state mRNA levels being directly proportional to the time receptors had been aggregated (73). This demonstrates a tight and rapid coupling of receptor activation with the transcriptional machinery and was different from the regulation of the immediate
156
ULRICH BLANK AND NADINE VARIN-BLANK
early gene c-fos (77). Several transcription factors implicated in the expression of immediate early genes such as NFAT, Oct/OAE NF-r,B or an NF-rA3-1ike factor also required continuous stimulation for their presence in the nucleus and/or their capacity to maintain gene transcription (73, 78, 79). These activities were highly dependent on the induced intracellular calcium levels as well as on the frequency of Ca 2+oscillations (79, 80). In contrast, the presence of AP-1 in the nucleus was not reversed after stimulus termination consistent with the data on c-fos mRNA (73, 77).
Fc~RI-mediated Signalling Mechanisms Involved in Gene Expression Although much progress has been made in the last decade in the understanding of how the aggregation of Fc~RI is turned into a meaningful response (81), our picture regarding the Fc~RI-mediated induction of TNF-~ gene expression is still far from complete due to the multiple levels and factors involved. Furthermore, growth factors present in the medium or natural environment can significantly affect Fc~RI-mediated responses. For example, while degranulation experiments in RBL-2H3 mast cells can be performed in Tyrode buffer, TNF-a production requires the presence of serum-containing medium (C. Pelletier and U. Blank, unpublished). Signalling initiated by the binding of a multivalent antigen and the consequent clustering of receptor-bound IgE launches within seconds the phosphorylation of specific tyrosine residues in the ITAM motifs of receptor [3 and y subunits (81). This implicates a transphosphorylation mechanism by the Src-related kinase lyn already associated with a fraction of [3 chains in unstimulated receptors (82). Phosphorylated y-ITAMs recruit the tandem SH2-containing protein tyrosine kinase syk, which is at the basis of a large number of functionally important signalling pathways implicated in gene expression (81). Activation of PLCq, by syk leads to the generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), responsible for the increase in intracellular Ca 2+ levels and activation of PKC. Intracellular Ca 2+ levels are also regulated via a phosphoinositide 3-kinase (PI3K) and btk-dependent pathway that leads to the sustained activation of PLC-~/(83). The sustained activation may be particularly important in late-phase anaphylactic responses including TNF-o~ gene expression (84). Syk activation is also necessary for the stimulation of MAPK cascades as it mediates the Shc-dependent activation of ras, an upstream regulator of erkl/erk2 (85) or the vavdependent activation of rac- 1, an upstream regulator of JNK (86). All of these events may then further lead to the activation of transcription factors regulating gene expression; however, precise mechanisms in this complex process remain to be defined.
Signalling Pathways Involved in FcERI-induced TNF-o~ Production Information on functional pathways relevant to TNF-c~ gene expression have been obtained through studies with pharmacological agents. Both the use of ionomycin and on reverse the Ca 2+ chelating agent EGTA have revealed the importance of Ca 2+ as a second messenger in TNF-~ mRNA induction (72, 73). The Ca2+-dependent induction of gene expression was shown to require activation of the phosphatase calcineurin. Incubation with a specific inhibitor cyclosporin A (CsA) resulted in a strong inhibition of TNF-~ production, even though 50% inhibitory doses differed between various cytokines tested (4 nM, 65 nM and 130 nM for IL-1, TNF-~ and IL-6, respectively) (87-90). This may reflect the complexity of the mechanisms involved as well as the data
10.
FceRI-MEDIATED INDUCTION OF TNF-~ GENE EXPRESSION
157
showing that calcineurin can target multiple pathways involved in cytokine gene expression including the cytoplasmic component of NFAT, IkB~ and JNK family kinases (48). When mast cells were activated with bacteria expressing the fimbrial protein FimH, TNF-~ production was less susceptible to blockade of calcineurin, suggesting the existence of additional albeit less potent pathways leading to TNF-c~ expression in mast cells (71). Secretion of bioactive TNF-~ strongly depends on the activation of PKC (see below). In contrast, transcription and intracellular accumulation of TNF-~ were largely independent of classical PKC isoforms (70, 89, 91). Two specific inhibitors of classical PKC isoforms as well as their depletion through long-term incubation with phorbol esters were relatively ineffective in inhibiting TNF-~ production. PKC activation could nevertheless have a modulatory role as pre-incubation with PKC-activating phorbol esters further increased Fc~RI-mediated TNF-~ production (89). In the CPII mast cell line evidence for a role of the atypical PKC member ~t (PKC~t) in the antigen-stimulated induction of a TNF-~ reporter construct has been reported (91). While the response was insensible to the depletion of classical PKC isoforms with phorbol myristate acetate (PMA) it was still susceptible to treatment with the pharmacological agent G6 6976, which inhibits classical PKC isoforms and the atypical form PKC-~t. Regarding PI3K activation, the results were contradictory depending on the mast cell line examined. Wortmannin, a specific inhibitor of PI3K, reduced Fc~RIdependent TNF-~ secretion in MC/9 and RBL-2H3 cell lines as well as in bone marrowderived mast cells (BMMC). The inhibitory action on TNF-~ mRNA accumulation or reporter-dependent gene expression was less pronounced, suggesting additional effects on protein secretion (89, 90, 92, 93). No inhibitory action of PI3K inhibitors on the antigen-induced TNF-~ reporter or on protein expression was found in the CPII mast cell line (94). Pathways of PI3K implicate the tyrosine kinase btk acting o n C a 2+ signalling, activation of p38 MAPK and JNK (83, 90, 93, 95, 96). The latter plays a role in TNF-c~ gene expression in mast cells, as overexpression of an inhibitory JNK2 mutant form suppressed the IgE-dependent expression of a TNF-~ promoter-dependent reporter construct in MC/9 mast cells (92), but alternatively several growth factor receptors present on mast cells could mediate Fc~RI- and PI3K-independent signalling (93). The resistance of the CPII cell line may be explained by such a growth factor-mediated signal. The situation is equally complex regarding the role of erkl/2. Specific inhibition of MEK1 the upstream activator of erkl/2 with PD 098059 did not affect TNF-~x production in MC/9 mast cells or BMMC (90, 92). However, it dose-dependently inhibited TNF-~ production in the RBL-2H3 and CPII mast cells (91, 97). In the latter an even more potent effect (ICs0 = 3 ~tM versus 30 ~tM) was noticed on TNF-~ promoterdependent reporter gene induction (91). As erkl/2 are involved in the induction of elk-1 transcription factor and c-fos which is part of the AP-1 complex the differences between cell lines remain unexplained (98). The use of selective inhibitors of p38 has revealed that this kinase, although clearly implicated in TNF-~ production in T cells and macrophages (Fig. 4), is not essential in mast cells (92, 97). However, in RBL-2H3 cells inhibition of p38 and subsequent erkl/2 activity rise led to an increased TNF-~ production (97). Several studies reported also inhibition of TNF-~ mRNA levels and secretion by glucocorticoids, although the level of inhibition achieved differed between the various mast cells (76, 88, 99, 100). As dexamethasone inhibits the erkl/2-dependent pathway at low nanomolar concentrations (101), this may at least partly explain the inhibitory action on TNF-~ production, although other mechanisms, notably on the JNK-mediated regulation of translational derepression, cannot be excluded (1). RBL-
1 58
ULRICH BLANK AND NADINE VARIN-BLANK
2H3 cells became less sensitive to the dexamethasone-induced blockade of TNF-~ production when a G protein, G~z, of yet unknown function was overexpressed (99).
Transcriptional Regulation
Several authors have studied the functional capacity of TNF-cz promoter sequences to induce reporter gene expression (Table I). In RBL-2H3 and MC/9 mast cells the Fc~RImediated induction with full-length promoter constructs was relatively modest, in the range of 4-6-fold (73, 92). In CPII mast cells a 796-bp promoter construct containing 3" UTR sequences was much more effective (30-fold) in inducing reporter gene expression and in these cells the minimal promoter could be resumed to the first 200 bp of the huTNF-c~ promoter (91,102). A similar construct in BMMC also induced an about 5-fold activation (84). Deletions mutants at n t - 1 2 8 in RBL-2H3 cells and at n t - 1 0 5 and n t - 8 6 in CPII cells abolished all inducibility (73, 91). This is in contrast to T cells, in which a deletion at n t - 9 8 conserving the kappa3 site still retains significant inducibility, albeit reduced as compared to a longer construct (nt-142) containing the adjacent CRE binding site (43). Since in CPII mast cells addition of the missing nucleotide T at position -106 restores binding of an NFATp transcription factor, the so-called extented kappa3 site could be critical for retention of functionality (91). However, this was not verified in reporter assays. This point also needs clarification since human, mouse or rat promoters are not identical at these sites (see Fig. 3). Characterization of key regulators in TNF-~ gene expression include the NFAT transcription factors first identified in RBL-2H3 cells after Fc~RI and ionophore-mediated stimulation (103). Analysis using isoform-specific antibodies or molecular cloning have detected the presence of both NFAT 1 (or NFATp) and NFAT 2 (isoforms NFATc.~ and NFATc.[3) in mast cells (102, 104, 105). Nuclear translocation of NFAT and binding to the extended kappa3 element requires both cytosolic Ca 2§ increase and activation of Rac-1 (103, 106). Possible synergistic and antagonistic interaction with basic leucine zipper proteins (bZip) have been reported (AP-1 proteins c-jun, junD, fosB as well as ATF-2 and Nrfl) (107). Nrfl which requires prior NFAT activation for binding may have an impact on TNF-cz production as overexpression of a transdominant-negative mutant form of Nrfl results in the inhibition TABLE I Induction Levels of TNF-o~ Reporter Gene Constructs in Mast Cells ,
,
,,
Mast cell line and stimulus
TNF-o~promoterconstruct
Induction levels*
Reference
CPII (F%RI)
huTNF-o~(-796)Luc;3"UTR(TNF) huTNF-cz(-200)Luc; 3"UTR(TNF) huTNF-~(-105)Luc; 3"UTR(TNF) huTNF-c~(-86)Luc; 3"UTR(TNF) huTNF-~(-796)Luc; 3"UTR(TNF) huTNF-ot(-796)Luc; 3"UTR(SV40) huTNF-o~(-1311)Luc moTNF-~(- 1229)CAT moTNF-~(- 128)CAT huTNF-~(-200)Luc
27-fold ll-fold No induction No induction 14-fold 4-fold 5.5-fold 2-fold No induction 4.5-fold
91
CPII (PMA/ionomycin) MC/9 (F%RI) RBL-2H3 (F%RI) BMMC (F%RI)
* Values are taken or estimatedfrom cited references.
102 92 73 84
10. FceRI-MEDIATED INDUCTION OF TNF-cz GENE EXPRESSION
159
of TNF-cz reporter gene expression in CPII mast cells (107). In RBL-2H3 cells evidence for the implication for another inducible factor binding to NF-rd3 sequences has been reported (73). Following stimulation with Fc~RI, the NF-~cB-like transcription factor appeared as an upper and a lower complex in bandshift assays. Although AP- 1 complexes were also induced in RBL-2H3 cells, the binding of the NF-~:B-like factor was independent ofAP- 1 and correlated with the induction of TNF-cz mRNA levels. Induction also required C a 2+ and activation of calcineurin, but did not depend on PKC activity (73; C. Pelletier and U. Blank, unpublished data). Pharmacological agents (PDTC and TPCK (N%tosyl-Phe-chloromethyl ketone)) inhibiting the nuclear activation of the NF-r,B-like factor concomitantly inhibited TNF-cz mRNA accumulation. Although this was reminiscent of NF-r,B or NFAT, none of the specific antibodies raised against the various isoforms of these transcription factors was able to recognize the factor in supershift assays. Analysis of the molecular mass upon UV cross-linking revealed three bands (90, 100 and 110 kDa) that were different from NF-~:B and NFAT proteins (73, 104). Interestingly, tissue-specific expression of NF-~cB-like complexes of similar size have also been described in brain during development (108). However, none of these factors has yet been characterized in terms of amino acid sequence. Examination of the various ~B and rd3-related sequences in the rat gene showed that this factor bound with a certain variability between upper and lower complexes to all r,B sites tested except r,B 1. The strongest binding was observed with a probe corresponding to a r,B site found approximately 220 bp downstream of the polyadenylation site and already shown to play a role in the inducible TNF-~ gene expression in other cells (see above). Although not yet verified, this may suggest that regions outside the promoter may also contribute to TNF
Post-transcriptional Regulatory Mechanisms Fc~RI stimulation leads to transient TNF-~z mRNA induction that cumulates at about 1 h and then declines rapidly. Incubation with cycloheximide significantly enhances TNF
Regulation of Secretion The IgE-dependent activation induces the release of TNF-tx from pre-formed stores and also stimulates the release of newly synthesized proteins. It became clear that secretion of
160
ULRICH BLANK AND NADINE VARIN-BLANK
de novo synthesized TNF-~ does not depend on the incorporation into secretory granules but requires a process analogous to the constitutive secretory pathway. Experiments conducted in the RBL-2H3 cell line which only secretes de novo synthesized TNF-~ showed that the release required Golgi processing. Secretion could be totally blocked with the Golgi-disrupting agent brefeldin A :in the absence of any effect on the release of inflammatory mediators stored in secretory granules (70). In contrast to the constitutively secreted cytokine transforming growth factor-~ (TGF-~), the release of TNF-o~ was regulated by Fc~RI and required both the activation of PKC and Ca 2§ influx (70, 110). Dexamethasone also suppressed the release of TNF-cz but had no effect on TGF-[3 release. An inducible component of TGF-~ release was, however, suppressed to the same extent as TNF-~ by dexamethasone and a PKC inhibitor, suggesting the existence of both constitutive and inducible mechanisms within the secretory pathway. Both mechanisms proceed through a Golgi compartment as they were both inhibited with brefeldin A (110). Mast cell-derived TNF-~ is synthesized as a 26-kDa membrane precursor. In BMMC, pro-TNF-c~ can be detected following Fc~RI stimulation and reaches plateau levels by 2-3 h (84). Preliminary experiments in RBL-2H3 cells using a highly specific inhibitor of the TNF-~-converting protease TACE have indicated that mast cells may use the same or a similar protease to release the secreted form (72). The mechanisms regulating the accumulation of TNF-~ protein in secretory granules are less well understood but seem to depend on the differentiation status of the cell, as rapidly dividing tumour cell lines do not contain significant amounts of pre-stored TNF-~ (16, 73). As mast cells do not seem to have a complete translational block observed in other cell types (60), it may be that the low levels of production of TNF-~z mRNA detectable in unstimulated cells may ultimately lead to the accumulation of protein in secretory granules. The absence of activation may be the signal for sorting TNF-cz into these cellular compartments. The granular storage has been confirmed by immunogold labelling using electron microscopy (19). These studies also confirm a significant reduction in TNF-~ density following stimulation (111). Some release from these compartments may also occur spontaneously as long-term incubation allows the detection of significant amounts of proteins in some types of mast cells (75).
CONCLUDING REMARKS
Since the discovery of TNF-~ as a mast cell-derived mediator, progress has been made in understanding the mechanisms responsible for its expression. Most of this knowledge has been brought about by studying various aspects of the Fc~RI-mediated TNF-~ production in a variety of mast cell lines. Figure 5 shows a summary of these data. Although they have allowed certain questions to be addressed and answered, they have also revealed important differences. Strong tissue-dependent regulatory mechanisms have been shown to be operative in TNF-~ gene expression. These may also apply to the different mast cell populations known to exhibit substantial structural and functional heterogeneity (112). Indeed, the heterogeneity of mast cells has recently been extended to their content in cytokines (113). Within the same biopsy, mast cells can express a heterogeneous array of cytokines (24). Thus besides Fc~RI, environmental factors may importantly contribute to TNF-~ gene expression. A modulatory role on TNF-~ expression in mast cells by several molecules involved in cell contact, cytokines or neuropeptides has been described (75, 114-116). Extensive analysis of TNF-~ gene expression in numerous cells indicates a complex regulatory relationship comprising several levels. Depending on the tissue and the
10.
FceRI-MEDIATED INDUCTION OF TNF-~ GENE EXPRESSION
161
Fig. 5 Summary representation of the different mechanisms implicated in FceRI-dependent regulation of TNF-~ biosynthesis in mast cells as presented in the text.
stimulus different transcription factors can be expressed and become activated. This is exemplified by a primary activatory mode involving NF-vd3 in stimulated macrophages, whereas T cells and potentially mast cells have been described to function primarily through NFAT-mediated mechanisms. The latter needs clarification, however, as studies in NFAT1and NFAT2-deficient mice have not revealed any significant effect on TNF-~ production (117-119). In mast cells, a recently described NF-rd3-1ike nuclear factor could play an important role in the tissue-specific TNF-~ gene expression in mast cells (73). Differences also became apparent at the post-transcriptional level as macrophages and T cells require the activation of p38 for translational control whereas mast cells seem to be independent of p38. Mast cells, at least when fully differentiated, can accumulate substantial amounts of TNF-~ in their cytoplasmic granules. Thus, the strict translational repression as observed in macrophages may not exist (60). Mast cells may express transdominant factors which can overcome translational silencing as already described for other cells (52). Much work still has to be accomplished to fully elucidate the different mechanisms that control TNF-~ gene expression in mast cells. These studies may be helped by the recent generation of mice deficient in particular transcription factors as well as mice in which the 3" UTR important for post-transcriptional mechanisms has been deleted.
162
U L R I C H B L A N K AND N A D I N E V A R I N - B L A N K
REFERENCES 1. Beutler, B. Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. Raven Press, New York, 1992. 2. Pennica, D., Nedwin, G. E., Hayflick, J. S., et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312:724-729, 1984. 3. Beutler, B., Greenwald, D., Hulmes, J. D., et al. Identity of tumour necrosis factor and the macrophagesecreted factor cachectin. Nature 316:552-554, 1985. 4. Gray, E W., Aggarwal, B. B., Benton, C. V., et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 312:721-724, 1984. 5. Browning, J. L., Ngam, A., Lawton, E, et al. Lymphotoxin-[~, a novel member of the TNF family that forms a heterodimeric complex with lymphotoxin on the cell surface. Cell 72:846-847, 1993. 6. Black, R. A., Rauch, C. T., Kozlosky, C. J., et al. A metalloproteinase disintegrin that releases tumor necrosis factor-~ from cells. Nature 385: 729-733, 1997. 7. Jones, E. Y., Stuart, D. I. and Walker, N. E Structure of tumour necrosis factor. Nature 338:225-228, 1989. 8. Farram, E. and Nelson, D. S. Mouse mast cells as anti-tumor effector cells. Cell. Immunol. 55:294-301, 1980. 9. Ghiara, E, Boraschi, D., Villa, L., Scapigliati, G., Taddei, C. and Tagliabue, A. In vitro generated mast cells express natural cytotoxicity against tumour cells. Immunology 55:317-324, 1985. 10. Okuno, T., Takagaki, D., Pluznik, D. and Djeu, J. Y. Natural cytotoxic (NC) cell activity in basophilic cells: release of NC-specific cytotoxic factor by IgE receptor triggering. J. Immunol. 136:4652-4658, 1986. 11. Young, J. D., Liu, C. C., Butler, G., Cohn, Z. A. and Galli, S. J. Identification, purification, and characterization of a mast cell-associated cytolytic factor related to tumor necrosis factor. Proc. Natl. Acad. Sci. USA 84:9175-9179, 1987. 12. Richards, A. L., Okuno, T., Takagaki, Y. and Djieu, J. Y. Natural cytotoxic cell-specific cytotoxic factor produced by IL-3-dependent basophilic/mast cells. Relationship to TNF. J. Immunol. 141:3061-3066, 1988. 13. Steffen, M., Abboud, M., Potter, G. K., Yung, Y. E and Moore, M. A. S. Presence of tumor necrosis factor or a related factor in human basophils/mast cells. Immunology 66:445-450, 1989. 14. Plaut, M., Pierce, J. H., Watson, C. J., Nordan, R. E and Paul, W. E. Mast cells produce lymphokines in response to cross-linkage of Fc~RI or to calcium ionophores. Nature 339:64-67, 1989. 15. Ohno, I., Tanno, Y., Yamauchi, K. and Takishima, T. Gene expression and production of tumour necrosis factor by a rat basophilic leukaemia cell line (RBL-2H3) with IgE receptor triggering. Immunology 70:88-93, 1990. 16. Gordon, J. R. and Galli, S. J. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin. Nature 346:274-276, 1990. 17. Walsh, L. J., Trinchieri, G., Waldorf, H. A., Whitaker, D. and Murphy, G. E Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc. Natl. Acad. Sci. USA 88:4220-4224, 1991. 18. Gordon, J. R. and Galli, S. J. Release of both preformed and newly synthesized TNF-~cachectin by mouse mast cells stimulated via the Fc~RI. A mechanism for the sustained action of mast cell-derived TNF-~ during IgE-dependent biological responses. J. Exp. Med. 174:103-107, 1991. 19. Beil, W. J., Login, G. R., Galli, S. J. and Dvorak, A. M. Ultrastructural immunogold localization of TNF-~ to the cytoplasmic granules of rat peritoneal mast cells with rapid microwave fixation. J. Allergy Clin. Immunol. 94:531-536, 1994. 20. Echtenacher, B., Mannel, D. N. and Htfltner, L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381:75-77, 1996. 21. Malaviya, R., Ikeda ,T., Ross, E. and Abraham, S. N. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-~. Nature 381:77-80, 1996. 22. Wershil, B. K., Wang, Z. S., Gordon, J. R. and Galli, S. J. Recruitment of neutrophils during IgEdependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against TNF-~. J. Clin. Invest. 87:446-453, 1991. 23. Broide, D. H., Lotz, M., Cuomo, A. J., Coburn, D. A., Federman, E. C. and Wasserman, S. I. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 89:958-967, 1992.
10. 24.
25. 26.
27. 28. 29. 30.
31.
32. 33.
34.
35. 36.
37.
38.
39. 40. 41.
42. 43. 44. 45. 46.
47.
F c ~ R I - M E D I A T E D I N D U C T I O N OF TNF-o~ G E N E E X P R E S S I O N
163
Bradding, R, Roberts, J. A., Britten, K. M., et al. Interleukin-4, -5, and -6 and tumor necrosis factoralpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 10:471-480, 1994. Bradding, E, Mediwake, R., Feather, I. H., et al. TNF-ot is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. Clin. Exp. Allergy 25:406--415, 1995. Spriggs, D. R., Deutsch, S. and Kufe, D. W. Genomic structure, induction and production of TNFo~. In: Tumor Necrosis Factors. Structure, Function and Mechanism of Action (Aggarwal, B. B. and Vilcek, J., eds), pp. 3-34. Marcel Decker, New York, 1994. Lawton, E, Nelson, J., Tizard, R. and Browning, J. L. Characterisation of the mouse lymphotoxin-beta gene. J. Immunol. 154:239-246, 1995. Kwon, J., Chung, I. Y. and Benveniste, E. N. Cloning and sequence analysis of the rat tumor necrosis factor-encoding genes. Gene 132:227-236, 1993. Chen, C. Y. and Shyu, A. B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20:465-470, 1995. Kuprash, D. V., Udalova, I. A., Turetskaya, R. L., Kwiatkowski, D., Rice, N. A. and Nedospasov, S. A. Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J. Immunol. 162:4045-4052, 1999. Shannon, M. E, Pell, L. M., Lenardo, M. J., et al. A novel tumor necrosis factor-responsive transcription factor which recognizes a regulatory element in hematopoietic growth factor genes. Mol. Cell. Biol. 10:2950-2959, 1990. Sariban, E., Imamura, K., Luebbers, R. and Kufe, D. Transcriptional and post-transcriptional regulation of tumor necrosis factor gene expression in human monocytes. J. Clin. Invest. 81:1506-1510, 1988. Collart, M. A., Baeuerle, E and Vassalli, E Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappa B-like motifs and of constitutive and inducible forms of NFkappa B. Mol. Cell. Biol. 10:1498-1506, 1990. Biragyn, A. and Nedospasov, S. A. Lipopolysaccharide-induced expression of TNF-a gene in the macrophage cell line ANA-1 is regulated at the level of transcription processivity. J. Immunol. 155:674-683, 1995. Goldfeld, A. E., Doyle, C. and Maniatis, T. Human tumor necrosis factor alpha gene regulation by virus and lipopolysaccharide. Proc. Natl. Acad. Sci. USA 87:9769-9773, 1990. Shakhov, A. N., Collart, M. A., Vassalli, P., Nedospasov, S. A. and Jongeneel, C. V. Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J. Exp. Med. 171:35-47, 1990. Kuprash, D.V., Udalova, I. A., Turetskaya, R. L., Rice, N. R. and Nedospasov, S. A. Conserved ~r element located downstream of the tumor necrosis factor-(x gene: distinct NF-rA3 binding pattern and enhancer activity in LPS activated murine macrophages. Oncogene 11:97-106, 1995. Udalova, I. A., Knight, J. C., Vidal, V., Nedospasov, S. A. and Kwiatkowski, D. Complex NF-rd3 interactions at the distal tumor necrosis factor promoter region in human monocytes. J. Biol. Chem. 273:21178-21186, 1998. L6ms Ziegler-Heitbrock, H. W., Sternsdorf, T., Liese, J., et al. Pyrrolidine dithiocarbamate inhibits NFkappa B mobilization and TNF production in human monocytes. J. Immunol. 151:6986-6993, 1993. Kwon, J., Lee, S. J. and Benveniste, E. N. A 3' cis-acting element is involved in tumor necrosis factor-c~ gene expression in astrocytes. J. Biol. Chem. 271:22383-22390, 1996. Goldfeld, A. E., McCaffrey, P. G., Strominger, J. L. and Rao, A. Identification of a novel cyclosporinsensitive element in the human tumor necrosis factor alpha gene promoter. J. Exp. Med. 178:1365-1379, 1993. McCaffrey, P. G., Goldfeld, A. E. and Rao, A. The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J. Biol. Chem. 269:30445-30450, 1994. Tsai, E. Y., Jain, J., Pesavento, P. A., Rao, A. and Goldfeld, A. E. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell. Biol. 16:459-467, 1996. Zagariya, A., Mungre, S., Lovis, R., et al. Tumor necrosis factor alpha gene regulation: enhancement of C/EBPl3-induced activation by c-Jun. Mol. Cell. Biol. 18:2815-2824, 1998. Kramer, B., Wiegmann, K. and Kronke, M. Regulation of the human TNF promoter by the transcription factor Ets. J. Biol. Chem. 270:6577-6583, 1995. Kramer, B., Meichle, A., Hensel, G., Charnay, P. and Kr6nke, M. Characterization of an Krox-24/Egr1-responsive element in the human tumor necrosis factor promoter. Biochim. Biophys. Acta 1219:413-421, 1994. Leitman, D. C., Mackow, E. R., Williams, T., Baxter, J. D. and West, B. L. The core promoter region of
164
48. 49. 50. 51. 52.
53. 54.
55. 56.
57.
58. 59. 60. 61. 62. 63.
64.
65. 66.
67.
68. 69. 70.
U L R I C H B L A N K AND N A D I N E V A R I N - B L A N K the tumor necrosis factor alpha gene confers phorbol ester responsiveness to upstream transcriptional activators. Mol. Cell. Biol. 12:1352-1356, 1992. Jain, J., Loh, C. and Rao, A. Transcriptional regulation of the 11-2 gene. Curr. Opin. Immunol. 7:333-342, 1995. Rhoades, K. L., Golub, S. H. and Economou, J. S. The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. J. Biol. Chem. 267:22102-22107, 1992. Wickens, M., Anderson, P. and Jackson, R. J. Life and death in the cytoplasm: messages from the 3' end. Curr. Opin. Genet. Dev. 7:220-232, 1997. Kruys, V., Marinx, O., Shaw, G., Deschamps, J. and Huez, G. Translational blockade imposed by cytokine-derived UA-rich sequences. Science 245:852-855, 1989. Kruys, V., Kemmer, K., Shakhov, A., Jongeneel, V. and Beutler, B. Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a transdominant factor overcomes this suppressive effect. Proc. Natl. Acad. Sci. USA 89:673-677, 1992. Beutler, B., Krochin, N., Milsark, I. W., Luedke, C. and Cerami, A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232:977-980, 1986. Beutler, B., Han, J., Kruys, V. and Giroir, B. P. Coordinated regulation of TNF biosynthesis at the levels of transcription and translation. Patterns of TNF expression in vivo. In: Tumor Necrosis Factors: the Molecules and their Emerging Role in Medicine (Beutler, I. B., ed.). Raven Press, New York, 1992. Han, J. H., Beutler, B. and Huez, G. Complex regulation of tumor necrosis factor mRNA turnover in lipopolysaccharide-activated macrophages. Biochim. Biophys. Acta 1090:22-28, 1991. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, E and Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gutassociated immunopathologies. Immunity 10:387-398, 1999. Yang, Y., Chang, J. E, Parnes, J. R. and Fathman, C. G. T cell receptor (TCR) engagement leads to activation-induced splicing of tumor-necrosis factor (TNF) nuclear pre-mRNA. J. Exp. Med. 188:247-254, 1998. Carballo, E., Lai, W. S. and Blackshear, P. J. Feedback inhibition of macrophage tumor necrosis factoro~production by tristetraprolin. Science 281:1001-1005, 1998. Peng, S. S., Chen, C. Y., Xu, N. and Shyu, A. B. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J. 17:3461-3470, 1998. Han, J., Brown, T. and Beutler, B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J. Exp. Med. 171:465-475, 1990. Lee, J. C., Laydon, J. T., McDonnell, P. C., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739-746, 1994. Kotlyarov, A., Neininger, A., Schubert, C., et al. MAPKAP kinase 2 is essential for LPS-induced TNFo~biosynthesis. Nat. Cell Biol. 1:94-97, 1999. Swantek, J. L., Cobb, M. H. and Geppert, T. D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of TNF-o~ translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol. Cell. Biol. 17:6274-6282, 1997. Prichett, W., Hand, A., Shields, J. and Dunnington, D. Mechanism of action of bicyclic imidazoles defines a translational regulatory pathway for tumor necrosis factor alpha. J. Inflamm. 45:97-105, 1995. Gueydan, C., Houzet, L., Marchant, A., Sels, A., Huez, G. and Kruys, V. Engagement of tumor necrosis factor mRNA by an endotoxin-inducible cytoplasmic protein. Mol. Med. 2:479-488, 1996. Hoffmeyer, A., Grosse-Wilde, A., Flory, E., et al. Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor o~ gene expression in T lymphocytes. J. Biol. Chem. 274:4319-4327, 1999. Pradines-Figueres, A. and Raetz, C. R. H. Processing and secretion of tumor necrosis factor ~ in endotoxin-treated Mono Mac 6 cells are dependent on phorbol myristate. J. Biol. Chem. 267:23261-23268, 1992. McGeehan, G. M., Becherer, J. D., Bast, R. C. Jr, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 370:558-561, 1994. Imamura, K., Spriggs, D., Ohno, D. and Kufe, D. Effect of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes. Mol. Cell. Biol. 9:2239-2243, 1989. Baumgartner, R. A., Yamada, K., Deramo, V. A. and Beaven, M. A. Secretion of TNF from a rat mast cell line is a brefeldin A-sensitive and a calcium/protein kinase C-regulated process. J. Immunol. 153:2609-2617, 1994.
10. 71. 72.
73.
74.
75. 76.
77. 78. 79. 80. 81. 82. 83. 84. 85.
86.
87.
88.
89.
90.
91.
92.
FceRI-MEDIATED I N D U C T I O N OF T N F - ~ GENE E X P R E S S I O N
165
Dreskin, S. and Abraham, S. Production of TNF-~ by murine bone marrow derived mast cells activated by the bacterial fimbrial protein, FimH. Clin. Immunol. 90:420-424, 1999. Hide, I., Toriu, N., Nuibe, T., et al. Suppression of TNF-~ secretion by azelastine in a rat mast (RBL2H3) cell line: evidence for differential regulation of TNF-alpha release, transcription, and degranulation. J. Immunol. 159:2932-2940, 1997. Pelletier, C., Varin-Blank, N., Rivera, J., et al. Fc epsilon RI-mediated induction of TNF-alpha gene expression in the RBL-2H3 mast cell line: regulation by a novel NF-kappa B-like nuclear binding complex. J. Immunol. 161:4768-4776, 1998. Gurish, M. E, Ghildyal, N., Arm, J., et al. Cytokine mRNA are preferentially increased relative to secretory granule protein mRNA in mouse bone marrow-derived mast cells that have undergone IgEmediated activation and degranulation. J. Immunol. 146:1527-1533, 1991. Bissonenette, E. Y., Chini, B. and Befus, A. D. Interferons differentially regulate histamine and TNF-~ in rat intestinal mucosal mast cells. Immunology 86:12-17, 1995. Schmidt-Choudhury, A., Furuta, G. T., Lavigne, J. A., Galli, S. J. and Wershil, B. K. The regulation of tumor necrosis factor-alpha production in murine mast cells: pentoxifylline or dexamethasone inhibits IgE-dependent production of TNF-~ by distinct mechanisms. Cell. Immunol. 171:140-146, 1996. Dogar, J. H., Nemeth, G. G., Durdik, J. M. and Dreskin, S. C. Fc epsilon RI-mediated expression of mRNA for c-fos in rat. Cell. Signal. 5:605-613, 1993. Dolmetsch, R. E., Lewis, R. S., Goodnow, C. C. and Healy, J. I. Differential activation of transcription factors induced by C a 2+ response amplitude and duration. Nature 386:855-858, 1997. Dolmetsch, R. E., Xu, K. and Lewis, R. S. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 392:933-936, 1998. Li, W., Llopis, J., Whitney, M., Zlokarnik, G. and Tsien, R. Y. Cell-permeant caged InsP3 ester shows that C a 2+ spike frequency can optimize gene expression. Nature 392:936-941, 1998. Kinet, J.-E The high affinity IgE receptor (FceRI): from physiology to pathology. Annu. Rev. Immunol. 17:931-972, 1999. Yamashita, T., Mao, S. Y. and Metzger, H. Aggregation of the high-affinity IgE receptor and enhanced activity of p53/561yn protein-tyrosine kinase. Proc. Natl. Acad. Sci. USA 91:11251-11255, 1994. Scharenberg, A. M. and Kinet, J. E PtdIns-3,4,5-P3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell 94:5-8, 1998. Hata, D., Kawakami, Y., Inagaki, N., et al. Involvement of Bruton's tyrosine kinase in FcepsilonRIdependent mast cell degranulation and cytokine production. J. Exp. Med. 187:1235-1247, 1998. Jabril-Cuenod, B., Zhang, C., Scharenberg, A., et al. Syk-dependent phosphorylation of Shc. A potential link between FceRI and the ras/mitogen-activated protein kinase signaling pathway through SOS and Grb2. J. Biol. Chem. 271:16268-16272, 1996. Teramoto, H., Salem, E, Robbins, K. C., Bustelo, X. R. and Gutkind, J. S. Tyrosine phosphorylation of the vav protooncogene product links FceRI to the rac-l-JNK pathway. J. Biol. Chem. 272:10751-10755, 1997. Kaye, R. E., Fruman, D. A., Bierer, M. W., et al. Effects of cyclosporin A and FK506 on Fc epsilon type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK 506 is associated with a deficiency in FK506-binding protein FKBP12. Proc. Natl. Acad. Sci. USA 89:8542-8546, 1992. Wershil, B. K., Furuta, G. T., Lavigne, J. A., Choudhury, A. R., Wang, Z. S. and Galli, S. J. Dexamethasone or cyclosporin A suppress mast cell-leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE- and mast cell-dependent cutaneous inflammation in the mouse. J. Immunol. 154:1391-1398, 1995. Pelletier, C., Guerin-Marchand, C., Iannascoli, B., et al. Specific signaling pathways in the regulation ofTNF-alpha mRNA synthesis and TNF-alpha secretion in RBL-2H3 mast cells stimulated through the high affinity IgE receptor. Inflamm. Res. 47:493-500, 1998. Ishizuka, T., Chayama, K., Takeda, K., et al. Mitogen-activated protein kinase activation through Fce receptor I and stem cell factor receptor is differentially regulated by phosphatidylinositol 3-kinase and calcineurin in mouse bone marrow-derived mast cells. J. Immunol. 162:2087-2094, 1999. Csonga, R., Prieschl, E. E., Jaschke, D., Novotny, V. and Baumruker, T. Common and distinct signaling pathways mediate the induction of TNF-~ and IL-5 in IgE plus antigen-stimulated mast cells. J. Immunol. 160:273-283, 1998. Ishizuka, T., Terada, N., Gerwins, N., et al. Mast cell tumor necrosis factor ~ production is regulated by MEK kinases. Proc. Natl. Acad. Sci. USA 94:6358-6363, 1997.
166 93.
94.
95. 96.
97.
98. 99. 100.
101.
102.
103. 104.
105. 106.
107.
108. 109.
110. 111.
112. 113. 114.
U L R I C H B L A N K AND N A D I N E V A R I N - B L A N K Ishizuka, T., Kawasome, H., Terada, N., et al. Stem cell factor augments FceRI-mediated TNF-~ production and stimulates MAP kinases via a different pathway in MC/9 mast cells. J. Immunol. 161:3624-3630, 1998. Pendl, G. G., Prieschl, E. E., Thumb, W., Harrer, N. E., Auer, M. and Baumruker, T. Effects of phosphoinositol-3-kinase inhibitors on degranulation and gene induction in allergically triggered mouse mast cells. Int. Arch. Allergy Immunol. 112:392-399, 1996. Kawakami, Y., Miura, T., Bissonnette, R., et al. Bruton's tyrosine kinase regulates apoptosis and JNK/SAPK kinase activity. Proc. Natl. Acad. Sci. USA 94:3983-3992, 1997. Kawakami, Y., Hartman, S. E., Holland, P. M., Cooper, J. A. and Kawakami, T. Multiple signaling pathways for the activation of JNK in mast cells: involvement of bruton's tyrosine kinase, protein kinase C, and JNK kinases, SEK1 and MKK7. J. Immunol. 161:1795-1802, 1998. Zhang, C., Baumgartner, R. A., Yamada, K. and Beaven, M. A. Mitogen-activated protein (MAP) kinase regulates production of tumor necrosis factor-alpha and release of arachidonic acid in mast cells. Indications of communication between p38 and p42 MAP kinases. J. Biol. Chem. 272:13397-13402, 1997. Turner, H. and Cantrell, D. A. Distinct Ras effector pathways are involved in Fc epsilon R1 regulation of the transcriptional activity of Elk-1 and NFAT in mast cells. J. Exp. Med. 185:43-53, 1997. Baumgartner, R. A., Hirasawa, N., Ozawa, K., Gusovsky, E and Beaven, M. A. Enhancement of TNFc~ synthesis by overexpression of G~z in a mast cell line. J. Immunol. 157:1625-1629, 1996. Eklund, K. K., Humphries, D. E., Xia, Z., et al. Glucocorticoids inhibit the cytokine-induced proliferation of mast cells, the high affinity IgE receptor-mediated expression of TNF-c~, and the IL-10induced expression of chymases. J. Immunol. 158:4373-4380, 1997. Rider, L. G., Hirasawa, N., Santini, E and Beaven, M. A. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J. Immunol. 157:2374-2380, 1996. Prieschl, E. E., Pendl, G. G., Elbe, A., et al. Induction of the TNF-~ promoter in the murine dendritic cell line 18 and the murine mast cell line CPII is differently regulated. J. Immunol. 157:2645-2653, 1996. Hutchinson, L. E., McCloskey, M. A. Fc epsilon RI-mediated induction of nuclear factor of activated Tcells. J. Biol. Chem. 270:16333-16338, 1995. Weiss, D. L., Hural, J., Tara, D., Timmermann, L. A., Henkel, G. and Brown, M. A. Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex. Mol. Cell. Biol. 16:228-235, 1996. Shermann, M. A., Powell, D. R., Weiss, D. L. and Brown, M. A. NFATc isoforms differentially expressed and regulated in murine T and mast cells. J. Immunol. 162:2820-2828, 1999. Turner, H., Gomez, M., McKenzie, E., Kirchem, A., Lennard, A. and Cantrell, D. A. Rac-1 regulates nuclear factor of activated T cells (NFAT) C 1 nuclear translocation in response to FcERI stimulation of mast cells. J. Exp. Med. 188:527-537, 1998. Novotny, V., Prieschl, E. E., Csonga, R., Fabjani, G. and Baumruker, T. Nrfl in a complex with fosB, cjun, junD and ATF2 forms the AP 1 component at the TNF~ promoter in stimulated mast cells. Nucleic Acids Res. 26:5480-5485, 1999. Cauley, K. and Verma, I. M. Kappa B enhancer-binding complexes that do not contain NF-kappa B are developmentally regulated in mammalian brain. Proc. Natl. Acad. Sci. USA 91:390-394, 1994. Nair, A. P. K., Hirsch, H. H., Colombi, M. and Moroni, C. Cyclosporin A promotes translational silencing of autocrine interleukin-3 via a ribosome-associated deadenylation. Mol. Cell. Biol. 19:889-898, 1999. Baumgartner, R. A., Deramo, V. A. and Beaven, M. A. Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. J. Immunol. 157:4087-4093, 1996. Beil, W. J., Login, G. R., Aoki, M., et al. TNF-~ immunoreactivity of rat peritoneal mast cell granules decreases during early secretion induced by compound 48/80: an ultrastructural immunogold morphometric analysis. Int. Arch. Allergy Immunol. 109:383-389, 1996. Galli, S. J. Biology of disease. New insights into the 'riddle of mast cells': microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab. Invest. 1:5-33, 1990. Bradding, P., Okayama, Y., Howarth, P. H., Church, M. K. and Holgate, S. T. Heterogeneity of human mast cells on cytokine content. J. lmmunol. 155:297-307, 1995. Ansel, J. C., Brown, J. R., Payan, D. G. and Brown, M. A. Substance P selectively activates TNF-alpha gene expression in mast cells. J. Immunol. 150:4478-4485, 1993.
10.
FceRI-MEDIATED INDUCTION OF TNF-~ GENE EXPRESSION
167
115. Arrock, M., Zuany-Amorim, C., Singer, M., Benhamou, M. and Pretolani, M. Interleukin-10 inhibits cytokine generation from mast cells. Eur. J. lmmunol. 26:166-170, 1996. 116. Tashiro, M., Kawakami, Y., Abe, R., et al. Increased secretion of TNF-c~ by costimulation of mast cells via CD28 and FceRI. J. Immunol. 158:2382-2389, 1997. 117. Xanthoudakis, S., Viola, J. P. B., Shaw, K. T. Y., et al. An enhanced response in mice lacking the transcription factor NFAT1. Science 272:892-895, 1996. 118. Yoshida, H., Nishina, H., Takimoto, H., et al. The transcription factor NF-ATc 1 regulates lymphocyte proliferation and TH2 cytokine production. Immunity 8:115-124, 1998. 119. Ranger, A. M., Hodge, M. R., Gravallese, E. M. et al. Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. Immunity 8:125-134, 1998.
This Page Intentionally Left Blank
CHAPTER
11
Regulation of Mast Cell Degranulation by SHIP MICHAEL HUBER, JACQUELINE E. DAMEN, MARK WARE, MICHAEL HUGHES, CHERYL D. HELGASON, R. KEITH HUMPHRIES and GERALD KRYSTAL* Terry Fox Laboratory, BC Cancer Agency, Vancouver, Canada
INTRODUCTION
Mast cells are present at all the portals between self and non-self in humans and other mammals and play a critical role in initiating acute inflammatory responses against invading bacteria, helminthic parasites and harmless allergens (1). Upon exposure to multivalent antigens or allergens, these cells rapidly discharge pre-formed inflammatory mediators, such as histamine, proteoglycans and neutral proteases, from their many cytoplasmic granules. These mediators then act on the vasculature, smooth muscles, connective tissue, mucous glands and inflammatory cells to cause immediate-type hypersensitivity reactions (2). Understanding how this degranulation process is regulated is key to our being able to effectively treat allergies, which affect as many as 20% of the Western population, and to modulate other inflammatory responses. For example, it has been shown recently that mast cell degranulation at the site of surgical implants is responsible for the encapsulation and subsequent failure of these non-immunogenic implants via histamine-mediated chemoattraction of neutrophils and macrophages (3). Thus a more thorough understanding of the degranulation process could have substantial clinical benefits. In this review we concentrate primarily on what is currently known about the biological properties of the recently cloned SH2-containing inositol 5'phosphatase (SHIP) and its role in IgE-induced cell signalling and degranulation. For its role in mediating the inhibition conferred by the negative co-receptor, FcvRIIB, we refer readers to recent articles by Scharenberg and Kinet (4), Bolland et al. (5) and Coggeshall
(6).
* Corresponding author. MAST CELLS AND BASOPHILS ISBN 0-12-473335-2
169
Copyright 9 2000 Academic Press All rights of reproduction in any form reserved
170
MICHAEL HUBER et al.
STRUCTURE AND BINDING PARTNERS OF SHIP
SHIP possesses an N-terminal SH2 domain, a central inositol polyphosphate 5'phosphatase (5-ptase) catalytic domain, two NPXY sequences, which, when phosphorylated, can bind phosphotyrosine-binding (PTB) domains, and a proline-rich Cterminus that is theoretically capable of binding to many Src-homology 3 (SH3) domaincontaining proteins (reviewed in ref. 7) (see Fig. 1). Interestingly, unlike most 5-ptases, SHIP selectively hydrolyses the 5'-phosphate from phosphatidylinositol 3,4,5trisphosphate (PI-3,4,5-P3) and inositol 1,3,4,5-tetrakisphosphate (I-3,4,5-P4) (8), two phosphoinositides that have been shown to play important roles in growth factormediated signalling (9). The human (1188 amino acids) and murine (1190 amino acids) forms of SHIP possess 87.2% identity at the amino acid level, and human SHIP maps to the long arm of chromosome 2 at the border between 2q36 and 2q37 (10). During murine development, SHIP is first detectable in 7.5-day embryos (coincident with and dependent upon the onset of haematopoiesis) and its protein expression pattern appears restricted to haematopoietic cells (11 ). Interestingly, its protein expression varies considerably during haematopoiesis (11, 12), increasing substantially, for example, with T cell maturation (11) and showing a bimodal expression pattern during B cell development (Helgason et al., unpublished). Also of note, SHIP is reduced in primary cells from leukaemic patients and induced expression of BCR-ABL in BA/F3 cells leads to a rapid reduction in the level of SHIP protein (13). It is thus possible that SHIP acts as a
Fig. 1 The structureof SHIRits knownbindingpartners and its putativecleavagesites.
11.
REGULATIONOF MAST CELL DEGRANULATION BY SHIP
1 71
haematopoietic-specific tumour suppressor during myelopoiesis and its downregulation is required for the development of chronic myeloid leukaemia. Since SHIP's 5-ptase activity does not change significantly following cytokine stimulation (8), the general consensus is that it exerts its effects via intracellular translocation to sites of synthesis of PI-3,4,5-P3 and I-1,3,4,5-P4 (although it has not been shown to hydrolyse I-1,3,4,5-P4 in vivo). Since association with other proteins may play a significant role in this process, we and others have attempted to identify SHIP-binding partners. These studies have shown that SHIP associates, following cytokine, B or T cell receptor activation, with the adaptor protein Shc and the tyrosine phosphatase SHP-2 (7) (see Fig. 1). In addition, it binds to Grb2 in certain cell types (e.g. B cells) but not in others (7); this could be due to the activation of different kinases in different cell types which, in turn, lead to the phosphorylation of different residues in SHIP or SHIP's binding partners. Very recently, Harmer and DeFranco (14) have proposed that, in BCRactivated B cells, SHIP exists in a ternary complex with one Shc molecule and two Grb2 molecules. Specifically, they propose that the two Grb2 molecules bind via their SH2 domains to a single Shc, phosphorylated at y239 and y3~3, and the SH3 domains of the Grb2 molecules bind the C-terminal proline-rich regions of SHIR SHIP has also been shown to bind via its SH2 domain, which binds preferentially to the sequence pY(Y/D)X(L/I/V) (15), to certain members of the immunoreceptor tyrosine-based inhibition motif (ITIM)-bearing family of inhibitory co-receptors. Specifically, it has been shown to bind both in vitro (16, 17) and in vivo (18) to the ITIM of FcvRIIB, and in vitro to the second ITIM of gp49B 1 (19). Recently, Tridandapani et al. (20) have proposed, based in part on kinetic studies, that, during co-ligation of the FcvRIIB to the activated BCR, SHIP first transiently associates with the FcvRIIB to promote its tyrosine phosphorylation and then it attracts Shc and dissociates with this new binding partner from the FcvRIIB. As well, SHIP's SH2 domain has been demonstrated to bind in vitro to the tyrosine-phosphorylated immunoreceptor tyrosinebased activation motif (ITAM) within the [3 (21) and y (15) subunits of the Fc~RI as well as the ~ chain of the T cell receptor (15). Complicating matters, SHIP can exist in at least four different molecular mass forms, depending on the cell type. The lower 135-, 125- and ll0-kDa forms appear to be generated from the 145-kDa full-length protein in vivo by cleavage of its proline-rich Cterminus (22). Although all forms become tyrosine-phosphorylated in response to cytokines, at one or both of the NPXY motifs, only the 145- and, to a lesser extent, the 135-kDa species bind Shc and only the 110-kDa form is associated with the cytoskeleton (22). These findings suggest that the different SHIP forms may actually be carrying out different functions. Interestingly, the relative proportion of the different forms has been reported to change with haematopoietic differentiation (12) and with leukaemogenesis (13, 23). Adding further complexity, Lucas and Rohrschneider (24) have recently demonstrated the presence of alternatively spliced forms of SHIP as well, consistent with earlier reports showing that, in addition to the predominant 5-kb mRNA, there are minor 6-kb, 4.5-kb and smaller SHIP mRNA species expressed in some cell types (8, 10, 12).
BIOLOGICAL PROPERTIES OF SHIP
SHIP recruitment via its SH2 domain to the tyrosine-phosphorylated ITIM of the inhibitory co-receptor FcvRIIB has been shown to inhibit Fc~RI- and BCR-induced
1 72
MICHAEL HUB ER et al.
degranulation and proliferation, respectively (18, 25). More recently, SHIP has been shown, even in the absence of FcvRIIB co-clustering, to suppress IgE-mediated mast cell degranulation (26) and prevent Steel factor (SF)-mediated mast cell degranulation (27). It has also been shown very recently to inhibit B cell chemotaxis (Kim et al., unpublished), and it is possible, given its ability to break down PI-3,4,5-P3, that it plays a critical role in regulating many if not all PI 3-kinase (PI3K)-induced events in haematopoietic cells. Mechanistically, these SHIP-induced effects appear to be mediated in large part if not exclusively by SHIP's ability to break down PI-3,4,5-P3 to PI-3,4-P2, thus reducing the ability of certain, pleckstrin homology (PH)-containing proteins [e.g, protein kinase B (PKB/Akt), phosphoinositide-dependent protein kinase 1 (PDK-1), Bruton's tyrosine kinase (Btk)] to target to the plasma membrane and be activated (5, 28-32). There is a good deal of support for this mode of action. For example, co-ligation of the FcvRIIB with either the Fc~RI or BCR has been shown to reduce their activation by lowering their induced PI-3,4,5-P3 levels. This, in turn, reduces the entry of extracellular calcium which is essential for downstream pathways leading to degranulation and proliferation, respectively (7, 25, 26). As well, it has been shown recently that SHIP breaks down both cytokine- and antigen-induced PI-3,4,5-P3 to PI-3,4-P2 in mast cells and B cells (27, 30), and this leads to a reduction in the activation of the survival-enhancing serine/threonine kinase, PKB/akt (30-32). SHIP's catalytic activity also appears to be essential for effects other than viability. For example, Vollenweider et al. (33) have reported that addition of catalytically active but not inactive SHIP to rat 1 fibroblasts overexpressing the insulin receptor inhibits insulin-induced GLUT4 translocation, membrane ruffling, mitogenactivated protein kinase (MAPK) phosphorylation and DNA synthesis. However, while there is much support for SHIP exerting its biological effects in large part through its ability to hydrolyse PI-3,4,5-P3 (and perhaps I-1,3,4,5-P4), there are, in addition, data showing that SHIP may also act in part by competing with Grb2 for Shc and thereby reducing Ras activation (6, 34). Since the Ras pathway has been shown to be important for survival in interleukin-3 (IL-3)-stimulated cells (35), this competition may be responsible, at least in part, for the reduced viability we observed in SHIP overexpression studies in DA-ER cells (36). In fact, strong evidence for this competition playing a role in F%RIIB-mediated inhibition of B cell activation has been reported (6).
PROPERTIES OF THE SHIP KNOCKOUT MOUSE
Gaining insights into the biological properties of SHIP from overexpression studies has been difficult both because of difficulties inherent in overexpressing this negative regulator (36, 37) and because results obtained from these overexpression studies, especially in cells that do not normally express SHIP, do not necessarily yield accurate insights into its normal function. Specifically, overexpressed SHIP would not, by definition, be present at physiological levels nor, perhaps, at physiologically relevant subcellular locations. Thus, to gain further insight into the role that SHIP plays in vivo we recently generated a SHIP knockout mouse by homologous recombination in embryonic stem (ES) cells (38). Although these mice are viable and fertile, they overproduce granulocytes and macrophages and suffer from progressive splenomegaly, massive myeloid infiltration of the lungs, wasting and a shortened life span (38). Notably, granulocyte-macrophage progenitors from the bone marrow of these mice are substantially more responsive to multiple cytokines than their wild-type littermates (38),
11.
REGULATION OF MAST CELL DEGRANULATION BY SHIP
173
suggesting once again that SHIP is a negative regulator of haematopoietic growth factorinduced proliferation/survival. Even in the absence of added growth factors, small colonies are present in fetal calf serum (FCS)-containing methylcellulose cultures from S H I P - / - but not +/+ bone marrow, suggesting yet again that S H I P - l - progenitors have a survival advantage. This is consistent with our findings and those of Liu et al. (30) showing that the survival-enhancing PKB/Akt is inhibited by SHIP recruitment to the plasma membrane in mast cells (Scheid et al., unpublished) and B cells (31, 32). Thus SHIP may be an important negative regulator of haematopoietic progenitor cell proliferation/survival as well as a negative regulator of end cell activation.
THE ROLE OF SHIP IN FC~RI-INDUCED DEGRANULATION OF MAST CELLS The high-affinity receptor for IgE, Fc~RI, is composed of one o~, one [3 and two covalently linked y subunits (39) (see Fig. 2). The cytoplasmic domains of the [~ and y subunits contain ITAMs that are critical for IgE-mediated activation (39). Since the SH2 domain of SHIP had been shown to be capable of binding to these tyrosine-phosphorylated ITAMs in vitro (15, 21), we investigated the role of SHIP in Fc~RI-mediated degranulation using bone marrow-derived mast cells (BMMCs) from SHIP +/+ a n d - / mice. Of note, the BMMCs from both SHIP +/+ and - / - mice, following 8 weeks in culture with IL-3, were greater than 99% c-kit- and Fc~RI-positive (with similar mean fluorescences) (26). Since the presence of these two cell surface receptors is a hallmark of mature mast cells, this finding indicated that SHIP is not essential for the differentiation of BMMCs. The standard degranulation assay, in which cells are first primed (passively presensitized) with an IgE against a specific antigen (e.g. a dinitrophenyl (DNP) group) and then exposed to a multivalent antigen [e.g. 20-30 moles of DNP covalently attached to human serum albumin (DNP-HSA)] was used to assess the degranulation potential of SHIP +/+ a n d - / - BMMCs. Interestingly, the S H I P - / - cells consistently released far more of their granule contents under these conditions than their +/+ counterparts. Even more remarkable, however, given that the addition of the Fc~RI-cross-linking multivalent antigen is thought to initiate the biochemical cascade that results in degranulation (39), was the finding that, when IgE alone was added (i.e. the presensitization step), there was a massive degranulation of S H I P - / - BMMCs, whereas SHIP +/+ cells, as previously reported, did not degranulate at all (26). This suggested that SHIP plays an important role in preventing inappropriate degranulation (e.g. in the absence of antigen). We also found that the influx of extracellular calcium was substantially higher in SHIP - / - BMMCs exposed to either IgE alone or IgE plus DNP-HSA (26). Addition of EGTA to deplete extracellular calcium both prevented degranulation and markedly reduced the increase in intracellular calcium to a level that was indistinguishable in +/+ a n d - / - mast ceils. This suggested that SHIP was acting most likely downstream of the initial release of intracellular calcium stores. Although current dogma states that crosslinking of the IgE-pre-loaded Fc~RI by a multivalent antigen is the essential first step in triggering the signalling cascades that lead to degranulation, the calcium influx into both SHIP +/+ a n d - / - BMMCs and the massive degranulation in SHIP - / - BMMCs with IgE alone suggested that substantial
174
M I C H A E L H U B E R et al.
Fig. 2 Model of IgE-induced degranulation in SHIP +/+ and - / - BMMCs. The ITAMs are depicted as light grey bars in the 13and y subunits. The SH2 domains of Lyn and Syk are shown in black.
intracellular signalling was already occurring during the IgE pre-loading step (i.e. in the absence of antigen). To test this hypothesis, we explored tyrosine phosphorylation events elicited by IgE alone in SHIP +/+ a n d - / - BMMCs and found that both the [3 and y subunits of the Fc~RI were indeed tyrosine-phosphorylated in both cell types in response to IgE alone. Moreover, in +/+ cells, SHIP was constitutively tyrosine-phosphorylated and its phosphorylation level increased upon addition of IgE. Intriguingly, immunoprecipitating Shc from these cells revealed that its tyrosine phosphorylation also occurred with IgE stimulation alone but its phosphorylation was markedly reduced in S H I P - / BMMCs. This suggested that Shc needed to bind to SHIP in order to become tyrosine-
11.
REGULATIONOF MAST CELL DEGRANULATION BY SHIP
1 75
phosphorylated after Fc~RI activation by IgE (26). The same result was obtained after antigen cross-linking of IgE-pre-loaded cells. The two mitogen-activated protein kinases (MAPKs) ERK 1 and 2 were also tyrosinephosphorylated by IgE alone in SHIP +/+ and - / - BMMCs, but in S H I P - / - cells this phosphorylation was dramatically prolonged. This is interesting for several reasons. First, since ERK activation has been shown to be dependent on Syk kinase activity (40), it suggests that IgE alone is also sufficient to activate Syk. Second, ERK activation has been shown to lead to the activation of phospholipase A2 and the subsequent synthesis of arachidonic acid-derived metabolites (41). Thus, since ERK activation is substantially prolonged in SHIP-/- BMMCs, this suggests that SHIP may play a role in regulating the synthesis of these inflammatory mediators as well. Third, this prolonged activation of ERK in SHIP-/- cells occurs in the absence of tyrosine-phosphorylated Shc, suggesting that Shc-dependent activation of the Ras pathway may not play a significant role in the IgE-mediated activation of MAPK in these cells. Interestingly, EGTA significantly reduced IgE-induced Erk 1 and 2 phosphorylation, especially in S H I P - / - c e l l s , suggesting that the entry of extracellular calcium is upstream of MAPK activation. We also measured PI-3,4,5-P3 and PI-3,4-P2 levels in SHIP +/+ a n d - / - c e l l s in response to IgE alone and found that PI-3,4,5-P3 levels increased far higher, and PI-3,4-P2 levels far lower, following 2 rain of IgE stimulation of S H I P - / - BMMCs. This demonstrated that SHIP was the primary enzyme responsible for breaking down PI-3,4,5P3 in vivo in response to IgE-induced activation of PI3K. Of note, PI3K activity in antiphosphotyrosine immunoprecipitates from IgE-stimulated SHIP +/+ a n d - / - BMMCs was identical, demonstrating that the elevation of PIP3 levels in the - / - cells was not due to a difference in PI3K activity in the two cell types.
THE ROLE OF SHIP IN STEEL FACTOR-INDUCED SIGNALLING IN MAST CELLS
Since we found that IgE alone triggered degranulation in SHIP-/- BMMCs, we asked if SF, which is known to enhance but not trigger degranulation by itself in normal BMMCs (42), might be capable of degranulating SHIP-/- cells. Interestingly, we found SF alone did indeed stimulate massive degranulation from S H I P - / - BMMCs but, as expected, none from +/+ BMMCs (27). Worthy of note, however, is that IL-3, which stimulates the proliferation and survival of both SHIP +/+ and - / - BMMCs, did not trigger the degranulation of SHIP-/-cells. This demonstrates that the S H I P - / - BMMCs do not simply degranulate in response to any cytokine that is capable of stimulating these cells. As was found with IgE, the SF-induced degranulation was not due to higher receptor levels on S H I P - / - cells and correlated with (and was dependent upon) higher, more sustained intracellular calcium than that in SHIP +/+ cells (27). Both this influx and subsequent degranulation were completely inhibited by PI3K inhibitors, indicating that SF-induced activation of PI3K was upstream of extracellular calcium entry (27). Studies to determine if SHIP affected SF-induced extracellular calcium entry before or after the release of intracellular calcium stores revealed that, while PI3K inhibitors blocked the release of intracellular calcium, implicating PI-3,4,5-P3 in this process, and PLC-72 was slightly more tyrosine-phosphorylated in SHIP - / - cells, the increases in I-1,4,5-P3 and intracellular calcium levels were identical i n - / - and +/+ BMMCs (27). This suggested that SHIP prevents SF-induced intracellular signalling in mature mast cells from
176
MICHAEL HUBER et al.
progressing to degranulation by hydrolysing PI-3,4,5-P3 and this, in turn, inhibits a crucial step between the release of calcium from intracellular stores and the influx of extracellular calcium via surface-operated calcium channels.
THE ROLE OF SHIP IN THAPSIGARGIN-INDUCED SIGNALLING IN MAST CELLS
As already mentioned, both IgE- and SF-mediated degranulation are strictly dependent on the influx of extracellular calcium (7). To study the role of SHIP in mast cell degranulation downstream of this calcium influx we used thapsigargin. This non-phorbol ester tumour promoter is a specific inhibitor of the sarcoplasmic-endoplasmic reticulum calcium-dependent ATPase which pumps calcium that leaks from the endoplasmic reticulum back into this organelle (43). Adding thapsigargin to mast cells thus results in the draining of calcium ions from the endoplasmic reticulum and PI3K-independent capacitative entry (Huber and Krystal, unpublished) of extracellular calcium through store-operated calcium surface channels, and subsequent degranulation (44). Interestingly, as was found previously with IgE and SF (7), thapsigargin stimulated far more degranulation in S H I P - / - BMMCs than in SHIP +/+ BMMCs, and this degranulation was blocked with the PI3K inhibitor, LY294002 (Huber and Krystal, unpublished). However, in contrast to IgE or SF, this heightened degranulation of SHIP - / - BMMCs was not due to a greater calcium influx into these cells, suggesting that the heightened thapsigargin-induced degranulation of SHIP-/- BMMCs was due to a PI3Kregulated pathway distinct from that regulating extracellular calcium entry. An investigation of intracellular pathways stimulated by thapsigargin in SHIP +/+ and - / BMMCs revealed that MAPK was heavily but equally phosphorylated in both cell types. Interestingly, the pan-specific PKC inhibitor, bisindolylmaleimide, totally blocked thapsigargin-induced degranulation in both SHIP +/+ a n d - / - BMMCs, suggesting that a PI3K-dependent step within the mast cell degranulation process might involve a PI-3,4,5P3-binding protein upstream of a PKC isoform. This is interesting, given that it has been known for some time that activation of PKC is a critical event for effective degranulation to occur (45). Moreover, it is also well documented that the combination of calciummobilizing probes and pharmacological PKC activators leads to a synergistic increase in mast cell degranulation (45). This downstream step was not detected with PI3K inhibitors in our studies employing IgE or SF to trigger mast cell degranulation because the degranulation pathway initiated by these two agonists was blocked by PI3K inhibitors at two much earlier steps (intracellular calcium release and extracellular calcium entry) (7). Thus, thapsigargin has proven useful, by bypassing PLC-y-induced calcium release and PI3K-mediated extracellular calcium entry, in revealing this third PI3K-regulated step in degranulation. These thapsigargin studies have also suggested that, while calcium is necessary for degranulation, it is the PI-3,4,5-P3 rather than the intracellular calcium level that determines the extent of degranulation. As far as the PI-3,4,5-P3-binding protein upstream of PKC is concerned, we observed transient PI3K-mediated activation of PKB in response to thapsigargin. This is especially interesting given that PKB activation requires co-localization of the PH-containing kinase PDK-1 (which phosphorylates PKB at Thr-308) at the plasma membrane. PDK-1 has been shown very recently to phosphorylate/activate various PKC isoforms (46-48). This, coupled with our data showing that the pan-specific PKC inhibitor,
ll.
REGULATIONOF MAST CELL DEGRANULATION BY SHIP
] 77
bisindolylmaleimide, prevents thapsigargin-induced degranulation and that phorbol myristate acetate (PMA) does not bring thapsigargin-induced degranulation in SHIP +/+ BMMCs to levels obtained with SHIP-/- BMMCs, suggests that PDK-1 may activate a diacylglycerol (DAG)-independent PKC isotype, such as PKC-~ (Fig. 2). Relevant to these findings, the initiation of BMMC degranulation stimulates dramatic morphological changes in these cells. They flatten out (spread) and their cell surface transforms from a microvillous to a lamellar (ruffled) topography. This is accompanied by the polymerization of the large pool of monomeric (G) actin [approx. 50% of the total actin (49)] in these cells, and the activation of PKC has been shown to be important in this process (50, 51), perhaps by phosphorylating the actin-associated protein, myosin (45). Complicating this picture, it seems that certain PKC isoforms may enhance degranulation (52), whereas others downregulate this process (49). Preliminary studies in our laboratory suggest that certain PKC isoforms are more attracted to the membrane fraction of SHIP-/- BMMCs than +/+ BMMCs, following IgE activation (Hughes and Krystal, unpublished) and further studies are currently under way to determine their role(s) in the degranulation process.
A MODEL OF IGE-INDUCED DEGRANULATION
Pooling our results with those of other investigators, we propose a model for IgE-induced degranulation of mast cells (Fig. 2) in which binding of IgE alone to the Fc~RI on normal primary mast cells activates a constitutively associated Src family member (predominantly Lyn) (53, 54), most likely via CD45 (55), to tyrosine phosphorylate the [~and y-ITAMs. Although we can not rule out at this time that this activation by IgE alone may be due to low levels of IgE aggregates (even though we obtain the same results with HPLC-purified monomeric IgE), it is conceivable that monomeric IgE triggers signalling by causing a conformational change in the multispanning [~ subunit (in a fashion analogous to that proposed for seven spanner receptors). Alternatively, in keeping with the transphosphorylation model of IgE-induced signalling (which states that Lyn can only phosphorylate neighbouring receptors and not the receptor to which it is constitutively bound) (56), a small number of Fc~RI aggregates may always be present even in unstimulated mast cells. Importantly, the presence of SHIP in normal mast cells ensures that this priming step does not lead to degranulation, perhaps by binding via its SH2 domain to either the C-terminal ITAM of the ~ chain (21) and/or the y chain (15), or to a transmembrane protein distinct from the Fc~RI that is tyrosine-phosphorylated in response to IgE binding. It may then become phosphorylated at one or both of its NPXY motifs and then attract Shc, via the latter's PTB domain, to be phosphorylated. Phosphorylated Shc may then vie with the ITAM of the Fc~RI for SHIP and wrest it away. Thus Shc may serve to terminate SHIP's hydrolysis of PI-3,4,5-P3. Inhibition of extracellular calcium entry by wortmannin or LY294002 suggests that PI3K is also translocated to the plasma membrane and activated very early in this process, but exactly how remains to be determined. Syk is attracted to the 7-ITAM (40), becomes phosphorylated by Lyn and stimulates the tyrosine phosphorylation of PLCq,1 and "/2 (57), which in turn leads to the initial release of intracellular calcium via IP3. This emptying of intracellular calcium triggers the entry of extracellular calcium and this entry is substantially augmented by PI3K-mediated generation of PI-3,4,5-P3. As to how an elevation in PI-3,4,5-P3 impacts on extracellular calcium entry, it has recently been
1 78
MICHAEL HUBER et al.
shown that activating the BCR attracts Btk to PI-3,4,5-P3 at the plasma membrane and this leads to its activation and subsequent phosphorylation/activation of PLC-y2 to generate I P 3 and the sustained emptying of intracellular calcium stores that are critical for activating the store-operated calcium entry from the extracellular medium (58, 59). However, since we observe no detectable difference in the release of intracellular calcium in IgE-stimulated SHIP +/+ a n d - / - BMMCs (i.e. in the presence of EGTA), we hypothesize that the elevated PI-3,4,5-P3 present in S H I P - / - c e l l s attracts and activates Btk or another PH-containing intermediate at a step between the draining of intracellular calcium stores and extracellular calcium entry. This is in agreement with Bolland et al. (5), who concluded, from studying SHIP's role in mediating FcvRIIB inhibition of BCR activation in the chicken DT40 B cell line, that SHIP regulates extracellular calcium entry after draining of intracellular calcium stores via its ability to control Btk association with the plasma membrane. Thus SHIP appears to function as a 'gatekeeper' in normal BMMCs by keeping PI3K-generated PI-3,4,5-P3 levels in check and this restricts extracellular calcium entry and subsequent degranulation. We also propose that SHIP regulates, via PI-3,4,5-P3 levels, the activation of PDK-1 and downstream PKC isoforms that play a role in the cytoskeletal changes important to the degranulation process (Fig. 2).
MAJOR QUESTIONS REMAINING One important question still to be answered is what attracts SHIP to the plasma membrane following IgE stimulation. Is it indeed the Fc~RI itself via its 13or 7 subunits or a molecule analogous to the recently identified, lymphoid-specific transmembrane Cdwl50 protein that is tyrosine-phosphorylated in response to BCR activation and attracts SHIP (60)? Related to this, it is still not known what attracts PI3K to the plasma membrane following IgE-stimulated degranulation. Very recently Gupta et al. (61) demonstrated that SHIP binding to the F%RIIB during co-clustering with the BCR induced the binding of PI3K, via its SH2 domains. It is thus possible that the binding of SHIP itself to a tyrosine-phosphorylated transmembrane protein following IgE-induced signalling plays a role in the attraction of at least some PI3K to the membrane in mast cells. Our data suggest there are at least three PI-3,4,5-P3-dependent pathways that must be activated by IgE for degranulation, one being required for intracellular calcium release, another for extracellular calcium entry and a third for PKC activation. It is likely that PHcontaining proteins are involved in these steps and, while there is some evidence that Btk may be the one involved in the first step and PDK-1 in the third, the nature of the protein(s) involved in the second remains to be determined. What pathways stimulated by calcium entry are critical to degranulation? Although calcium is known to trigger many intracellular events (62, 63), it is not known exactly which ones are critical for degranulation. What is the role of the SHIP-Shc interaction in IgE-induced signalling? Does it serve to terminate the association of SHIP with the plasma membrane or does it serve to tie up Shc and thus reduce Grb2/Sos activation of Ras? Another key question of course is which PKCs stimulate and which inhibit IgEmediated degranulation. Once this is answered, the more difficult task of determining the pathways they activate (inactivate) to modulate degranulation can be addressed.
11.
R E G U L A T I O N OF MAST CELL D E G R A N U L A T I O N BY SHIP
179
SUMMARY AND CONCLUSIONS
Our results both challenge the current paradigm for passive sensitization of mast cells with IgE and reveal a vital role for SHIP in both setting the threshold for and limiting degranulation by hydrolysing PI-3,4,5-P3 and thus restricting the entry of extracellular calcium and activation of certain PKC isoforms. This raises the intriguing possibility that naturally occurring mutations in SHIR PI3K or PTEN (64), which together determine PI3,4,5-P3 levels following Fc~RI activation, could contribute to specific hyperallergic conditions in man. In addition, these studies suggest that the development of drugs that can specifically increase SHIP activity in mast cells might dramatically reduce allergic responses.
ACKNOWLEDGEMENTS
We would like to thank Christine Kelly for typing the manuscript. This work was supported by the NCI-C, with funds from the Terry Fox Foundation, and the MRC-C with core support from the BC Cancer Foundation and the BC Cancer Agency. M. Huber is supported by the Deutsche Forschungsgemeinschaft. M. Hughes is supported by NSERC. G. K. is a Terry Fox Cancer Research Scientist of the NCI-C supported by funds from the Canadian Cancer Society and the Terry Fox Run.
REFERENCES 1. Galli, S. J. and Wershil, B. K. The two faces of the mast cell. Nature 381:21-22, 1996. 2. Schwartz, L. B. Mast cells: function and contents. Curr. Opin. Immunol. 6:91-97, 1994. 3. Tang, L., Jennings, T. A. and Eaton, J. W. Mast cells mediate acute inflammatory responses to implanted biomaterials. Proc. Natl. Acad. Sci. USA 95:8841-8846, 1998. 4. Scharenberg, A. M. and Kinet, J.-E PtdIns-3,4,5-P3: a regulatory nexus between tyrosine kinases and sustained calcium signals. Cell 94:5-8, 1998. 5. Bolland, S., Pearse, R. N., Kurosaki, T. and Ravetch, J. V. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 8:509-516, 1998. 6. Coggeshall, K. M. Inhibitory signaling by B cell FcTRIIb. Curr. Opin. Immunol. 10:306-312, 1998. 7. Huber, M,. Helgason, C. D., Damen, J. E., Scheid, M., Duronio, V., Liu, L., Ware, M. D., Humphries, R. K. and Krystal, G. The role of SHIP in growth factor induced signalling. In: Progress in Biophysics & Molecular Biology, Vol. 71 (Pawson, A. J., ed.), pp. 423-434. Elsevier Science, Amsterdam, 1999. 8. Damen, J. E., Liu, L., Rosten, E, Humphries, R. K., Jefferson, A. B., Majerus, E W. and Krystal, G. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 93:1689-1693, 1996. 9. Irvine, R. Inositol phospholipids: translocation, translocation, translocation. Curr. Biol. 8:R557-R559, 1998. 10. Ware, M. D., Rosten, E, Damen, J. E., Liu, L., Humphries, R. K. and Krystal, G. Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation. Blood 88:2833-2840, 1996. 11. Liu, Q., Shalaby, E, Jones, J., Bouchard, D. and Dumont, D. J. The SH2-containing inositol polyphosphate 5-phosphatase, Ship, is expressed during hematopoiesis and spermatogenesis. Blood 91:2753-2759, 1998. 12. Geier, S. J., Algate, E A., Carlberg, K., Flowers, D., Friedman, C., Trask, B. and Rohrschneider, L. R. The human SHIP gene is differentially expressed in cell lineages of the bone marrow and blood. Blood 89:1876-1885, 1997.
180
13.
14.
15.
16.
17.
18. 19.
20.
21.
22.
23.
24. 25. 26.
27.
28. 29. 30.
31. 32. 33.
MICHAEL HUBER et al. Sattler, M., Salgia, R., Shrikhande, G., Verma, S., Choi, J.-L., Rohrschneider, L. R. and Griffin, J. D. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors. Oncogene 15:2379-2384, 1997. Harmer, S. L. and DeFranco, A. L. The Src homology domain 2-containing inositol phosphatase SHIP forms a ternary complex with Shc and Grb2 in antigen receptor-stimulated B lymphocytes. J. Biol. Chem. 274:12183-12191, 1999. Osborne, M. A., Zenner, G., Lubinus, M., Zhang, X., Songyang, Z., Cantley, L. C., Majerus, E, Burn, E and Kochan J. E The inositol 5'-phosphatase SHIP binds to immunoreceptor signaling motifs and responds to high affinity IgE receptor aggregation. J. Biol. Chem. 271:29271-29278, 1996. V61y,F., Olivero, S., Olcese, L., Moretta, A., Damen, J. E., Liu, L., Krystal, G., Cambier, J. C., DaCron, M. and Vivier, E. Differential association of phosphatases with hematopoietic co-receptors bearing immunoreceptor tyrosine-based inhibition motifs. Eur. J. Immunol. 27:1994-2000, 1997. Tridandapani, S., Kelley, T., Pradhan, M., Cooney, D., Justement, L. B. and Coggeshall, K. M. Recruitment and phosphorylation of SH2-containing inositol phosphatase and Shc to the B-cell Fc gamma immunoreceptor tyrosine-based inhibition motif peptide motif. Mol. Cell. Biol. 17:4305-4311, 1997. Ono, M., Okada, H., Bolland, S., Yanagi, S., Kurosaki, T. and Ravetch, J. V. Deletion of SHIP or SHP- 1 reveals two distinct pathways for inhibitory signaling. Cell 90:293-301, 1997. Kuroiwa, A., Yamashita, Y., Inui, M., Yuasa, T., Ono, M., Nagabukuro, A., Matsuda, Y. and Takai, T. Association of tyrosine phosphatases SHP- 1 and SHP-2, inositol 5-phosphatase SHIP with gp49B 1, and chromosomal assignment of the gene. J. Biol. Chem. 273:1070-1074, 1998. Tridandapani, S., Pradhan, M., LaDine, J. R., Garber, S., Anderson, C. L. and Coggeshall, K. M. Protein interactions of Src homology (SH2) domain-containing inositol phosphatase (SHIP): association with Shc displaces SHIP from FcTRIIb in B cells. J. Immunol. 162:1408-1414, 1999. Kimura, T., Sakamoto, H., Appella, E. and Siraganian, R. E The negative signaling molecule SH2 domain-containing inositol-polyphosphate 5-phosphatase (SHIP) binds to the tyrosine-phosphorylated beta subunit of the high affinity IgE receptor. J. Biol. Chem. 272:13991-13996, 1997. Damen, J. E., Liu, L., Ware, M. D., Ermolaeva, M., Majerus, E W. and Krystal, G. Multiple forms of the SH2-containing inositol phosphatase, SHIP, are generated by C-terminal truncation. Blood 92:1199-1205, 1998. Odai, H., Sasaki, K., Iwamatsu, A., Nakamoto, T., Ueno, H., Yamagata, T., Mitani, K., Yazaki, Y. and Hirai, H. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colonystimulating factor, erythropoietin, and Bcr-Abl. Blood 89:2745-2756, 1997. Lucas, D. M. and Rohrschneider, L. R. A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development. Blood 93:1922-1933, 1999. Ono, M., Bolland, S., Tempst, E and Ravetch, J. V. Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc-gamma-RIIB. Nature 383:263-266, 1996. Huber, M., Helgason, C. D., Damen, J. E., Liu, L., Humphries, R. K. and Krystal, G. The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. Proc. Natl. Acad. Sci. USA 95:11330-11335, 1998. Huber, M., Helgason, C. D., Scheid, M. E, Duronio, V., Humphries, R. K. and Krystal, G. Targeted disruption of SHIP leads to steel factor induced degranulation of mast cells. EMBO J. 27:7311-7319, 1998. Marte, B. M. and Downward, J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22:355-358, 1997. Belham, C., Wu, S. and Avruch, J. Intracellular signalling: PDK1 - a kinase at the hub of things. Curr. Biol. 9:R93-R96, 1999. Liu, Q., Sasaki, T., Kozieradzki, I., Wakeham, A., Itie, A., Dumont, D. J. and Penninger, J. M. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 13:786-791, 1999. Aman, M. J., Lamkin, T. D., Okada, H., Kurosaki, T. and Ravichadran, K. S. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273:33922-33928, 1998. Jacob, A., Cooney, D., Tridandapani, S., Kelley, T. and Coggeshall, K. M. Fq,RIIb modulation of surface immunoglobulin-induced Akt activation in murine B cells. J. Biol. Chem. 274:13704-13710, 1999. Vollenweider, E, Clodi, M., Martin, S. S., Imamura, T., Kavanaugh, W. M. and Olefsky, J. M. An SH2 domain-containing 5' inositolphosphatase inhibits insulin-induced GLUT4 translocation and growth
11. R E G U L A T I O N OF MAST CELL D E G R A N U L A T I O N BY SHIP 34.
35. 36.
37.
38.
39.
40.
41.
42.
43.
44. 45.
46.
47. 48.
49. 50.
51. 52.
53. 54.
181
factor-induced actin filament rearrangement. Mol. Cell. Biol. 19:1081-1091, 1999. Liu, L., Damen, J. E., Cutler, R. L. and Krystal, G. Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc. Mol. Cell. Biol. 14:6926-6935, 1994. Kinoshita, T., Yokota, T., Arai, K. and Miyajima, A. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J. 14:266-275, 1995. Liu, L., Damen, J. E., Hughes, M. R., Babic, I., Jirik, E R. and Krystal, G. The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis. J. Biol. Chem. 272:8983-8988, 1997. Lioubin, M. N., Algate, P. A., Tsai, S., Carlberg, K., Aebersold, A. and Rohrschneider, L. R. p150 ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev. 10:1084-1095, 1996. Helgason, C. D., Damen, J. E., Rosten, P., Grewal, R., Sorensen, P., Chappel, S. M., Borowski, A., Jirik, E, Krystal, G. and Humphries, R. K. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology and a shortened lifespan. Genes Dev. 12:1610-1620, 1998. Alber, G., Miller, L., Jelsema, C. L., Varin-Blank, N. and Metzger, H. Structure-function relationships in the mast cell high affinity receptor for IgE. Role of the cytoplasmic domains and the beta subunit. J. Biol. Chem. 266:22613-22620, 1991. Hirasawa, N., Scharenberg, A., Yamamura, H., Beaven, M. A. and Kinet, J.-P. A requirement for Syk in the activation of the microtubule-associated protein kinase/phospholipase A2 pathway by Fc-epsilon RI is not shared by a G protein-coupled receptor. J. Biol. Chem. 270:10960-10967, 1995. Hirasawa, N. A., Santini, E and Beaven, M. A. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. J. Immunol. 154:5391-5402, 1995. Vosseller, K., Stella, G., Yee, N. S. and Besmer, P. c-kit receptor signaling through its phosphatidylinositide-3"-kinase-binding site and protein kinase C: role in mast cell enhancement of degranulation, adhesion, and membrane ruffling. Mol. Biol. Cell 8:909-922, 1997. Thastrup, O., Dawson, A. P., Scharff, O., Foder, B., Cullen, P. J., Drobak, B. K., Bjerrum, P. J., Christensen, S. B. and Hanley, M. R. Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage. Agents Actions 43:187-193, 1994. Putney, J.W. JrandBird, G.S. The signal for capacitative calcium entry. Cei175:199-201, 1993. Ludowyke, R. I., Scurr, L. L. and McNally, C. M. Calcium ionophore-induced secretion from mast cells correlates with myosin light chain phosphorylation by protein kinase C. J. Immunol. 157:5130-5138, 1996. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P. and Parker, P. J. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281:2042-2045, 1998. Dutil, E. M., Toker, A. and Newton, A. C. Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). Curr. Biol. 8:1366-1375, 1998. Chou, M. M., Hou, W., Johnson, J., Graham, L. K., Lee, M. H., Chen, C.-S., Newton, A. C., Schaffhausen, B. S. and Toker, A. Regulation of protein kinase C ~ by PI 3-kinase and PDK-1. Curr. Biol. 8:1069-1077, 1998. Frigeri, L. and Apgar, J. R. The role of actin microfilaments in the down-regulation of the degranulation response in RBL-2H3 mast cells. J. Immunol. 162:2243-2250, 1999. Pfeiffer, J. R., Seagrove, J. C., Davis, B. H., Deanin, G. G. and Oliver, J. M. Membrane and cytoskeletal changes associated with IgE-mediated serotonin release from rat basophilic leukemia cells. J. Cell Biol. 101:2145-2155, 1985. Apgar, J. R. Regulation of the antigen-induced F-actin response in rat basophilic leukemia cells by protein kinase C.J. Cell Biol. 112:1157-1163, 1991. Ozawa, K., Szallasi, Z., Kazanietz, M. G., Blumberg, E M., Mischak, H., Mushinski, J. E and Beaven, M. A. CaZ+-dependent and CaZ+-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with C a 2+ and purified isozymes in washed permeabilized cells. J. Biol. Chem. 268:1749-1756, 1993. Nishizumi, H. and Yamamoto, T. Impaired tyrosine phosphorylation and C a 2+ mobilization, but not degranulation, in lyn-deficient bone marrow-derived mast cells. J. Immunol. 158:2350-2355, 1997. Vonakis, B. M., Chen, H., Haleem-Smith, H. and Metzger, H. The unique domain as the site on lyn kinase for its constitutive association with the high affinity receptor for IgE. J. Biol. Chem. 272:24072-24080, 1997.
182 55. 56.
57.
58.
59.
60.
61.
62. 63. 64.
MICHAEL HUBER et al. Berger, S. A., Mak, T. W. and Paige, C. J. Leukocyte common antigen (CD45) is required for immunoglobulin E-mediated degranulation of mast cells. J. Exp. Med. 180:471-476, 1994. Pribluda, V. S., Pribluda, C. and Metzger, H. Transphosphorylation as the mechanism by which the highaffinity receptor for IgE is phosphorylated upon aggregation. Proc. Natl. Acad. Sci. USA 91:11246-11250, 1994. Zhang, J., Berenstein, E. H., Evans, R. L. and Siraganian, R. E Transfection of Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. J. Exp. Med. 184:71-79, 1996. Scharenberg, A. M., E1-Hillal, O., Fruman, D. A., Beitz, L. O., Li, Z., Lin, S., Gout, I., Cantley, L. C., Rawlings, D. J. and Kinet, J.-E Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinasedependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J. 17:1961-1972, 1998. Fluckiger, A.-C., Li, Z., Kato, R. M., Wahl, M. I., Ochs, H. D., Longnecker, R., Kinet, J.-P., Witte, O. N., Scharenberg, A. M. and Rawlings, D. J. Btk/Tec kinases regulate sustained increases in intracellular C a 2+ following B-cell receptor activation. EMBO J. 17:1973-1985, 1998. Mikhalap, S., Shlapatska, L. M., Berdova, A. G., Law, C -L., Clark, E. A. and Sidorenko, S. E CDw 150 associates with Src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J. Immunol. 162:5719-5727, 1999. Gupta, N., Scharenberg, A. M., Fruman, D. A., Cantley, L. C., Kinet, J.-E and Long, E. O. The SH2 domain-containing inositol 5'-phosphatase (SHIP) recruits the p85 subunit of phosphoinositide 3-kinase during FqRIIb 1-mediated inhibition of B cell receptor signaling. J. Biol. Chem. 274:7489-7494, 1999. Berridge, M. J. The AM and FM of calcium signalling. Nature 386:759-760, 1997. Putney J. W. Jr. Calcium signalling: Up, down, up, down .... What's the point? Science 279:191-192, 1998.